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Background – Antibiotic resistance is a well-recognised global health problem which is 
mostly driven by antibiotic use that is not evidence based. Acute otitis media (AOM), an 
acute middle ear inflammation mostly found in children, has a high antibiotic prescribing rate, 
although only one third of AOM cases (severe AOM) will benefit from antibiotics. Therefore, 
an effective non-antibiotic treatment for AOM is needed. To date, studies on these 
alternatives (e.g., decongestants, probiotics) for AOM have demonstrated insufficient 
evidence of efficacy. Due to the inflammatory nature of AOM, an anti-inflammatory agent, 
such as corticosteroids, could be a potential candidate. Although corticosteroids have been 
used for inflammatory and autoimmune diseases, their efficacy in AOM remains unknown.  
Aim – To assess the effectiveness of systemic corticosteroids as a monotherapy for mild 
AOM and as an addition to antibiotics for severe AOM.  
Methods – We conducted four studies. The first study was a Cochrane systematic review 
where we identified, appraised, and synthesised available randomised clinical trials (RCTs) of 
systemic corticosteroids versus placebo for AOM in children. Our second study was a 
feasibility study surveying Indonesian physicians to understand their current management of 
children with AOM and their willingness to participate in our planned RCT. Following the 
feasibility survey study, we conducted our third study, a pilot pragmatic, randomised, single-
blind, controlled study. This pilot study also included a mechanistic sub-study using 
tympanometry. The study tested the feasibility of all pre-specified procedures and measures 
of the planned large trial, as well as assessing the effects of oral corticosteroids in improving 
the middle ear effusion (MEE) in AOM and the correlation between ear pain and other 
symptom resolution and MEE. Our last study was the finalisation of the protocol for the full-
sized RCT based on the results from the pilot study. 
Results – Our first study, a Cochrane review, demonstrated insufficient evidence for both 
efficacy and harm for corticosteroids in AOM thus justifying our decision to design a large, 
high-quality RCT. 
To inform the design of the RCT, we conducted our second study, a feasibility survey study. 
This confirmed it was feasible to conduct the main RCT in Indonesia by identifying there 
were sufficient numbers of paediatric AOM cases and physicians who would be willing to: (1) 
[ii] 
withhold antibiotics and choose observation for mild AOM; (2) prescribe corticosteroids; and 
(3) participate in our RCT.
Our third study, a pilot study (62 children were recruited, 60 were analysed), demonstrated 
that it was feasible to successfully implement all pre-specified procedures and measures, and 
verified we needed fewer children for the main RCT than initially envisaged. We found oral 
corticosteroids may potentially reduce pain intensity measured using a 100-mm Visual 
Analogue Scale at Day 3 (mean difference [MD] -7.37, 95% CI -13.36 to -1.39, P = 0.017), 
but cause more drowsiness than placebo (relative risk [RR] 1.77, 95% CI 1.11 to 2.81, P = 
0.016; number needed to harm (NNTH) 3). No excess of other adverse events (e.g., nausea, 
vomiting, diarrhea) was attributed to oral corticosteroid use and there were no serious adverse 
events. Oral corticosteroids may also improve tympanometry curves at Day 7 (RR 1.76, 95% 
CI 1.04 to 2.97; P = 0.047; number needed to treat to benefit (NNTB) 3), but with only a 
small correlation between pain and other AOM-relevant symptoms and MEE.  
The findings and feedback from these studies helped us to improve and finalise our fourth 
study, which is the protocol for a full-scale pragmatic, parallel, randomised double-blind, 
placebo-controlled study.  
Conclusions – Our Cochrane review demonstrated there was insufficient evidence about the 
effects of systemic corticosteroids for AOM and therefore, the need for a large high-quality 
RCT.  Our feasibility survey and pilot study also confirmed it was feasible and important to 
conduct a pragmatic, parallel, randomised, double-blind, placebo-controlled study, to be able 
to provide definitive conclusions about the effectiveness and harm of oral corticosteroids for 
children with AOM. If this study demonstrates positive results, physicians would be able to 
withhold antibiotics and prescribe oral corticosteroids as a monotherapy for mild AOM and 
prescribe corticosteroids in addition to antibiotics for severe AOM. Long term or second-
line antibiotics would not be required.  The consequent reduction in antibiotic use 
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Figure 1. Research flowchart 
My journey as a student 
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as other research fields through workshops (e.g., EBP, systematic reviews (SR), publication 
skills) and other several internal scientific sessions for staff and students, such as journal club 
and skill sessions. I found these sessions were very helpful. The journal club sessions have 
built my knowledge and skill in identifying and critically appraising published studies, and 
then summarising and interpreting the results for their applicability to clinical practice by 
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CHAPTER 1: GENERAL INTRODUCTION AND  
THESIS OUTLINE 
“There is no one who goes out of his house in order to seek 
knowledge, but the angels lower their wings in approval of his 
action.”  





1.1.1  ANTIBIOTIC RESISTANCE 
Antibiotic resistance is a global public health problem [1]. It is defined as an alteration of the 
ability of bacteria to survive and grow in the presence of antibiotics aimed at killing or 
limiting their growth [1-4]. One of the main drivers of antibiotic resistance is antibiotic use 
[2-5].  
Antibiotics are commonly prescribed for infections, such as acute respiratory infection (ARI) 
[4,6,7]. Acute respiratory infections are frequently found in children, with those under two 
years of age experiencing up to nine ARI episodes per year [7,8].  Most ARIs are self-limiting 
and have a low risk of serious complications [8]. Therefore, treatment aims to manage 
symptoms [8-10]. Antibiotics have consistently been shown to have little or no clinical benefit 
for ARIs, yet, high rates of antibiotic prescribing continue [9,10]. In Indonesia, a survey study 
collecting prescriptions of children aged five years and younger with ARIs (2008-2009) 
demonstrated that 67% of antibiotics were prescribed for these children [11]. In Australian 
general practice, at least one antibiotic is prescribed for approximately 5.97 million ARI cases 
annually, which is equivalent to 4.64 out of 8.11 per 100 encounters of new ARI cases [12]. 
In the United States, the antibiotic prescribing rate for ARIs in primary care (2007-2009) was 
62% [13].  
1.1.2 ACUTE OTITIS MEDIA 
Prevalence, aetiology, and pathogenesis 
Acute otitis media (AOM), one type of ARI, is an inflammation of the middle ear with several 
symptoms such as rapid onset of specific (e.g., ear pain) or non-specific symptoms (e.g., 
irritability, fevers); and signs such as acute inflammation (e.g., red ear drum) and middle ear 
effusion (e.g., air fluid level, bulging) [14,15]. It is most common in children younger than 
two years [16]. Approximately 75% of children in their first five years of life experience an 
episode of AOM [17]. In East Jakarta (Indonesia), the point prevalence rate of AOM in 
children aged 2-5 years was 5.4% [18]. In Australia, severe AOM is particularly a problem for 
indigenous children (7.9%), compared to non-indigenous (1.7%) [19].   
Out of all the symptoms of AOM, pain is one of the most distressing for AOM [20]. It is 
seven times more likely to be found in a child with AOM, compared to a child without. 
[3] 
 
However, younger children are less likely to complain of ear pain as they are less able to 
localise the pain [20].  
The basic pathogenesis of AOM is an inflammatory mechanism, which can be induced by 
microbia such as viruses (e.g., respiratory syncytial virus, rhinovirus, influenza virus, 
adenovirus) and/or bacteria (e.g., Streptococcus pneumoniae, Nontypeable Hemophillus 
influenzae, Moraxella catarrhalis) [21]. This mechanism is mediated by inflammatory 
mediators (e.g., cytokines, chemokines, mast cells, prostaglandins, leukotrienes) that are 
responsible for altering “vascular permeability changes, chemotaxis, stimulation of epithelial 
secretory activity, enhancement of mucous glycoprotein secretion, and production of other 
mediators” [22]. Later, inflammation may promote a dysfunction of the eustachian tube 
resulting in middle ear effusion [23].   
Management with antibiotics 
Following the introduction of antibiotics for infectious disease, specifically for AOM, rates of 
complication rapidly declined. Physicians may prescribe antibiotics due to potential 
complications following AOM, such as spontaneous tympanic membrane perforation, 
persistent middle ear effusion, and acute mastoiditis [17,24,25]. A Cochrane review 
demonstrates that antibiotics reduced the number of children who had persistent middle ear 
effusion at six to eight weeks by 12% (RR 0.88, 95% CI 0.78 to 1.00; NNTB 16) and had 
tympanic membrane perforations by 63% (RR 0.37, 95% CI 0.18 to 0.76; NNTB 33) [26]. It 
was originally believed this was due to the routine use of antibiotics and high rates of 
prescribing antibiotics for AOM have continued [12,27]. Initially, the evidence showed that 
this antibiotic treatment could be potential as there were 13.7% more children had resolution 
of AOM symptoms and signs compared to placebo [28].  However, more recent, high quality 
meta-analyses show that, on average, antibiotics have no effect on pain at Day 1 and minimal 
at Day 2 [26], although some children are more likely than others to benefit from antibiotics 
(i.e., children: with severe symptom and signs (e.g., moderate to severe ear pain, fever ≥39°
C), aged < two years with bilateral AOM, and/or with tympanic membrane perforation) 
[14,29]. 
This introduces a level of uncertainty for clinicians, and guideline developers [30]. In 
Indonesia, there is inconsistency in treatment guidelines for AOM [31,32]. The Indonesian 
Otorhinolaryngologist and Head-Neck Surgery Society (PERHATI-KL) guideline 
[4] 
 
recommends antibiotics only for high risk AOM; however, without clear definitions of “high” 
and “low risk” AOM [31]. In contrast, the Ministry of Health Republic of Indonesia practice  
guideline for primary care practitioners recommends antibiotic treatment for all cases of 
AOM. This is regardless of case severity and dose is differentiated by the severity (lower dose 
for mild AOM versus higher dose for severe AOM) [32]. This inconsistency potentially leads 
to differences in antibiotic prescribing for AOM amongst physicians in Indonesia. 
Even with the use of antibiotics, 11% to 19% of children with AOM experience persistent 
symptoms after three to six days [33]. This signifies that we need more effective treatment for 
AOM. 
Alternative treatments for acute otitis media 
There is a need for other effective treatments for AOM (e.g., acetaminophen, non-steroidal 
anti-inflammatory drug [NSAID], decongestants, anaesthetic-analgesic ear drops) [34-36]. 
Acetaminophen or NSAID, alone or combination, were found to be effective for pain relief in 
AOM. However, this conclusion was drawn from one study in a Cochrane review of poor-
quality evidence [34]. Other common alternative treatments, such as decongestants and/or 
antihistamines may also be effective in reducing the incidence of persisting AOM. However, 
they also increase the risk of adverse effects (e.g., diarrhoea, rash, dizziness) up to five to 
eight times, particularly the decongestant alone [35]. Anaesthetic-analgesic ear drops were 
found beneficial in reducing pain at Day 2 and antibiotic consumption by Day 8 compared  to 
usual care. However, we are not confident to the result because of a small sample size (did not 
achieve the sample size target) [36] (see Appendix 1.1 for further details and other potential 
alternative treatment for AOM). 
1.1.3 CORTICOSTEROIDS AS A POTENTIAL ALTERNATIVE TREATMENT FOR 
ACUTE OTITIS MEDIA 
There are theoretical reasons why corticosteroids might be effective. Based on the 
pathogenesis of AOM, an intervention which suppresses the inflammatory process could have 
an important role in the resolution of AOM [22]. Corticosteroids play an important role in 
inhibiting the inflammation process, including the inhibition of the mediators that are 
involved in inflammatory process in the middle ear [22]. Corticosteroids suppress the immune 
response to reduce the inflammation by facilitating apoptosis of T lymphocytes and 
polymorphonuclear leukocytes (i.e., neutrophils, eosinophils, and basophils), suppressing 
[5] 
 
production of inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6) and cell adhesion molecules, 
and inhibiting the Th1- and Th2-derived cytokines [37]. Corticosteroids also inhibit 
inflammatory enzyme activities such as phospholipases, which prevent arachidonic acid from 
synthesising leukotrienes and prostaglandins, pro-inflammatory mediators [38]. Therefore, 
corticosteroids are potentially superior as an anti-inflammatory agent compared to NSAIDs. 
Non-steroidal anti-inflammatory drugs only inhibit cyclooxygenase, an enzyme that mediates 
arachidonic acid in releasing prostaglandin [38]. 
Corticosteroids have been widely used in inflammatory and autoimmune diseases in children. 
However, despite the favourable effect of corticosteroids for inflammation, there are still 
several potential adverse effects. A systematic review identified several side effects of short-
course of corticosteroids (less than two weeks) in children, such as gastrointestinal 
disturbances (i.e., vomiting, gastritis, nausea), behavioural changes (i.e., mood swings, 
nervousness), HPA axis suppression, increased blood pressure, hyperglycaemia, weight gain, 
and decreased bone mineralisation [39]. However, the review included studies that used a 
range of corticosteroid types and duration. This may have resulted in uncertain results on the 
important beneficial and harmful effects of corticosteroid [39].  
Corticosteroids have also been used for ARIs, such as acute sinusitis, sore throat, acute 
bacterial meningitis, and chronic otitis media with effusion [33,40-44] (see Table 1). 
In acute sinusitis, a Cochrane review of low to moderate quality evidence showed that oral 
corticosteroids as an addition to antibiotics may improve short-term symptoms (e.g., facial 
pain) [40] (see Appendix 1.2 for further details).  
In acute sore throat, a Cochrane review of moderate to high quality evidence demonstrated 
that oral corticosteroids (as an addition to antibiotics or monotherapy) may improve pain 
complete resolution at 24 to 48 hours and reduce the mean time to complete resolution [41]. A 
recent RCT of adults without initial antibiotic treatment also demonstrated that a single dose 
oral dexamethasone may be effective in improving the symptom resolution at 48 hours and 
reduce the initiation of antibiotics [42]. This beneficial effect is also found in a recent 




In acute bacterial meningitis, a Cochrane review of high-quality evidence showed that 
corticosteroids may reduce the incidence of any hearing loss, including severe hearing loss 
[44]. 
In addition, one RCT (n = 389) testing oral corticosteroids for children aged two to eight 
years with chronic otitis media with effusion (OME) for minimum three months duration 
found that oral corticosteroids have no benefit in the resolution of both audiometry and 
tympanometry findings, as well as the resolution of middle ear effusion at five weeks, six and 
12 months [45]. 
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Effective Moderate to 
high 
*For further details see Appendix 1.2. Corticosteroids for acute respiratory infections. 
ARIs= acute respiratory infections; ICU= Intensive Care Unit; RCT= randomised controlled trial; 
SR= Systematic review.  
Several studies of corticosteroids for AOM showed inconsistent results regarding the benefits 
and risks. Given the limitations described above, we still do not know if corticosteroids are 
effective in improving symptoms, such as ear pain and middle ear effusion, in children with 
AOM. We also do not know the adverse effects of corticosteroids in this population. 
Therefore, it is important to identify, assess, and synthesise the quality of existing evidence of 
corticosteroids for AOM for both the effectiveness and risks, before implementing this 
treatment in practice.  
1.2 RESEARCH AIM 
The overall aim is to identify the effectiveness of corticosteroids as a monotherapy for mild 
AOM and as an addition to antibiotics for severe AOM in children. To address this, we 





1.3 RESEARCH QUESTIONS AND OBJECTIVES 
1.3.1 RESEARCH QUESTION 1 
Are oral corticosteroids effective for children with AOM either as a monotherapy for mild 
AOM or as an addition to antibiotics for severe AOM?  
Objectives: To systematically review the evidence of corticosteroids for AOM in children. 
Project or Study 1: Cochrane review of systemic corticosteroids for AOM in children  
Publication: Protocol and systematic review were published in Cochrane Database of 
Systematic Reviews.  
1.3.2 RESEARCH QUESTION 2 
1. How do physicians (i.e., general practitioners, ear-nose-throat specialists, and 
paediatricians) in DKI Jakarta, Depok, and Bekasi (Indonesia) manage AOM in 
children? 
2. Is it feasible to conduct a clinical trial testing oral corticosteroids for children with 
AOM in these Indonesian cities? 
Objectives: 
1. To identify the current management of AOM in children among Indonesian physicians. 
2. To assess a feasibility of a large clinical trial of oral corticosteroids for children with 
AOM in Indonesia. 
Project or Study 2: Current management of children with acute otitis media: a feasibility 
survey for a pragmatic study in Jakarta, Depok, and Bekasi. 







1.3.3 RESEARCH QUESTION 3 
1. Is it feasible to conduct all pre-specified methods and procedures feasible to be 
conducted in the main study, which is a large, pragmatic, parallel, randomised, double-
blind, placebo-controlled trial of oral prednisolone for children with AOM in Jakarta, 
Indonesia? 
2. Does oral corticosteroid improve middle ear inflammation by reducing MEE in 
children with AOM, and does the resolution of MEE correlate with pain and other 
AOM relevant symptoms? 
Objectives:  
1. To pilot a clinical trial of oral corticosteroids for children with AOM in Indonesia by 
testing the feasibility of all pre-specified methods and procedures of the main study 
(e.g., the overall process, resources, management, scientific components) in a smaller 
study. 
2. To assess the efficacy of oral corticosteroids in improving middle ear inflammation by 
reducing MEE in children with AOM measured using tympanometry. 
3. To identify the correlation between the resolution of MEE and pain and other AOM-
relevant clinical symptoms. 
Project or Study 3: Oral prednisolone for acute otitis media in children: a pilot pragmatic, 
randomised, open-label, controlled study (OPAL study). 
Publication: The protocol paper was published in Pilot and Feasibility Studies. The results 
paper was also submitted to Pilot and Feasibility Studies (under review). 
1.3.4  RESEARCH QUESTION 4 
Are oral corticosteroids effective as a monotherapy for mild AOM and as an addition to 
antibiotics for severe AOM in improving clinical outcomes and what are common harm 
related to short-term oral corticosteroids in children? 
Objectives: To develop the protocol for a large, pragmatic, parallel, randomised, double-blind, 
placebo-controlled trial of oral prednisolone for children with AOM in Indonesia, based on 
the results from conducting a pilot of the OPAL study. 
[11] 
 
Project or Study 4: Oral prednisolone for acute otitis media in children: a proposed 
pragmatic, parallel, randomised, double-blind, placebo-controlled study (OPAL study). 
Publication: Protocol for a full-scale clinical trial (OPAL study) was submitted for 
publication as an appendix of the results paper of Study 3 submitted to Pilot and Feasibility 
Studies. 
1.4 THESIS OUTLINE  
Chapter 1 – General introduction  
The first chapter describes a brief background to the research questions which were driven by 
the need for an effective alternative treatment to antibiotics for children with AOM. We 
conducted four projects or studies to respond to our research questions. This chapter will help 
the readers to understand our justification for our research and follow the whole thesis 
systematically by project.  
Chapter 2 – Systemic corticosteroids for acute otitis media in children (Study 1) 
This chapter reports on our first study of the thesis, a Cochrane review of systemic 
corticosteroids for children with AOM (Study 1). This study collected and summarised 
information from existing RCTs of children who received either systemic corticosteroids or 
placebo for AOM. We found insufficient evidence to recommend oral corticosteroids for use 
in clinical practice. This confirmed the requirement for a high-quality clinical trial to assess 
the effects of oral corticosteroids for children with AOM. 
Chapter 3 – Current management of children with acute otitis media: A 
feasibility survey for a pragmatic study in Jakarta, Depok, and Bekasi (Study 2).  
Prior to the implementation of a clinical trial assessing the effects of oral corticosteroids for 
children with AOM, we conducted two studies to assess the feasibility of our planned clinical 
trial. This chapter reports on the first of these, a survey of the current management of children 
with AOM among Indonesian physicians. It also showed that there was a feasible number of 




Chapter 4 – Oral prednisolone for acute otitis media in children: a pilot 
pragmatic, randomised, open-label, controlled study / OPAL study (Study 3). 
Following our survey, we conducted a pilot study as our third study, which was part two in 
demonstrating feasibility of the planned RCT. This chapter reports on the feasibility of all 
study procedures and outcome measures to be conducted successfully in the main study or the 
full-size RCT. This smaller scale study also identified obstacles during the process by 
collecting and assessing the feedback from participating healthcare personnel involved in the 
study, as well as from parents/caregivers of our study participants. We also conducted a 
mechanistic sub-study as part of this pilot study to identify the efficacy of oral corticosteroids 
in the resolution of MEE using tympanometry. We also identified whether the resolution of 
MEE correlates with pain and other AOM-relevant clinical symptoms.   
Chapter 5 – Oral prednisolone for acute otitis media in children: a proposed 
pragmatic, parallel, randomised, double-blind, placebo-controlled study / OPAL 
study (Study 4). 
Our previous studies led us to finalise our protocol for the main study, which is the last study 
in this thesis (Study 4). Our observations in the pilot study for the implementation of study 
procedures and outcome measures, as well as all feedback collected in the pilot study assisted 
us to improve the study design and modify several aspects in the study process to make the 
main study feasible to be successfully conducted in Jakarta, Indonesia or elsewhere. 
Chapter 6 – Conclusions and implications. 
This last chapter describes the key results of each study and brings all the studies together to a 
final conclusion in order to respond to the research questions of the thesis.  This chapter also 
presents the limitations and strengths of the completed studies, which help us to identify the 
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2.1  Summary 
As mentioned in Chapter 1, existing studies have shown inconsistent evidence regarding the 
effects of corticosteroids in improving clinical symptoms of acute otitis media (AOM) in 
children, particularly for reducing pain. To address this, we systematically compiled and 
assessed all available randomised clinical trials (RCTs) which tested systemic corticosteroids 
for AOM in children. Systematic reviews of RCTs are the highest-level of evidence for 
interventions. Therefore, we conducted a Cochrane review of RCTs of children aged six months 
to 12 years with AOM who received either systemic corticosteroids or placebo. We assessed 
the effects of corticosteroids in: (1) improving pain severity, (2) reducing the duration of pain 
and other AOM symptoms, (3) improving middle ear effusion, (4) reducing the complications 
of AOM (e.g., tympanic membrane perforation, mastoiditis), (5) AOM recurrence, and (6) 
adverse effects of corticosteroids.  
This Cochrane review identified two studies of low to very low-quality, meaning the effects of 
systematic corticosteroids on important clinical outcomes in AOM, such as in the resolution of 
ear pain and other AOM symptoms, middle ear effusion, as well as AOM recurrence and 
complications, are uncertain. This review was also not able to provide sufficient information 
on adverse effects of corticosteroids. A large, high-quality clinical trial is therefore required to 
resolve the question.  
However, since the studies in our Cochrane review only included children with severe AOM 
who received antibiotic treatment, the results of the review should be translated to the 
population with severe AOM. Since most AOM cases are mild, it is crucial to identify the 
effectiveness of systemic corticosteroids for children with mild or uncomplicated AOM who 
do not require initial antibiotic treatment. To support this, a clear guideline in diagnosing AOM 
(mild and severe) including evidence-based treatment is required, particularly in the primary 
care setting. 
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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of corticosteroids, with and without antibiotics, for AOM in children.
B A C K G R O U N D
Description of the condition
Acute otitis media (AOM) is a common complication of an acute
respiratory infection (ARI); it mostly affects children aged six to
12 months (Lieberthal 2013; SACHCN 2014).
A 2015 update of a clinical practice guideline on the diagnosis
and management of AOM states that “Clinicians should diagnose
AOM in children who present with moderate-to-severe bulging
of the tympanic membrane or new onset of otorrhoea not due
to acute otitis externa; and may diagnose AOM in children who
present with mild bulging of the tympanic membrane and re-
cent (< 48 hours) onset of ear pain (holding, tugging, rubbing
of the ear in a nonverbal child) or intense erythema of the tym-
panic membrane” (Pichichero 2015). The 2014 New South Wales
Health (Australia) clinical practice guideline defines AOM as an
“acute onset of middle ear inflammation characterised by 1) dis-
tinct otalgia (ear pain) that interferes with normal activity or sleep;
2) bulging tympanic membrane and erythema; and 3) possible
perforation and otorrhoea (ear discharge)” (NSW Health 2014).
In young children aged from six months to three years the overall
incidence of AOM as a complication of ARIs (mostly caused by
rhinovirus and adenovirus) was shown to be 37% in a prospective,
longitudinal cohort study (Chonmaitree 2008). Fifty per cent of
acute symptoms (pain and systemic symptoms) resolve within 24
hours and 80% within 72 hours. Children aged up to two years
often experience more severe and protracted illness (Chonmaitree
2008). Studies from Europe and the US have reported that 62%
of children aged up to 12 months, and 83% of children aged
between one and three years, experience at least one episode of
AOM. Among these children, between 10% and 30% experience
1Systemic corticosteroids for acute otitis media in children (Protocol)
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recurrent AOM, and 2% to 25% experience persistent middle
ear effusion for three months, many requiring ventilation tube
(grommet) insertion (Gribben 2012; Kitamura 2015).
The prevalences of AOM are slightly varied across Asian countries.
In Korea, a 1991 national survey reported a point prevalence of
0.08% for AOM in children aged up to 15 years (Lee 2012); in
Malaysia, 9% of children aged from three months to 12 years
experienced AOM over the previous three years (Tikaram 2012).
A 2005 study in Taiwan found that 13.2% of children aged up to
seven years had experienced AOM (Ting 2012). In East Jakarta,
Indonesia, the point prevalence of AOM in children aged from
two to five years was 5.4% (Umar 2013).
As the risk of AOM increases in the indigenous population, a
cluster survey in Indigenous versus non-Indigenous children in
Australia found that severe otitis media was more prevalent in
Indigenous children (7.9%) compared to non-Indigenous children
(1.7%) (Gunasekera 2007).
Pain is one of the most common and distressing symptoms of
AOM. Many clinical practice guidelines have recommended anal-
gesic (e.g. paracetamol, ibuprofen) as an initial treatment option
for pain management in AOM (Lieberthal 2013; NSW Health
2014; SACHCN 2014). A study on the use of ibuprofen versus
acetaminophen and placebo for the symptoms of AOM in chil-
dren showed no significant differences between treatment groups
in the improvement of tympanic membrane inflammation, rec-
tal temperature, appetite, sleep and playing activity 48 hours af-
ter treatment (Bertin 1996). However, there was a modest bene-
fit of ibuprofen over placebo in reducing pain. There was no sig-
nificant difference between acetaminophen and placebo. Topical
analgesics have limited evidence of efficacy in reducing ear pain
(Foxlee 2011).
Antibiotics are also commonly prescribed in the treatment for
AOM. Antibiotics have a modest effect in reducing pain at two to
three days, with a number needed to treat to benefit (NNTB) of
20 children (Venekamp 2015). Despite using antibiotics, 11% to
19% of children with AOM experience persistent symptoms for
more than six days (Lieberthal 2013). Ear effusions may persist in
30% to 60% of children for up to one month, and in 15% to 25%
of children for up to three months (Chonmaitree 2003). Almost
one-third of these children do not have bacterial growth from
their MEE. One-third of affected children experience recurrence
within a month (Chonmaitree 2003). Nevertheless, the clinical
practice guideline of the American Academy of Pediatrics strongly
recommends antibiotics for children aged six months and older
with bilateral or unilateral AOM and severe signs or symptoms.
Antibiotics are also recommended for children younger than two
years with bilateral AOM without severe signs or symptoms (
Lieberthal 2013).
An alternative strategy for the management of AOM in children
is close observation through follow-up, based on joint decision-
making with the parent or caregiver. However, close observation
requires accessible follow-up and continuity of care (Lieberthal
2013; Pichichero 2015). Observation alone may not be suitable for
high-risk or vulnerable populations such as Indigenous children
in remote settings or those with complications such as cleft palate,
Down syndrome or immunodeficiency syndromes (Morris 2009;
NSW Health 2014).
Other treatments, such as decongestants or antihistamines, are not
recommended for children due to the risk of adverse events and
the lack of benefit. There is limited evidence on the use of de-
congestant/antihistamine combinations for AOM in children: a
Cochrane review found a small statistical benefit from the combi-
nation medication, but the clinical significance was minimal and
the contributing studies may have been biased (Coleman 2008).
However, the 2015 Japanese clinical practice guideline on the di-
agnosis and management of AOM in children recommended use
of complementary nasal treatment for children with AOM asso-
ciated with nasal disease (Kitamura 2015). A study on the use of
intranasal steroid spray (triamcinolone acetonide) for otitis me-
dia with effusion and negative middle ear pressure showed there
was no statistically significant difference in the normalization of
the tympanometric findings between intranasal steroid group and
placebo in six weeks (Gluth 2011). A Cochrane review on the use
of topical intranasal steroids for otitis media effusion in children
also found no evidence of benefit in terms of symptoms (including
ear symptoms that are crucial in the management of AOM) either
at short- or longer-term follow-up (Simpson 2011).
Description of the intervention
Corticosteroids are natural steroid hormones produced by the
adrenal cortex, which can be synthetically manufactured. They
have an important anti-inflammatory role (Gupta 2008), and they
have been used for a wide range of both acute and chronic inflam-
matory illnesses in adults and children (Coutinho 2011).
There are concerns about the possible risks associated with cor-
ticosteroid use, such as increased appetite, weight gain, fluid re-
tention, gastritis, headache, mood swings, increased blood glu-
cose and Addisonian crisis from abrupt stopping of the corticos-
teroid, all of which can occur with protracted use. However, in
general, short-term use (one week or less) does not cause these
harms or require dose-tapering (Deshmukh 2007). A randomised
controlled trial (RCT) of corticosteroids for AOM found no cor-
relation between the emergence of viral infection and corticos-
teroid use (Chonmaitree 2003). A Cochrane review on the use of
systematic corticosteroids for acute sinusitis found no serious side
effects (Venekamp 2014).
How the intervention might work
Persistent middle ear effusion (MEE) after resolution of AOM is
a concern. MEE has been found in 60% to 70% of children two
weeks after successful antibiotic treatment of AOM. Presentation
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decreases to 10% to 25% at three months, but in 5% to 10%
of cases MEE is present one year later (Lee 2012; Lieberthal
2013; Lighthall 2015; Mahadevan 2012; Rosenfeld 2001). One
cause of MEE is dysfunction of the Eustachian tube due to the
inflammation process. The Eustachian tube has an important role
in maintaining ventilation and protecting the middle ear cavity,
and in the drainage of middle ear fluid (Coticchia 2013). MEE
is also caused by dysfunction of the epithelial sodium channel
(ENaC) in controlling the periciliary fluid that is essential for
maintaining a fluid-free middle ear cavity. An in vitro study showed
that interleukin-1β (IL-1β), an important inflammatory cytokine
mostly found in the MEE, inhibits fluid absorption by suppressing
ENaC in various epithelia including airway epithelial cells (Choi
2006; Choi 2007).
Despite the benefits of using antibiotics for some ear infections,
they have several consequences due to bacterial death and the re-
lease of inflammatory bacterial products. This may induce and pro-
long inflammation in the middle ear and lead to otitis media with
effusion (OME) and further episodes of AOM (Principi 2013).
This suggests that the inflammatory mechanism may be involved
in the basic pathogenesis of AOM. This mechanism is induced
by both cellular and chemical mediators in the middle ear. These
mediators (i.e. cytokines, chemokines, mast cells, prostaglandins,
leukotrienes) contribute by altering vascular permeability, increas-
ing mucous glycoprotein secretion and stimulating the chemotaxis
process, epithelial secretion activity and other mediators (Juhn
2008).
Based on this pathogenesis, an intervention that suppresses the
inflammatory process could have an important role in the res-
olution of AOM, including inhibition of the interleukin-1 (IL-
1) and tumour necrosis factor-alpha (TNF-α) early-response cy-
tokines that are commonly found in children. Corticosteroids play
an important role in inhibiting the inflammation process through
genomic and non-genomic mechanisms, including inhibition of
mediators that are involved in middle ear inflammatory processes
(Juhn 2008). An animal study showed that AOM inflammatory
disease generally peaks between three and five days and resolves
by 10 to 14 days (MacArthur 2006). However, a randomised con-
trolled trial (RCT) has shown no significant clinical benefits of
the use of corticosteroids for AOM (Chonmaitree 2003). A tem-
porary improvement in tympanometry in patients who received
corticosteroids suggested the possibility that discontinuation after
a five-day course of corticosteroid induced a rebound effect due to
ongoing middle ear inflammation, which indicated the need for a
longer duration of treatment (Chonmaitree 2003).
Corticosteroids have been found to be effective in some ARIs, for
example when combined with antibiotics for patients with sore
throat (Hayward 2012). A recent study has shown that the use
of oral corticosteroids as an additional treatment to antibiotics
for AOM with discharge through tympanostomy tubes shortened
the duration of otorrhoea (McCormick 2003). However, a few
small trials on the use of corticosteroids as an additional treatment
to antibiotics for AOM in children have reported varied results
(Wang 2007).
As a monotherapy, oral corticosteroids are not effective for adults
with clinically diagnosed acute sinusitis (Venekamp 2014). Never-
theless, when combined with antibiotics, oral corticosteroids may
have a modest beneficial effect (Venekamp 2014). An RCT also
reported no significant difference between oral prednisolone as a
standalone therapy and placebo in hospitalised patients with acute
viral mild-to-moderate wheezing (Panickar 2009). However, as
close observation (without antibiotic administration) is a treat-
ment option for AOM, there is a risk of persistent and recurrent
AOM in some cases, and there is involvement of an inflammatory
mechanism in the middle ear, it is worthwhile identifying the ef-
fects of corticosteroids as a monotherapy for AOM in children.
Why it is important to do this review
The therapeutic options for the management of AOM in chil-
dren are currently unsatisfactory. An effective treatment modality
is needed and systemic corticosteroids may fill that role, either as
a monotherapy or in addition to antibiotics. A recent literature
review concluded that there was insufficient evidence to recom-
mend corticosteroids for AOM (Principi 2013). However, poten-
tially relevant studies were not included in that review and there-
fore there is need for a further systematic assessment (McCormick
2003; Ruohola 1999; Wang 2007). An up to date Cochrane re-
view is warranted to assess the effects of corticosteroids, as another
treatment option, for the treatment of AOM in children.
O B J E C T I V E S
To assess the effects of corticosteroids, with and without antibi-
otics, for AOM in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs).
Types of participants
We will include children aged up to 15 years with AOM. AOM
often correlates with immaturity of the immune system, therefore
we will set the age limit at 15 years because maturation of the B-
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cells involved in the immune system commences at that point and
beyond (McKenna 2001).
AOM is defined as “the rapid onset of ear pain accompanied with
bulging and/or hyperaemic tympanic membrane and the presen-
tation of middle ear effusion” (Lieberthal 2013; Pichichero 2015).
We will include both unilateral and bilateral AOM. Participants
will be included irrespective of the setting from which they were
recruited.
We will exclude children with contraindications to corticosteroid
therapy (e.g. immunodeficient or immunocompromised, or both),
children with anatomic or physiological disorders of the ear or
nasopharynx and those with chronic MEE. We will also exclude
children with ventilation tubes because this procedure is princi-
pally used for non-acute (chronic) otitis media with effusion.
Types of interventions
We will include studies that compare any type of systemic corti-
costeroids (e.g. oral, parenteral) with placebo, either without an-
tibiotics (i.e. corticosteroid versus placebo) or with antibiotics (i.e.
antibiotics plus corticosteroid versus antibiotics plus placebo).
We will exclude studies using any type of topical corticosteroids
(e.g. intranasal).
For symptomatic treatment, patients may have received ac-
etaminophen as an antipyretic and analgesic treatment (Bertin
1996).
Types of outcome measures
Primary outcomes
1. Proportion of children with pain at various time points (24
hours; two to three days; and four to seven days - time points
taken from Venekamp 2015).
2. Reduction of overall or specific symptoms (e.g. ear
discomfort, hearing loss, irritability, sleep disturbance,
diminished appetite). Reduction of overall or specific symptoms
may be measured using visual analogue scales or validated
symptom scales specific to otitis media such as the Acute Otitis
Media Severity of Symptoms Scale (AOM-SOS), Otitis Media
Outcome-22 questionnaire (OMO-22), Otitis Media-6 quality
of life survey (OM-6), or others (Timmerman 2007).
3. Reduction in overall or specific symptom duration.
4. Adverse effects.
Secondary outcomes
1. Changes in tympanometry measurements at various time
points as an objective assessment of the resolution of AOM (e.g.
middle ear pressure, tympanogram curve types).
2. Tympanic membrane perforation.
3. Contralateral otitis (in children with unilateral infection).
4. AOM recurrence, which is defined as the occurrence of
AOM episodes within one month after completion of antibiotic
therapy (Pichichero 2000).
5. Serious complications related to AOM such as mastoiditis
and meningitis.
Search methods for identification of studies
Electronic searches
We will search the following databases from inception to the
present:





5. Web of Science (Thomson Reuters); and
6. LILACS (BIREME).
We will combine the search terms set out in Appendix 1 with
the Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity and precision-maximis-
ing version (2008 revision) (Lefebvre 2011). We will assess whether
we need to apply a filter for retrieving studies in children (Boluyt
2008). This will depend on the number of search results retrieved.
We will not impose language or publication restrictions.
Searching other resources
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP) (
http://apps.who.int/trialsearch/). We will check the reference lists
of all primary studies and review articles for additional references.
We will contact experts in the field to identify additional unpub-
lished materials.
Data collection and analysis
Selection of studies
Three review authors (RR, YP, EDS) will independently screen
the titles and abstracts of all potential studies identified as a result
of the searches. We will retrieve full-text study reports of poten-
tially relevant studies. Three review authors (RR, YP, EDS) will
independently screen the retrieved reports to identify studies for
inclusion and they will record the reasons for exclusion of ineligi-
ble studies. We will resolve disagreements through discussion or, if
required, consult with a third review author (EMB or CDM). We
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will identify and exclude duplicates and collate multiple reports
of the same study so that each study rather than each report is
assessed in the review. We will record the selection process in suf-
ficient detail to complete a PRISMA flow diagram (Moher 2010).
Data extraction and management
We will use a data collection form, which has been piloted on at
least one study in the review, to collate study characteristics and
outcome data. Three review authors (RR, YP, EDS) will indepen-
dently extract study characteristics from included studies. We will
extract the following study characteristics:
1. methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study;
2. participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, inclusion criteria and exclusion
criteria;
3. interventions: intervention, comparison, concomitant
medications and excluded medications;
4. outcomes: primary and secondary outcomes specified and
collected, and time points reported; and
5. notes: funding for trial and notable conflicts of interest of
trial authors.
Three review authors (RR, YP, EDS) will independently extract
outcome data from the included studies. We will note in the ’Char-
acteristics of included studies’ table if outcome data were not re-
ported in a usable way. We will resolve disagreements by consen-
sus. A review author (RR) will input data into the Review Man-
ager software (RevMan 2014). We will double-check that data are
entered correctly by comparing the data presented in the system-
atic review with the study reports. Two review authors (YP, EDS)
will spot-check study characteristics for accuracy against the trial
report.
Assessment of risk of bias in included studies
Three review authors (RR, YP, EDS) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion with another re-
view author (EMB or CDM). We will assess the risk of bias ac-
cording to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We will grade each potential source of bias as high, low or unclear
and we will provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the risk of bias judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes, where necessary. Where information
on risk of bias relates to unpublished data or correspondence with
a trialist, we will note this in the ’Risk of bias’ table.
We will take into account the risk of bias for the studies that
contribute to that outcome when considering treatment effects.
Measures of treatment effect
We will enter the outcome data for each study into the data tables
in RevMan 2014 to calculate the treatment effects. We will use the
risk ratio (RR) with 95% confidence interval (CI) for dichotomous
outcomes and the mean difference (MD) or standardised mean
difference (SMD) for continuous outcomes.
We will undertake meta-analyses only where this is meaningful, i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
Unit of analysis issues
We do not expect any trials in this area to have applied cross-over
or cluster-randomised designs.
For studies with more than two intervention groups, where more
than two of the groups are eligible for this review, we will follow
the methods in theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). That is, in studies with more than
one control group or more than one intervention group, we will
combine the results of the control or intervention groups, respec-
tively.
Dealing with missing data
We will contact trial authors to verify key study characteristics and
to obtain missing numerical outcome data where possible (e.g.
when a study is identified as an abstract only). Where this is not
possible, and the missing data are thought to introduce serious
bias, we will explore the impact of including such studies in the
overall assessment of results using the ’Risk of bias’ assessment.
If numerical outcome data are missing, such as standard devia-
tions (SDs) or correlation coefficients, and they cannot be ob-
tained from the trial authors, we will calculate the missing param-
eters from other available statistics such as P values according to
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). If values are imputed (e.g.
correlation coefficients), rather than calculated, we will perform
sensitivity analyses to assess how sensitive the results are to reason-
able changes in the assumptions that are made in the imputation.
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Assessment of heterogeneity
We will use the Chi² test and the I² statistic to measure heterogene-
ity among the studies in each analysis. If we identify substantial
heterogeneity (over 50% as explained in the Cochrane Handbook
for Systematic Reviews of Interventions; Higgins 2011), we will re-
port this and explore the possible causes by conducting prespeci-
fied subgroup analysis. Nonetheless, we are aware that there is un-
certainty in the I² statistic measurement when there are few studies
in a meta-analysis. In that case, we will use a P value of 0.10 rather
than 0.05 in the Chi² test to determine statistical heterogeneity
(Higgins 2011).
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and exam-
ine a funnel plot to explore possible small study and publication
biases.
Data synthesis
We will pool data from studies that we judge to be clinically homo-
geneous using RevMan 2014, with a fixed-effect model. If a single
true effect is not plausible, due to variation in populations and
interventions or substantial heterogeneity, we will use a random-
effects model instead (DerSimonian and Laird method) (Higgins
2011). If more than one study provides usable data in any sin-
gle comparison, we will perform a meta-analysis. We will analyse
primary outcomes at three time points, namely 24 hours; two to
three days; and four to seven days.
GRADE and ’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
primary outcomes: proportion of children with pain at various
time points (24 hours; two to three days; and four to seven days);
reduction of overall or specific symptoms; reduction in overall or
specific symptom duration; and adverse effects of corticosteroids.
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates to
the studies that contribute data to the meta-analyses for the pre-
specified outcomes (Atkins 2004; GRADE 2004). We will use
the methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), using GRADEproGDT software
(GRADEproGDT 2015). We will justify all decisions to down-
grade or upgrade the quality of studies using footnotes and we will
make comments to aid readers’ understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses if there are
sufficient studies:
1. short- versus long-term use of corticosteroids ( ≤ one week
versus > one week);
2. type of corticosteroids (i.e. prednisolone, dexamethasone,
etc.); and
3. corticosteroids as monotherapy versus adjuvant to
antibiotics.
We will use the Chi² test to test for subgroup interactions in Review
Manager (RevMan 2014).
Sensitivity analysis
We plan to carry out sensitivity analyses by identifying and ex-
cluding studies with high risk of bias or low methodological qual-
ity based on the Cochrane ’Risk of bias’ assessment, if there are
sufficient included studies to make this feasible.
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A B S T R A C T
Background
Acute otitis media (AOM) is a common acute infection in children. Pain is its most prominent and distressing symptom. Antibiotics
are commonly prescribed for AOM, although they have only a modest effect in reducing pain at two to three days. There is insufficient
evidence for benefits of other treatment options, including systemic corticosteroids. However, systemic corticosteroids are potent anti-
inflammatory drugs, and so theoretically could be effective, either alone or as an addition to antibiotics.
Objectives
To assess the effects of systemic corticosteroids (oral or parenteral), with or without antibiotics, for AOM in children.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) which contains the Cochrane ARI Group’s Specialised
Register, MEDLINE (Ovid), Embase (Elsevier), CINAHL (EBSCO), Web of Science (Thomson Reuters), and LILACS (BIREME) for
published studies, and ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform
(ICTRP) for completed and ongoing studies, to 20 February 2018. We checked the reference lists of all primary studies and review
articles for additional references and contacted experts in the field to identify additional unpublished materials.
Selection criteria
We included randomised controlled trials of children with AOM that compared any systemic corticosteroid (oral or parenteral) with
placebo, either with antibiotics (corticosteroid plus antibiotic versus placebo plus antibiotic) or without antibiotics (corticosteroid
versus placebo).
Data collection and analysis
Three review authors (EDS, RR, YP) independently screened the titles and abstracts and retrieved the full texts of potentially relevant
studies. We independently extracted study characteristics and outcome data from the included studies, and assessed the risk of bias for
each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. We assessed study quality using
the GRADE method.
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Main results
We included two studies involving 252 children with AOM aged from three months to six years receiving hospital ambulatory care
who were treated with intramuscular ceftriaxone, and who were then randomised to the corticosteroid group (corticosteroid and
corticosteroid plus antihistamine) or the placebo group (antihistamine and double placebo). In one study, children also had a needle
aspiration of middle ear fluid. Both studies were at unclear risk of bias for allocation concealment, and unclear to high risk of bias for
selective reporting.
One study (N = 179) included pain as an outcome, but we were unable to derive the proportion of children with persistent pain at
Day 5 and Day 14. Reduction of overall or specific symptoms was presented as improvement in clinical symptoms and resolution of
inflamed tympanic membranes without the need for additional antibiotic treatment: at Day 5 (94% of children in the treatment group
(N = 89) versus 89% in the placebo group (N = 90); risk ratio (RR) 1.06, 95% confidence interval (CI) 0.97 to 1.16) and Day 14 (91%
versus 87%; RR 1.05, 95% CI 0.95 to 1.17). Low-quality evidence meant that we are uncertain of the effectiveness of corticosteroids
for this outcome.
The second study (N = 73) reported a reduction of overall or specific symptoms without additional antibiotic treatment during the first
two weeks as a favourable outcome. Children in the treatment group had more favourable outcomes (adjusted odds ratio 65.9, 95%
CI 1.28 to 1000; P = 0.037), although the numbers were small. We were unable to pool the results with the other study because it did
not report the proportion of children with this outcome by treatment group. Only one study reported adverse effects of corticosteroids
(e.g. drowsiness, nappy rash), but did not quantify incidence, so we were unable to draw conclusions about adverse effects. Neither
study reported a reduction in overall or specific symptom duration.
Authors’ conclusions
The evidence for the effect of systemic corticosteroids on AOM is of low to very low quality, meaning the effect of systemic corticosteroids
on important clinical outcomes in AOM remains uncertain. Large, high-quality studies are required to resolve the question.
P L A I N L A N G U A G E S U M M A R Y
Systemic corticosteroids for improving symptoms in children with acute middle ear infection
Review question
We reviewed the evidence on the effects of corticosteroids given by mouth or injection for acute middle ear infection (acute otitis media
(AOM)) in children, particularly in improving symptoms such as ear pain, fever, irritability, lack of sleep, and lack of appetite. We also
looked at the side effects of corticosteroids.
Background
Acute otitis media is common in children and causes ear pain and non-specific symptoms such as fever, irritability, and deafness. It is
often treated with antibiotics, although ear pain generally resolves within two days, and antibiotics help symptoms only slightly. Other
treatments (such as over-the-counter antihistamines and decongestants) do not help very much.
Corticosteroids are often prescribed to reduce inflammation in children for other illnesses, and so may also help symptoms of AOM,
which is an inflammatory process. We investigated whether using corticosteroids was better or worse than nothing in improving AOM-
related symptoms.
Search date
Our evidence is current to 20 February 2018.
Study characteristics
We included two studies involving 252 children with AOM, aged from three months to six years, receiving hospital ambulatory care.
Children were treated with an antibiotic injection and either oral corticosteroid or a placebo (treatment with no effect). In one study,
fluid from the middle ear was collected by inserting a needle through the eardrum to measure the level of inflammation.
Study funding sources
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The National Institutes of Health (NIH) and the National Center for Research Resources, NIH, US Public Health Service funded
both studies. Pharmaceutical companies provided the drug but did not contribute any other scientific or financial support.
Key results and quality of evidence
Corticosteroids did not make a significant difference in improving the symptoms and inflammation of the eardrum(s) at Day 5 and Day
14, but we are unsure of this effect due to the small numbers of children in the studies. There were no significant differences between
the corticosteroid and placebo groups in terms of resolving fluid in children’s middle ears (at 1, 2, and 3 months) and experiencing new
episodes of AOM (at 1, 2, 3 months, and 4 and 6 months). Neither study reported a reduction in the duration of overall or specific
symptoms, rupture of eardrum(s), the occurrence of middle ear inflammation in the other ear following the current ear infection, or
serious complications. Only one study reported the overall side effects identified during the trial (e.g. drowsiness, dry mouth, diaper
rash, nervousness).
We could not draw any conclusions regarding the effects of corticosteroids for AOM in children.
The quality of evidence included in this review was low to very low due to few children included in two small studies. We are uncertain
about whether or not corticosteroids are useful in relieving pain from AOM.
3Systemic corticosteroids for acute otitis media in children (Review)
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B A C K G R O U N D
Description of the condition
Acute otitis media (AOM) is a common complication of acute
respiratory infections. A prospective, longitudinal cohort study
found an overall incidence of 37% over one year for AOM fol-
lowing an acute respiratory infection usually caused by viruses, in
children aged six months to three years (Chonmaitree 2008). Be-
fore the age of three years, approximately 80% of children experi-
ence at least one episode of AOM, mostly affecting those younger
than two years old (Lieberthal 2013; SACHCN 2014; Vergison
2010). Immaturity and the anatomy of the Eustachian tube may
contribute to AOM (SACHCN 2014).
Clinicians commonly diagnose AOM in children who present with
ear pain (holding, tugging, rubbing of the ear in a non-verbal child)
or intense erythema of the tympanic membrane, or moderate-to-
severe bulging of the tympanic membrane, or ear discharge not
from otitis externa (NSW Health 2014; Pichichero 2015).
Acute symptoms (pain and systemic symptoms) resolve in 60% of
children within 24 hours and 80% within 72 hours (Morris 2009;
Venekamp 2015). Children aged up to two years often experience
more severe and protracted illness (Chonmaitree 2008). Studies
have reported that 62% of children aged up to 12 months experi-
ence at least one episode of AOM. Acute otitis media is recurrent
in 10% to 30%, and 2% to 25% of children experience persistent
middle ear effusion for three months, which may require ventila-
tion tube (grommet) insertion to relieve the accompanying deaf-
ness (Gribben 2012; Kitamura 2015).
The prevalence of AOM varies across Asian countries. In Korea,
a 1991 national survey reported a point prevalence of 0.08% for
AOM in children aged up to 15 years (Lee 2012); in Malaysia,
9% of children aged three months to 12 years experienced AOM
over the previous three years (Tikaram 2012). A 2005 study in
Taiwan found that 13.2% of children aged up to seven years had
experienced AOM (Ting 2012). In East Jakarta, Indonesia, the
point prevalence of AOM in children aged less than 18 years was
5.4% (Umar 2013).
The risk of AOM is high in Australian indigenous populations:
a cluster survey in Indigenous versus non-Indigenous children
found that severe otitis media was more prevalent in Indigenous
children (7.9%) compared to non-Indigenous children (1.7%)
(Gunasekera 2007).
Pain is the most common symptom of AOM. Guidelines rec-
ommend analgesics such as paracetamol or ibuprofen (Lieberthal
2013; NSW Health 2014; SACHCN 2014). Analgesics have
been trialed against placebo in AOM, with ibuprofen (7% versus
25.3%; risk ratio (RR) 0.28, 95% confidence interval (CI) 0.11
to 0.71) and paracetamol (9% versus 25.3%; RR 0.38, 95% CI
0.17 to 0.85) both significantly reducing ear pain 48 hours after
treatment (Bertin 1996; Bradley-Stevenson 2007). However, there
is insufficient evidence of efficacy for topical analgesics reducing
ear pain in AOM (Foxlee 2011).
Antibiotics are also commonly prescribed in the treatment of
AOM. Antibiotics have a modest effect in reducing pain at two to
three days, with a number needed to treat for an additional ben-
eficial outcome (NNTB) of 20 children (Venekamp 2015), and
yet 11% to 19% of children still experience symptoms to Day 6
(Chonmaitree 2003; Lieberthal 2013). Antibiotics have no effect
on deafness caused by middle ear effusion, which persists in 30%
to 60% of children one month following AOM, and three months
in 15% to 25% (Chonmaitree 2003).
Recurrent AOM after an initial attack is common, with about
one-third of children experiencing recurrence within a month (
Chonmaitree 2003).
Antibiotics are not considered mandatory. An alternative strategy
is observation (Lieberthal 2013; Pichichero 2015).
There is limited evidence for the use of decongestant/antihis-
tamine combinations for AOM in children: a Cochrane Review
found a small statistical benefit from the combination medication,
but the clinical significance was minimal and the contributing
studies may have been biased (Coleman 2008).
Description of the intervention
Corticosteroids are natural steroid hormones produced by the
adrenal cortex, which can be synthetically manufactured. Cor-
ticosteroids have many physiological effects, including an anti-
inflammatory role (Gupta 2008), which is exploited for many
acute and chronic inflammatory illnesses in adults and children
(Coutinho 2011).
How the intervention might work
The pathophysiology of AOM is complex. However, inflamma-
tion is an important mechanism. This mechanism is induced
by both cellular and chemical mediators, such as cytokines,
chemokines, mast cells, prostaglandins, and leukotrienes (Juhn
2008). Corticosteroids could act by suppressing inflammation.
Corticosteroids are effective in some other acute respiratory infec-
tions, for example when combined with antibiotics for sore throat
(Hayward 2012), acute sinusitis (Venekamp 2014), and acute bac-
terial meningitis (Brouwer 2015). A Cochrane Review on the use
of topical intranasal steroids for otitis media effusion in children
found no evidence of benefit in terms of symptom relief (including
ear symptoms that are crucial in the management of AOM) either
at short- or longer-term follow-up (Simpson 2011).
Several studies have investigated corticosteroids for chronic otitis
media with effusion (OME). A Cochrane Review on the use of
topical intranasal steroids for OME in children found no evidence
of benefit in improving ear symptoms, either at short- or longer-
term follow-up (Simpson 2011). However, a recent randomised
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controlled trial on the use of oral steroids, with and without in-
tranasal steroids, compared to watchful waiting in children with
OME demonstrated that fewer children had incomplete resolu-
tion or persistent middle ear effusion, or both, with corticosteroids
compared with the watchful-waiting group at six weeks after treat-
ment, but not in the longer term (three to nine months) (Hussein
2017). These findings demonstrate that corticosteroids may work
for middle ear inflammation.
There are theoretical risks associated with corticosteroids, espe-
cially with long-term use, including Addisonian crisis after stop-
ping treatment abruptly. However, short-term use (≤ 1 week) has
not been found to cause adverse effects, nor require dose-tapering
(Chonmaitree 2003; Deshmukh 2007; Venekamp 2014).
Why it is important to do this review
Antibiotics for treating AOM in children are weakly effective, but
are used very often in the absence of a more effective treatment.
Treatment with antibiotics also risks antibiotic resistance. Alter-
native, more effective treatments are therefore needed. Systemic
corticosteroids may fill that role, either as a monotherapy or in
addition to antibiotics. However, there is insufficient evidence
to support corticosteroid treatment for AOM (Principi 2013). A
Cochrane Review is important to assess studies that have not been
systematically reviewed.
O B J E C T I V E S
To assess the effects of systemic corticosteroids (oral or parenteral),
with and without antibiotics, for AOM in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included children aged up to 15 years with AOM (this upper
age being the limit for adolescence) (UNICEF 2011).
We defined AOM as “...the rapid onset of ear pain accompanied
with bulging and/or hyperaemic tympanic membrane and the
presentation of middle ear effusion” (Lieberthal 2013; Pichichero
2015). We included both unilateral and bilateral AOM. We in-
cluded children from all recruitment settings.
We excluded children with contraindications to corticosteroid
therapy (e.g. immunodeficient or immunocompromised); chil-
dren with anatomic or physiological disorders of the ear (includ-
ing those with ventilation tubes, because this procedure is princi-
pally used for non-acute (chronic) otitis media with effusion) or
nasopharynx; and those with chronic middle ear effusion.
Types of interventions
We included studies that compared any type of systemic corticos-
teroid (e.g. oral or parenteral) with placebo, either without antibi-
otics (i.e. corticosteroid versus placebo) or with antibiotics (i.e.
corticosteroid plus antibiotic versus placebo plus antibiotic).
We excluded studies using topical corticosteroid such as intranasal
spray.
Participants could have used paracetamol as an antipyretic anal-
gesic (Bertin 1996).
Types of outcome measures
Primary outcomes
1. Proportion of children with pain at various time points (24
hours; 2 to 3 days; and 4 to 7 days (time points taken from
Venekamp 2015)).
2. Reduction of overall or specific symptoms (e.g. ear
discomfort, hearing loss, irritability, sleep disturbance,
diminished appetite). Reduction of overall or specific symptoms
may have been measured using visual analogue scales or validated
symptom scales specific to otitis media such as the Acute Otitis
Media Severity of Symptoms Scale (AOM-SOS), Otitis Media
Outcome-22 questionnaire (OMO-22), Otitis Media-6 quality
of life survey (OM-6), or others (Timmerman 2007).
3. Reduction in overall or specific symptom duration.
4. Adverse effects.
Secondary outcomes
1. Changes in tympanometry measurements at various time
points as an objective assessment of the resolution of AOM (e.g.
middle ear pressure, tympanogram curve types).
2. Tympanic membrane perforation. This is considered to be a
mild complication of AOM (Principi 2017), usually
spontaneously healing in a few days (four to six days) (Principi
2017; Slovik 2008).
3. Contralateral otitis (in children with unilateral infection).
4. AOM recurrence, which was defined as the occurrence of
AOM episodes within one month after completion of antibiotic
therapy (Pichichero 2000).
5. Serious complications related to AOM such as mastoiditis
and meningitis.
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Search methods for identification of studies
Electronic searches
We searched the following databases up to 20 February 2018:
• Cochrane Central Register of Controlled Trials, which
contains the Cochrane ARI Group’s Specialised Register,
(CENTRAL; Issue 1, 2018, in the Cochrane Library) using the
strategy in Appendix 1;
• MEDLINE via Ovid (from 1946 to 20 February 2018)
using the strategy in Appendix 2;
• EMBASE via Elsevier (from 1974 to 20 February 2018)
using the strategy in Appendix 3;
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature) via EBSCO (from 1981 to 20 February 2018) using
the strategy in Appendix 4;
• Web of Science via Thomson Reuters (from 1900 to 20
February 2018) using the strategy in Appendix 5; and
• LILACS (Latin American and Caribbean Literature in
Health Sciences) via BIREME (from 1985 to 20 February 2018)
using the strategy in Appendix 6.
We searched the following trials registries on 20 February 2018:
• ClinicalTrials.gov (www.clinicaltrials.gov); and
• the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) (apps.who.int/
trialsearch/).
We did not restrict results by language or publication status (pub-
lished, unpublished, in press, or in progress).
We combined the MEDLINE (Ovid) search strategy (Appendix
2) with the Cochrane Highly Sensitive Search Strategy to iden-
tify randomised trials in MEDLINE: sensitivity and precision-
maximising version (2008 revision) (Lefebvre 2011). We adapted
these search terms to search other databases (Embase, CENTRAL,
CINAHL, Web of Science and LILACS). We planned to assess
whether we would need to apply a filter for retrieving studies in
children (Boluyt 2008). (This was not required because searches
identified relatively few records). We imposed no language or pub-
lication restrictions.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We contacted experts in the field
to identify additional unpublished materials.
Data collection and analysis
Selection of studies
Three review authors (EDS, RR, YP) independently screened the
titles and abstracts of all studies identified by the searches. We re-
trieved full-text study reports of potentially relevant studies. Three
review authors (EDS, RR, YP) independently screened the re-
trieved reports to identify studies for inclusion, and the reasons for
exclusion of ineligible studies were recorded. Any disagreements
were resolved through discussion and consulting with a fourth re-
view author (EMB). We identified and excluded duplicates and
collated multiple reports of the same study so that each study,
rather than each report, was assessed in the review. We recorded
the selection process in sufficient detail to complete a PRISMA
flow diagram (Moher 2010).
Data extraction and management
We used a data collection form that had been piloted to col-
late study characteristics and outcome data. Three review authors
(EDS, RR, YP) independently extracted study characteristics from
the included studies. We extracted the following study character-
istics:
1. methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study;
2. participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, inclusion criteria, and exclusion
criteria;
3. interventions: intervention, comparison, concomitant
medications, and excluded medications;
4. outcomes: primary and secondary outcomes specified and
collected, and time points reported; and
5. notes: funding for the trial and notable conflicts of interest
of trial authors.
We noted if outcome data were not reported in a usable way in the
Characteristics of included studies table. Any disagreements were
resolved by consensus. A review author (RR) entered data into
Review Manager 5 (Review Manager 2014). We double-checked
that data were entered correctly by comparing data presented in
the systematic review with the study reports. Two review authors
(EDS, YP) spot-checked study characteristics for accuracy against
the trial report.
Assessment of risk of bias in included studies
Three review authors (EDS, RR, YP) independently assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements were resolved by discussion with another re-
view author (EMB). We assessed the risk of bias according to the
following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
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5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised the
’Risk of bias’ judgements across different studies for each of the
domains listed. We considered blinding separately for different
key outcomes where necessary. Where information on risk of bias
related to unpublished data or correspondence with a trialist, we
noted this in the ’Risk of bias’ table.
We took into account the risk of bias for the studies that con-
tributed to that outcome when considering treatment effects.
Measures of treatment effect
We entered outcome data for each study into data tables in Review
Manager 5 to calculate the treatment effects (Review Manager
2014). We intended to use the risk ratio (RR) with 95% confi-
dence interval (CI) for dichotomous outcomes and the mean dif-
ference (MD) or standardised mean difference (SMD) for contin-
uous outcomes. Because several outcomes were incompletely re-
ported or unavailable for pooling, we did not undertake meta-anal-
ysis. Nonetheless, we used RR with 95% CI in reporting both our
primary and secondary outcomes reported by one study (i.e. the
proportion of children with pain, reduction of overall or specific
symptoms, changes in tympanometry measurements, and AOM
recurrence at various time points).
Unit of analysis issues
We did not expect any trials to have applied cross-over or cluster-
randomised designs.
For studies with more than two intervention groups, where more
than two groups were eligible for our review, we planned to fol-
low the methods in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), that is in studies with more than
one control group or more than one intervention group, we would
combine the results of the control or intervention groups, respec-
tively.
Dealing with missing data
We contacted trial authors to verify key study characteristics and to
obtain missing numerical outcome data (i.e. numbers of children
in each group for several outcomes). However, the trial authors
were unable to provide these data.
We were unable to locate missing numerical outcome data such
as standard deviations or correlation coefficients. We thus did not
calculate the missing parameters from other available statistics such
as P values according to the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We did not impute values (e.g. correlation coefficients), therefore
we did not perform sensitivity analyses to assess how sensitive the
results were to reasonable changes in the assumptions that were
made in the imputation.
Assessment of heterogeneity
We planned to use the Chi² test and I² statistic to measure het-
erogeneity among the studies in each analysis. If we identified
substantial heterogeneity (over 50% as specified in the Cochrane
Handbook for Systematic Reviews of Interventions) (Higgins 2011),
we would report this and explore the possible causes by conducting
prespecified subgroup analysis. We were aware that when there are
few studies in a meta-analysis there is uncertainty in the I² statistic
measurement. In such case, we planned to use a P value of 0.10
rather than 0.05 in the Chi² test to determine statistical hetero-
geneity (Higgins 2011). However, due to insufficient numbers of
studies and available outcome data, we were unable to pool the
included studies and assess their heterogeneity.
Assessment of reporting biases
We had planned to use funnel plots to explore possible small-study
and publication biases if we were able to pool more than 10 trials.
However, the small number of included studies precluded this.
Data synthesis
We had planned to pool data from studies that we judged to be clin-
ically homogeneous using Review Manager 5 (Review Manager
2014), employing a fixed-effect model. If a single true effect was
not plausible due to variation in populations and interventions or
substantial heterogeneity, we would use a random-effects model
instead (DerSimonian and Laird method) (Higgins 2011). If more
than one study provided usable data in any single comparison,
we would perform a meta-analysis. However, we could not do so
because there were only includable data from one study.
GRADE and ’Summary of findings’ table
We had planned to create a ’Summary of findings’ table using the
following primary outcomes: proportion of children with pain at
various time points (24 hours; 2 to 3 days; 4 to 7 days); reduction
of overall or specific symptoms; reduction in overall or specific
symptom duration; and adverse effects of corticosteroids. How-
ever, due to insufficient available outcome data, we were only able
to report one primary outcome, that is reduction of overall or spe-
cific symptoms.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence as it relates to the studies
that contribute data to the meta-analyses for the prespecified out-
comes (Atkins 2004; GRADE 2004). We used the methods and
recommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
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2011), employing GRADEpro GDT software (GRADEpro GDT
2014). We justified all decisions to downgrade or upgrade the qual-
ity of studies using footnotes and made comments to aid readers’
understanding of the review.
Subgroup analysis and investigation of heterogeneity
We had planned to carry out the following subgroup analyses using
the Chi² test to test for subgroup interactions (Review Manager
2014):
1. short- versus long-term use of corticosteroids ( ≤ 1 week
versus > 1 week);
2. type of corticosteroids (i.e. prednisolone, dexamethasone,
etc.); and
3. corticosteroids as monotherapy versus adjuvant to
antibiotics.
However, the small number of included studies precluded this.
Sensitivity analysis
We had planned to carry out sensitivity analyses by identifying
and excluding studies with high risk of bias or low methodological
quality based on the Cochrane ’Risk of bias’ assessment. However,
the small number of included studies precluded this.
R E S U L T S
Description of studies
Results of the search
We retrieved 1250 records from electronic databases and 21
records from clinical trial registry searches (Figure 1). After re-
moving duplicates, three review authors (EDS, RR, YP) indepen-
dently assessed 868 records based on titles and abstracts, and then
reviewed the full-text reports. After reviewing the full-text reports
based on the eligibility criteria, we identified 35 articles. We ex-
cluded 33 articles: one included only adults (Arusgamov 1966);
one included children with tympanostomy tubes (Ruohola 1999);
13 included chronic otitis media (Califano 2014; Chinski 2003;
Choung 2008; Daly 1991; Endo 1997; Hearey 1990; Hussein
2017; Persico 1978; Puhakka 1985; Saffar 2001; Schwartz 1979;
Schwartz 1981; Woodhead 1986); four included non-systemic
corticosteroids (Cajgfinger 1967; Chirileanu 1978; Martin 1975;
Terjung 1967); 13 included non-RCTs (Albernaz 2001; Capella
1984; Carvalho 1984; Crysdale 1984; Fradis 1983; Han 2009;
Matsubara 2007; Oppenheimer 1968; Pulkki 2006; Rosenfeld
1992; Roydhouse 1978; Seehusen 2012; Sergienko 1975); and
one did not include a placebo (Wang 2007).
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Figure 1. Study flow diagram.
12Systemic corticosteroids for acute otitis media in children (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[46]
We included two studies in the review (Chonmaitree 2003;
McCormick 2003).
Included studies
We included two studies with a total of 252 children with AOM
(Chonmaitree 2003; McCormick 2003). We contacted both trial
authors and obtained additional information regarding the ran-
domisation and allocation concealment procedures, and the blind-
ing of the outcome assessors for these two studies. Methods, par-
ticipants, interventions, and outcomes of the included studies are
presented in the Characteristics of included studies table.
Design
Chonmaitree 2003 and McCormick 2003 were 2 x 2 factorial,
double-blind, randomised, placebo-controlled trials.
Participants and settings
Chonmaitree 2003 and McCormick 2003 included 198 and 80
children, respectively, aged from three months to six years with
AOM. Both studies analysed children who had at least 70% ad-
herence to the treatment measured by diary entries, weight of
medicine bottles, and the availability of outcome data on the sec-
ond visit and subsequent other visits. Chonmaitree 2003 analysed
179 of 198 children, and McCormick 2003 analysed 73 of 80
children due to their adherence to the trial. We therefore analysed
these studies based on available cases instead of intention-to-treat.
The two studies had similar exclusion criteria. Children were ex-
cluded if they had:
• anatomic or physiologic ear and/or nasopharyngeal defects;
• major medical or immunology disorders;
• current treatment with other medication;
• antibiotic use in the previous week;
• history of allergy to cephalosporin drugs;
• tympanostomy tube or perforated tympanic membrane;
• previous exposure to chickenpox in preceding three weeks.
Both studies were conducted at the paediatric outpatient clinic of
the University of Texas Medical Branch at Galveston, USA.
The main difference between the studies was that McCormick
2003 performed tympanocentesis to measure the level of histamine
and leukotriene B (LTB4) in the middle ear in all children, whereas
Chonmaitree 2003 did not. Because all children in McCormick
2003 underwent tympanocentesis, any confounding effect of this
procedure was eliminated. However, the potential pain relief ef-
fect of tympanocentesis, which might modify outcomes for both
groups, made McCormick 2003 more difficult to generalise.
Interventions and comparators
Children in both Chonmaitree 2003 and McCormick 2003 were
randomly allocated to one of four groups:
1. corticosteroid (prednisolone 2 mg/kg/day) and placebo;
2. antihistamine (chlorpheniramine maleate 0.35 mg/kg/day)
and placebo;
3. corticosteroid plus antihistamine;
4. two placebos of corticosteroid and antihistamine.
All medicines were given in three divided doses for five days, in-
cluding the placebos, which were matched with prednisolone and
chlorpheniramine maleate for their colour and taste. Following the
methods in theCochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011), we therefore combined the results of these
groups into corticosteroid group (corticosteroid and the combi-
nation of corticosteroid and antihistamine groups) and placebo
group (antihistamine and double placebo groups). All children in
these studies received a single-dose antibiotic intramuscular injec-
tion of ceftriaxone (50 mg/kg) at the baseline visits.
Outcomes
Chonmaitree 2003 reported the main outcomes as:
1. the rate of treatment failure during the first two weeks (Day
5 and Day 14);
2. duration of middle ear effusion (1, 2, and 3 months); and
3. rate of recurrence of AOM (at 1, 2, 3, and 4 to 6 months).
Treatment failure was defined as the persistence of any clinical
symptom(s) and the inflammation of tympanic membrane requir-
ing antibiotic treatment. Chonmaitree 2003 also reported the re-
duction of symptoms and signs severity score during the first two
weeks, persistent middle ear effusion measured using pneumatic
otoscope and tympanometry during the first three months, and
the side effects (i.e. drowsiness, dry mouth, excitability, diaper
rash, increased or decreased urine amount) measured using symp-
tom diaries. Recorded symptoms consisted of nine clinical symp-
toms that were scored ranging from zero (no symptom), one (mild
symptom) to two (severe symptom). The symptoms were: fever
(> 38 °C rectally), ear pain, irritability, poor feeding, rhinorrhoea,
nasal stuffiness, cough, sneezing, and watery eyes. The severity of
the signs was measured and scored based on the otoscopic exam-
ination of three characteristics of the tympanic membrane: po-
sition, colour/transparency, and mobility of the tympanic mem-
brane. Each sign was scored ranging from zero (normal, shiny) to
two (bulging, red/yellow, immobile) with a maximum score of six.
McCormick 2003 assessed:
1. clinical outcome (improvement or failure) at visit 2 (Day 4
to Day 6) and visit 3 (Day 14) and bacterial outcome at visit 2;
2. the changes of histamine and leukotriene B4 (LTB4) of the
middle ear fluid taken by tympanocentesis at the baseline and
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visit 2 (Day 4 to Day 6);
3. the duration of middle ear effusion; and
4. AOM recurrence during the first four months.
Clinical improvement was defined as an improvement in clinical
symptoms, clinical signs (reduced/absent of redness and bulging of
tympanic membrane), and no drainage of middle ear fluid. Clin-
ical failure was defined as persistent clinical symptoms and signs
indicated by redness and bulging of tympanic membrane, puru-
lent drainage of middle ear, with or without a positive bacterial
culture. Bacterial failure was defined as the persistence of pathogen
bacterial from middle ear fluid collected at visit 2 and the require-
ment of another cycle of antibiotic treatment. Children were con-
sidered to have a satisfactory or favourable total outcome if they
experienced clinical improvement at visit 2 and visit 3 without
bacterial failure and did not require antibiotic treatment during
the first two weeks.
Funding sources
Both Chonmaitree 2003 and McCormick 2003 were funded by
National Institutes of Health (NIH) Grant R01 DC 2620 and
National Center for Research Resources, NIH, US Public Health
Service (USPHS) Grant M01 RR 00073. The prednisolone oral
liquid was supplied by Fisons Pharmaceuticals, Rochester, NY, and
the chlorpheniramine maleate was supplied by Schering-Plough,
Kenilworth, NJ. There was no other scientific or financial contri-
bution from these pharmaceutical companies.
Excluded studies
We excluded 33 studies (Characteristics of excluded studies):
• one included only adults (Arusgamov 1966);
• one included children with tympanostomy tubes (Ruohola
1999);
• 13 included chronic otitis media (Califano 2014; Chinski
2003; Choung 2008; Daly 1991; Endo 1997; Hearey 1990;
Hussein 2017; Persico 1978; Puhakka 1985; Saffar 2001;
Schwartz 1979; Schwartz 1981; Woodhead 1986);
• four included non-systemic corticosteroids (Cajgfinger
1967; Chirileanu 1978; Martin 1975; Terjung 1967);
• one did not include a placebo (Wang 2007);
• 13 included non-RCTs (Albernaz 2001; Capella 1984;
Carvalho 1984; Crysdale 1984; Fradis 1983; Han 2009;
Matsubara 2007; Oppenheimer 1968; Pulkki 2006; Rosenfeld
1992; Roydhouse 1978; Seehusen 2012; Sergienko 1975).
Risk of bias in included studies
Overall, the risk of bias in the included studies was unclear to
high (see Figure 2 and Figure 3). The two concerning biases were:
1) unclear description of allocation concealment, and 2) unclear
to high risk of selective reporting due to insufficient information
provided in published papers and clinical trial registries and un-
availability of the trial protocols. McCormick 2003 reported the
favourable total outcomes during the first two weeks as a P value,
adjusted odds ratio, and 95% confidence intervals, and not as the
proportion of children who had favourable or unfavourable total
outcome by their treatment groups (Characteristics of included
studies). However, both studies had unclear to high risk of bias for
other domains, and we therefore assessed both studies at high risk
of bias overall (Chonmaitree 2003; McCormick 2003).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Neither study clearly described the randomisation process and the
allocation concealment. We contacted the trial authors and were
informed that the randomisation in both studies used computer-
generated block randomisation. There was no clear description
regarding allocation concealment. Based on information provided
by the trial author, only the statistician who generated the ran-
domisation schedule knew the code, but it is unclear whether
this was a group code or individual codes. We therefore assessed
both studies as at unclear risk of bias for allocation concealment
(Chonmaitree 2003; McCormick 2003).
Blinding
In Chonmaitree 2003 and McCormick 2003, the parents/care-
givers and the examining clinicians were unaware of the type of
treatment allocation. Furthermore, placebos for both corticos-
teroid and antihistamine were prepared similarly to the active
medicine based on colour and taste. This blinding method also
prevented the children and their parents/caregivers from being
aware of the treatment that they had received. This information
was not provided in the papers, and was obtained by contacting the
trial authors. We therefore graded this as low risk for performance
bias and detection bias (blinding of participants, personnel, and
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In Chonmaitree 2003, of 198 children who were enrolled and ran-
domised, 179 children (90.4%) were analysed for the outcomes;
in McCormick 2003, of 80 children, 73 children (91.2%) were
analysed for the outcomes. The requirement for being included in
final analyses was at least 70% adherence to the treatment mea-
sured by the diary, the weight of medicine bottles, and the avail-
ability of the outcome data on the second visit and after. Based
on the low rate of missing outcome data due to non-compliance
to the study (< 10%), which was found to be mostly even in each
treatment group, we graded this as low risk for attrition bias or
incomplete outcome data.
Selective reporting
We were unable to retrieve the protocols for either study. Although
both were registered on a clinical trial registry, there was no infor-
mation regarding the primary or the secondary outcomes for both
studies. In addition, McCormick 2003 did not provide the results
of clinical outcome at visit 2 and visit 3. We therefore judged
Chonmaitree 2003 as at unclear risk and McCormick 2003 as at
high risk for reporting bias or selective reporting.
Other potential sources of bias
We identified no other potential sources of bias. We contacted
the trial authors (Chonmaitree 2003; McCormick 2003), who
declared that there was no scientific or financial contribution from
the pharmaceutical industry. We therefore judged this domain as
at low risk of bias.
Effects of interventions
See: Summary of findings for the main comparison Systemic
corticosteroids compared to placebo for children with acute otitis
media
Primary outcomes
1. Proportion of children with pain at various time points
Chonmaitree 2003 recorded pain as one of nine clinical symp-
toms. However, the trial authors only reported the proportion of
children with pain before treatment (at the baseline visit) and not
the proportion of children with pain after treatment. We contacted
the trial authors but they could not provide the data (the study
was conducted 15 years ago).
2. Reduction of overall or specific symptoms
Chonmaitree 2003 recorded nine clinical symptoms: fever > 38
°C rectally, ear pain, irritability, poor feeding, rhinorrhoea, nasal
stuffiness, cough, sneezing, and watery eyes, based on three grad-
ing scores. The author only reported the proportion of children
with pre-treatment symptoms in each group. The post-treatment
symptoms were reported as overall results of reduction in symptom
severity score and otoscopic sign scores. There were no significant
differences between groups at each follow-up visit. We contacted
the trial authors but they could not provide the data.
Chonmaitree 2003 reported clinical failure as a main outcome at
various time points: visit 2 (Day 5) and visit 3 (Day 14). We con-
verted the outcome to clinical improvement in order to represent
the reduction of overall or specific symptoms. At visit 2, there
were 84 children in the corticosteroid group (N = 89) compared
to 80 children in the placebo group (N = 90) with improvement
of clinical symptom(s) and otoscopic signs of AOM (94% versus
89%; risk ratio (RR) 1.06, 95% confidence interval (CI) 0.97 to
1.16), whilst at visit 3, there were 81 children in the corticosteroid
group compared to 78 children in the placebo group (91% versus
87%; RR 1.05, 95% CI 0.95 to 1.17; Analysis 1.1). Although
these results reflected the benefit of corticosteroids, there were no
statistically significant differences between the two groups at these
time points.
McCormick 2003 defined favourable total outcome as the im-
provement of clinical outcomes (e.g. reduced or absence of tym-
panic membrane inflammation, no ear discharge) at visit 2 (Day
4 to Day 6) and visit 3 (Day 14) without bacterial finding in
the middle ear fluid at visit 2, without the need for additional
antibiotic treatment during the first two weeks. The favourable
total outcome was more likely to be found in the corticosteroid
group compared to other groups (adjusted odds ratio 65.9, 95%
CI 1.28 to 1000; P = 0.037). As the trial author did not report the
proportion of children who had favourable total outcome in the
other groups (i.e. corticosteroid plus antihistamine group, corti-
costeroid plus placebo group, antihistamine plus placebo group,
double placebo group), we could not pool the data from this study
with Chonmaitree 2003.
We rated the evidence from these studies as low quality due to seri-
ous risk of bias (unclear description of the allocation concealment)
and indirect results, which was caused by the difference between
the outcome of interest (i.e. reduction of overall or specific symp-
toms) and the outcomes reported (i.e. combination of persistent
clinical symptom(s) and signs of inflammation of the tympanic
membrane(s) that required another cycle of antibiotic treatment)
(Summary of findings for the main comparison). Systemic cor-
ticosteroids may therefore make little or no difference to clinical
outcomes.
3. Reduction in overall or specific symptom duration
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Neither included trial reported the reduction in overall or specific
symptom duration.
4. Adverse effects
Chonmaitree 2003 recorded unfavourable effects in symptom di-
aries daily. However, the trial authors reported adverse effects as
overall side effects across all groups: drowsiness (22% to 34%), dry
mouth (16% to 27%), increased urine amount (14% to 27%),
nappy rash (7% to 32%), nervousness (7% to 20%), and decreased
urine amount (0% to 11%). No correlation was reported between
the use of corticosteroid and the risk of viral infection by compar-
ing the persistence and the occurrence of new viral infections in
the two weeks following the baseline visit. We contacted the trial
authors, but outcome data by individual group were not available.
Secondary outcomes
1. Changes in tympanometry measurements at various time
points
Chonmaitree 2003 represented changes in tympanometry mea-
surement at various time points as the proportion of children with
persistent middle ear effusion measured by pneumatic otoscope
and tympanometry. We converted this to the proportion of chil-
dren who had resolution of middle ear effusion. Resolution of
middle ear effusion was reported at three different time points as
follows: at one month, 45 children in the corticosteroid group (N
= 89) versus 38 children in the placebo group (N = 90) (50% versus
42%; RR 1.20, 95% CI 0.87 to 1.64); at two months, 62 versus
52 children in the corticosteroid and placebo groups, respectively
(70% versus 58%; RR 1.21, 95% CI 0.96 to 1.51); and at three
months, 61 versus 61 children in the corticosteroid and placebo
groups, respectively (76% versus 68%; RR 1.13, 95% CI 0.94
to 1.35; Analysis 1.2). None of these results showed statistically
significant differences between the two groups. McCormick 2003
did not report this outcome.
We rated this evidence as very low quality due to serious risk of
bias from unclear allocation concealment; imprecision because the
CI included both the possibility of resolution and persistent mid-
dle ear effusion during these time points; and indirect results due
to the difference between the outcome of interest (i.e. changes in
tympanometry measurements) and those reported (i.e. proportion
of children with persistent middle ear effusion). It therefore re-
mains uncertain whether systemic corticosteroids improve middle
ear effusion.
2. Tympanic membrane perforation
Neither included trial reported tympanic membrane perforation.
3. Contralateral otitis (in children with unilateral infection)
Neither included trial reported contralateral otitis.
4. AOM recurrence
Chonmaitree 2003 reported recurrence cumulatively during the
six-month period of follow-up: at one month, there were 15 chil-
dren in the corticosteroid group versus 12 children in the placebo
group with recurrence of AOM (17% versus 13%; RR 1.26, 95%
CI 0.63 to 2.55); at two months, 20 versus 24 children in cor-
ticosteroid and placebo groups, respectively (22% versus 27%;
RR 0.84, 95% CI 0.50 to 1.41); at three months, 19 versus 29
children in corticosteroid and placebo groups, respectively (21%
versus 32%; RR 0.66, 95% CI 0.40 to 1.09); and at four to six
months, 33 and 36 children in corticosteroid and placebo groups,
respectively (37% versus 40%; RR 0.93, 95% CI 0.64 to 1.34;
Analysis 1.3).
McCormick 2003 reported that there were no statistically signifi-
cant differences in terms of AOM recurrence at the first or fourth
month between the groups.
We rated this evidence as low quality due to serious risk of bias
from unclear allocation concealment and imprecise results. The
wide CIs may include favourable and unfavourable effects of cor-
ticosteroids on AOM recurrence. It is therefore uncertain whether
corticosteroids improve or reduce the recurrence of AOM.
5. Serious complications
Neither included trial reported serious complications.
D I S C U S S I O N
Summary of main results
We included two small randomised, double-blind, placebo-con-
trolled studies with a total of 252 participants (Chonmaitree 2003;
McCormick 2003). Low- to very low-quality evidence demon-
strated that corticosteroids did not make a significant difference in
improving clinical outcomes (e.g. symptoms, inflammation of the
eardrum), resolution of middle ear effusion, and AOM recurrence.
However, we are uncertain of these results due to wide confidence
intervals around the estimates.
Although McCormick 2003 reported a significant difference be-
tween the children in the corticosteroid and placebo groups who
had clinical improvement during the first two weeks, we were un-
able to meta-analyse the results due to insufficient information
from the published paper and incompleteness of outcome report-
ing. This study also reported that there was no significant differ-
ence between corticosteroid and placebo groups in AOM recur-
rence at the first or fourth month.
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Adverse effects, as one of our primary outcomes, was reported
by Chonmaitree 2003 as an overall result (i.e. drowsiness, ner-
vousness, dry mouth, diaper rash, increased and decreased urine
amount) but not by treatment group. Neither of the included
studies reported reduction of overall or specific symptom dura-
tion, tympanic membrane perforation, contralateral otitis, or se-
rious complications related to AOM.
Overall completeness and applicability of
evidence
All participating children in both studies received antibiotics at
their baseline visits; this was because only children with high-risk
AOM were included in Chonmaitree 2003, but no reason was
provided for McCormick 2003. These results are therefore best
generalised to children with high-risk AOM.
Pain is one of the most common symptoms of AOM and is dis-
tressing for both children and their parents. Although for more
than 50% of children with AOM, symptoms resolve within 24
hours with or without antibiotic treatment, almost one-fifth of
children with AOM treated with antibiotics have symptoms that
persist for up to six days (Chonmaitree 2003; Venekamp 2015).
To date, physicians tend to prescribe medication for AOM to re-
lieve pain and other distressing symptoms, including antibiotics,
despite the self limiting nature of AOM. Antibiotics are still com-
monly prescribed for AOM, although evidence demonstrates that
they are most likely beneficial for severe cases (i.e. fever ≥ 39 ºC,
moderate to severe ear pain), bilateral AOM in young children, or
AOM with perforated tympanic membrane(s) (Lieberthal 2013;
NSW Health 2014; Venekamp 2015). Due to the modest benefits
of antibiotics and their potential side effects and risk of antibi-
otic resistance (Venekamp 2015), alternative treatment for AOM,
such as corticosteroids as an anti-inflammatory medication, could
improve clinical symptoms of AOM, particularly pain. The pro-
portion of children with pain (a primary outcome of this review)
was evaluated by Chonmaitree 2003. However, this outcome was
only reported before treatment, therefore we could not assess the
effect of corticosteroids in improving pain alone.
Aside from the beneficial effects of corticosteroids on clinical out-
comes, assessing adverse effect or harm is also very important.
Unfortunately, we could not assess data for this outcome due to
incomplete outcome reporting (Chonmaitree 2003).
This review demonstrated insufficient and low- to very low-quality
evidence for the effects of systemic corticosteroids. We are uncer-
tain whether corticosteroids improve important clinical outcomes
of AOM (i.e. pain and overall symptoms, middle ear effusion,
AOM recurrence) due to the small number of included studies.
Consequently, the overall completeness and applicability of evi-
dence is very low.
Quality of the evidence
We judged the evidence as low to very low quality.
We downgraded the quality of the evidence to low for the primary
outcomes due to serious risk of bias and indirectness of the results.
Serious risk of bias was due to unclear allocation concealment
and unclear to high risk of selective reporting. Indirectness was
due to the differences between the outcomes of interest and those
reported in the included studies.
Potential biases in the review process
A potential bias inherent in this review was the difference in out-
come reporting and measurement for both our primary and sec-
ondary outcomes. For the outcome of reduction of overall or spe-
cific symptoms, we presented results as the proportion of chil-
dren who had clinical improvement measured using symptoms
and signs severity score, and not the absolute change of the scores.
Similarly, we presented the results for changes in tympanometry
measurement as the proportion of children who had resolution of
middle ear effusion measured using pneumatic otoscope and tym-
panometry, rather than the absolute changes of middle ear pressure
or the tympanogram curve types. This resolution was determined
by the normalisation of tympanogram curve to type A curve (the
absence of middle ear effusion).
Agreements and disagreements with other
studies or reviews
A literature review of the effectiveness of corticosteroids in several
acute respiratory infections (i.e. acute pharyngitis, community-ac-
quired pneumonia, and AOM) similarly concluded that the effect
of corticosteroids for AOM is still unknown due to insufficient
evidence (Principi 2013). This review poorly reported the search-
ing method or eligibility criteria, and the conclusion was based on
only one RCT (Chonmaitree 2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review did not demonstrate that systemic corticosteroids im-
prove important clinical outcomes in acute otitis media, and there-
fore has no implication for clinical practice.
Implications for research
Large, high-quality randomised controlled trials are needed to eval-
uate the effectiveness of corticosteroids in uncomplicated acute
otitis media.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chonmaitree 2003
Methods Randomised: yes, it was computer-generated with block randomisation (RCT)
Concealment of allocation: yes, the list of randomisation was in codes and only the
statistician who had generated the randomisation was aware of the code
Double-blind: yes, syrups similar in taste and colour to prednisolone were used as
placebo
Intention-to-treat: not an ITT analysis. Analysis was done on children who had more
than 70% adherence. Adherence to treatment was assessed by diary and the weight of
medication bottles (available-case analysis)
Loss to follow-up: unclear
Design: 2 x 2 factorial design
Participants N: 198 children (N = 179 children included in analysis)
Age: 3 months to 6 years
Setting: the paediatric outpatient clinic of the University of Texas Medical Branch at
Galveston, USA
Inclusion criteria: (1) children who had experienced 2 or more previous AOM episodes
(with the first AOM episode before 1 year of age) or (2) infants younger than 6 months
of age having the first or second episode of AOM
Exclusion criteria: children who had: (1) anatomic or physiologic defect of the ear
or nasopharynx; (2) major medical condition; (3) other concurrent medication; (4)
received antibiotic treatment within 1 week; (5) history of previous allergic reaction to
cephalosporin drugs; (6) indwelling tympanostomy tube; (7) history of exposure to an
individual with chickenpox in the previous 3 weeks
Baseline characteristics: most of the baseline characteristics were balanced except for
breastfeeding and fever. There were fewer numbers of children in the corticosteroid group
compared to the placebo group in terms of breastfeeding (16% versus 34%) and clinical
symptoms of fever (49% versus 63%)
Interventions All children received single-dose antibiotic intramuscular injections of ceftriaxone (50
mg/kg) and were randomised to either:
Intervention: corticosteroid (prednisolone) 2 mg/kg per day in 3 divided doses for 5
days (N = 89), or
Comparison: matching placebo for 5 days (N = 90)
Due to the factorial design, the corticosteroid group was a combination of a corticos-
teroid-only group (prednisolone 2 mg/kg per day in 3 divided doses; N = 45) and cor-
ticosteroid plus antihistamine group (prednisolone plus chlorpheniramine maleate; N
= 44). The placebo group was a combination of an antihistamine group (chlorpheni-
ramine maleate; N = 44) and a double placebo group (N = 46). We therefore analysed
the outcomes of prednisolone versus placebo
Outcomes Primary outcomes
1. Treatment failure defined as persistent clinical symptoms (i.e. fever > 38 °C
rectally, ear pain, irritability, poor feeding, rhinorrhoea, nasal stuffiness, cough,
sneezing, watery eyes) with inflamed tympanic membrane at either visit 2 (Day 5) or
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Chonmaitree 2003 (Continued)
visit 3 (Day 14) that required additional antibiotic treatment
2. Duration of middle ear effusion
3. AOM recurrence during the first 6 months
Secondary outcomes
1. Reduction of symptom severity scores: fever > 38 °C rectally, ear pain, irritability,
poor feeding, rhinorrhoea, nasal stuffiness, cough, sneezing, watery eyes with the range
of zero (none) to 2 (severe) and sign severity scores. The sign severity scores were
characterised by: position (0 = normal to 2 = bulging), colour/transparency (0 = shiny
to 2 = red/yellow), and mobility (0 = normal to 2 = non-mobile) with 6 as the
maximum otoscopic score.
2. Presence of middle ear effusion measured using tympanometry
3. Side effects
Notes 1. Information on the randomisation and concealment of allocation was not
provided in the published paper, therefore we contacted the trial author to retrieve this
information
2. Data of sign and symptom severity scores and side effects from each group at
various time points were not provided in the published paper. The trial author was not
able to provide this information
3. Out of 198 randomised children, 19 were not analysed (9.6%). However, the
allocation of these children to their treatment group was evenly distributed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated based on additional information ob-
tained from the trial author
Allocation concealment (selection bias) Unclear risk There was no clear description of how the
allocation was concealed. We contacted the
trial author, who merely reported that only
the statistician who generated the randomi-
sation schedule knew the code
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “colored syrups similar to the drugs
in taste and color were used as the placebos”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Based on additional information obtained
from the trial author, the clinicians as the
outcome assessors were not aware of the
codes or the treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19 children (9.6%) were excluded from the
analysis due to their non-adherence to the
treatment drug and the follow-up visits and
have not been analysed. However, their dis-
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Chonmaitree 2003 (Continued)
tribution into each treatment group was
generally even
Selective reporting (reporting bias) Unclear risk We could not retrieve the trial protocol.
Despite this study being registered in the
clinical trial registry, the primary or sec-
ondary outcomes were not clearly described
Other bias Low risk No other bias detected. We contacted the
trial author, who declared that there was no
scientific or financial contribution from the
pharmaceutical industry
McCormick 2003
Methods Randomised: yes, it was computer-generated with block randomisation (RCT)
Concealment of allocation: yes, the list of randomisation was in codes and only the
statistician who had generated the randomisation was aware of the code
Double-blind: syrups similar to prednisolone in taste and colour were used as placebo
Intention-to-treat: not an ITT analysis. Analysis was done on children who had more
than 70% adherence. Adherence to treatment was assessed by diary and medication
bottle weight (available-case analysis)
Loss to follow-up: unclear
Design: 2 x 2 factorial design
Participants N: 80 children (N = 73 children included in analysis)
Age: 3 months to 6 years
Setting: the paediatric outpatient clinic of the University of Texas Medical Branch at
Galveston, USA
Inclusion criteria: acute otitis media was diagnosed based on: (1) acute symptoms (i.e.
fever, irritability, ear pain, lack of appetite, or lack of sleep); (2) signs of acute inflamma-
tion of the tympanic membrane (i.e. red, yellow, or bulged tympanic membrane); and
(3) the presence of middle ear effusion identified with tympanocentesis procedure
Exclusion criteria: children who had: (1) received treatment for AOM in the preceding
30 days; (2) received antibiotic treatment within 1 week; (3) allergy to treatment medi-
cation; (4) other concurrent medication; (5) perforation of the tympanic membrane or
with tympanostomy tube(s); (6) a major medical condition or immunologic disorders;
(7) anatomic or physiologic defect of the ear or nasopharynx; (8) been exposed to chick-
enpox during the past 3 weeks
Baseline characteristics: most of the baseline characteristics were balanced except day-
care attendance and passive smoking. There were fewer numbers of children in the
corticosteroid group compared to placebo group who had attended a day-care centre
(30% versus 45%), and there were more children in the corticosteroid group compared
to the placebo group who had been exposed to smoking (50% versus 35%)
Interventions All children received single-dose antibiotic intramuscular injection of ceftriaxone (50
mg/kg) and were randomised to either:
Intervention: corticosteroid (prednisolone) 2 mg/kg per day in 3 divided doses for 5
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McCormick 2003 (Continued)
days (N = 37), or
Comparison: matching placebo for 5 days (N = 36).
Due to the factorial design, the corticosteroid group was a combination of a corticos-
teroid-alone group (prednisolone 2 mg/kg per day in 3 divided doses; N = 18) and
corticosteroid plus antihistamine group (prednisolone plus chlorpheniramine maleate;
N = 19). The placebo group was a combination of an antihistamine group (chlorpheni-
ramine maleate; N = 18) and a double placebo group (N = 18). We therefore analysed
the outcomes of prednisolone versus placebo
Outcomes Primary outcomes
1. Total outcome defined as clinical outcomes at visit 2 (Day 4 to Day 6) and visit 3
(Day 14) and bacterial outcome at visit 2
2. The changes in histamine and leukotriene B4 (LTB4) in the middle ear fluid
taken by tympanocentesis at the baseline and visit 2 (Day 4 to Day 6)
Secondary outcomes
1. The duration of the middle ear effusion
2. AOM recurrence during the first 4 months following the baseline visit
Notes 1. Information on the randomisation and concealment of allocation was not
provided in the published paper, therefore we contacted the trial author to retrieve this
information
2. Data on clinical outcomes at visit 2 and visit 3 were not provided in the published
paper. The trial author was not able to provide this information
3. Out of 80 randomised children, 7 children were not analysed (8.7%). However,
the allocation of these children to their treatment group was evenly distributed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was computer-gener-
ated based on additional information ob-
tained from the trial author
Allocation concealment (selection bias) Unclear risk There was no clear description of how the
allocation was concealed. We contacted the
trial author, who merely reported that only
the statistician who generated the randomi-
sation schedule knew the code and that nei-
ther the parent nor the examining physi-
cian was informed of the type of treatment
given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “A light straw-colored solution sim-
ilar to the drug was used as the placebo”
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McCormick 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Neither the parent nor the exam-
ining physician was informed of the type
of treatment given”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Seven cases were lost to follow-up
after the enrolment visit”
7 children (8.7%) who were lost to fol-
low-up after randomisation were excluded
from the analysis. However, their distribu-
tion into each treatment group was gener-
ally even
Selective reporting (reporting bias) High risk The authors did not report the clinical out-
come at visit 2 (Day 4 to Day 6) and visit 3
(Day 14). This information was crucial to
determine the total outcome. We also could
not retrieve the trial protocol, and neither
the primary nor secondary outcomes were
clearly described in the clinical trial registry
Other bias Low risk We detected no other bias. We contacted
the trial author, who declared that there was
no scientific or financial contribution from
the pharmaceutical industry
AOM: acute otitis media
ITT: intention-to-treat
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Albernaz 2001 STUDY DESIGN
Study was a literature review (non-English language article)
Arusgamov 1966 PARTICIPANTS
Adults only (non-English language article)
Cajgfinger 1967 INTERVENTIONS
Trial using topical or ear drop corticosteroid instead of systemic corticosteroid (non-English language article)
Califano 2014 PARTICIPANTS
Trial including non-acute otitis media effusion
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(Continued)
Capella 1984 STUDY DESIGN
Study was a retrospective observation using medical records (non-English language article)
Carvalho 1984 STUDY DESIGN
Study was a literature review (non-English language article)
Chinski 2003 PARTICIPANTS
Trial including non-acute otitis media effusion (more than 2 months)
Chirileanu 1978 INTERVENTIONS
Trial using an invasive intervention method by opening Eustachian tube ostium employing a probe and not
using a systemic corticosteroid (non-English language article)
Choung 2008 PARTICIPANTS
Trial excluding children with acute otitis media
Crysdale 1984 STUDY DESIGN
Study was a literature review.
Daly 1991 OTHERS
Children eligible to receive corticosteroid treatment were those whose otitis media effusion did not improve
after 2 weeks of antibiotic treatment
Endo 1997 PARTICIPANTS
Trial including children with persistent middle ear effusion for more than 3 months (non-English article)
Fradis 1983 STUDY DESIGN
Study was a letter to the Editor
Han 2009 COMPARATORS
Study was a quasi-randomised controlled trial and did not use placebo as a comparator (non-English language
article)
Hearey 1990 PARTICIPANTS
Trial including children with longstanding effusion for more than 10 weeks
Hussein 2017 PARTICIPANTS
Trial including children with chronic middle ear effusion
Martin 1975 INTERVENTIONS
Trial using topical or ear drop corticosteroid instead of systemic corticosteroid (non-English article)
Matsubara 2007 STUDY DESIGN
Study was a literature review (non-English article)
Oppenheimer 1968 ALLOCATION
Trial was a non-randomised study and did not include a placebo
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Trial was a non-randomised study and did not include a placebo
Puhakka 1985 PARTICIPANTS
Trial excluding children who had an acute otitis media episode during the preceding 3 months
Pulkki 2006 STUDY DESIGN
Study was a retrospective observation using medical records
Rosenfeld 1992 STUDY DESIGN
Study was a literature review
Roydhouse 1978 STUDY DESIGN
Study was a literature review
Ruohola 1999 PARTICIPANTS
Trial including children with tympanostomy tubes
Saffar 2001 PARTICIPANTS
Trial including children with otitis media with effusion for more than 3 months
Schwartz 1979 PARTICIPANTS
Trial including children with persistent otitis media effusion for 3 weeks or more
Schwartz 1981 PARTICIPANTS
Trial including children with persistent otitis media effusion for 3 weeks or more
Seehusen 2012 STUDY DESIGN
Study was a clinical scenario
Sergienko 1975 ALLOCATION
Study was a non-randomised controlled trial (pre- and post study)
Terjung 1967 INTERVENTIONS
Trial using topical or ear drop corticosteroid instead of systemic corticosteroid (non-English article)
Wang 2007 COMPARATORS
Study did not use placebo as a comparator (non-English article)
Woodhead 1986 PARTICIPANTS
Trial including children without inflammation signs of the tympanic membrane
Several articles did not provide abstracts or provided an unclear definition of otitis media effusion in their abstracts. We therefore had
to retrieve the full text, and they were not included in our eligibility criteria (e.g. literature reviews, non-acute otitis media studies).
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D A T A A N D A N A L Y S E S
Comparison 1. Systemic corticosteroids versus placebo for children with acute otitis media




participants Statistical method Effect size
1 Reduction of overall or specific
symptoms at various time
points
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Day 5 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Day 14 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Changes in tympanometry
measurement at various time
points
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Month 1 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Month 2 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Month 3 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 AOM recurrence at various time
points
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Month 1 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Month 2 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Month 3 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 During Month 4 to
Month 6
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Systemic corticosteroids versus placebo for children with acute otitis media,
Outcome 1 Reduction of overall or specific symptoms at various time points.
Review: Systemic corticosteroids for acute otitis media in children
Comparison: 1 Systemic corticosteroids versus placebo for children with acute otitis media
Outcome: 1 Reduction of overall or specific symptoms at various time points
Study or subgroup Corticosteroids Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 5
Chonmaitree 2003 84/89 80/90 1.06 [ 0.97, 1.16 ]
2 Day 14
Chonmaitree 2003 81/89 78/90 1.05 [ 0.95, 1.17 ]
0.5 0.7 1 1.5 2
Favours placebo Favours corticosteroids
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Analysis 1.2. Comparison 1 Systemic corticosteroids versus placebo for children with acute otitis media,
Outcome 2 Changes in tympanometry measurement at various time points.
Review: Systemic corticosteroids for acute otitis media in children
Comparison: 1 Systemic corticosteroids versus placebo for children with acute otitis media
Outcome: 2 Changes in tympanometry measurement at various time points
Study or subgroup Corticosteroids Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Month 1
Chonmaitree 2003 45/89 38/90 1.20 [ 0.87, 1.64 ]
2 Month 2
Chonmaitree 2003 62/89 52/90 1.21 [ 0.96, 1.51 ]
3 Month 3
Chonmaitree 2003 68/89 61/90 1.13 [ 0.94, 1.35 ]
0.2 0.5 1 2 5
Favours placebo Favours corticosteroids
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Analysis 1.3. Comparison 1 Systemic corticosteroids versus placebo for children with acute otitis media,
Outcome 3 AOM recurrence at various time points.
Review: Systemic corticosteroids for acute otitis media in children
Comparison: 1 Systemic corticosteroids versus placebo for children with acute otitis media
Outcome: 3 AOM recurrence at various time points
Study or subgroup Corticosteroids Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Month 1
Chonmaitree 2003 15/89 12/90 1.26 [ 0.63, 2.55 ]
2 Month 2
Chonmaitree 2003 20/89 24/90 0.84 [ 0.50, 1.41 ]
3 Month 3
Chonmaitree 2003 19/89 29/90 0.66 [ 0.40, 1.09 ]
4 During Month 4 to Month 6
Chonmaitree 2003 33/89 36/90 0.93 [ 0.64, 1.34 ]
0.05 0.2 1 5 20
Favours placebo Favours corticosteroids
A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library)
#1MeSH descriptor: [Otitis Media] explode all trees
#2otitis media:ti,ab,kw (Word variations have been searched)
#3“middle ear” near/5 (infect* or inflam* or effusion):ti,ab,kw (Word variations have been searched)
#4ome or aom:ti,ab,kw (Word variations have been searched)
#5#1 or #2 or #3 or #4
#6MeSH descriptor: [Adrenal Cortex Hormones] explode all trees
#7adrenal cortex hormone*:ti,ab,kw (Word variations have been searched)
#8corticosteroid* or corticoid* or steroid* or glucocorticoid*:ti,ab,kw (Word variations have been searched)
#9MeSH descriptor: [Pregnenediones] explode all trees
#10pregnenedione* or pregnenolone* or hydrocortisone* or hydroxypregnenolone* or tetrahydrocortisol* or cortodoxone* or cortone
acetate or cortisone or corticosterone:ti,ab,kw (Word variations have been searched)
#11aristocort or triamcinolone:ti,ab,kw (Word variations have been searched)
#12deltasone or prednisone or prednicot:ti,ab,kw (Word variations have been searched)
#13prednisolone or bubbli-pred or cotolone or prelone or pediapred or pms-prednisolone:ti,ab,kw (Word variations have been searched)
#14paramethasone or methylprednisolone or baycadron or dexamethasone or decadron:ti,ab,kw (Word variations have been searched)
#15clobetasol or beclomethasone or betamethasone or budesonide:ti,ab,kw (Word variations have been searched)
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#16efcortesol or hydrocortone or solu-cortef or cortef or A-Hydrocort:ti,ab,kw (Word variations have been searched)
#17betnelan or betnesol or celestone:ti,ab,kw (Word variations have been searched)
#18deflazacort or calcort:ti,ab,kw (Word variations have been searched)
#19medrone or medrol or solu-medrone or depo-medrone or methylpred-DP:ti,ab,kw (Word variations have been searched)
#20kenalog or novolizer or pulmicort or symbicort or entocort EC:ti,ab,kw (Word variations have been searched)
#21beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte:ti,ab,kw (Word
variations have been searched)
#22cortisol:ti,ab,kw (Word variations have been searched)
#23MeSH descriptor: [Mineralocorticoids] explode all trees
#24mineralocorticoid* or mineralcorticoid*:ti,ab,kw (Word variations have been searched)
#25MeSH descriptor: [Aldosterone] explode all trees
#26aldosterone or florinef acetate or fludrocortisone:ti,ab,kw (Word variations have been searched)
#27#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
or #25 or #26
#28#5 and #27 in Trials
Appendix 2. MEDLINE (Ovid) search strategy
1 exp Otitis Media/
2 otitis media.tw.
3 (middle ear adj5 (infect* or inflam* or effus*)).tw.
4 (ome or aom).tw.
5 or/1-4
6 exp Adrenal Cortex Hormones/












19 (cortone acetate or cortisone).tw,nm.
20 corticosterone.tw,nm.
21 (aristocort or triamcinolone).tw,nm.
22 (deltasone or prednisone or prednicot).tw,nm.
23 (prednisolone or bubbli-pred or cotolone or prelone or pediapred or pms-prednisolone).tw,nm.
24 paramethasone.tw,nm.
25 methylprednisolone.tw,nm.





31 (efcortesol or hydrocortone or solu-cortef or cortef or A-Hydrocort).tw,nm.
32 (betnelan or betnesol or celestone).tw,nm.
33 (deflazacort or calcort).tw,nm.
34 (medrone or medrol or solu-medrone or depo-medrone or methylpred-DP).tw,nm.
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35 kenalog.tw,nm.
36 (novolizer or pulmicort or symbicort or entocort EC).tw,nm.
37 (beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte).tw,nm.
38 cortisol.tw,nm.
39 exp Mineralocorticoids/
40 mineralocorticoid*.tw. or mineralcorticoid*.tw,nm.
41 Aldosterone/
42 aldosterone.tw,nm.
43 (florinef acetate or fludrocortisone).tw,nm.
44 or/6-43
45 5 and 44
Appendix 3. Embase (Elsevier) search strategy
#31 #27 AND #30
#30 #28 OR #29
#29 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR
’cross-over’:ab,ti OR factorial:ab,ti OR volunteer*:ab,ti OR
allocat*:ab,ti OR assign*:ab,ti OR ((singl* OR doubl*)
NEAR/2 blind*):ab,ti AND [embase]/lim
#28 ’single blind procedure’/de OR ’double blind procedure’/de
OR ’crossover procedure’/exp OR ’randomized controlled
trial’/de
#27 #5 AND #26
#26 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #
13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25
#25 aldosterone:ab,ti OR ’florinef acetate’:ab,ti OR fludrocor-
tisone:ab,ti AND [embase]/lim
#24 ’aldosterone’/de AND [embase]/lim
#23 mineralcorticoid*:ab,ti OR mineralocorticoid*:ab,ti AND
[embase]/lim
#22 ’mineralocorticoid’/exp AND [embase]/lim
#21 cortisol:ab,ti AND [embase]/lim
#20 beclometasone:ab,ti OR aerobec:ab,ti OR asmabec:ab,ti OR
beclazone:ab,ti OR becodisks:ab,ti OR becotide:ab,ti OR
’clenil modulite’:ab,ti OR qvar:ab,ti OR becloforte:ab,ti
AND [embase]/lim
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(Continued)
#19 novolizer:ab,ti OR pulmicort:ab,ti OR symbicort:ab,ti OR
’entocort ec’:ab,ti AND [embase]/lim
#18 kenalog:ab,ti AND [embase]/lim
#17 medrone:ab,ti OR medrol:ab,ti OR ’solu-medrone’:ab,ti OR
’depo-medrone’:ab,ti OR ’methylpred-dp’:ab,ti AND [em-
base]/lim
#16 deflazacort:ab,ti OR calcort:ab,ti AND [embase]/lim
#15 betnelan:ab,ti OR betnesol:ab,ti OR celestone:ab,ti AND
[embase]/lim
#14 clobetasol:ab,ti OR beclomethasone:ab,ti OR betametha-
sone:ab,ti OR budesonide:ab,ti OR efcortesol:ab,ti OR hy-
drocortone:ab,ti OR ’solu-cortef ’:ab,ti OR cortef:ab,ti OR
’a-hydrocort’:ab,ti AND [embase]/lim
#13 paramethasone:ab,ti OR methylprednisolone:ab,ti OR
baycadron:ab,ti OR dexamethasone:ab,ti OR decadron:ab,
ti AND [embase]/lim
#12 prednisolone:ab,ti OR ’bubbli-pred’:ab,ti OR cotolone:ab,
ti OR prelone:ab,ti OR pediapred:ab,ti OR ’pms-pred-
nisolone’:ab,ti AND [embase]/lim
#11 pregnenedione*:ab,ti OR pregnenolone*:ab,ti OR hydro-
cortisone:ab,ti OR hydroxypregnenolone:ab,ti OR tetrahy-
drocortisol:ab,ti OR cortodoxone:ab,ti OR ’cortone ac-
etate’:ab,ti OR cortisone:ab,ti OR corticosterone:ab,ti OR
aristocort:ab,ti OR triamcinolone:ab,ti OR deltasone:ab,ti
OR prednisone:ab,ti OR prednicot:ab,ti AND [embase]/lim
#10 ’pregnane derivative’/de AND [embase]/lim
#9 corticoid*:ab,ti OR steroid*:ab,ti OR glucocorticoid*:ab,ti
AND [embase]/lim
#8 corticosteroid*:ab,ti AND [embase]/lim
#7 ’adrenal cortex hormone’:ab,ti OR ’adrenal cortex hor-
mones’:ab,ti AND [embase]/lim
#6 ’corticosteroid’/exp AND [embase]/lim
#5 #1 OR #2 OR #3 OR #4
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(Continued)
#4 ome:ab,ti OR aom:ab,ti AND [embase]/lim
#3 (’middle ear’ NEAR/5 (infect* OR inflam* OR effusion)):
ab,ti AND [embase]/lim
#2 ’otitis media’:ab,ti AND [embase]/lim
#1 ’otitis media’/exp AND [embase]/lim
Appendix 4. CINAHL (EBSCO) search strategy
S1 (MH “Otitis Media+”)
S2 TI otitis media OR AB otitis media
S3 TI ( middle ear N5 (infect* or inflam* or effusion) ) OR AB ( middle ear N5 (infect* or inflam* or effusion) )
S4 TI ( ome or aom ) OR AB ( ome or aom )
S5 S1 OR S2 OR S3 OR S4
S6 (MH “Adrenal Cortex Hormones+”)
S7 TI adrenal cortex hormone* OR AB adrenal cortex hormone
S8 TI ( corticosteroid* or corticoid* or steroid* or glucocorticoid* ) OR AB ( corticosteroid* or corticoid* or steroid* or gluco-
corticoid* )
S9 TI ( pregnenedione* or pregnenolone* or hydrocortisone* or hydroxypregnenolone* or tetrahydrocortisol* or cortodoxone* )
OR AB ( pregnenedione* or pregnenolone* or hydrocortisone* or hydroxypregnenolone* or tetrahydrocortisol* or cortodox-
one* )
S10 TI ( aristocort or triamcinolone ) OR AB ( aristocort or triamcinolone )
S11 TI ( prednisolone or bubbli-pred or cotolone or prelone or pediapred or pms-prednisolone ) OR AB ( prednisolone or bubbli-
pred or cotolone or prelone or pediapred or pms-prednisolone )
S12 TI ( paramethasone or methylprednisolone ) OR AB ( paramethasone or methylprednisolone )
S13 TI ( baycadron or dexamethasone or decadron ) OR AB ( baycadron or dexamethasone or decadron )
S14 TI ( clobetasol or beclomethasone or betamethasone or budesonide ) OR AB ( clobetasol or beclomethasone or betamethasone
or budesonide )
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(Continued)
S15 TI ( efcortesol or hydrocortone or solu-cortef or cortef or A-Hydrocort ) OR AB ( efcortesol or hydrocortone or solu-cortef or
cortef or A-Hydrocort )
S16 TI ( betnelan or betnesol or celestone ) OR AB ( betnelan or betnesol or celestone )
S17 TI ( deflazacort or calcort ) OR AB ( deflazacort or calcort )
S18 TI ( medrone or medrol or solu-medrone or depo-medrone or methylpred-DP ) OR AB ( medrone or medrol or solu-medrone
or depo-medrone or methylpred-DP )
S19 TI kenalog OR AB kenalog
S20 TI ( novolizer or pulmicort or symbicort or entocort EC ) OR AB ( novolizer or pulmicort or symbicort or entocort EC )
S21 TI ( beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte ) OR
AB ( beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte )
S22 TI cortisol OR AB cortisol
S23 (MH “Mineralocorticoids+”)
S24 TI ( mineralcorticoid* or mineralocorticoid* ) OR AB ( mineralcorticoid* or mineralocorticoid* )
S25 (MH “Aldosterone”)
S26 TI aldosterone OR AB aldosterone
S27 TI ( florinef acetate or fludrocortisone ) OR AB ( florinef acetate or fludrocortisone )
S28 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20
OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
S29 S5 AND S28
S30 (MH “Clinical Trials+”)
S31 PT clinical trial
S32 TI clinic* N1 trial* OR AB clinic* N1 trial*
S33 TI ( (singl* or doubl* or tripl* or trebl*) N1 (mask* or blind*) ) OR AB ( (singl* or doubl* or tripl* or trebl*) N1 (mask* or
blind*) )
S34 (MH “Random Assignment”)
S35 TI random* OR AB random*
S36 (MH “Placebos”)
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(Continued)
S37 TI placebo* OR AB placebo*
S38 S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37
S39 S29 AND S38
Appendix 5. Web of Science (Thomson Reuters) search strategy
#4 AND #3
Refined by: PUBLICATION YEARS: ( 2016 OR 2017 )
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
#4 AND #3
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
TOPIC: (random* or placebo* or crossover* or “cross over” or allocat* or ((singl* or doubl*) NEAR/1 blind*)) OR TITLE: (trial)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
#2 AND #1
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
TOPIC: (“adrenal cortex hormone*” or corticosteroid* or corticoid* or steroid* or glucocorticoid*) OR TOPIC: (pregnenedione* or
pregnenolone* or hydrocortisone or hydroxypregnenolone or tetrahydrocortisol or cortodoxone or “cortone acetate” or cortisone or
corticosterone or aristocort or triamcinolone or deltasone or prednisone or prednicot or prednisolone) OR TOPIC: (“bubbli-pred”
or cotolone or prelone or pediapred or “pms-prednisolone” or paramethasone or methylprednisolone or baycadron or dexamethasone
or decadron or clobetasol or beclomethasone or betamethasone or budesonide or efcortesol or hydrocortone or solu-cortef or cortef
or A-Hydrocort or betnelan) OR TOPIC: (betnesol or celestone or deflazacort or calcort or medrone or medrol or solu-medrone
or depo-medrone or methylpred-DP or kenalog or novolizer or pulmicort or symbicort or entocort or beclometasone or aerobec or
asmabec or beclazone or becodisks or becotide) OR TOPIC: (“clenil modulite” or qvar or becloforte or cortisol or mineralcorticoid*
or aldosterone or “florinef acetate” or fludrocortisone)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
TOPIC: (“otitis media”) OR TOPIC: (“middle ear” NEAR/5 (infect* or inflam* or effus*)) OR TOPIC: (ome or aom)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=
All years
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Appendix 6. LILACS (BIREME) search strategy
tw:((mh:“Otitis Media” OR “Otitis Media” OR “Otite Média” OR mh:c09.218.705.663* OR “middle ear infection” OR “middle ear
inflammation” OR “middle ear effusion” OR “serous otitis media” OR “OME” OR “AOM”) AND (mh:“Adrenal cortex hormones”
OR “Adrenal Cortex Hormones” OR corticoesteroides OR corticosteroides OR corticoides OR corticosteroides OR “Hormonas
de la Corteza Suprarrenal” OR corticoid* OR corticoesteroides OR “Hormônios do Córtex Suprarrenal” OR mh:d06.472.040*
OR corticosteroid* OR corticoid* OR steroid* OR glucocorticoid* OR esteroid* OR corticoid* OR mineralocorticoid* OR mh:
pregnenediones OR pregnenodionas OR mh:d04.808.745.745.654* OR dicetopregnenos OR pregnenedionas OR pregnenedione*
OR pregnenolone OR hydrocortisone OR hydroxypregnenolone OR tetrahydrocortisol OR cortodoxone OR “cortone acetate” OR
cortisone OR corticosterone OR aristocort OR triamcinolone OR deltasone OR prednisone OR prednicot OR prednisolone OR
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3.1  SUMMARY 
Our previous study (Study 1 – Cochrane review of systemic corticosteroids for acute otitis 
media [AOM] in children) showed that large, high-quality studies are required to address the 
effects of systemic corticosteroids for AOM.  
Therefore, we planned to conduct a large quality, pragmatic, randomised, double-blinded, 
controlled trial (RCT) to address the effect of corticosteroids for AOM in children.  Prior to 
this, we conducted a feasibility study (Study 2 – Current management of children with acute 
otitis media: a feasibility survey for a pragmatic study in Jakarta, Depok, and Bekasi) to 
identify the current management of children with AOM among general practitioners, Ear-
Nose-Throat (ENT) specialists, and paediatricians who worked at primary care centres and 
hospitals in Jakarta, Depok, and Bekasi, Indonesia. This cross-sectional study also identified 
the number of children presenting with AOM in a week and the number of physicians who 
would participate in our planned pragmatic clinical trial. The study results were aimed at 
supporting the development of the strategy and methods for our protocol of a large, pragmatic 
RCT of oral corticosteroids for children with AOM in Indonesia, including the estimation of 
study duration, identification of potential obstacles and operational requirements in the study.  
This study which consisted of responses from 352 clinicians (general practitioners=285, 
pediatricians=35, ENT specialists=32) retrieved from paper-based (N=339) and web-based 
questionnaires (N=13) showed that, given hypothetical clinical scenarios, most of the 
Indonesian physicians surveyed, particularly ENT specialists, would prescribe antibiotics for 
mild AOM. Slightly over half of the physicians, mostly paediatricians, would withhold 
antibiotic treatment and choose expectant observation. The number of participating physicians, 
who potentially would consider using corticosteroids, indicated that it would be feasible to 
conduct a clinical trial of oral corticosteroids for children with AOM in Indonesia. The 
following pages in this chapter include the results paper that has been published.  
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Acute otitis media (AOM) is a common self-limiting 
infection where antibiotics confer limited benefit. Other treat-
ments, such as anti-inflammatory agents have been proposed as 
an alternative to antibiotics, but no high-quality clinical trials 
have tested this. 
 To identify current AOM management practices among 
Indonesian clinicians. We also required this information for our 
proposed corticosteroids clinical trial for AOM. 
 This cross-sectional study surveyed a convenience sample 
of general practitioners (GPs), pediatricians, and Ear-Nose-Throat 
(ENT) specialists in Jakarta, Depok, and Bekasi. We addressed their 
current AOM management practices and willingness to participate 
in a future trial on corticosteroids.
 We distributed 2,694 questionnaires through conferences, 
primary care/hospital visits, and by mail-list group. Of 492 ques-
tionnaires received (response rate 18%), 352 were from eligible 
clinicians. Most clinicians diagnosed AOM by using an otoscope 
(64-91%). Tympanometry was used by a quarter of ENT special-
ists. Amoxicillin-clavulanate was the most common antibiotic for 
AOM, prescribed by pediatricians and ENT specialists, whilst most 
GPs prescribed amoxicillin. Clinical scenarios indicated most ENT 
specialists (88%) would prescribe antibiotics and most pediatricians 
(54%) would choose expectant observation by withholding antibi-
otics for mild AOM. Almost half of clinicians would consider using 
corticosteroids in a trial.
 Most clinicians would prescribe antibiotics for mild 
AOM. However, slightly over half of pediatricians would solely 
choose expectant observation. Adequate numbers of potential 
participating clinicians, who would consider using corticosteroids, 
make our proposed corticosteroids trial for AOM feasible. We found 
gaps between clinical practice and evidence requiring further inves-
tigation to improve AOM management in Indonesia.  
].
Antibiotics are commonly used for treating infectious diseases, including acute otitis media (AOM) in children.1,2 International guidelines recommend 
expectant observation for mild AOM, with antibiotics 
only given for severe cases.3,4 Although antibiotics are 
effective for AOM, their effects in improving pain and 
middle ear effusion are weak, they have potentially 
harmful side effects, and may lead to antibiotic 
resistance.5,6 Currently, there are two conflicting 
Indonesian guidelines for AOM. One recommends 
antibiotics for both mild and severe AOM, while 
the other recommends antibiotics only for severe 
cases (although ‘severe’ is not clearly defined).7,8 
This potentially contributes to high use of antibiotics 
in the management of AOM in Indonesia, thereby 
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increasing the risk of antibiotic resistance and other 
side effects.5,9,10 Finding alternative treatment options 
could be one way to mitigate the risk of antibiotic 
resistance. Theoretical considerations suggest that 
the anti-inflammatory effect of corticosteroids might 
reduce symptoms.1 Conflicting evidence on the 
potential benefits requires a large randomized placebo-
controlled trial (RCT) to test efficacy.12,13 We plan 
to undertake a large RCT in Indonesia to further 
investigate this issue.
To date, there is no available data on the 
current AOM management for children in Indonesia. 
However, there have been several studies surveying 
the management of AOM in other countries.14-16 A 
survey study in Turkey showed pediatricians were 
likely to prescribe antibiotics (60%) and analgesics 
(e.g., acetaminophen, ibuprofen) for children with 
AOM.14 Surveys in India and Israel showed most ENT 
specialists prescribed antibiotics for AOM (62-98%). 
Analgesics and decongestants and/or antihistamines 
were also commonly prescribed. Most ENT specialists 
in India used an otoscope as a diagnostic tool for 
AOM, whilst a microscope was more preferable in 
Israel.15,16 
We identified the current management, particu-
larly with regards to prescribing antibiotics for AOM 
in three cities in Indonesia. This survey study was 
done to help us identify existing gaps between clinical 
practice and evidence in the management of AOM 
in Indonesia.  Our survey was also designed to gauge 
clinicians’ willingness to use corticosteroids in a future, 
randomized trial.
This study primarily aimed to identify the current 
management of AOM among clinicians. It also 
identified the feasibility of a proposed clinical trial 
to test corticosteroids for AOM in children. We 
conducted a cross-sectional study for our survey 
(April - August 2016). Our eligibility criteria were 
clinicians from three specialties (general practitioners, 
pediatricians, and ENT specialists) working in 
primary/secondary or tertiary healthcare facilities in 
Jakarta, Depok, and Bekasi, Indonesia. We established 
clinicians’ specialties and email addresses from 
the national professional organizations of general 
practitioners ( ), 
pediatricians ( ), and ENT 
specialists (
). We then distributed paper-
based questionnaires through workshops, conferences, 
primary healthcare and hospital visits. We also 
distributed electronic-based questionnaires through 
mailing lists of primary care clinician graduates from 
two medical schools in Jakarta (Universitas Indonesia 
and Universitas Pembangunan Nasional Veteran), 
identified by alumni and colleagues. 
We invited participation in a 10-minute presen-
tation at the following workshops and conferences: (i) 
The Indonesian National Committee for the Preven-
tion and Management of Hearing Impairment and 
Deafness Meeting (20 May 2016), (ii) The Continuing 
Professional Development Program: The Comprehen-
sive Management of Vestibulocochlear Disorders (20-
21 May 2016), (iii) The Third Neurotology Update 
Management: Hearing and Vestibular Disorders in 
Children (21 May 2016), (iv) The Annual Scientific 
Meeting of the Indonesian Medical Association (27-
29 May 2016), and (vi) The Second Jakarta Pediatric 
Respiratory Forum (29-30 May 2016). We distributed 
the questionnaires at the registration table on the first 
day of the workshops or conferences and collected the 
questionnaires at the end of the events. 
We identified several primary healthcare clinics 
and hospitals located in Jakarta, Depok, and Bekasi 
that were conveniently accessible. We contacted the 
heads or directors of the appointed healthcare facilities 
and distributed the questionnaires to the emergency, 
pediatric, and otorhinolaryngology departments. We 
collected the questionnaires at most 4 weeks after 
their distribution, unless completed earlier. 
Consenting clinicians typically completed the 
questionnaires in 10-20 minutes ( ). It 
had 3 sections: 1) current management of AOM 
in children, including diagnostic treatment items; 
2) 3 clinical scenarios [(a.) a child aged < 2 years
mild AOM; and (c.) an older child with recurrent and 
bilateral AOM] in which respondents were invited 
to describe their management ( ); and 3) a 
feasibility survey to identify the number of pediatric 
AOM patients and clinicians who might be willing to 
participate in our clinical trial on corticosteroids as 
an alternative treatment for AOM. 
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We did not formally determine a sample size esti-
mate. We used convenience sampling based on ease of 
accessibility to the healthcare facilities and clinicians 
who attended workshops and conferences specifically 
for general practitioners, pediatricians, and ENT spe-
cialists. The results of this study are reported as the per-
centage of clinicians in each category of responses. We 
used Chi-square test to identify the differences between 
specialty groups using  software. 
All proportions are expressed from respondents who 
answered that question in the questionnaires.
This study protocol was reviewed and approved by 
the Ethics Committee of the Universitas Indonesia Medi-
Table 1. Clinical scenarios and their interpretation
Clinical scenarios Interpretation/diagnosis Treatment recommendation3
Clinical scenario 1:
“A one-year old boy, accompanied by 
his mother, came to your practice with a 
complaint of pain in his left ear for one day. 
The pain was not severe. He has had a cold 
for the last two days with a mild fever. At the 
physical examination, he looked well and 
alert with temperature 37.8°C. At his ear, 
nose, and throat examination, there was 
mucous discharge on the nasal cavities, 
and his throat looked normal. An otoscopic 
examination showed redness and bulging 
tympanic membrane of the left ear.”
A young child (aged < 2 years) with mild 
AOM
Expectant observation (begin antibiotics if 
child worsens or fails to improve within 48 
to 72 hours of AOM onset) OR antibiotic 
therapy if close observation and follow-up 
cannot be ensured.
Clinical scenario 2:
“A four-year old girl, accompanied by her 
parents, came to your practice with a 
complaint of pain in her right ear for one day. 
She has had a cold for the last four days. She 
had no fever. At the physical examination, 
the patient looked well and alert. At her 
ear, nose, and throat examination, there 
was serous secretion in the nasal cavities 
and her throat looked normal. An otoscopic 
examination showed redness and bulging 
tympanic membrane of the right ear.”
AOM
Expectant observation (begin antibiotics if 
child worsens or fails to improve within 48 
to 72 hours of AOM onset) OR antibiotic 
therapy if close observation and follow-up 
cannot be ensured. 
Clinical scenario 3:
parents, came to your practice with a 
complaint of pain in her right ear for one day, 
followed by left ear this morning and she had 
a mild fever. She had experienced acute 
otitis media in her right ear one month ago. At 
the physical examination, the patient looked 
well and alert with temperature 36.8°C. At 
her ear, nose, and throat examination, there 
was minimal serous discharge in her nasal 
cavities and her throat looked normal. An 
otoscopic examination showed redness and 
bulging on both tympanic membranes.”
An older child with recurrent bilateral AOM Expectant observation (begin antibiotics if 
child worsens or fails to improve within 48 
to 72 hours of AOM onset) OR antibiotic 
therapy if close observation and follow-up 
cannot be ensured. However, this guideline 
does not specify the need of antibiotics for 
recurrent AOM. 
cal School and Bond University Human Research Ethics 
Committee. We provided a paper- and electronic-based 
information sheet and consent form to all respondents. 
Consent was received in written form and the consent 
process was free of coercion. All information obtained 
from the respondents was treated as confidential.
Of 2,694 questionnaires distributed, 492 were 
returned (response rate 18%). Of these, 445 (90%) 
participated in the survey, . There were 352 
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clinicians who responded (general practitioners 81%, 
pediatricians 10%, and ENT specialists 9%) and they 
were based at primary/secondary (44%) and tertiary 
healthcare (54%) facilities (no response 2%) in 
Jakarta (82%), Depok (10%), and Bekasi (8%), our 
target regions. Most were young, <31 years (44%), 
and female (67%).
A total of 705 children with AOM visited 
352 clinicians over a period of seven days prior to 
answering the questionnaire. Most clinicians had less 
than three AOM cases during this period (75%), and 
most of these children were between two and five years 
of age. ENT specialists had more AOM cases (three to 
five cases) per week compared to general practitioners 
and pediatricians. 
Most clinicians diagnosed AOM by using an 
otoscope (64-91%) ( ). Three quarters of 
ENT specialists and 9% of general practitioners 
used an endoscope. Pediatricians did not use an 
endoscope. A quarter of ENT specialists, but very 
few pediatricians (3%) or general practitioners (1%), 
used tympanometry to identify middle ear effusion. 
Few clinicians (0-6%) used a pneumatic otoscope, 
audiometry (0-9%), or tympanocentesis (0-3%) to 
diagnose AOM.
Amoxicillin-clavulanate was the most common 
antibiotic prescribed by ENT specialists (58%), 
pediatricians (46%), and general practitioners (16%) 
(T ). Amoxicillin was the second most common 
antibiotic prescribed by general practitioners (43%) 
and pediatricians (37%), whilst ENT specialists 
prescribed cefixime as the second common antibiotics 
for AOM (23%). Azithromycin (0-13%), cefadroxil 
(0-9%), erythromycin (3%), ampicillin (0-3%), 
and cotrimoxazole (0-3%) were the least common 
antibiotics prescribed for AOM. General practitioners 
(66%) mostly prescribed amoxicillin for three to five 
days, whilst ENT specialists (56%) and pediatricians 
(54%) prescribed amoxicillin-clavulanate for more 
than five days.
The clinicians’ treatment choices for the three 
clinical scenarios are shown in .  In the first 
scenario, 88% of ENT specialists would prescribe 
antibiotics for AOM, followed by general practitioners 
(71%) and pediatricians (57%). More ENT specialists 
(44%) would prescribe corticosteroids when compared 
to other specialties (general practitioners 30%; 
pediatricians 23%). In the second scenario, 66% of 
ENT specialists would prescribe antibiotics, followed 
by general practitioners (52%) and pediatricians 
Figure 1







352 respondents were eligible 
(based in Jakarta, Depok, Bekasi) 
492 respondents returned the questionnaires
445 respondents gave their consent 
and completed the questionnaires
2,202 did not return 
the questionnaires
47 respondents did not 
give their consent
93 respondents were excluded 
(not based in Jakarta, Depok, Bekasi)
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Table 2. The common diagnostic tools and type of antibiotic prescribed among clinical specialties
Management General practitioners* (Total=284), 
n(%)













































































*One missing data in general practitioner group 
**Total 281 general practitioners and 31 ENT specialists provided their options of antibiotic types for AOM
†
‡ENT specialist did not mention any antibiotic by name but only reported ‘depends on the condition’.
§
Table 3. Treatment options for three clinical scenarios among all specialties
Treatment options
Scenario 1 

































140 (49)  8 (25) 20 (57) 168 (48) 136 (49)
  9 (28)   17 (49) 
162 (47) 132 (47) 8 (25) 16 (46) 156 (45)
Antibiotics 200 (71) 28 (88) 20 (57) 248 (71) 147 (52) 21 (66) 16 (46) 184 (53) 170 (61) 27 (84) 20 (57) 217 (63)
Corticosteroids 85 (30) 14 (44) 8 (23) 107 (31) 73 (26) 12 (37)  7 (20)   92 (27) 95 (34) 14 (44) 11 (31) 120 (35)
Acetaminophen  217 (77) 19 (59) 31 (89) 267 (76) 151 (54) 12 (37) 22 (63) 185 (53) 128 (46) 13 (41) 18 (51) 159 (46)
Ibuprofen 49 (17)  9 (28) 8 (23) 66 (19) 74 (26) 11 (34)  9 (26)   94 (27) 78 (28) 9 (28) 13 (37) 100 (29)
Decongestant/
antihistamine
201 (71) 29 (91) 24 (69) 254 (73) 222 (79) 30 (94) 29 (83) 281 (81) 145 (52) 29 (91) 21 (60) 195 (56)
Topical antibiotics 71 (25) 2 (6) 7 (20) 80 (23) 69 (25) 2 (6) 6 (17)   77 (22) 73 (26) 2 (6) 11 (31) 86 (25)
Topical analgesics 32 (11) 0 (0) 4 (11) 36 (10) 33 (12) 1 (3)   3 (9)   37 (11) 41 (15) 1 (3) 5 (14) 47 (14)
Physiotherapy   18 (6) 2 (6) 2 (6)  22 (6)   19 (7) 1 (3) 4 (11) 24 (7)   17 (6) 1 (3)   1 (3)  19 (6)
*Clinicians may choose more than one treatment option
(46%). Thirty-seven per cent of ENT specialists and 
only up to quarter of general practitioners (26%) and 
pediatricians (20%) would choose corticosteroids. 
In the third scenario, 84% of ENT specialists would 
prescribe antibiotics for AOM, followed by general 
practitioners (61%) and pediatricians (57%). 
Corticosteroids were more likely to be prescribed by 
ENT specialists (44%) compared to other specialties 
(general practitioners 34%, pediatricians 31%). 
Clinicians would mostly prescribe acetaminophen 
(59-89%), decongestant/antihistamine (69-91%), 
and antibiotics (57-88%) for a young child with 
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mild AOM (Scenario 1) compared with other 
treatment (e.g., ibuprofen, corticosteroids, topical 
antibiotics, or topical analgesics). From all clinical 
scenarios, ENT specialists were more likely to 
prescribe corticosteroids (37-44%) and were less 
likely to choose expectant observation (25-28%), 
whereas pediatricians (46-57%) followed by general 
practitioners (47-49%) were more likely to choose 
expectant observation compared to ENT specialists. 
However, as clinicians may choose more than one 
treatment for the clinical scenario section, there were 
respondents who chose both expectant observation 
and antibiotics, which by definition should be 
mutually exclusive. By identifying those who solely 
chose expectant observation by withholding 
antibiotic treatment, pediatricians (43-54%) were 
still more likely to choose expectant observation 
compared to other specialties in all three scenarios. 
The rate of corticosteroid prescribed by pediatricians 
and general practitioners ranged from 20% to 34% 
across the three scenarios. A significant difference 
between specialty groups was identified in the first 
scenario, where pediatricians were significantly less 
likely to prescribe antibiotics (P=0.024) compared to 
general practitioners and ENT specialists, and in the 
third scenario where ENT specialists were more likely 
to prescribe antibiotics (P=0.026) compared to other 
specialties. With regards to prescribing antibiotics 
in each scenario among these specialties, ENT 
specialists were more likely to prescribe antibiotics 
compared to other specialties, particularly in the first 
and third scenarios.
As shown in , of the 352 clinicians 
from Jakarta, Depok, and Bekasi, 171 respondents 
(49%) indicated their willingness to participate in 
our proposed clinical trial testing corticosteroids 
as an alternative treatment for AOM in children. 
Their characteristics were similar to the whole survey 
sample. They managed 443 children with AOM in 
a week. Most clinicians had less than three cases of 
AOM during this period (75%), with most of these 
children aged older than five years. ENT specialists 
had more AOM cases (three to five cases) per week 
compared to other specialties. These clinicians had 
a similar practice in the management of AOM and 
responses to clinical scenarios to the whole sample. 
Up to 44% of clinicians, mostly ENT specialists, would 
consider using corticosteroids in a trial.
Our sample of clinicians who worked in Jakarta, Depok, 
and Bekasi, reported that they mostly diagnosed AOM 
by using an otoscope. Most general practitioners 
would prescribe amoxicillin for a short duration (3-5 
days), whilst ENT specialists and pediatricians were 
more likely to prescribe amoxicillin-clavulanate for 
a longer duration. Clinical scenario results showed 
there was a high rate of antibiotics prescribed for mild 
AOM. Up to 44% of clinicians would have prescribed 
corticosteroids for children with AOM. Both 
corticosteroids and antibiotics were mostly prescribed 
by ENT specialists in the scenarios. There is no clear 
justification for a high rate of antibiotic prescribing 
by ENT specialists. As ENT specialists saw more 
patients with AOM in the sampled week compared 
to other specialties, their contribution to antibiotic 
prescribing would be higher and, therefore, the risks 
correlated with antibiotic use, such as adverse events 
and antibiotic resistance would be increased.5,9,10
Another reason for this high use was due to potential 
complications following AOM, such as spontaneous 
perforation of the tympanic membrane (15%) and 
persistent middle ear effusion (25%).17,18 High rates 
of antibiotic prescribing by general practitioners might 
be influenced by the Indonesian practice guideline 
recommending antibiotics for both mild and severe 
AOM.7 Interestingly, we found pediatricians were 
less likely to prescribe antibiotics for all scenarios in 
the study. One potential justification for this was that 
international pediatrics practice guidelines do not 
recommend antibiotics for common colds and only 
recommend antibiotics for AOM with high risks (e.g., 
children with severe signs and symptoms, children < 
2 years with bilateral AOM, or tympanic membrane 
perforation).3,4,19 Corticosteroids and antibiotics were 
more likely to be prescribed for AOM in younger 
children and recurrent bilateral AOM. These are 
not entirely in accordance with the guidelines, as 
corticosteroids have not been recommended by any 
guidelines. The guidelines only recommend the use 
of antibiotics for children under two years of age 
with bilateral AOM, whilst our scenario was a case 
of unilateral AOM.3 
Unfortunately, few clinicians (<7%, and none 
of the ENT specialists) used pneumatic otoscopy, 
which enables the assessment of tympanic membrane 
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mobility.3,20 A systematic review showed that a 
pneumatic otoscope performed by a skilled clinician 
can accurately diagnose AOM with high predictive 
values. It can replace tympanometry as one diagnostic 
tool for AOM, as the pneumatic otoscope is a more 
affordable.21 Our clinical scenarios demonstrated 
that most clinicians would prescribe antibiotics over 
expectant observation for mild AOM. Evidence 
recommends expectant observation with sufficient 
pain management for mild AOM.3-5,9 Only 30% 
of AOM cases are severe and require antibiotic 
treatment.5,9 However, antibiotic prescribing rates for 
AOM in developed and developing countries are still 
relatively high. In terms of data from general practices 
in Australia over five years, 89% of new AOM cases 
were managed with antibiotics.22 Meanwhile, data 
from the 
(NAMCS) demonstrated 83.1% of children with 
isolated AOM were managed with antibiotics.23 Our 
study demonstrated that up to 88% of clinicians would 
prescribe antibiotics for a mild case of AOM. 
recommends antibiotics 
for both mild and severe AOM, which may influence 
the high rate of antibiotic prescribing for AOM in 
Indonesia.7 A red and bulging tympanic membrane 
could be the other reason for antibiotic treatment in all 
scenarios. However, the sign of red tympanic membrane 
is not sensitive (18%), with a low likelihood ratio for 
a positive result of 1.1, regardless of its high specificity 
(84%). Although a bulging tympanic membrane will 
help make the diagnosis, it requires the combination of 
cloudiness and the impaired mobility of the tympanic 
membrane to robustly diagnose AOM.20  
Recurrent AOM was the second most common 
reason for antibiotic prescribing in this study. This 
is defined as “the occurrence of 3 or more episodes 
of AOM in a 6-month period or the occurrence of 
4 or more episodes of AOM in a 12-month period 
that includes at least 1 episode in the preceding 6 
months”.3 
 does not recommend the use of 
prophylactic antibiotics for reducing the number of 
episodes of AOM in recurrent AOM cases, and yet 
tympanostomy tubes should be offered.3 Systematic 
reviews showed that recurrent AOM is not included 
as one indicator for antibiotic treatment in the 
management of AOM.5,9 However, 
 includes recurrent AOM into 
the high-risk middle ear infection category, which 
requires immediate antibiotic treatment. 24
The high rate of antibiotic prescribing in AOM 
indicates the need for alternative non-antibiotic 
treatment for AOM. We propose to test corticosteroids 
for AOM.  Inflammation has been indicated as 
an important mechanism in AOM, despite the 
complexity of the pathophysiology of AOM. This 
involves both cellular and chemical mediators (e.g., 
cytokines, chemokines, mast cells, and leukotrienes). 
Corticosteroids could act as an anti-inflammatory 
agent, particularly in the middle ear,12 and therefore 
reduce pain. Insufficient evidence of the effects of 
corticosteroids for AOM requires a large, high-quality, 
clinical trial to evaluate corticosteroid efficacy to 
improve the resolution of AOM, as a monotherapy 
in mild cases or as an addition to antibiotic therapy 
in severe cases.12
Our feasibility survey demonstrated that there 
were 171 clinicians who were willing to participate 
in our clinical trial and who saw 443 children with 
AOM in a week. They also had similar practices in 
the management of AOM and responses to clinical 
scenarios to the whole sample. This study also 
demonstrated that a sufficient number of clinicians 
would consider using corticosteroids for AOM. This 
finding was surprising; however, this high rate could be 
primed by clinicians’ knowledge of the nature of the 
upcoming clinical trial, which had been provided in 
the consent form and at the conference presentations 
prior to the completion of the questionnaires. As nearly 
half of the clinicians were interested in participating 
in our trial, it is feasible to conduct a clinical trial on 
corticosteroids for AOM in children in Indonesia, 
according to the pre-specified timeline (12 months, 
including a three-month follow-up).
We believe this the first survey of current 
practices of clinicians in the management of pediatric 
AOM in Indonesia, which was the strength of this 
study. We identified clinicians’ preferred treatment 
options, particularly in choosing corticosteroids, 
expectant observation, and antibiotics. However, this 
study also had several limitations, including the low 
response rate, unclear definition of ‘observation for 
48 to 72 hours’ as one answer option in the clinical 
scenario, and a narrow study-site coverage. We tried 
several recruitment strategies to increase the response 
rate, however, as participation was voluntary, it was 
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the respondents’ decision to consent and participate 
in this survey study. There is no gold standard for an 
acceptable minimum survey response rate, however, a 
response rate of at least 70% is desirable.25 Nonetheless, 
surveys involving voluntary clinicians mostly have 
low response rates (< 30%).25 There are several 
factors that influence the willingness of clinicians to 
participate in a survey study, such as concerns about 
disruption of their practice, time, and relevance of the 
survey topic.26 A review assessing survey response rates 
of general practitioners from published primary care 
journals demonstrated that the mean response rate 
was 61% (95% confidence interval 59% to 63%).27 
A cross-sectional study comparing the response 
rates between postal and online survey of general 
practitioners across Australia showed low response 
rates for both (12.4% and < 0.1%, respectively), 
which were similar to our study.28 Several contributing 
factors were workload of the general practitioners, 
increasing number of other similar surveys, and no 
incentives for participating general practitioners. A 
systematic review identifying strategies to improve 
response rates on postal and electronic questionnaires 
demonstrated that the responses were likely almost 
doubled when there were monetary/non-monetary 
incentives, recorded delivery, shorter questionnaires, 
and interesting survey topics.29 We did not have 
any funding to provide incentives. Other weakness 
of the study was Wwe did not clearly define the 
answer option of ‘observation for 48 to 72 hours’ in 
the clinical scenarios. The option for observation for 
48 to 72 hours was meant for clinicians who would 
choose to closely observe the AOM patients without 
antibiotics treatment for 48 to 72 hours. Without 
a clear definition, clinicians who would prescribe 
antibiotics, may also choose observation to see the 
effect of antibiotics. This would limit us to precisely 
identify the proportion of clinicians who would 
solely choose observation by withholding antibiotic 
treatment. As the last study weakness, this study 
only covered three adjacent cities in two provinces 
(Jakarta and a small part of West Java), which certainly 
does not represent the current management practice 
of AOM in Indonesia in general (total provinces in 
Indonesia is 34). To generalize these findings to the 
rest of Indonesia requires a national scale study that 
includes multiple cities (rural and urban) representing 
each province in Indonesia, supported by the 
 Given that the self-
reported nature of our study is a further limitation, a 
national study should collect objective data on the 
actual number of AOM cases (including diagnosis 
and treatment) from primary care or hospital patient 
databases. However, our purpose was to survey likely 
practice and participation in a proposed trial.
There is still a high rate of antibiotic prescribing 
among Indonesian clinicians for children with 
AOM. Although it has not been recommended 
in the guidelines, clinicians would consider using 
corticosteroids for AOM. Given nearly half of 
clinicians were interested in participating in a 
future trial on corticosteroids, our proposed trial is 
feasible. This survey demonstrated existing gaps in 
the management of AOM between clinical practice 
and evidence. It is crucial to translate scientific 
evidence to clinical practice to improve the quality 
of the AOM management in children, particularly in 
Indonesia, by promoting an accurate and affordable 
diagnostic tool for AOM, such as a pneumatic 
otoscope, as well as by prescribing antibiotics only 
for severe AOM, and offering an observation under 
adequate pain management for mild cases. Therefore, 
further investigation is required to identify other 
contributing factors to be able to tackle this problem 
comprehensively. 
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4.1  SUMMARY 
Our second study (Study 2 – Current management of children with acute otitis media: a 
feasibility survey for a pragmatic study in Jakarta, Depok, and Bekasi) showed it was feasible 
to conduct a large clinical trial testing oral corticosteroids for children with acute otitis media 
(AOM). It was crucial to pilot our pre-specified procedures and measures in a smaller scale 
study or a pilot study (Study 3 – A pilot pragmatic, randomised, open-label, controlled study of 
oral prednisolone for acute otitis media in children). Due to budget constraints, our pilot study 
did not use placebo as a control, which made this study a single-blind study, instead of double-
blind. This pilot study carried out all planned procedures in the protocol of the main study, 
identified potential obstacles from participating practitioners and study participants, and 
verified the sample size of the main study.  
We also conducted a mechanistic sub-study (tympanometry sub-study) as part of the pilot study 
to identify whether oral corticosteroids could improve middle ear effusion (MEE) and whether 
these improvements correlated with the resolution of pain and other AOM-related symptoms.  
Our pilot study showed that it was feasible to implement all pre-specified procedures and 
measures in the main study by all participating healthcare personnel, study participants, and 
their parents. We will need a smaller sample size compared to our original sample size 
calculation. We found that oral prednisolone may potentially reduce the pain intensity at Day 
3, and improve tympanometry at Day 7, but may cause drowsiness. The pilot study confirms 
the importance of conducting our main study, which is a large, pragmatic, randomised, double-
blind, placebo-controlled study. This chapter consists of the published protocol paper for the 
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Background: Acute otitis media (AOM) is associated with high antibiotic prescribing rates. 
Antibiotics are somewhat effective in improving pain and middle ear effusion (MEE) however 
they have unfavourable effects. Alternative treatments, such as corticosteroids as anti-
inflammatory agents, are needed. Evidence for the efficacy of these remains inconclusive. We 
conducted a pilot study to test feasibility of a proposed large-scale randomised controlled trial 
(RCT) to assess the efficacy of corticosteroids for AOM.  
Methods: We conducted a pilot, pragmatic, parallel, open-label RCT of oral corticosteroids for 
paediatric AOM in primary and secondary/tertiary care centres in Indonesia. Children aged 6 
months-12 years with AOM were randomised to either prednisolone or control (1:1). Physicians 
were blinded to allocation. Our objectives were to test the feasibility of our full RCT procedures 
and design, and assess the mechanistic effect of corticosteroids, using tympanometry, in 
suppressing middle ear inflammation by reducing MEE. 
Results: We screened 512 children; 62 (38%) of 161 eligible children were randomised and 60 
were analysed for the primary clinical outcome. All study procedures were completed 
successfully by healthcare personnel and parents/caregivers, despite time constraints and high 
workload. All eligible, consenting children were appropriately randomised.  One child did not 
take the medication and four received additional oral corticosteroids. Our revised sample size 
calculation verified 444 children are needed for the full RCT. Oral corticosteroids did not have 
any discernible effects on MEE resolution and duration. There was no correlation between pain 
or other symptoms and MEE change. However, prednisolone may reduce pain intensity at Day 
3 (Visual Analogue Scale mean difference -7.4 mm, 95% confidence interval (CI) -13.4 to -1.3, 
p=0.018), but cause drowsiness (relative risk (RR) 1.8, 95% CI 1.1 to 2.8, p=0.016).  
Tympanometry curves at Day 7 may be improved (RR 1.8, 95% CI 1.0 to 2.9). We cannot yet 
confirm these as effects of corticosteroids due to insufficient sample size in this pilot study. 
Conclusions: It is feasible to conduct a large, pragmatic RCT of corticosteroids for paediatric 
AOM in Indonesia. Although oral corticosteroids may reduce pain and improve tympanometry 
curves, it requires an adequately powered clinical trial to confirm this.   
Keywords: Otitis media, Acute disease, Anti-bacterial agents, Glucocorticoids, 
Corticosteroids, Middle ear effusion, Pilot projects, Acoustic impedance tests. 
Trial registration: Study registry number: ACTRN12618000049279. Name of registry: the 





Antibiotic resistance is a global health threat, largely because of antibiotic use [1-3]. Use of 
antibiotics is also associated with unfavourable effects (e.g. vomiting, diarrhoea) [4]. There is 
a particularly high rate of antibiotic prescribing for acute respiratory infections (ARIs) in 
outpatient settings (primary and secondary care): 50% in the United States; 53% in European 
countries; 34% in Malaysia; and up to 78% in Indonesia [5-8].  
 
Acute otitis media (AOM), a middle ear inflammation, is an ARI that is commonly found in 
children, particularly before the age of five [9-10]. Antibiotics are commonly prescribed. A 
Cochrane review showed antibiotics are effective in improving acute pain and tympanometry 
results, as well as other clinical outcomes (e.g. tympanic membrane perforation, contralateral 
AOM). However, due to their modest benefits along with significant potential for unfavourable 
effects, antibiotics are not mandatory treatment for AOM, particularly for mild AOM. 
Therefore, it is important to emphasize both benefits and harm of antibiotic use to the patients 
and their parents and involve them in treatment decision making in the management of AOM.  
 
In Australia, 89% of new AOM cases were managed by antibiotics between 2010 and 2015 
[11]. In Indonesia, our feasibility survey showed that up to 88% of physicians would prescribe 
antibiotics for mild AOM, although antibiotics are most beneficial for severe AOM (i.e. severe 
symptoms, young children with bilateral AOM, tympanic membrane perforation) [9]. These 
rates are higher compared to other western countries such as the United States (57.6%), Iceland 
(70.4%), Denmark (73.7%), and Sweden (86.7%) [12-14]. This condition may be affected by 
two contradictory Indonesian practice guidelines for AOM [15,16]. The AOM guideline for 
primary care practitioners recommends the use of antibiotics for both mild and severe AOM. 
The only difference is the antibiotic dose, which recommends a higher dose for severe AOM 
[15]. On the other hand, the guideline for Ear, Nose, and Throat (ENT) specialists recommends 
antibiotic use for only severe AOM, although it does not specifically describe the definition of 
severe AOM [16].  In addition, despite of the existence of national regulation on antibiotic use, 
its implementation is less enforced in Indonesia and leads to antibiotic self-medication [17,18]. 
 
High rates of antibiotic use, despite of its modest benefits and side effects and antibiotic 
resistance, indicate the necessity to find effective alternative treatments for AOM (e.g. 
decongestants, herbal preparations, corticosteroids) [19-21]. The existing alternative treatments 
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have insufficient evidence to be recommended in clinical practice [19-21]. Since inflammation 
is a key mechanism of AOM, corticosteroids are a potential treatment. Although they have been 
effectively used for other ARIs (e.g. pneumonia, bacterial meningitis) [22,23], their effect on 
AOM remains unclear [24,25]. Aside from potential beneficial effects on inflammation, 
corticosteroids also may cause side effects. Gastrointestinal disturbances and behavioural 
changes have been identified as common side effects [26]. Although short-term use of a 
corticosteroid is unlikely to induce serious harm, one systematic review reported 1% of children 
experienced increased susceptibility to infections due to the immunosuppression effect of 
corticosteroids [26]. 
 
Our Cochrane review shows that systemic corticosteroids may effective in improving clinical 
symptoms of AOM [24]. However, this was based on one small study demonstrating uncertain 
effects of systemic corticosteroids for AOM due to a wide confidence interval that included 
both benefits and harm.  High-quality evidence is crucial to address uncertainties around the 
effects of corticosteroids for AOM. Therefore, we plan to conduct an adequately powered 
clinical trial to assess both benefits and harm of corticosteroids for children with AOM. Our 
original sample size calculation demonstrated that we need 760 children to be able to detect 
actual effects of oral corticosteroids for children with AOM. Prior to this, we conducted a pilot 
study to test the feasibility of characteristics of our full RCT design and procedures in 60 
children, including a mechanistic sub-study using tympanometry (tympanometry sub-study) to 
study the effect of corticosteroids on middle ear effusion (MEE). The clinical findings from this 
study, although they cannot be definitive due to a small sample size, can indicate the direction 
of potential clinical effects of oral corticosteroids for AOM, which can then be confirmed in an 
adequately powered clinical trial.  
 
Methods 
Study aims and objectives 
This pilot study aimed to test all pre-specified methods and procedures that are planned to be 
implemented in the full RCT, but in a smaller sized study. 
 
The objectives for the pilot study were to assess the feasibility of  characteristics of the full 
RCT design and procedures (e.g. recruitment, randomisation, outcome measurement, 
experience and obstacles of physicians and parents/caregivers, sample size verification) and  
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assess the mechanistic effect of corticosteroids in suppressing inflammation in the middle ear 
specifically by reducing MEE.  
 
Prior to our study implementation, our study protocol was reviewed and approved by the Ethics 
Committee Faculty of Medicine Universitas Indonesia and the Bond University Human 
Research Ethics Committee (BUHREC) Australia  (see Declarations section).  
 
Study design and setting 
This was a pilot parallel, pragmatic, stratified, randomised, open-label, single-blind, controlled 
study in an allocation ratio of 1:1. We planned to conduct this study in seven hospitals in Jakarta 
and Bekasi as described in our protocol [27], however we only received research permits from 
six hospitals. Due to low rate of recruitment, we added two primary care centres in Jakarta to 




We included children aged six months to 12 years old with AOM, defined as current onset 
(within 48 hours) of AOM-relevant symptoms (e.g. earache, ear tugging/rubbing or irritability 
in non-verbal children). Otoscopic findings of acute inflammation (e.g. erythema) and middle 
ear effusion (e.g. bulging, air-fluid level) confirmed the diagnosis.  
 
Exclusion criteria 
We excluded children (1) with major and severe medical conditions (e.g. heart diseases, 
tuberculosis), (2) who were immunocompromised (e.g. HIV infection, under cancer treatment), 
(3) with congenital malformations and/or syndromes (e.g. cleft palate, Down syndrome), (4) 
with high risk of strongyloidiasis infections, (5) with ear ventilation tube(s), (6) who had been 
exposed to persons with varicella or active Zoster infection in the preceding three weeks without 
prior varicella immunisation or infection, (7) who had taken systemic (oral, injection) or topical 
steroids in the preceding four weeks, (8) who had taken antibiotics in the preceding two weeks, 
and (9) who were hypersensitive to prednisolone or prednisone, or other corticosteroids. Further 






Study intervention arm 
We gave prednisolone tablets (Lupred®5) at a daily dose of 1–2 mg/kg of body weight for five 
days, which was operationalised based on age: 10 mg/day for children aged six months to up to 
two years; 20 mg/day for children aged two up to six years; and 30 mg/day for children aged 
six to 12 years [28]. We provided liquid sweetener to make prednisolone more palatable. 
Children with mild AOM who were randomised to the intervention arm received prednisolone 
plus expectant observation, whilst those with severe AOM received prednisolone plus 
antibiotics (see Figure 1). Further details of administration and timing of study medication are 
described in our protocol [27]. 
 
Control arm 
Children with mild AOM who were randomised to the control arm received expectant 
























Physicians were able to prescribe medications for symptoms (e.g. analgesic, decongestant) as 
per  their usual practice. The physicians were not able to prescribe oral corticosteroids.  
 
Outcomes 
For the first objective of assessing the feasibility of characteristics of our full RCT design and 
procedures, we measured four outcomes: (1) recruitment rates; (2) successful completion of the 
study procedures; (3) successful measurement of planned outcomes; (4) the experiences and 
barriers of participating healthcare personnel (i.e. physicians, nurses, audiologists, pharmacists) 
and parents/caregivers in measuring planned outcomes; (5) adherence to study visits and study 
medication; and (6) verification of the sample size calculation for the full RCT using pain 
measures in the control group. 
 
For the second objective of assessing the mechanistic effect of corticosteroids in suppressing 
inflammation in the middle ear, we measured three outcomes: (a) change in MEE at various 
time points; (b) duration of MEE; and (c) correlation between ear pain and other symptoms 
with the changes in MEE at various time points. 
 
Recruitment rate was defined as the proportion of consultations with potentially eligible 
children who provided their consent to be included in the study. We assessed this outcome 
monthly using a logbook completed by participating nurses and physicians.  
 
The successful completion of the study procedures and outcome measures was defined as the 
proportion of participating healthcare personnel and parents/caregivers who were able to 
conduct study procedures and measure outcomes in order to obtain valid results. The study 
procedures were: (1) obtaining consent; (2) recruitment and stratification; (3) otoscopic 
assessment; (4) pain measures using Visual Analogue Scale (VAS) and Acute Otitis Media 
Severity of Symptoms (AOM-SOS) scale; (5) randomisation, treatment allocation, and 
prescription dispensing; (6) preparation, completion, compilation, and storage of case report 
forms (CRFs); (7) tympanometry examination and interpretation; (8) preparation and 
dispensing of study medication; and (9) completion of the symptom diary. These outcomes 
were measured using the logbook, case report form, and the symptom diary (Additional file 1. 




For the assessment of the experience and barriers to measuring outcomes, we used a feedback 
form (see Additional file 1. Case report forms). Each question represented a study procedure 
and had five responses (‘very easy’, ‘easy’, ‘neutral’, ‘difficult’, and ‘very difficult’). We asked 
the healthcare personnel and parents to choose one response. We asked those who chose 
‘difficult’ to choose obstacle(s) describing their experience during that procedure or 
measurement. They could choose more than one option or write their personal experience.  
 
We assessed the adherence to study medication by identifying the proportion of children who 
took the study medication (prednisolone) for five days per protocol divided by all children in 
the prednisolone group. This outcome was measured using the symptom diary. The adherence 
to the study visit was assessed by identifying the proportion of children who came to follow-up 
visits at Day 3, Day 7, Day 30, and Day 90 per protocol divided by all children randomised to 
the study. This outcome was measured using the follow-up card, the consent form, and the 
symptom diary. 
 
The verification of sample size for the full RCT was calculated by identifying the proportion of 
children with mild and severe AOM in the pilot study with ongoing pain represented as VAS 
score ≥ 5 mm, at Day 3, in the control group.  
 
We assessed change in MEE at Day 3, Day 7, Day 30, and Day 90 by measuring static acoustic 
admittance (SAA), which is defined as ‘the amount of energy absorbed by the tympanic 
membrane and middle ear’. We assumed that a difference of 0.3 mmho was a minimum 
clinically important one for SAA [29]. 
 
For duration of MEE, we only conducted tympanometry at follow-up visits. We were not able 
to identify whether the effusion had persisted, disappeared, or reappeared between these visits. 
Therefore, we reported this as the proportion of children who had a complete resolution of MEE 
which is represented by a type A curve at follow-up visits. We used the modification of Jerger 
to classify the tympanogram curve types, as follows: (1) a type A curve indicating a normal 
middle ear; (2) type C curves including a C1 curve, which indicates a transition from a normal 
middle ear to an early MEE, and a C2 curve representing an early MEE;  and (3) a type B curve, 




We assessed the correlation between ear pain and other symptoms (i.e. ear tugging, irritability, 
crying, lack of sleep, lack of appetite, loss of playfulness, fever) using VAS and AOM-SOS 
assessed by parents in the symptom diary with the changes in SAA at Day 3, Day 7, Day 30, 
and Day 90. 
 
The planned primary outcome of the full RCT is the proportion of children with pain that has 
not reduced by the minimum clinically important amount (10 mm VAS) by Day 3 [34,35]. The 
secondary outcomes are: (1) the proportion of children with ongoing pain (VAS ≥ 5 mm) [36] 
at Day 1, 3, 5, 7, and 14; (2) reduction of pain intensity measured using VAS at similar time 
points; (3) reduction of overall symptoms measured using AOM-SOS at similar time points 
[37]; (4) reduction of overall pain duration; (5) complications related to AOM; (6) the 
proportion of children with mild AOM requiring antibiotics and those with severe AOM 
requiring second-line antibiotics; (7) AOM recurrence; (8) adverse effects; and (9) the 
adherence to study medication. For the VAS and AOM-SOS assessment, we used data from the 
symptom diary completed by the parents. As this is a pilot, we do not report here the primary 
outcome of the full RCT. However, we do report the first secondary outcome. Further details 
of data collection for the pilot and full RCT are described in our protocol paper [27]. 
 
Sample size 
We did not formally determine the sample size for this pilot study. We included 60 children 
with AOM in our pilot study based on sample size calculation for the tympanometry sub-study 
[27]. Our feasibility survey demonstrated that it would require nine months including 3-month 
follow-up to recruit 60 children. We did not conduct an interim analysis due to the small sample 
size and short study duration.  
 
Recruitment and stratification  
For the full RCT, we plan to stratify children by clinical specialty or healthcare centre level 
(primary care or secondary/tertiary healthcare centres) and severity of AOM (mild or severe). 
As we intended to only include ENT specialists who worked at secondary/tertiary centres in 
this pilot study, we stratified children based only on AOM severity. Details on stratification 
criteria are in the protocol paper [27].  
 
To help the recruitment and stratification process, including randomisation and tympanometry 
examination where necessary, we recruited and trained seven research assistants, including one 
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administrative assistant, to support the implementation of the study (RO, DN, IG, RA, RS, FR, 
VV).  
Randomisation and allocation concealment 
After confirmation of eligibility, and completion of the clinical examination, but prior to 
randomisation, physicians dispensed two prescriptions to the nurse. The first prescription was 
for general AOM medications (e.g. antibiotics, decongestants). The second one was for the 
study medication. The nurse then only dispensed the second prescription to patients who were 
randomised to the intervention arm. Further details of randomisation process, including the 
preparation, dispensing and central storage of study medication are in the protocol paper [27].  
Blinding 
The appointed nurses and patients or parents/caregivers were aware of the intervention 
allocation. The physicians and audiologists were blinded to the allocation [27]. At the primary 
care centre, the principal investigator (RR) and research assistants (RO, DN, IG, RA, RS, FR) 
conducted randomisation and tympanometry examination because of the limited availability of 
healthcare personnel for the study. Therefore, it was not possible to conceal allocation after 
randomisation. However, the research assistants were not involved in the treatment decisions 
and ensured the clinician was not aware of the intervention allocation. 
Statistical methods 
We report the outcomes of the pilot study (e.g.  recruitment rate, the success and ability of study 
procedures and measures, adherence to study visits and medication) as proportions in 
percentages (n, %).  
For the verification of sample size calculation, we used the proportion of the children in both 
mild and severe groups, and pain measures among the controls to update our calculation of 
failure rate of ongoing pain at Day 3.  We did not change the assumed relative of risk on ongoing 
pain at Day 3, as the pilot results arise from a small sample.  
For the clinical outcomes, since it was a pilot study and we did not want to reveal the result of 
the primary outcome of the proposed full RCT, we only report the proportion of children with 
ongoing pain (binary outcome) and reduction of pain and other symptom severity (continuous 
outcome) at: Day 1, Day 3, Day 5, Day 7, and Day 14. For clinical and tympanometry 
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continuous outcomes (i.e. pain and symptoms scores measured by VAS and AOM-SOS, SAA 
value), we conducted linear regression to determine the unadjusted and adjusted mean 
difference (MD), 95% confidence interval (CI), and the p values for the comparison between 
groups at Day 3 as a primary time point . The adjusted MD used the baseline result (equivalent 
to ANCOVA). Spearman’s correlation coefficient was calculated to determine the correlation 
between ear pain using VAS and SAA values on the affected ear for unilateral AOM and the 
worst ear for bilateral AOM, as well as between other relevant symptoms using AOM-SOS and 
the similar SAA values.  We used STATA 15.1 software for statistical analysis.  
 
For clinical and tympanometry binary outcomes (i.e. the proportion of children with persisting 
pain of VAS ≥ 5 mm and those who had complete MEE resolution at various time points), we 
conducted chi-squared tests and reported relative risk (RR) and 95% CI for the comparison 
between groups. We presented the p values of the outcomes measured at Day 3 (primary time 
point). We used Fisher’s exact test to determine statistically significant differences in effect 
estimates of binary outcomes between the prednisolone and control group where there were 
small event numbers (< 10 per variable cell).  
 
For time to pain resolution, we identified the time point where children had resolution of pain 
(VAS < 5 mm) and presented these as a median, and then compared the median between the 




We screened 512 children with ear pain (22 February-30 November 2018) and 161 children 
(31%) were assessed using the eligibility criteria (see Figure 2). All physicians were able to 
confirm AOM using an otoscope. Sixty-two (38%) eligible children were stratified to mild and 
severe AOM. Thirty-one children were randomly allocated to the prednisolone group (8 mild 
and 23 severe AOM) and 31 children to the control group (7 mild and 24 severe AOM). Two 
children left the study before data collection at Day 3 resulting in 60 children (29 prednisolone 
versus 31 control group) were analysed for the planned primary outcome of the full RCT. The 








The baseline characteristics between the two groups were similar in gender and had an age 
range of 61 to 73 months (see Table 1). There were more children in the control group whose 
parents had a low education level (primary and secondary education), were exposed to parental 
smoking (passive smoking), or received amoxicillin and amoxicillin/clavulanate and 
acetaminophen at baseline. Children in the prednisolone group were more likely to receive 
cefixime. Forty-seven per cent of the children were found to have hyperaemic tympanic 
membrane only on the otoscopic examination.  
 
Table 1. Baseline and clinical characteristics of randomised children by treatment group. 
 Characteristics Prednisolone (n=31) Control (n=31) 
Baseline characteristics   
Age (months) mean ± SD 60. 7 ± 32.2 73.2 ± 38.3 
Sex - male (n; %)  15 (48) 18 (58) 
Breastfeeding (n; %) 28 (90) 27 (87) 
Breastfeeding until at least the first 6 months of life (n; %) 20 (71) 19 (70) 
Child day care attendance (n; %) 1 (3) 1 (3) 
Duration per week (hours) mean ± SD 50 35 
Pre-school or school attendance (n; %) 21 (68) 20 (64) 
Duration per week (hours) mean ± SD 4.9 ± 2.0 4.7 ± 2.0 
Parental education (father)*    
Primary education (i.e. elementary school) 1 (3) 2 (6) 
Secondary education (i.e. middle and high school) 13 (42) 17 (55) 
Tertiary education (e.g. diploma, bachelor, masters) 16 (52) 11 (35) 
Parental education (mother)*   
Primary education (i.e. elementary school) 0 (0) 2 (6) 
Secondary education (i.e. middle and high school) 12 (39) 17 (55) 
Tertiary education (e.g. diploma, bachelor, masters) 19 (61) 11 (35) 
Pneumococcal vaccinations (n; %) 9 (29) 7 (23) 
Influenzae vaccinations (n; %) 6 (19) 7 (23) 
≥3 episodes of acute respiratory infections in the past year (n; %) 23 (74) 22 (71) 
First episode of AOM 20 (64) 21 (68) 
First episode of AOM at ≤2 years of age (n; %) 8 (26) 3 (10) 
≥3 episodes of ear infection in the past year (n; %) 3 (10) 2 (6) 
>3 children in one house (n; %) 0 (0) 0 (0) 
Passive smoking (n; %) 14 (45) 20 (64) 
Ear discharge (n; %) 11 (35) 8 (26) 




 Characteristics Prednisolone (n=31) Control (n=31) 
Allergic rhinitis  3 (10) 2 (6) 
Bronchial asthma  0 (0) 1 (3) 
History of atopy in the family  12 (39) 9 (29) 
AOM lateralisation – unilateral (n; %) 20 (64) 18 (58) 
Clinical characteristics   
Common cold 27 (87) 28 (90) 
Nose abnormalities (e.g. oedema, discharge)  23 (85) 23 (82) 
Tonsil abnormality (e.g. hyperaemic, oedema) 15 (55) 15 (53) 
Throat abnormality (e.g. hyperaemic, oedema) 15 (55) 8 (28) 
Diagnosis of AOM   
Confirmed by otoscope    
Hyperaemic tympanic membrane only 12 (39) 17 (55) 
Hyperaemic tympanic membrane and other signs of 
inflammation/middle ear effusion†  
23 (74) 21 (68) 
Confirmed by otoscope and clarified by tympanometry‡ 25 (86) 25 (86) 
Initial antibiotic given (n; %)   
Amoxicillin 4 (13) 11 (35) 
Amoxicillin/clavulanate 5 (16) 8 (26) 
Cefixime 12 (39) 3 (10) 
Cefadroxil 1 (3) 1 (3) 
Trimethoprim/sulfamethoxazole  0 (0) 1 (3) 
Clarithromycin  1 (3) 0 (0) 
Other treatment given by doctors at initial visit (n; %)   
Acetaminophen 9 (29) 16 (52) 
Nonsteroidal Anti-inflammatory Drugs 4 (13) 5 (16) 
Decongestants and/or antihistamine 26 (84) 22 (71) 
Cough medicine 18 (58) 14 (45) 
Antibiotic ear drops 9 (29) 6 (19) 
Nasal (topical) decongestant 6 (19) 2 (6) 
Nasal corticosteroid 0 (0) 1 (3) 
Vitamins or herbals 3 (10) 8 (26) 
Ear diathermy 0 (0) 1 (3) 
Inhalation 0 (0) 1 (3) 
Others (e.g. mefenamic acid, nasal douching) 3 (10) 5 (16) 
Tympanometry test (n; %) 29 (93) 29 (93) 
Complete 15 (52) 18 (62) 
Partial completion 0 (0) 6 (21) 
Sufficient values for analysis 15 (52) 22 (76) 
Type A 4 (27) 6 (27) 
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 Characteristics Prednisolone (n=31) Control (n=31) 
Type C1 2 (13) 4 (18) 
Type C2 1 (7) 1 (4) 
Type B (or flat) 8 (53) 11 (50) 
*We could not obtain the information of father’s (n=2) and the mother’s education level (n=1); †A child with 
bilateral AOM may have two different otoscopic results (e.g. hyperaemic tympanic membrane only and 
hyperaemic tympanic membrane with other signs of inflammation/middle ear effusion); ‡Four patients did not 
undergo tympanometry examination due to: severe pain, not recommended by physicians due severe bulging, 
uncooperative child, and  nurse forgot. Patients with tympanic membrane perforation were considered as 
confirmed by otoscope and tympanometry. 
 
Numbers analysed 
For the primary outcomes of the full RCT, we analysed 60 children at Day 3. For the secondary 
outcomes, we analysed 58 children (29 prednisolone versus 29 control group) as two more 
children left the study after data collection at Day 3. For the tympanometry sub-study, we 
conducted tympanometry examinations on 58 children (93%) and analysed 37 children (15 
prednisolone versus 22 control group) who had sufficient tympanometry findings at both 
baseline and Day 3. We were not able to fulfil the sample size to 60 children due to difficulty 
in recruitment and budget constraints which prevented the extension of the recruitment period. 
 
Outcomes and estimation  
Recruitment rate  
We collected logbooks from each study site to measure the recruitment rate. However,  most 
nurses did not complete the logbook appropriately. The average recruitment rate was 38.5% of 
potentially eligible children (see Table 2). The main reasons for exclusion were: (a) onset > 2 
days (24%); (b) lack of interest or reluctance of parents to participate (14%); and (c) prior intake 
of antibiotics/steroids (10%). Three sites did not contribute to patient recruitment because of no 
eligible cases. Only one private hospital contributed to the study recruitment. Therefore, we 
added two primary care centres to the study.   
 
Table 2.  Recruitment rates 
Recruitment details 
according logbook 
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Monthly 
Mean 
Recruitment rate* (%) 0 48 33.3 44.4 33.3 66.7 40 40 35.7 20.7 38.5 
Screened children with 
AOM 
1 25 18 9 6 15 15 15 28 29 16.1 
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*recruitment rate = children with AOM aged six month to 12 years who were recruited into the study divided by 
all children with AOM aged six months to 12 years who were being assessed for the study by participating 
physicians.  
 
The successful completion of the study procedures and outcome measures 
Prior to the study, we provided training to 66 physicians (i.e. ENT specialists, GPs, 
paediatricians), 39 nurses, 35 pharmacists, and 6 audiologists. During the training, we coached 
and assisted them in conducting all study procedures and measures per protocol.  
 
Twenty-three of 85 parents/caregivers of eligible children (27%) declined to participate in the 
study (see Table 2). All physicians (100%) successfully recruited and stratified eligible children 
based on their AOM severity, performed an otoscopic assessment, and measured pain and other 
relevant symptoms using VAS and AOM-SOS, and reported the findings as self-reporting 
assessment in the CRF. All eligible children were successfully randomised and allocated to 
their randomised intervention by nurses/research assistants. All patients had the study 
medication prescriptions dispensed as per protocol. All nurses were able to appropriately 
prepare, compile, and store the CRF. All audiologists successfully performed tympanometry 
examination.  However, there were incomplete values caused by lack of sensitivity of 
tympanometry. One of 31 study medication packages (3%) was not dispensed by the 
pharmacist, which had to be home delivered by the researcher (RR).   
 
One hundred per cent of symptom diary data was completed for analysis. However, only 60% 
of parents/caregivers were able to complete the symptom diary per protocol, which required us 
to collect data and clarify unclear responses by interviewing 25 parents retrospectively (see 
Table 3). We regularly checked the completion of the symptom diary of: Day 0 to 3 at the first 
Recruited to the study 0 12 6 4 2 10 6 6 10 6 6.2 
Did not meet study criteria 0 7 4 2 2 4 7 8 14 21  
Onset >2 days 0 4 3 2 1 3 4 4 7 10  
Prior antibiotic/steroid 
intake 0 3 1 0 0 1 1 2 4 8 
 
Chronic/ immunosupp 
disorders 0 0 0 0 0 0 2 0 0 0 
 
Unable for follow-up 
visits 0 0 0 0 1 0 0 2 3 3 
 
Declined to participate 1 5 6 3 1 1 0 1 4 1  
Not offered participation 0 1 2 0 1 0 2 0 0 1  
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follow-up visit (Day 3) and Day 4 to 7 at the second visit (Day 7), and after the diary collection 
at Day 14. We expected this strategy may reduce recall bias. We interviewed the parents directly 
during the consultation at the follow-up visits and at the follow-up by phone at Day 14. 
 
Experiences and barriers to measuring planned outcomes of the full RCT. 
We measured this outcome using a feedback form. We only invited physicians and nurses who 
recruited patients or were involved in data collection for at least two patients to provide 
feedback. We obtained feedback from 15 ENT specialists (15/51; 29%), six GPs (6/9; 67%), 
16 nurses (16/39; 41%), six pharmacists (6/35; 17%), and four audiologists (4/6; 67%). 
 
Most ENT specialists and GPs rated obtaining consent from parents, recruiting and stratifying 
patients into the study, and using otoscopes as ‘easy’. The common obstacles were: (1) 
reluctance to participate due to the term ‘research’ in the consent form; (2) lengthy time to 
deliver extensive study information; (3) time constraints due to the need for an increased 
appointment length and pressure of patient numbers; and (4) a complex eligibility form. General 
practitioners found using an otoscope was challenging in some patients due to the narrowness 
of ear canals and uncooperative children. Most ENT specialists (73%) rated completing the 
CRFs as ‘easy’, whilst most GPs rated this as ‘neutral’ (50%). The ENT specialists 
recommended simplification of the CRFs.  
 
Most ENT specialists and GPs rated VAS (71% and 75%, respectively) and AOM-SOS (85% 
and 100%)  as ‘easy’, although more information on pain description was required. They 
suggested using a facial scale to measure pain. They found AOM-SOS was suitable to assess 
pain in young children. 
 
Most nurses rated the randomisation process and CRF compilation, preparation and storing as 
‘easy’, and rated treatment allocation and prescription dispensing as ‘neutral’. They found 
obstacles when accessing the randomisation website due to complicated access steps and 
unstable internet connection. They also found these were time-consuming, particularly in terms 
of randomisation and CRF compilation, which were not always feasible due to workload. Most 




The pharmacists and audiologists rated the preparation and dispensing of study medication, and 
tympanometry examination as ‘very easy’ to ‘easy’. We also obtained feedback from our 
research assistants (n = 6) who conducted tympanometry examination in primary care centre. 
Only one rated this as ‘difficult’ due to the narrowness of ear canals. 
We obtained feedback from parents regarding the completion of the symptom diary (see Figure 
3). The majority of parents rated VAS (47%), AOM-SOS (71%), and the completion of 
symptom diary (62%) as ’easy’. Parents preferred to use a numeric pain scale.  
Figure 3. Parents’ experience in measuring planned outcomes for the main study 
Adherence to study visits and study medication 
Fifty-eight children completed all follow-up visits and four children left the study (see Table 
3). We visited homes of those who were not able to come for their follow-up visits. During this 
visit, we did not prescribe any medication and recommended they visit the hospital/primary 
care centre for any concerning condition (e.g. worsening AOM, complications). 
Four children received additional oral corticosteroids: one from a participating physician for 
AOM and three children received it from other physicians for asthma, prolonged cough due to 




Table 3.  The adherence to the study. 




Not compliant to the completion of symptom diary   
No data after baseline for primary outcome analysis 2 0 
Data collected retrospectively by interview 4 13 
Unclear responses clarified by interview 5 3 
Not compliant to study medication*   
Missed one dose, but taken on the next day 1 - 
Vomited constantly and stopped the study medication 1 - 
Took half of dose, vomited <30 minutes) and took another half of dose 1 - 
Took medicine in the afternoon (not in the morning) 2 - 
Not compliant to the follow-up visits   
Delayed timing of follow-up visit 3 3 
Left study 2 2 
Additional interventions   
Received additional oral corticosteroids 3† 1‡ 
Received intervention of co-medication from study investigator 2 5 
*Nine patients did not complete diary, but the adherence confirmed by interview; †At Day: 10, 12, and 60; ‡At 
Day 7. 
 
Interference by research investigator. 
Due to the lack of available second-line antibiotics and other medications in primary care 
centres, the principal investigator (RR), who was not blinded to the intervention allocation, 
provided several medications to seven patients: second-line antibiotics (4/62; 6%); ibuprofen 
(4/62; 6%); combined decongestant-antihistamine (6/62; 10%); cough syrup (5/62; 8%); topical 
decongestant (4/62; 6%); and nasal saline drops (1/62; 2%). More children in the control group 
received interference, since most children in primary care centres were randomly allocated to 
this group by chance.  
 
Verification of sample size calculation for the full RCT. 
Based on our original sample size calculation, we need to enrol 760 children with AOM. We 
estimated, based on data by Rovers et al. [38], that there would be 35% of the total sample of 
children with AOM in the severe group, of which 57.5% would have ongoing pain at Day 3 in 
the control group. However, in our study, 78% of our total sample was in the severe group with 
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risk of ongoing pain (≥ 5 mm VAS) at Day 3 in control group of 42%.  Of the children with 
mild AOM, 57% in the control group had ongoing pain at Day 3. The average proportion of 
children with ongoing pain when combining the mild and severe groups was 45.2%. With our 
original assumption of 0.70 risk ratio with steroids, we will need to study 201 experimental and 
201 control subjects to be able to reject the null hypothesis with probability (power) 0.8 and 
type I error probability of 0.05.  We will use an uncorrected chi-squared statistic to evaluate 
this null hypothesis. With a 10% allowance for dropouts, the total sample size becomes 444.  
There is a notable difference in the sample size estimation between our original sample size and 
our pilot study (see Table 4). The calculation of our original sample size was based on 
assumptions from a meta-analysis of studies conducted in developed countries. Our updated 
sample size using the pilot study results demonstrated that we need a smaller sample size for 
the full RCT if it is conducted in an urban setting in a developing country. The sample size may 
change if the study is conducted in different settings or countries. We are therefore presenting 
our assumptions for the sample size calculation for a clinical trial conducted in different settings 
(see Table 4). 
Table 4. Sample size assumptions for a clinical trial of corticosteroids for AOM conducted 
in different settings. 






With severe AOM 35% 56% 78% 
With severe AOM AND ongoing pain 57.5% 50% 42% 
With mild AOM 65% 43% 22% 
With mild AOM AND ongoing pain 36% 46% 57% 
With severe and mild AOM AND ongoing 
pain 
31.6% 38.4% 45.2% 
Sample size calculation‡ 760 570 444 
*From a meta-analysis of studies conducted in developed countries; †Our pilot study was conducted in a
developing country, urban setting; ‡The sample size includes a 10% allowance for dropouts. 
Change of middle ear effusion (MEE). 
We found no difference in MEE change represented by SAA between the prednisolone and 
control groups at: Day 3 (MD 0.04 mmho, 95% -0.07 to 0.16), Day 7  (MD 0.07 mmho, 95% -
0.06 to 0.19), Day 30  (MD -0.05 mmho, 95% -0.19 to 0.09), and Day 90 (MD 0 mmho, 95% -
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0.14 to 0.14). Consistent results were found after adjustment for the baseline results (see Table 
5). All differences were well below the minimum clinical important difference of 0.3 mmho. 
Table 5. Static acoustic admittance values in the affected (unilateral AOM) or the worst 
ear (bilateral AOM). 
Static acoustic 
admittance: 














Day 0 (Visit 1) 0.19 ± 0.13 0.24 ± 0.22 -0.05 (-0.18, 0.08)
Day 3 (Visit 1) 0.26 ± 0.15 0.22 ± 0.17 0.04 (-0.07, 0.16) 0.43 0.07 (-0.02, 0.16) 0.13 
Day 7 (Visit 2) 0.32 ± 0.15 0.25 ± 0.20 0.07 (-0.06, 0.19) 0.08 (-0.03, 0.20) 
Day 30 (Visit 3) 0.32 ± 0.18 0.37 ± 0.22 -0.05 (-0.19, 0.09) -0.03 (-0.16, 0.10)
Day 90 (Visit 4) 0.41 ± 0.18 0.41 ± 0.22 0 (-0.14, 0.14) 0.02 (-0.11, 0.16)
*Adjusted for the baseline static acoustic admittance value.
Duration of middle ear effusion. 
Although the confidence interval was very wide, there was no difference in the proportion of 
children who had complete resolution of MEE between the prednisolone and control groups at: 
Day 3 (RR 1.76, 95% CI 0.65 to 4.73); Day 7 (RR 1.47, 95% CI 0.71 to 3.04), Day 30 (RR 
1.07, 95% CI 0.57 to 2.00), and Day 90 (RR 1.17, 95% CI 0.80 to 1.72). We also identified any 
improvement of curve type from the baseline and previous results. Improvement was defined 
as an improvement from type B curve to type C2, C1, or A curve; or from type C2 curve to type 
C1 or A curve; or type C1 to A curve; or persisting type A curve. Table 6 shows the 
tympanometry curve improved compared to the baseline in more children in the prednisolone 
group at Day 7 (RR 1.76, 95% CI 1.04 to 2.97). 
Table 6. Tympanometry finding in the affected (unilateral AOM) or the worst ear 
(bilateral AOM). 








Complete middle ear effusion resolution* (n, %) 
Day 3 (Visit 1) 6 (40) 5 (23) 1.76 (0.65, 4.73) 0.29 
Day 7 (Visit 2) 8 (53) 8 (36) 1.47 (0.71, 3.04) 
Day 30 (Visit 3) 8 (53) 11(50) 1.07 (0.57, 2.00) 
Day 90 (Visit 4) 12 (80) 15 (68) 1.17 (0.80, 1.72) 
[128] 
 
Improvement of curve type from baseline visit† (n, 
%) 
    
    Day 3 (Visit 1) 7 (47) 7 (32) 1.47 (0.65, 3.32) 0.49 
    Day 7 (Visit 2) 12 (80) 10 (45) 1.76 (1.04, 2.97)  
    Day 30 (Visit 3) 10 (67) 14 (64) 1.05 (0.65, 1.69)  
    Day 90 (Visit 4) 14 (93) 16 (73) 1.28 (0.96, 1.71)  
Improvement of curve type from previous visit‡ (n, 
%) 
    
    Day 3 (Visit 1) 7 (47) 7 (32) 1.47 (0.65, 3.32) 0.49 
    Day 7 (Visit 2) 9 (60) 9 (41) 1.47 (0.76, 2.81)  
    Day 30 (Visit 3) 9 (60) 13 (59) 1.01 (0.59, 1.74)  
    Day 90 (Visit 4) 13 (87) 15 (68) 1.27 (0.89, 1.80)  
*Complete resolution is defined as a type A curve in tympanometry examination; †Improvement of curve type is 
defined as an improvement from type B curve to type C2, C1, or A curve; or from type C2 curve to type C1 or A 
curve; or type C1 to A curve; or persisting type A curve at particular time point compared to the baseline; 
‡Improvement of curve type is defined as an improvement from type B curve to type C2, C1, or A curve; or 
from type C2 curve to type C1 or A curve; or type C1 to A curve; or persisting type A curve at particular time 
point compared to the previous visit. 
 
Correlation between ear pain and other relevant symptoms and the change of MEE. 
We expected there would be a strong negative correlation between lower VAS (no or less pain) 
scores or lower AOM-SOS scores (no or less AOM-relevant symptoms) and higher values of 
SAA (no middle ear effusion), particularly at early timepoints. However, our analysis 
demonstrated only a small correlation between pain and other AOM-relevant symptoms and 
















































































































For clinical outcomes of this pilot study, we found prednisolone reduced pain severity at Day 3 
by 7 mm (MD -7.37, 95% CI -13.36 to -1.39, p = 0.018). Although it was less than 10 mm (the 
minimum clinical important difference), the CI included 10 mm which indicates there may be 
a clinically important reduction in pain severity. There was no statistically significant difference 
in the proportion of children with ongoing pain at Day 1, 3, 5, 7, and 14 (see Appendix 1). 
Neither was there a difference between groups in reduction of pain severity at these timepoints 
except Day 3. The results remained consistent after being adjusted for the baseline pain score 
(ANCOVA). 
Harm 
Regarding harm or adverse events (AEs), there were more children in the prednisolone group 
experienced drowsiness (RR 1.77, 95% CI 1.11 to 2.81, p = 0.016), Table 7. This can be 
translated as for every three paediatric AOM patients who received oral prednisolone, one 
additional patient experienced drowsiness (number needed to harm/NNTH of 3). However, 
there were no serious AEs of any kind attributed to study medication. There were no significant 
differences in the proportion of children experiencing other AEs between two groups, including 
those AEs commonly attributed to short-course oral corticosteroids use such as gastrointestinal 
problems (e.g. nausea, vomiting, diarrhea). We found one child in the prednisolone group who 
had microcytic hypochromic anemia at Day 6 based on low haemoglobin and serum iron counts. 
He was referred to a paediatrician who then confirmed this was most likely caused by iron 
deficiency and not by steroid intake.  
Table 7. Adverse events in the study. 
Adverse events Prednisolone group (n=31) Control (n=31) 





Increased appetite 18 11 15 17 17 9 10 7 
Increased urine volume 11 8 9 7 14 12 7 4 
Weight gain 13 5 6 6 11 4 4 10 
Gastritis 2 3 2 0 4 2 0 0 
Nausea 6 4 1 0 7 5 4 1 
Vomiting 5 3 0 0 3 3 1 1 
Diarrhea 2 3 1 1 4 1 0 0 
Drowsiness 23 14 9 6 13 16 10 5 
Anxiety 4 3 3 3 6 3 1 1 
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Headache 4 1 0 1 6 7 2 3 
Skin rash 3 0 1 0 0 2 0 0 
Candidiasis 3 2 1 0 1 1 0 0 
Dry mouth 7 5 4 0 6 6 3 1 
Sleep disturbance 17 5 5 3 10 9 1 0 
Others 1 0† 1 0 0 0 0 0 
Serious adverse effects 0 0 0 0 0 0 0 0 
*Total number of patients having the adverse event during the first two weeks; †Patient was detected to have 




Sensitivity analysis  
Due to interference of the principal investigator who was not blinded to study medication 
allocation, we conducted a sensitivity analysis by excluding the children who received 
interference. This did not change the results.  
 
Discussion 
Our pilot study met our two key objectives related to the feasibility of the full-size RCT and 
mechanistic effect of corticosteroids on MEE. We found that less than 40% of screened children 
were recruited. Most physicians and parents rated study procedures as ‘neutral’ to ‘easy’. 
However, most healthcare personnel found time constraints due to workload as their most 
common obstacle in the study. The sample size needed to power a full randomised controlled 
trial is lower than anticipated. Most children completed the study (97%), and a minority 
received concomitant oral corticosteroids and other co-treatments from an unblinded 
researcher. There is the potential that corticosteroids may reduce pain severity at Day 3 and 
improve tympanometry curve by Day 7. We found only a small correlation between the change 
in MEE and pain and other AOM-relevant symptoms. We also found drowsiness as the most 
common side effect of oral corticosteroid. 
 
There were several limitations of this pilot study. Our recruitment rate was low and similar 
(38.5%) to other studies conducted in developing countries [39]. This could be because we 
started recruiting at hospital centres, but well-implemented national coverage insurance 
required patients to access healthcare services via primary care centres. It could also be due to: 
(1) low research awareness/interest among physicians, nurses, and patients [40]; (2) workload 
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of physicians and nurses; and (3) cultural factors (e.g. patients seeking family/relatives’ consent 
to participate in research, and insufficient clinical trials facilities [40].  To improve recruitment, 
future studies could: (1) recruit from more primary care centres; (2) provide incentives for 
participating healthcare personnel despite insufficient evidence of effects on recruitment rate 
[41]; and (3) simplify the study process (simplifying and improving the layout of CRFs and 
symptom diary and allocating research assistants to support study procedures including 
randomisation).  
 
We could not provide a matched placebo control. Parents’ subjective responses to pain 
assessment could have been biased by this, as they knew which treatment their child received. 
However, we plan to use a placebo in the full RCT where we will involve an independent 
specialised drug manufacturer to provide a placebo that is similar in form and taste with oral 
prednisolone. 
 
Four children received additional oral corticosteroids. Although we asked parents to contact us 
before they sought consultation from other physicians for any relevant or other concurrent 
conditions, this was not sufficiently implemented. Therefore, for the full RCT, we will provide 
a handy information card that provides detailed information about the study, including 
medication that should not be given. This card should be shown to any physicians that the parent 
consults. 
 
Imbalanced randomisation meant that there were more children in the control group who had 
low parental education level, were exposed to parental smoking, and received amoxicillin and 
acetaminophen compared to those in the prednisolone group. One potential contributing factor 
was that, by chance, most children in the control group were recruited from the primary care 
centres. Out of 31 children in the control group, 13 were recruited from the primary care centres 
(55%) and out of 31 children in the prednisolone group, only six were recruited from primary 
care centres (19%). Low parental education level may be associated with higher rates of passive 
smoking in the control group. This was supported by evidence showing education attainment 
and length of education negatively correlated with smoking behaviour [42]. Parental smoking 
has been identified as a strong risk factor for AOM [43-45]. First line antibiotics for AOM and 
analgesics in primary care centres in Indonesia are amoxicillin and acetaminophen [15]. This is 
consistent with the antibiotic recommended for AOM in guidelines, but at a lower dose (50 
mg/kg body weight/day) [15]. This chance imbalance in randomisation will likely be reduced 
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by stratification on the type of healthcare facility (primary versus secondary/tertiary care 
centre). 
 
The last limitation was missing tympanometry values, which was caused by the inability of 
tympanometry to detect key values (i.e. SAA, middle ear pressure) in some severe cases of 
MEE. However, this problem was detected after several incomplete test values which resulted 
in missing data from several cases. Despite this, given the lack of clinical benefit of this 
examination in AOM cases, the need of specific skills and facilities, and cost, we do not intend 
to include the tympanometry measurement in the full RCT. 
 
We also found positive impacts of this study. The first strength of this study is its ability to 
identify potential issues particularly in the recruitment and data collection which allows us to 
modify study procedures and strategies for a successful implementation of the full RCT [46].  
Secondly, we also believe this pilot study has introduced a clinical trial to healthcare personnel 
at several levels of healthcare service in Indonesia. We expect this will trigger their interest in 
research since they now have some knowledge and experience in conducting a clinical trial.   
 
Our original primary outcome was the proportion of children with ongoing pain that has not 
reduced by the minimum clinically important amount (VAS score of 10 mm) by Day 3. 
However, our pilot study demonstrated that the majority of the children had their pain 
significantly improved at Day 3. Therefore, we will change the primary outcome in the main 
RCT to be the proportion of children with persisting pain (defined as the VAS score greater 
than 5 mm). We will retain the secondary outcome, that is the reduction of pain intensity using 
VAS, which will allow us to identify the effectiveness of oral prednisolone to improve pain by 
the previously-defined minimum clinically important amount. 
 
As we included different levels of healthcare service in several districts in Jakarta in the pilot 
study, we are confident that it is feasible to conduct the full RCT in other cities in Indonesia, 
particularly on Java. Training prior to the trial customised to education level of healthcare 
personnel is crucial. The availability of an otoscope will be a potential limitation for a large-
scale RCT.  
 
This study also showed that the incidence of severe AOM (47/62; 76%) was higher compared 
to other trials referenced in this study that were mainly conducted in developed countries. If a 
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large RCT is conducted in Indonesia or other developing countries with similar AOM 
characteristics, then it will predominantly evaluate the effects of oral corticosteroids as an 
addition to antibiotics.  
 
Decongestants and/or antihistamines were commonly prescribed at baseline consultation. Most 
AOM patients experienced symptoms of the common cold which could explain this finding. 
Evidence shows the combination of decongestants and antihistamine is beneficial for general 
recovery in adults and older children with common cold, but not in young children (age < 5 
years) [47]. Regarding its effects for AOM, decongestants and/or antihistamines have only a 
modest benefit in reducing the risk of persistent AOM in two weeks with significant adverse 
events overweighting the benefits [19]. 
 
We re-introduced the use of pain assessment tools (i.e. VAS and AOM-SOS) which have not 
been routinely used in the management of children with AOM in our clinical setting. Most 
parents assessed their children’s pain by observation. Only few older children (5/62; 6%) did a 
self-rated pain assessment.  
 
We also found that most parents and physicians preferred to use a numeric or facial pain scale. 
One of the commonly used  self-report numeric scales for acute pain is the 11-point Numeric 
Rating Scale (NRS-11). Children, particularly aged 6 years and older, determine their pain 
intensity by choosing a number between 0 (representing ‘no hurt’) and 10 (representing ‘the 
worst hurt’) scale [48,49]. For facial pain scale, a Faces Pain Scale-Revised (FPS-R) was 
recommended as a self-report acute pain scale for children aged 7 years and older. It consists 
of six faces ranging from ‘no pain’ to ‘very much pain’, where each face was represented by 
numbers of 0-2-4-6-8-10 [48,50]. However, since there was no strong evidence supporting the 
recommendation of any particular parent-report pain assessment for paediatric population with 
acute pain, we still consider it appropriate to use VAS and AOM-SOS for the full RCT. This 
pilot study also verified that these pain assessment tools were successfully implemented by the 
parents in assessing pain. 
 
We did not find clinically significant benefits of tympanometry examination for the 
management of AOM. It was costly and difficult to implement in children experiencing pain. 
Evidence demonstrates that only certain children may be at risk of prolonged MEE resolution 
(children with AOM aged < 2 years or, children with recurrent AOM).  Therefore, 
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tympanometry examination should be prioritized for those children and not to be generalised 
for all AOM cases [9,51]. We will further investigate any prognostic factors and characteristics 
of our study participants in the tympanometry sub-study that may influence the improvement 
or prolongation of MEE.  
 
We found drowsiness as the most common side effect of oral corticosteroid, which is consistent 
with AEs related to a short-term use of oral corticosteroids in other studies [21,26]. However, 
this requires further investigation since more children in the prednisolone group received 
decongestants and/or antihistamines, and drowsiness has been identified as common side effect 
of decongestants and/or antihistamines with risk up to eight-fold of risk in the treatment group 
[19,52,53]. 
 
Compared to other feasibility interventional studies, our pilot study had similar recruitment 
issues which required additional recruitment time and modification of the recruitment strategy 
[54]. Our study had a lower recruitment rate compared to other feasibility studies [55]. 




Our pilot study shows it is feasible to conduct a large, pragmatic, randomised, double-blind 
placebo- controlled trial. However, several modifications should be made to improve 
feasibility: simplifying study procedures, improving the layout of CRF and symptom diary, 
recruiting through primary care centres, stratifying children based on severity and healthcare 
centre level, and the use of placebo as a control. We will use VAS and AOM-SOS as pain 
assessment tools since there is no strong evidence recommending a particular parent-report 
assessment tool for children with acute pain. The sample size required is less than we 
anticipated due to the high proportion of severe AOM cases, and it is not necessary to use 
tympanometry for a future trial. Based on the findings and results from this pilot study, we 
modified our protocol for the full RCT (see Appendix 2). 
 
Our clinical results do not rule out the benefit of oral corticosteroids for AOM. However, the 
signal of its benefits is small. We also identified drowsiness as one side effect of a short-term 
us of oral corticosteroids, with no excess of other AEs commonly attributed to short-course oral 
corticosteroids use (i.e. nausea, vomiting, diarrhea) found. Therefore, our pilot study confirms 
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the importance of conducting our planned full RCT to assess the actual effects, both benefits 
and harm, of oral corticosteroids for children with AOM. 
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Appendix 1. Clinical outcomes of the pilot OPAL study. 
 Figure 1 Panel A. Correlation between pain measured using VAS and change in middle 
ear effusion*   
ρ = Spearman's rank correlation coefficient 
A1. Visit 0 (Day 0) A2. Visit 1 (Day 3) 
A3. Visit 2 (Day 7) A4. Visit 3 (Day 
30)
A5. Visit 4 (Day 90) 
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Figure 1 Panel B. Correlation between AOM-relevant symptoms measured using AOM-
SOS and change in middle ear effusion. 
ρ = Spearman's rank correlation coefficient 
B1. Visit 0 (Day 0) B2. Visit 1 (Day 3) 
B3. Visit 2 (Day 7) B4. Visit 3 (Day 
30)
B5. Visit 4 (Day 90) 
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Table 1 Panel A – Clinical binary outcomes 








Proportion of children with pain that has not reduced 
by 10 mm VAS at Day 3 (n; %) 
3 (10) 5 (16) 1.07 (0.88, 1.30) 0.71 
Proportion of children with pain represented by VAS ≥ 5mm (n: %) 
Day 0 (Visit 0) 27 (93) 27 (87) 1.07 (0.90, 1.26) 
Day 1 24 (83) 22 (71) 1.17 (0.88, 1.54) 
Day 3 (Visit 1) 6 (21) 14 (45) 0.46 (0.20, 1.03) 0.06 
Day 5 3 (10) 8 (28) 0.37 (0.11, 1.27) 
Day 7 (Visit 2) 2 (7) 5 (17) 0.40 (0.08, 1.89) 
    Day 14 1 (3) 2 (7) 0.50 (0.05, 5.21) 
Initiation of antibiotics or second-line antibiotics 
during Visit 1 to Visit 2 (n; %) 
9 (31) 10 (32) 0.96 (0.46, 2.02) > 0.999
  Initiation of antibiotic for mild AOM in Visit 1 or Visit 2   
  (n; %)** 
2 (33) 6 (86) 0.39 (0.12, 1.25) 0.11 
Complications (n; %) 1 (3)† 0 (0) 0.49 
Recurrence (n; %) 
  Day 30 (Visit 3) 1 (3) 2 (7) 0.50 (0.05, 5.21) > 0.999
  Day 90 (Visit 4) 5 (17) 2 (7) 2.50 (0.53, 11.86) 0.42
Other descriptive outcomes 
Improvement of otoscopic findings compared to previous visit (n; %) 
     Day 3 (Visit 1) 23 (79) 17 (55) 
     Day 7 (Visit 2) 15 (52) 15 (52) 
     Day 30 (Visit 3) 22 (76) 22 (76) 
     Day 90 (Visit 4) 22 (76) 24 (83) 
Improvement of otoscopic findings compared to baseline (n; %) 
     Day 3 (Visit 1) 23 (79) 17 (55) 
     Day 7 (Visit 2) 21 (72) 21 (72) 
     Day 30 (Visit 3) 24 (83) 25 (86) 
     Day 90 (Visit 4) 26 (90) 27 (93) 
Tympanic membrane perforation (n; %) 
     Day 0 (Visit 0) 11 (38) 8 (26) 
     Day 3 (Visit 1) 4 (14) 6 (19) 
     Day 7 (Visit 2) 3 (10) 3 (10) 
     Day 30 (Visit 3) 1 (3) 2 (7) 
     Day 90 (Visit 4) 1 (3) 1 (3) 
Treatment given by doctors in the study in two weeks following initial visit (n; %) 
     Acetaminophen 9 (31) 17 (55) 
     NSAIDs 5 (17) 8 (26) 
     Decongestants and/or antihistamine 27 (93) 29 (93) 
     Cough medicine 24 (83) 21 (68) 
     Antibiotic ear drops 8 (28) 8 (26) 
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*Two missing data from control group after Day 3 made total number of control group 29; **There were 6 cases
of mild AOM in the prednisolone group and 7 cases in the control group; †Tympanic membrane perforation at 
Day 30, which healed at Day 90; ‡Others (e.g. mefenamic acid, nasal wash). 
     Nasal topical decongestant 6 (21) 5 (16) 
     Nasal topical corticosteroid 8 (28) 3 (10) 
     Additional oral prednisolone 0 (0) 1 (3) 
     Vitamins or herbals 4 (14) 10 (32) 
     Ear diathermy 0 (0) 2 (6) 
     Inhalation 1 (3) 1 (3) 
     Others‡ 4 (14) 7 (23) 
Treatment given by other doctors or self-medication/over the counter in two weeks following initial visit (n; %) 
     Antibiotics 1 (3) 1 (3) 
     Acetaminophen 2 (7) 1 (3) 
     NSAIDs 0 (0) 0 (0) 
     Decongestants and/or antihistamine 4 (14) 2 (6) 
     Cough medicine 5 (17) 4 (13) 
     Antibiotic ear drops 0 (0) 1 (3) 
     Nasal topical decongestant 0 (0) 0 (0) 
     Nasal topical corticosteroid 0 (0) 0 (0) 
     Additional oral prednisolone 2 (7) 0 (0) 
     Vitamins or herbals 3 (10) 2 (6) 
     Ear diathermy 0 (0) 0 (0) 
     Inhalation 0 (0) 0 (0) 
     Others‡  2 (7) 0 (0) 
Additional visit required (n; %) 6 (21) 10 (32) 
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Table 1 Panel B – Clinical continuous outcomes 












Pain measured by VAS (mm) mean (SD)† 
     Day 0 (Visit 0) 48.9 ± 27.1 49.6 ± 31.1 -0.63 (-15.74, 14.48) 0.93 
 Day 1 25.7 ± 20.7 23.5 ± 20.9 2.14 (-8.63, 12.91) 0.69 2.33 (-7.54, 12.19) 
     Day 3 (Visit 1) 3.9 ± 5.6 11.3 ± 15.2 -7.37 (-13.36, -1.39) 0.017 -7.36 (-13.40, -1.33) 0.018 
 Day 5 4.2 ± 15.2 5.5 ± 12.7 -1.27 (-8.63, 6.08) 0.73 -1.20 (-8.38, 5.98)
     Day 7 (Visit 2) 1.1 ± 2.8 3.9 ± 9.3 -2.84 (-6.47, 0.78) 0.12 -2.84 (-6.51, 0.82)
 Day 14† 0.6 ± 2.8 0.8 ± 1.9 -0.21 (-1.45, 1.04) 0.74 -0.21 (-1.46, 1.05)
     Day 30 (Visit 3) 1.5 ± 6.8 0.2 ± 0.6 1.33 (-1.21, 3.87) 0.30 1.32 (-1.24, 3.89) 
     Day 90 (Visit 4) 2.3 ± 10.3 2.2 ± 11.7 0.05 (-5.76, 5.86) 0.99 0.04 (-5.81, 5.89) 
Symptoms measured by AOM-SOS mean (SD)† 
     Day 0 (Visit 0) 6.4 ± 3.8 6.1 ± 3.6 0.32 (-1.61, 2.24) 0.74 
 Day 1  3.2 ± 3.0 3.1 ± 2.5 0.07 (-1.35, 1.50,) 0.92 -0.03 (-1.31, 1.25)
     Day 3 (Visit 1) 1.2 ± 1.9 0.9 ± 1.6 0.27 (-0.63, 1.17) 0.55 0.22 (-0.64, 1.09) 0.60 
 Day 5 1.1 ± 1.7 0.7 ± 1.2 0.38 (-0.39, 1.15) 0.33 0.38 (-0.40, 1.16) 
     Day 7 (Visit 2) 0.5 ± 0.9 0.8 ± 1.5 -0.31 (-0.96, 0.34) 0.34 -0.31 (-0.97, 0.35)
 Day 14†  0.9 ± 2.3 0.2 ± 0.5 0.72 (-0.16, 1.61) 0.11 0.71 (-0.16, 1.57) 
     Day 30 (Visit 3) 0.2 ± 0.6 0.5 ± 1.2 -0.27 (-0.79, 0.24) 0.29 1.34 (-1.22, 3.90) 
     Day 90 (Visit 4) 0.1 ± 0.4 0.1 ± 0.3 0.03 (-0.17, 0.23) 0.73 0.11 (-5.70, 5.92) 
Time to pain resolution‡ 
(median days) 
2 3 -1 0.71 
*Two missing data from control group after Day 3 made total number of control group 29; **Adjusting for the
baseline and intervention allocation; †VAS (ranged 0 to 100 mm), higher score representing worse pain. AOM-
SOS (ranged 0 to 14 points), higher score for worse symptom; ‡We analysed 55 out of 60 children (28 
prednisolone and 27 control): 5 children not included were four controls (two left the study and two did not have 
pain resolution in two weeks ) and one prednisolone did not have pain resolution in two weeks observation. 
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CHAPTER 5: ORAL PREDNISOLONE FOR ACUTE OTITIS
MEDIA IN CHILDREN: A PROPOSED PRAGMATIC,
PARALLEL, RANDOMISED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY (OPAL STUDY)  
(STUDY 5) 
Ranakusuma RW, McCullough AR, Safitri ED, Pitoyo Y, Widyaningsih, Del Mar CB, 
Beller EM. Oral prednisolone for acute otitis media in children: a proposed pragmatic, 




Our previous studies showed that it was feasible to conduct a large, pragmatic, randomised 
clinical trial to test the effectiveness of oral corticosteroids for children with AOM in Indonesia. 
The pilot study also indicated that oral corticosteroids may be beneficial in reducing pain 
intensity and improving the tympanometry curve, but may cause drowsiness.  
These findings confirmed that it is important to conduct an adequately powered, large, parallel, 
pragmatic, multicentre, stratified, double-blind, randomised, placebo-controlled study to test 
both the benefits and harm of oral corticosteroids in children with AOM.   
This chapter presents the protocol for the proposed main trial, incorporating the necessary 
alterations derived from the results of the pilot study. The following pages in this chapter are 
the protocol for the main study that has been submitted for publication as an appendix of the 
pilot study results paper and is under review. 
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Protocol of the main OPAL study: 
Oral prednisolone for acute otitis media in children: a proposed pragmatic, 
parallel, randomised, double-blind, placebo-controlled study (OPAL study) 
Ranakusuma RW1,2, McCullough AR1, Safitri ED2, Pitoyo Y2, Widyaningsih W2, Del Mar 
CB1, Beller EM1. 
1Institute for Evidence-Based Healthcare, Bond University, Robina, Queensland, Australia. 
2Clinical Epidemiology and Evidence-Based Medicine Unit, Dr Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia. 
1. Executive Summary
Background: Acute otitis media (AOM) is an acute middle ear infection particularly found in 
children. Antibiotics are commonly prescribed, despite most cases being sufficiently managed 
by observation and adequate pain management. Due to weak effects and potential risks of 
antibiotic use, such as side effects and antibiotic resistance, an alternative non-antibiotic 
treatment for AOM is required. Corticosteroids could be a candidate for AOM, yet there is 
insufficient evidence on their efficacy. We have planned a high-quality clinical trial to test the 
effectiveness of oral corticosteroids in improving clinical outcomes including reducing middle 
ear effusion (MEE) in children with AOM. Our trial is justified by our pilot study showing that 
oral corticosteroids potentially reduce pain intensity at Day 3 and improve tympanometry 
results at Day 7, although the observed difference was small. This adequately powered clinical 
trial will allow us to definitively conclude whether corticosteroids are an effective treatment for 
AOM along with its effect size. 
Methods: This multicentre, pragmatic, randomised, double-blind, placebo-controlled study 
will recruit 444 children aged 6 months to 12 years with onset of AOM within 48 hours. We 
will stratify children based on healthcare facility type and AOM severity. Children will be 
randomly allocated to receive either prednisolone or placebo plus observation in mild AOM 
and either prednisolone or placebo plus antibiotics in severe AOM. Our primary aim is to assess 
the effectiveness of oral corticosteroids in improving pain at three days after randomisation. 
Secondary aims are to assess: (1) the effectiveness of corticosteroids in improving pain at other 
time points, reducing pain intensity and overall AOM-relevant symptoms, reducing time to pain 
resolution, and the need for antibiotic initiation (mild AOM) or second-line antibiotics (severe 
AOM), AOM complications and recurrence;  and (2) the adverse effects of corticosteroids. 
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Discussion: High rates of antibiotic use for AOM indicates the need for alternative treatments. 
Due to the inflammatory nature of AOM, corticosteroids may be a suitable treatment. If our 
study shows positive results with enough benefits and sufficient effect size outweighing harm, 
we can offer oral corticosteroids as one potential alternative treatment for AOM and thereby 
reduce antibiotic use. This study will contribute to adding to the range of AOM non-antibiotic 
treatment and updating current AOM management guidelines which do not make 
recommendations about oral corticosteroids for AOM. 
Keywords: Otitis media, Acute disease, Glucocorticoids, Anti-bacterial agents, Clinical trial 
protocol. 
Trial registration: Not yet. 
2. Background
Acute otitis media (AOM) is an acute middle ear infection commonly found in children [1-3]. 
High rates of antibiotic prescribing are evident [4,5], although only one third of children with 
AOM, namely those who have severe cases, will likely benefit from antibiotics [4,6,7].  
Due to the potential harm of antibiotic use and its weak benefits in improving clinical outcomes, 
alternative treatments for AOM, such as  corticosteroids as anti-inflammatory agents, are 
needed. Due to the uncertain effects of corticosteroids for AOM [8,9], we plan to conduct a 
high-quality clinical trial to assess the effectiveness of corticosteroids for children with AOM. 
We recently tested the feasibility of this in a pilot, pragmatic, randomised, single-blind, 
controlled trial, which demonstrated it was feasible to conduct all planned procedures and 
measurement for a high-quality clinical trial. We found that oral prednisolone may potentially 
reduce pain intensity at Day 3. We also found drowsiness as the most common adverse event 
in children in the prednisolone group, with no other adverse events commonly attributed to 
short-course oral corticosteroids nor serious adverse effects found.  Therefore, we will conduct 
a large, pragmatic, double-blind, randomised, placebo-controlled to test the effectiveness of 
corticosteroids, including benefits and harm, in children with AOM. 
3. Methods/Design
3.1 Aim and objectives 
We aim to assess the effectiveness of oral corticosteroid as a monotherapy for children with 
mild AOM and as an addition to antibiotics for severe AOM. 
[152] 
 
Our primary objective is to assess the effectiveness of corticosteroids in improving pain at three 
days after randomisation. 
Our secondary objectives are to assess: (1) the effectiveness of corticosteroids in: (a) improving 
pain at other time points; (b) reducing pain intensity; (b) reducing overall AOM-relevant 
symptoms; (c) reducing duration to pain resolution; (d) reducing the need of antibiotic initiation 
for children with mild AOM or second-line antibiotics treatment for children with severe AOM 
after 48-hour observation; (e) reducing the risk of AOM complications; and (f) reducing the 
risk of AOM recurrence;  and (2) the adverse effects of corticosteroids. 
3.2 Design 
We will conduct a large, parallel, pragmatic, multicentre, stratified, double-blind, randomised, 
placebo-controlled with an allocation ratio of 1:1, where children will be randomly allocated to 
either receive oral prednisolone or placebo.  
3.3 Study setting 
This multicentre study will be conducted at six primary care centres and two hospitals in Central 
and East Jakarta, Indonesia. We will include four healthcare centres which participated in our 
previous pilot study (two primary care centres and two hospitals). We will identify four other 
primary care centres based on an adequate number of paediatric AOM patient visits and the 
convenience of study monitoring.  
We will include general practitioners (GPs) from the primary care centres and ear-nose-throat 
(ENT) specialists from the hospitals in the recruitment and assessment process of the study. We 
will also include nurses for study randomisation and pharmacists for study medication storage, 
preparation, and dispensing. 
3.4 Eligibility criteria 
3.4.1 Inclusion criteria 
We will include children aged six months to 12 years old with AOM, defined as current onset 
(within 48 hours) of AOM-relevant symptoms (e.g. earache, ear discharge, ear tugging/rubbing 
or irritability in non-verbal children). Otoscopic findings of acute inflammation (e.g. erythema) 
and middle ear effusion (e.g. bulged tympanic membrane, air-fluid level) will confirm the 
diagnosis. Due to potential obstacles in otoscopic assessment in children (e.g. uncooperative, 
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narrow ear canal, ear wax) and the pragmatic nature of this study in reflecting real practice in 
the management of AOM, we will include children with symptoms strongly indicating AOM 
whose diagnosis cannot be confirmed using an otoscope, and diagnose these children with 
suspected AOM.  
3.4.2 Exclusion criteria 
We will exclude children who (1) have major and severe medical conditions (e.g. heart diseases, 
kidney failure, tuberculosis), (2) are immunocompromised (e.g. HIV infection, under cancer 
treatment), (3) have congenital malformations and/or syndromes (e.g. cleft palate, Down 
syndrome), (4) have high risk of strongyloidiasis infections, (5) have ear ventilation tube(s), (6) 
have been exposed to persons with varicella (chicken pox) or active Zoster infection in the past 
three weeks without prior varicella immunisation or infection, (7) have taken systemic (oral, 
injection) or topical steroids in the preceding four weeks, (8) have taken antibiotics in the 
preceding two weeks, and (9) are hypersensitive to prednisolone or prednisone, or other 
corticosteroids. 
3.5 Interventions 
3.5.1 Prednisolone  
Prednisolone tablets (Lupred®5) will be given as a single daily dose of 1–2 mg/kg of body 
weight for five days.  A wide therapeutic dose window of prednisolone allows the simplification 
of randomisation and dispensing as follows: 10 mg/day for children aged six months to up to 
two years; 20 mg/day for children aged two up to six years; and 30 mg/day for children aged 
six to 12 years [10]. We strongly recommend children take prednisolone as a whole (single 
dose) in the morning (6 to 8 am) to minimise the risk of hypothalamic–pituitary–adrenal (HPA) 
axis suppression and for the convenience of both the patients and their parents or care givers. 
We will provide a liquid sweetener to be added to the study medication to make it more 
palatable for the children. The parents or care givers will be asked to give the prednisolone with 
food or milk to decrease the risk of gastrointestinal disturbance.  
Children with mild AOM who are randomly allocated to the intervention arm will receive 
prednisolone plus expectant observation, whilst those with severe AOM will receive 





Children in the control group will receive a 5-day course of matched placebo which has similar 
form, colour, and taste to prednisolone.  
Children with mild AOM who are randomly allocated to the control arm will receive placebo 
plus expectant observation, whilst those with severe AOM will receive placebo plus antibiotics. 
3.6 Criteria for study drug discontinuation or modification 
If a child vomits less than 30 minutes after taking a dose of study medication, parents will be 
instructed to give another dose and report to the research team for an additional dose for 
completing a 5-day course of study medication. However, if a child vomits after 30 minutes, 
parents should not give another dose until the next dose on the next morning.  If a child keeps 
vomiting or experiencing other unfavourable effects (e.g. nausea, diarrhea) after receiving the 
study medication, parents should contact the research team. If the parents forget to give study 
medication, they can give the missed dose as soon as they remember on the same day. Any 
modification of taking study medication, such as above, should be recorded in the symptom 
diary.  
If there are any adverse events and adverse drug reactions where the research team assesses 
discontinuation of study medication is required, the treatment will be discontinued; however, 
follow-up will continue, where possible. 
3.7 Strategies to improve adherence to the intervention protocol 
We will remind parents to complete a symptom diary and give the study medication to their 
children every morning for five days by sending them text-message reminders every morning 
for two weeks. We have also added a note at the bottom of the questionnaire in the first booklet 
of the symptom diary to remind them to give the study medication every morning for five days. 
We will ensure that all parents have enough study medication to complete a 5-day course of 
intervention. 
We will ask parents to keep the paper wrap packaging from the 5-day course of study 
medication. We will collect these paper wraps during their second visit at Day 7 to check the 
adherence of the study participants in taking study medication per protocol. 
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We will provide an information card for each patient at the baseline visit. This card will provide 
a summary of the study, including the intervention used in the study, and will state no additional 
oral corticosteroid should be prescribed during the study where possible. The parents should 
take and show the information card to any doctor consultations, to avoid additional oral 
corticosteroid intake. The parents should record all prescribed medications from these 
consultations or any over-the-counter medications in the symptom diary.  
3.8 Concurrent treatment 
Physicians may prescribe medications for symptoms (e.g. antipyretic, analgesic, decongestant, 
inhalation) according to their usual practice and record all medication prescribed in the outcome 
form, which is one of the case report forms (CRFs) developed for the study. 
The physicians must not prescribe oral corticosteroids. The nurses and research assistant will 
cross-check all prescriptions before dispensing them to the parents, to ensure no oral 
corticosteroids are prescribed. If a child unintentionally receives any additional oral 
corticosteroids, we will not exclude the child from the study due to intention-to-treat analysis 
of the study. At the end of the study, we will identify any additional oral corticosteroids 
prescribed either from participating physicians or other physicians using the outcome form and 
symptom diary. All decisions on prescribing by physicians will be made prior to randomisation. 
3.9 Outcomes 
3.9.1 Primary outcome 
For the primary objective of assessing the effectiveness of corticosteroids in improving pain, 
we will assess the proportion of children with ongoing pain represented by visual analogue 
scales (VAS) score of 5 mm or more [11] at Day 3 following the randomisation. We will assess 
this outcome using the VAS from the symptom diary. 
3.9.2 Secondary outcomes 
For the secondary objective of assessing the effectiveness of oral corticosteroids in improving 
pain at other time points, reducing pain intensity, overall AOM-relevant symptoms, and time 
to pain resolution, we will measure: (1) the proportion of children with ongoing pain (VAS 
score of ≥ 5 mm) using VAS  in the symptom diary at 24 hours, Day 5, Day 7, and Day 14; (2) 
reduction of pain intensity using VAS in the symptom diary; (3) reduction of overall AOM-
relevant symptoms using the overall score of acute otitis media severity of symptoms scale 
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(AOM-SOS); and (4) time duration to pain resolution using VAS in the symptom diary. The 
reduction of pain intensity and overall AOM-relevant symptom outcomes will be measured at 
24 hours, Day 3, Day 5, Day 7, and Day 14. The time duration to pain resolution outcome will 
be measured during a 2-week observation period. 
For the objective of reducing the need for antibiotic initiation for AOM, we will measure the 
proportion of children who require antibiotic initiation after 48-hour observation in children 
with mild AOM or second-line antibiotic treatment for children with severe AOM by two weeks 
after randomisation (Day 14). 
For the objective of reducing the risk of AOM complications, we will measure the proportion 
of children who experience any complications of AOM, such as perforation of tympanic 
membrane or acute mastoiditis within two weeks following the baseline visit.  
For the objective of reducing the risk of AOM recurrence, we will measure the proportion of 
children who experience at least one new episode of AOM within one and three months 
following the baseline visit.  
For the objective of assessing the adverse effects of corticosteroids, we will measure the 
proportion of children who experience unfavourable side effects after taking the medication 
prescribed for the study within two weeks following the baseline visit. 
3.10 Participant timeline 
Table 1 illustrates the timeline for visits and follow-ups. Patients should visit the primary care 
centres or hospitals at Day 3 and Day 7 for re-assessment where physicians will identify the 
resolution of AOM symptoms (e.g. ear pain and other AOM-related symptoms) and clinical 
signs using an otoscope. During these visits, we will collect the first two booklets of the 
symptom diary. The first booklet records the symptoms, complications, side effects, other 
doctor consultations, and list of medications taken from baseline until Day 3, whilst the second 
booklet records similar outcomes from Day 4 to Day 7. At Day 3, the nurse will check the left-
over study medication and ensure the study medication is available for a 5-day course of 
intervention. At Day 7, the nurses will collect and count the paper wraps and any left-over study 
medication. The third booklet of the symptom diary also records similar outcomes from Day 8 
to Day 14 and will be collected during the home visit at Day 14. During the home visit, we will 
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not provide any prescriptions. Research assistants will contact all parents at Day 30 and Day 90 
by phone to obtain information of AOM symptoms and recurrence of AOM.  
Table 1. Follow-up timeline 


























ENROLMENT:        
Eligibility screen X       
Informed consent X       
Allocation X       
INTERVENTIONS:        
[Intervention A] 
Prednisolone 
       
[Intervention B] 
Placebo  
       
ASSESSMENTS:        
General examination X X  X    




X X X X X   
Otoscopic examination X X  X    
Requirement of 1st line or 
2nd line antibiotic initiation 
 
X X X X 
  
Complications X X X X X   
AOM recurrence      X X 
Adverse events  X X X X   
*Data will be collected from the symptom diary; †The follow-up on these time-points will be 
conducted through phone-calls.  
 
3.11 Sample size 
Based on our initial size calculation, we needed to enrol 760 children with AOM [12]. We had 
assumed that 30% of participants would have severe AOM [7], however our pilot study 
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demonstrated that 78% of our total sample was in the severe group with the risk of ongoing 
pain (≥ 5 mm VAS) in the control group at Day 3 of 42%.  Of the children with mild AOM, 
57% in the control group had ongoing pain at Day 3. The average proportion of children in the 
mild and severe groups with ongoing pain at Day 3 was 45.2%. With our original assumption 
of 0.70 risk ratio with steroids [7], we will only need to study 201 experimental and 201 control 
subjects to be able to reject the null hypothesis with probability (power) 0.8 and type I error 
probability of 0.05.  We will use an uncorrected chi-squared statistic to evaluate the null 
hypothesis of no difference between groups. The total sample size becomes 444 with a 10% 
allowance for dropouts. 
The significant difference in the sample size estimation between our original sample size and  
the pilot study, which was conducted in an urban setting in a developing country, is mostly 
influenced by our original calculation that used effect assumptions originating from a meta-
analysis of clinical trials conducted in developed countries. This indicates that the study sample 
size may change depending on the settings where the study will be conducted. Table 2 presents 
our sample size assumptions if study is conducted in three different settings.    
Table 2. Sample size assumptions for a clinical trial of corticosteroids for AOM 
conducted in different settings. 






With severe AOM 35% 56% 78% 
With severe AOM AND ongoing pain 57.5% 50% 42% 
With mild AOM 65% 43% 22% 
With mild AOM AND ongoing pain 36% 46% 57% 
With severe and mild AOM AND ongoing 
pain 
31.6% 38.4% 45.2% 
Sample size calculation‡ 760 570 444 
*From a meta-analysis of studies conducted in developed countries; †Our pilot study was conducted in
a developing country, urban setting; ‡The sample size includes a 10% allowance for dropouts. 
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3.12 Recruitment and stratification 
Prior to the study, we will provide training and study procedure manuals for the participating 
healthcare personnel (i.e. GPs, ENT specialists, nurses, pharmacists) which describe all 
processes and procedures for recruitment, stratification, outcome measures, and randomisation, 
including data collection and recording using CRFs and the symptom diary. We will also detail 
the severity criteria for AOM and instructions for clinical assessment using an otoscope. We 
expect the participating healthcare personnel will be able to effectively and sufficiently conduct 
these study procedures and measures. We will allocate research assistants to assist the study 
recruitment and randomisation at study sites.  
We will recruit and stratify children based on the eligibility and stratification criteria. Since we 
will involve both GPs and the ENT specialists at the primary care centres and hospitals, we will 
stratify children based on healthcare centre levels (primary care versus secondary/tertiary care 
centres) and AOM severity (mild versus severe AOM). Children will be stratified into the 
severe group if they have at least one of the following criteria: (1) moderate or severe symptoms 
of AOM, locally (e.g. moderate or severe ear pain, mastoiditis), and/or systemically (e.g. fever 
with temperature 39°C or higher, irritable, vomiting); (2) moderate or severe signs of middle 
ear inflammation (e.g. hyperaemic tympanic membrane) and effusion (e.g. bulging, bulla 
formation, yellowish purulent appearance of tympanic membrane); (3) aged younger than two 










• Definite or suspected acute otitis media 
(e.g. pain, ear tugging, irritability, 
otoscopic examination shows bulging, 
middle ear effusion, ear discharge) 
• Aged 6 months to 12 years 
• Available for follow-up visits 
Inclusion criteria Exclusion criteria 
• Major/severe medical conditions (e.g. heart diseases) 
• Immunocompromised (e.g. HIV, cancer treatment) 
• Congenital malformations/syndromes (e.g. cleft palate) 
• Ear ventilation tube(s) 
• Exposed to persons with varicella/active Zoster infection in the 
past 3 weeks with no prior varicella immunisation or infection 
• High risk of risk of strongyloidiasis infection  
• Has taken oral/injection/topical steroids in the past 4 weeks  
• Has taken antibiotics in the past 2 weeks 
• Hypersensitive to prednisolone/prednisone/other steroids 
Is this child eligible 
for the trial? 
All ‘YES’ at the inclusion criteria, AND  
All ‘NO’ at the exclusion criteria 
INCLUDE 
At least one ‘NO’ at the inclusion criteria, OR 
At least one ‘YES’ at the exclusion criteria 
EXCLUDE 
Does this child have 
following symptoms? 
• Moderate or severe symptoms, locally or systemically (moderate or 
severe ear pain, fever ≥39°C, complications) 
• Aged < 2 years with bilateral acute otitis media 
• Perforation of tympanic membrane(s) 
• Otoscopic finding shows moderate or severe bulging, yellowish 
purulent tympanic membrane(s) 
All ‘NO’ 
MILD AOM 




3.13 Randomisation and allocation concealment 
All consenting eligible children and their parents will be enrolled and stratified based on 
healthcare service levels and AOM severity (see Figure 2). The physician will record the 
recruitment and the stratification in the eligibility form, whilst the nurse will later collect and 
record personal information of the study participants and their parents (e.g. date of birth, mobile 
phone numbers, home address) in the study registration form. Each study participant will be 
identified by a 3-digit study ID, which will be written on every CRF. The nurse will use the 
eligibility and study registration forms for randomisation purposes. We will provide two options 
to access the study randomisation: either the nurse can access MASCoT (an online 
randomisation generator developed by the Institute for Evidence-Based Healthcare (IEBH), 
Bond University, Queensland, Australia), or contact our 24-hour call centre, if using MASCoT 
is not possible. A successful randomisation will provide a 3-digit randomisation ID, which will 
be recorded in the randomisation form and study prescription. A permuted block randomisation 
sequence will be computer-generated by MASCoT, prior to study commencement. The 
allocation sequence will remain concealed throughout the study. No one but the statistician, 
who is blinded to study condition and concurrent medication, has access to MASCoT except 
for any emergency cases requiring unblinding. The children will then be randomly allocated to 
either prednisolone plus expectant observation, or placebo plus expectant observation alone in 












































During the consultation, the physician will dispense two prescriptions to the nurse. The first 
prescription is for concurrent medications (e.g. antibiotics for severe AOM, analgesics, 
decongestants); whilst the second prescription is for study medication. The second prescription 
will provide clear information on the dose of study medication (based on the age), date of birth 
(to confirm the dose), and registration ID (for the allocation of the study medication). 
Randomisation ID will be added after the randomisation process by the study nurse. 
 
Is this child eligible for the study? 




































Figure 2. Flow chart of the stratification and randomization of the study 
suspected AOM 
AND 
aged 6 months to 12 years old 
AND 
symptoms suggestive of AOM (e.g. ear tugging, irritability, pain) 
AND 
Available for follow-up visits 
AND/OR 
otoscopic examination shows bulging, middle ear level, and/or immobile tympanic membrane(s), if 
feasible 
 
With moderate to severe symptoms, locally or systemically  
(e.g. moderate to severe ear pain, fever ≥ 39°C, complications) 
OR 
aged < 2 years with bilateral AOM 
OR 
both AOM and tympanic membrane perforation 
OR 
additional otoscopic finding: the appearance of moderate to severe bulging and/or 








Primary care centre 
(General Practitioners) 
 
Secondary/Tertiary care centre 
(ENT Specialists, Paediatricians) 
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Using the information in the prescription, the pharmacist will prepare the study medication, 
either the prednisolone or placebo, by crushing the tablets based on the prescribed dose and 
mixing them with sweeteners, then pack the mixed powder in five daily paper wraps. The 
pharmacist will then dispense the study medication along with instructions for the parents, and 
record the dispensing on the form provided by the study for this purpose. Batches of study 
medication will be dispatched to participating healthcare centres from a central pharmacy 
facility at the Clinical Research Supporting Unit, Faculty of Medicine Universitas Indonesia 
(CRSU FMUI). 
3.14 Blinding 
The physicians, nurses, pharmacists, research assistants, and both study participants and their 
parents will be blinded to the intervention allocation throughout the study. Emergency 
unblinding can occur if there are serious adverse events (SAEs). The unblinding result will be 
limited only to the treating physician, the parent/caregiver of the study participant who is 
experiencing the SAE, the study statistician, and the principal investigator. 
3.15 Data collection methods 
We will collect all data and outcome using CRFs (i.e. consent form, eligibility form, outcomes 
form, randomisation form, serious adverse effects form) and a symptom diary.  
To assess the proportion of children with ongoing pain (VAS score of ≥ 5 mm) and reduction 
of pain intensity at various timepoints, we will use the VAS score in the symptom diary which 
will be completed by the parents or older capable study participants. The VAS is a well-
established and validated scale for pain assessment and commonly used for research [13]. This 
100-mm horizontal pain scale has a ‘no pain’ anchor at the left and a ‘the most severe pain’ at 
the right endpoint. We will measure the distance between the left endpoint to a vertical line 
crossing the horizontal scale which represents the intensity of the pain. This vertical line will 
be marked by the parents or study participants aged eight years or older who are capable of self-
pain measurement [14]. We will identify whether the reduction of pain intensity is clinically 
meaningful by using VAS score of 10 mm as a minimum clinically important difference 
between groups [15,16]. 
To assess the reduction of overall AOM-relevant symptoms, we will use the AOM-SOS that 
will be completed by the parents in the symptom diary. We will use AOM–SOS to identify 
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other symptoms that are commonly found in young children with AOM [17]. The scale consists 
of three possible intensities of symptoms, which are ‘no’ (0 point), ‘a little’ (1 point), and ‘a 
lot’ (2 points), Table 2. The minimum clinically important difference between groups for total 
AOM-SOS points is 4.2 points [17]. Prior to the pilot study, we translated the AOM-SOS to the 
Indonesian language [12]. 
Table 3. Acute otitis media severity of symptoms scale (AOM-SOS) [17] 
We are interested in finding out how your child has been doing. For each question, please 
place a check mark in the box corresponding to your child’s symptoms.  




Over the past 12 hours, has your child been tugging, rubbing, or 
holding the ear(s) more than usual? 
Over the past 12 hours, has your child been crying more than 
usual? 
Over the past 12 hours, has your child been more irritable or fussy 
than usual? 
Over the past 12 hours, has your child been having more difficulty 
sleeping than usual? 
Over the past 12 hours, has your child been less playful or active 
than usual? 
Over the past 12 hours, has your child been eating less than usual? 
Over the past 12 hours, has your child been having fever or feeling 
warm to touch? 
To assess the need for antibiotics, we will use the outcome form completed by participating 
clinicians and the symptom diary completed by the parents to identify any antibiotic prescribing 
from other physicians for AOM or other health issues. We will identify any antibiotic initiation 
for children in the mild group or second line antibiotics for children in the severe group during 
the first two weeks of the study.  
To assess complications and adverse events, we will also use the outcome form and the 
symptom diary. In terms of adverse events, we will provide several common side effects related 
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to corticosteroid use in the symptom diary. We will also ask parents to record any other side 
effects that are not listed in the symptom diary. 
To assess AOM recurrence, we will interview the parents by phone at Day 30 and Day 90.  We 
will identify any new episode of AOM and record this in the outcome form.  
To promote study retention and complete follow-up, we will send a daily text message reminder 
to the parents during the first two weeks. This message will remind the parents to give the study 
medication to their children for five days and to complete the symptom diary for two weeks. 
We will remind the parents to take their children for the follow-up visits at Day 3 and Day 7. 
We will confirm their visit one to three days prior to the scheduled time, which allows us to 
organise another time or home visit if they are not able to come. If the study participants are 
not able to come at the scheduled follow-up time, we will encourage them to come up to 
maximum of three days over the scheduled time. We will provide an incentive in the form of 
reimbursement for their transportation to and from the primary care centres/hospitals and a 
small souvenir for study participants. We will advise the parents to take their children to the 
primary care centres/hospitals if there are any concerning conditions or no improvement. We 
will record any cases of discontinuation or deviation from study protocol in CRFs and 
continually follow these study participants per protocol where possible. 
3.16 Data management 
We will consistently conduct cross-checks during and after data entry to maintain the integrity 
and completion of data, particularly for missing data or errors. We will document all data entry 
and modifications in the database which will be available for viewing. Any modifications to the 
study data will be completed with the name, date, and signature of the person who is responsible 
for data modification. For missing or erroneous data, we will confirm the study data in the 
database using the original CRFs or by sending queries to the originating site. The central data 
coordinator will check the validity and completeness of study data on a regular basis. All data 
in the central database will be protected with a regular complete back up system.  
3.17 Statistical methods 
For dichotomous outcomes (i.e. the proportion of children with ongoing pain at various time 
points, who require antibiotic initiation in mild group or second-line antibiotics treatment for 
children with severe group after 48-hour observation, with complications related to AOM, and 
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with AOM recurrence), we will conduct a chi-squared test to determine the differences between 
two groups in outcome, expressed as relative risk (RR) with 95% confidence intervals (CI) and 
p values. A secondary analysis will use multiple logistic regression to adjust the primary 
outcome for allergy or atopy, siblings, first episode of AOM before the age of 12 months, 
passive smoking, breastfeeding duration less than three months, low parental education level, 
and day care attendance.  
We will report the proportion of children with adverse events and children who are adherent to 
the study and study medication in percentages.  
For continuous outcomes of reduction of pain intensity measured using VAS and overall AOM-
relevant symptoms measured using AOM-SOS, we will conduct independent t-tests to 
determine the differences between two groups in mean score, expressed as mean difference 
(MD) with 95% CIs and p values. We will also conduct multiple linear regression, adjusting 
for similar factors as the multiple logistic regression above (equivalent to ANCOVA). For 
outcome of time duration to pain resolution, we will use a log rank test to compare the time to 
pain resolution between the two groups. We will use Kaplan-Meier survival plots to show the 
proportion of children who experienced the outcomes at each time point. We will use STATA 
15.1 software for statistical analysis. 
We plan to analyse by intention-to-treat; however, if there is loss to follow-up, we will use an 
available case analysis. We will still record data on study participants who stop study 
medication, where possible, and will include them in the analysis where outcome data are 
available. 
4. Data monitoring 
An independent person from Clinical Epidemiology and Evidence-Based Medicine (CEEBM) 
Unit, Dr. Cipto Mangunkusumo Hospital (CMH) – Faculty of Medicine Universitas Indonesia 
(FMUI) will perform data monitoring periodically. She will review the process of patient 
recruitment, data entry, and study data storage in the central database, and report the results to 
the steering committee and sponsor as to whether the research has been conducted appropriately 
based on the approved research protocol. 
We will perform an interim-analysis when 50% of patients have been randomised and have 
completed the 3-month follow-up. The interim analysis will be conducted by independent 
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statistician from CRSU FMUI, who will be blinded to the treatment allocation and will report 
to a data and safety monitoring committee (DSMC) in CRSU FMUI. The DSMC will receive 
access to unblinded data of the trial if requested and will make recommendations to the steering 
committee without revealing specific details of the results unless there is a strong 
recommendation to cease the study. The decision on the continuation of the trial will be decided 
by the steering committee based on the recommendation from the DSMC. 
5. Harm 
We define adverse events (AEs) as ‘any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with study medication’, whereas adverse effects or adverse 
drug reactions (ADRs) are defined as ‘all noxious and unintended responses to a study 
medication related to any dose’ [12]. Data collection of any AEs and ADRs commences after 
we obtain consent from the parents and enrol the eligible children into the study.  We will record 
all AEs or/and ADRs following the enrolment during the study in the outcome form and serious 
adverse effects form. We will also use an adverse event assessment form which will be 
completed by an expert team established for this purpose. The expert team includes 
paediatricians and ENT specialists who have experience in conducting a clinical trial and are 
competent in the clinical fields of paediatric inflammatory disorders.  
We define serious adverse events as ‘any untoward medical occurrence at any dose that may 
result in-patient and/or prolonged hospitalisation, persistent or significant disability, medically 
important events, life-threatening events, and death’ [12]. A detailed information of the 
management of serious adverse events in the study can be retrieved from our pilot study 
protocol [12].  
6.  Auditing 
We will establish an independent audit committee from the CRSU FMUI and CEEBM Unit 
CMH-FMUI. This independent committee will conduct monitoring of source paper and 
electronic documents in the electronic database, monitor the conduct of trial in multicentre sites, 
interview the investigators and coordinators, and check the storage, distribution, and the use of 
study medication. Before the commencement of the study, the committee will ensure that the 
research staff are competent in data entry and in using the electronic database. These processes 
will be conducted according to the protocol and International Conference Harmonization – 
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Good Clinical Practice (ICH-GCP) standards. The data monitoring is scheduled to be conducted 
every six months from the research head office (CEEBM Unit CMH-FMUI) and trial sites. 
7. Ethics and dissemination 
Research ethics approval 
This study will be conducted according to the Declaration of Helsinki and ICH-GCP guidelines. 
We will obtain research ethics approval from the Bond University’s Human Research Ethics 
Committee (BUHREC) Australia and the Ethics Committee FMUI Indonesia. We will also seek 
permits to conduct clinical research from the One Stop Integrated Service Agency, Province of 
DKI Jakarta and from each study site.  
Protocol amendments 
Any modifications to the protocol which may impact on the trial process (e.g. the modification 
of study objectives, study design or/and procedures, study population, sample sizes), potential 
benefits and safety of the study participants will require a formal amendment to the protocol. 
This amendment will be sent to and approved by the funding body and the Ethics committee 
prior to its implementation. Notification will also be sent to the health authorities in accordance 
with local regulations. Minor modifications that may not impact on the trial process will also 
be notified and approved by the funding body and will be notified to The Ethics Committee. 
Consent or assent 
Before obtaining consent for their participation in the study, we will provide structured and 
detailed study information, such as the justification for the study, all study procedures, and 
expected commitment of the parents/caregivers during the study (e.g. give the study medication, 
complete the symptom diary, and come to follow-up visits per protocol), as well as potential 
side effects from the study medication.  We will obtain the consent of study participation from 
children aged 12 years and over. The person who delivers the consent interview will also 
provide their signature on the consent form, stating that they have provided information and 
opportunity for potential participants to understand and raise relevant questions about the study. 
We will ensure the consent process is free of coercion, and that parents understand their right 
to withdraw from the study at any time without any consequences on healthcare services, as 





The original CRFs and other study information will be stored in a secure locked file cabinet at 
each participating site, with copies at the central research office.  All study information stored 
in the study database will be secured with password-protected systems under limited access. 
We will use a 3-digit study ID as an identifier for CRFs and other forms related to the study. 
The study data storage will separate forms containing names (i.e. consent form, study 
registration form) from CRFs and other study forms. All counselling sessions will be conducted 
in private rooms. We will ask all participating healthcare personnel to maintain the 
confidentiality of study participants.  
Data on every participant will be kept confidentially and will not be distributed externally 
without the written permission of the participant, except if it is required for trial monitoring by 
national regulatory authorities related to medical and research safety. 
8. Access to data 
The principal investigator (RR) will be given access to the cleaned data sets. RR will also have 
direct access to each site’s data sets on request. Project data sets will be secured using 
passwords. To ensure confidentiality, data dispersed to project team members will be blinded 
of any identifying participant information. We will make our cleaned study data publicly 
available in the Bond University research repository (https://research.bond.edu.au/) after the 
completion of the study and the publication of the study results.  
9. Ancillary and post-trial care 
Any complications of AOM and potential adverse effects from the study will be closely 
monitored using the symptom diary. In case there is an emergency or worsening condition that 
requires comprehensive assessment and management, we will provide a 24-hour call centre and 
list of phone numbers and addresses of healthcare providers. We will be responsible for the 
treatment of any adverse effects that occur from the study medication during the study. The 
compensation will include costs such as consultation visits, additional examinations, and 
treatment (e.g. medicine, hospitalisation cost). Due to other potential concurrent treatments 
within the study, there will be robust review and analysis to ascertain the cause of adverse 
events. Information on management of adverse effects will be provided by physicians during 
the consent approval process before entering the study. We will also include this information 
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in the patient symptom diary. We will provide contact details of the 24-hour call centre and a 
list of recommended healthcare providers on the follow-up card. 
10. Dissemination policy 
We will report the study results in a medical journal and by presentations at conferences or 
other medical meetings. All investigators will review the manuscript and provide their consent 
for their acknowledgment and contribution before submission.  
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6.1 KEY RESULTS  
Antibiotic resistance is identified as a global health threat [1]. This health problem is mostly 
driven by the wide use of antibiotics for common diseases such as acute respiratory infections 
(ARI) [2-4]. One ARI with a high rate of antibiotic prescribing, despite its self-limiting nature, 
is acute otitis media (AOM) [5,6]. Alternative treatments which can replace antibiotic use are 
required, particularly for mild cases of AOM. 
Our research was conducted in Indonesia based on the candidate’s clinical experience as a 
clinician who witnessed the overuse of antibiotic treatment and oral corticosteroids for AOM. 
Although the use of corticosteroids (anti-inflammatory agent), as an alternative treatment, 
makes biological sense (the basic pathophysiology of AOM is middle ear inflammation), there 
is no evidence confirming the efficacy of oral corticosteroids for AOM.  
This thesis identified the available evidence on systemic corticosteroids as an alternative 
treatment for AOM in children, assessed, and addressed the existing research gap in this field.  
Study 1 – Cochrane review of systemic corticosteroids for acute otitis media in 
children. 
A Cochrane review of low to very low quality evidence (2 trials, n = 252) demonstrated that 
there is uncertainty around the effect of systemic corticosteroids in improving clinical 
symptoms of AOM (e.g., ear pain, bulging membrane inflammation, longer duration of 
antibiotic treatment), particularly at Day 5 (relative risk [RR] 1.06, 95% confidence interval 
[CI] 0.97 to 1.16) and Day 14 (RR 1.05, 95% CI 0.95 to 1.17).  
Strengths 
This review was the first systematic review on oral corticosteroids for children with AOM that 
used a robust, systematic, and transparent process in methods and reporting. The uncertain 
result of this review reflected insufficient evidence about the efficacy of corticosteroids for 
AOM. 
Limitations  
We found only two small clinical trials with low to very low quality of evidence testing the 
efficacy of corticosteroids for children with AOM [7,8]. All children in both trials received 




antibiotics for children with severe AOM. Therefore, we were unable to assess the effects of 
systemic corticosteroids as a monotherapy for mild AOM where antibiotic is not indicated. 
None of the trials specifically assessed ear pain as one of the outcomes, which limited our ability 
to identify the effects of systemic corticosteroids for the resolution of ear pain. We also could 
not identify adverse events caused by systematic corticosteroids due to incomplete outcome 
reporting.  
 
There was insufficient additional data provided by the authors of the included studies in the 
review. We contacted the authors, but they only provided us additional information regarding 
the randomisation, allocation concealment, and the blinding process of the clinicians and 
outcome assessors. They were unable to provide: (1) additional information on the proportion 
of children who had clinical failure/improvement from each group at each visit; (2) clinical 
information on children who did not complete the study (drop-out, loss of follow-up); (3) details 
of tympanometry results; and (4) adverse events in each group.  
 
Our study demonstrated that there was insufficient evidence identifying the effect of 
corticosteroids for AOM, indicating more studies are needed in this field. Therefore, we planned 
to conduct a large high-quality clinical trial to assess the effectiveness of systemic 
corticosteroids for AOM in children. 
Study 2 – Current management of children with acute otitis media: a feasibility 
survey for a pragmatic study in Jakarta, Depok, and Bekasi. 
Insufficient evidence on systemic corticosteroids for AOM has confirmed the necessity for a 
high-quality clinical trial to assess the effectiveness of systemic corticosteroids for AOM in 
children. We planned to conduct a high-quality clinical trial to resolve this gap. As part of our 
plan to conduct a large, pragmatic randomised controlled trial (RCT) of systemic corticosteroids 
for AOM in children in Indonesia, we conducted a feasibility study surveying the current 
practice of Indonesian physicians in the management of AOM. Clinical scenarios in our 
feasibility survey showed that most Ear-Nose-Throat (ENT) specialists would prescribe 
antibiotics for children with mild, as well as recurrent AOM, whilst paediatricians were more 
likely to choose expectant observation by withholding antibiotic initiation. This study also 




would use oral corticosteroids; and (3) physicians who were willing to participate in our planned 
large RCT.  
Strengths 
This was the first survey study identifying the current management of AOM in children in 
Indonesia. This was a valuable contribution since physicians in Indonesia use two conflicting 
practice guidelines for AOM [9,10]. We also had the opportunity to re-introduce principles for 
the management of AOM adopted from international practice guidelines to Indonesian 
physicians, particularly in terms of antibiotic use, during dissemination of our survey at several 
workshops and conferences.  
Limitations   
We had a low response rate for this survey study that most likely was caused by voluntary 
participation and other potential factors (e.g., relevance of the topic to physicians, workload, 
insufficient access to obtain physicians’ contact information) [11,12]. We were also unable to 
make the survey representative of all Indonesian physicians as we only included three cities in 
Indonesia due to the study purpose of a feasibility study for our future RCT. We planned to 
conduct our RCT in three adjacent cities, which were Jakarta, Depok, and Bekasi. We chose 
these cities for the convenience of conducting our RCT. Since all three cities are dominated by 
urban communities, we might not have captured any practice variation in rural communities, 
which was one of the limitations of this survey study. Collaboration with the Ministry of Health 
Republic of Indonesia, would have enabled us to identify the current management of AOM 
among physicians on a national scale. Another limitation of the study was the impact of study 
dissemination in workshops and conferences which may have influenced physicians in 
responding to the clinical scenarios in the questionnaire. The high antibiotic prescribing rate 
reported in our clinical scenarios may be an underestimation, as we had educated physicians 
about the limited efficacy and potential harms of antibiotic use in the management of AOM in 
children before distributing the survey. 
In terms of the clarity of the questionnaire, we did not provide a clear description of 
corticosteroid treatment in our vignettes which could lead to different assumptions of the 
administration route of corticosteroids, whether it was oral or topical (nasal spray). This may 





Findings from this study, despite its low response rate, supported our plan to conduct a  large 
RCT of oral corticosteroids for children with AOM in Indonesia. To ensure the successful 
conduct of a large RCT, we conducted a pilot study to test our planned study procedures and 
measures. 
Study 3 – Oral prednisolone for acute otitis media in children: a pilot pragmatic, 
randomised, open-label, controlled study (OPAL study). 
Our feasibility survey study confirmed it was feasible to conduct a clinical trial testing 
corticosteroids for children with AOM in Indonesia. Prior to the implementation of a large 
clinical trial, we piloted this study on a smaller scale. Within this study, we also conducted a 
mechanistic study (tympanometry study) to assess the mechanistic effect of corticosteroids, 
using tympanometry, in suppressing middle ear inflammation by reducing middle ear effusion 
(MEE). 
A pilot pragmatic, randomised, open-label, controlled study  
We conducted a pilot, randomised, open-label, controlled study in 62 children with AOM (mild 
AOM=15 and severe AOM=47) which demonstrated that all study procedures and measures 
were successfully conducted by all participating healthcare personnel, study participants, and 
their parents. It also showed that we needed to involve more primary care centres as recruiting 
sites, simplify study procedures, stratify children based on AOM severity and healthcare centre 
levels, and use placebo as a control. Our sample size re-calculation verified that we required a 
smaller number of study participants for our full RCT than originally thought. Our pilot study 
also showed that oral corticosteroids may potentially reduce pain intensity at Day 3.   
Strengths 
As well as refining the protocol for the main study, conducting the pilot enabled us to introduce 
the implementation of a clinical trial to healthcare personnel from different specialties and 
professional backgrounds who worked in several different healthcare institutions (primary care 
centres and hospitals). This experience will enhance their knowledge and skills to understand 
the principles of good clinical practice in clinical research and encourage their enthusiasm and 
willingness to conduct or to be involved in research in the future. Our study also introduced 
pain assessment tools and treatment options, such as expectant observation for mild AOM and 




explored the mechanism of oral corticosteroids in improving middle ear inflammation in AOM 
cases, which has not been sufficiently explored by existing studies. 
Limitations  
We found several limitations in this study: (1) the lengthy research administration process in 
the central and district-level government bodies; (2) a low recruitment rate due to lack of 
enthusiasm, time, and commitment among healthcare personnel; (3) the potential for 
performance bias due to the unavailability of placebo as a control; (4) technical obstacles in 
accessing the randomisation generator website (e.g., unstable internet connection, inadequate 
command of English); (5) unintentional additional oral corticosteroid prescriptions during the 
study; and (6) a limited generalizability of the results due to the majority of severe AOM cases 
in the pilot study. This meant our study result can only be generalised to countries which have 
similar practice to Indonesian clinicians (i.e., antibiotics and corticosteroids prescribing for 
AOM) and characteristics with our sample study, for which the majority were children with 
severe AOM. To resolve this issue in our future RCT, we plan to include more primary care 
centres to improve our recruitment, particularly of children with mild AOM. 
These findings, despite the limitations, indicate that it was feasible and important to conduct a 
full-size pragmatic, randomised, double-blind, placebo-controlled study to assess the effects of 
oral corticosteroids for children with AOM. The results of the pilot study also indicated a 
potential trend of the beneficial effects of oral corticosteroids toward to the improvement of 
clinical outcomes of AOM, which requires to be confirmed in a large RCT. 
A Mechanistic study using tympanometry (tympanometry study) 
Within the pilot study, we also conducted a mechanistic study in 37 children (mild AOM=13 
and severe AOM=24) by assessing middle ear effusion (MEE) using tympanometry. We found 
no difference in MEE change and in the proportion of children who had complete resolution of 
MEE between the prednisolone and control groups at Day 3, Day 7, Day 30, and Day 90. 
However, we found that oral corticosteroids may potentially improve tympanometry curve 
results at Day 7 (RR 1.76, 95% CI 1.04 to 2.97). We expected that there would be a strong 
correlation between the improvement of pain represented by lower scores on the VAS scale and 
AOM-SOS and resolution of MEE represented by higher values of static acoustic admittance. 
However, we found only a small correlation between the improvement of pain and other AOM-





By conducting this tympanometry study, we explored the mechanism of oral corticosteroids in 
improving middle ear inflammation in AOM cases, which has not been sufficiently explored 
by existing studies. 
Limitations  
We found tympanometry results were unreliable in demonstrating key findings in AOM cases 
with severe MEE. The tympanometry examination was costly and difficult to implement in 
children experiencing pain. It also required specific skills and facilities.  
This mechanistic study showed that the tympanometry examination did not demonstrate a 
significant clinical benefit for the management of AOM. As only certain children may be at 
risk, this examination should be prioritized for children with risks of prolonged MEE (e.g., 
children with AOM aged < 2 years or, children with recurrent AOM), and not used for all AOM 
cases [13,14]. 
Study 4 – A protocol of a pragmatic, randomised, double-blind, placebo-controlled 
study of oral prednisolone for acute otitis media in children (OPAL study). 
The previous three studies have led us to design our main study, which is a protocol for a 
pragmatic, multicentre, parallel, randomised, double-blind, placebo-controlled study of oral 
prednisolone for acute otitis media in children. The implementation of the pilot study 
demonstrated that it was feasible to successfully conduct all pre-specified procedures and 
outcome measures in the main study. There were several modifications needed to make all 
objectives of the main study achievable: 
1. Study sites: more primary care centres (n = 6) and two private hospitals should be 
included 
2. Research resources and logistics: more full-time research assistants should be employed. 
3. CRFs should be modified and simplified. 
 
Strengths 
This study would be the first large, pragmatic, randomised double-blind, placebo-controlled 




for severe AOM. If the study demonstrates positive results, it would then justify the use of oral 
corticosteroid as an effective treatment that can be used as a monotherapy in non-severe AOM, 
or as an addition to antibiotics in severe AOM to improve the resolution of ear pain and other 
clinical outcomes (e.g., other AOM-relevant symptoms, the need for initial antibiotics for non-
severe AOM and the second-line antibiotics or a longer duration of antibiotic treatment for 
severe AOM, complications and recurrence of AOM). 
6.2  IMPLICATIONS 
6.2.1 IMPLICATION FOR PRACTICE 
As our study was a pilot, it was not powered to demonstrate the effects of oral corticosteroids 
for children with AOM. However, it did not rule out an important benefit from corticosteroids. 
It demonstrated several potential harms (e.g., drowsiness) from the study which can be used by 
physicians to identify and sufficiently monitor side effects of a short-term use of oral 
corticosteroids in children. Other known side effects of corticosteroids (e.g., vomiting, 
diarrhoea) were not significantly higher in the corticosteroid group compared with control. One 
potential reason for physicians’ reluctance to use corticosteroids for bacterial infections is due 
to the theoretical risk of  immunosuppression with corticosteroids. Our pilot study demonstrated 
that there was no statistically significant difference between children in the corticosteroid and 
control groups in terms of experiencing worsening clinical episodes (e.g., requiring antibiotic 
initiation for mild AOM or second-line antibiotics for severe cases) or other outcomes (e.g., 
complications). Therefore, this study suggests that short-term corticosteroids are safe and not 
likely to cause worsening episodes of primary nor secondary infections of AOM. 
The management of AOM based on the severity of AOM has been implemented in the pilot 
study. This has been recommended by the Indonesian practice guideline for ENT specialists 
[10], but not for GPs [9]. By implementing this in the primary care centres, we were able to 
disseminate a comprehensive management plan for AOM, which included the identification, 
diagnosis of AOM, as well as a rational and evidence-based treatment based on AOM severity. 
Although the national practice guideline for GPs recommends antibiotics for all AOM cases 
[9], our pilot study has shown that providing the treatment based on the AOM severity in 
primary care centres is a feasible and safe practice. Healthcare services provided by primary 
care centres is based on residential districts. This allows for sufficient follow-up visits during 




observation for mild AOM cases can reduce antibiotic prescribing in primary care centres, 
which would contribute in reducing the risk of antibiotic resistance.  
As pain is the most common symptom found in AOM [15], pain assessment is an essential 
procedure in the management of AOM. This is not routinely practiced among Indonesian 
physicians. Therefore, identifying the baseline pain intensity and assessing its improvement 
during the follow-up visit will allow physicians to provide the best treatment for children with 
AOM.  
Only half of surveyed physicians stated they would participate in our study. This demonstrated 
there was a lack of motivation of physicians to participate in research. In order to improve this, 
the Ministry of Health could support the implementation of clinical research by granting them 
rewards. One of the most valuable rewards is acknowledging physicians’ contribution or 
collaboration to research by granting substantial additional credits for individuals and 
institutions. The individual credit can be added as extra points in the continuing professional 
development program of physicians and nurses, or as one requirement for their practice licence. 
The institutional credit could be acknowledged as part of the institutional accreditation 
program. This demonstrates that a particular healthcare institution has been involved in the 
implementation of research and the improvement of the quality of healthcare services, which 
could be an additional value for that institution. Direct involvement and contribution in the 
study will also contribute to the scientific publication rate of that particular institution.  
6.2.2   IMPLICATIONS FOR RESEARCH 
A large, high-quality clinical trial in assessing the effects of corticosteroids for children with 
AOM, particularly in uncomplicated and non-severe cases, is required. Our pilot study 
demonstrated that oral prednisolone may reduce pain intensity at Day 3. Although the difference 
did not quite reach the level deemed clinically important, a 10-mm score representing a 
clinically important difference was included in the confidence interval of the result from the 
pilot. This finding justified the importance of conducting a large and high-quality clinical trial 
to assess the effectiveness of oral corticosteroids for children with AOM.  
Our tympanometry sub-study demonstrated a lack of benefit, and difficulties in conducting a 
tympanometry examination in paediatric AOM patients. However, it will be very useful to 
investigate specific baseline and clinical characteristics in our study which might contribute to 




assessment. Therefore, by recommending this only for children with high risk for persisting 
MEE and not in all AOM cases, this costly and difficult procedure will be more cost-effective 
[13,16]. 
We are aware that both Indonesian practice guidelines for AOM, particularly for ENT 
specialists, need to be updated since it was published in 2007 by the Otology Working Group 
of Indonesian Otorhinolaryngologist Head and Neck Surgeon Society [10]. We expect an 
updated guideline can provide more detailed information regarding the diagnosis and treatment 
for AOM, particularly the justification for antibiotic treatment, which was not provided in the 
current guideline. It would also provide information on other non-antibiotic treatments 
recommended or not recommended for AOM, along with the supporting evidence (e.g., 
acetaminophen, decongestants, corticosteroids). This updated guideline can then be 
implemented across specialties in Indonesia, including GPs and paediatricians. Following this, 
it is important to assess the adherence of physicians in sufficiently implementing this guideline 
in their daily practice. This will be a long-term plan for another potential research project 
assessing the implementation of the Indonesian practice guideline of AOM among physicians 
in Indonesia.  
This pilot study showed that almost 80% of AOM cases were classified as severe, which is high 
compared with incidence rates found in studies conducted in developed countries. It would be 
very useful to have sufficient data about middle ear pathogens in AOM cases in Indonesia along 
with their antibiotic susceptibilities. This could be achieved with tympanocentesis or a less-
invasive procedure, such as a nasal swab cross-sectional representative study of AOM cases. 
There are also underlying factors that may potentially influence antibiotic susceptibilities 
among Indonesian children: (1) lack of recommendation of the pneumococcus vaccination for 
Indonesian children; (2) geographical and demographical factors; and (3) practice of antibiotic 
prescribing in Indonesia. Identifying the causative AOM pathogens could contribute to 
improvements in the quality of prevention and comprehensive management of AOM, thereby 
improving the ear and hearing health in Indonesian children. 
High antibiotic prescribing rates are also influenced by parents’ expectations for antibiotic 
treatment [16]; there are many studies conducted mostly in developed countries identifying this 
issue. Our survey study identified current practice in the management of AOM among 
physicians. However, it will also be useful to identify the parents’ and physicians’ beliefs and 




information can help physicians, researchers and health policy bodies to identify initial 
problems which influence the practice of antibiotic prescribing among Indonesian physicians 
and develop a strategy to limit this accordingly. 
For the sustainability of the implementation of clinical trials in Indonesia, it would be very 
useful to survey healthcare practitioners who have been involved or participated in any clinical 
research regarding their experience, and their perception and expectation from conducting 
clinical research, including the limitations and obstacles that hold them back from being 
involved in research. 
 
These research implications are important because of their potential contribution in tackling the 
antibiotic resistance problem in Indonesia. If these research projects are all implemented 
effectively, they can support reducing antibiotic use for AOM and eventually decrease the 
antibiotic resistance rate in Indonesia. 
6.3   CONCLUSIONS 
1. Our Cochrane review demonstrated there was insufficient evidence confirming efficacy 
of systemic corticosteroids for children with AOM, which indicated a requirement for 
high quality clinicals trials to be able to address this research gap. 
2. Our feasibility survey study demonstrated: 
a. There was high rate of antibiotic prescribing for mild AOM among Indonesian 
physicians, particularly ENT specialists and GPs.  
b. Almost half of physicians would prescribe oral corticosteroids for children with 
AOM, although this is not recommended by existing AOM practice guidelines. 
c. It is feasible to conduct a clinical trial testing oral corticosteroids for children 
with AOM in Indonesia. A sufficient number of AOM paediatric patients and 
physicians would prescribe oral corticosteroids for AOM cases and were willing 
to participate in a clinical trial of oral corticosteroids for children with AOM. 
3. Our pilot study demonstrated: 
a. It was feasible to apply all pre-specified procedures and outcome measures in 
the main study; however, several modifications are required (e.g., modification 
of recruitment and randomisation process, modification of case report forms). 
b. There was a lack of commitment to participate in the study among healthcare 




c. Oral corticosteroids may potentially improve ear pain at Day 3. This result 
confirmed it is crucial to have an adequate sample size and high-quality clinical 
trial for a definitive conclusion on the effectiveness of oral corticosteroids for 
AOM.   
d. Drowsiness is one of the unfavourable effects of corticosteroids in this study. 
However, there was no increased rate of other side effects compared with 
control. 
e. Our under-powered tympanometry study indicated that oral corticosteroids may 
improve MEE at one week which was represented by the improvement of 
tympanometry curve type. However, due to lack of clear benefits and the 
difficulties in conducting this examination in paediatric AOM patients, we will 
not include tympanometry examination in the main study. 
f. It is important to investigate predictor factors for persisting MEE in AOM cases 
to effectively restrict tympanometry examination for high risk patients as part of 
routine assessment in a comprehensive management of children with AOM. We 
have exploratory data from the pilot study to begin this process. 
4. Conflicting Indonesian clinical practice guidelines may cause a discrepancy in the 
management of AOM among Indonesia physicians, particularly in terms of antibiotic 
treatment. This means it is crucial to update the current practice guidelines based on 
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APPENDICES – CHAPTER 1 
 
Appendix 1.1. Alternative non-antibiotic treatment for acute otitis media 










A Cochrane review of very low to low quality evidence (3 trials; n = 
327) assessing acetaminophen or NSAID, alone or in combination for 
AOM found that both paracetamol and ibuprofen as monotherapy 
were more effective than placebo in relieving pain at 48 hours: 
paracetamol versus placebo with the proportion of children with pain 
10% versus 25% (1 trial; n = 148; relative risk (RR) 0.38, 95% 
confidence interval (CI) 0.17 to 0.85; P = 0.018; number needed to 
treat to benefit (NNTB) 7); ibuprofen versus placebo with proportion 
of children with pain 7% versus 25% (1 trial; n = 146; RR 0.28, 95% 





A Cochrane review (15 trials; n = 2695) included RCTs of children 
with AOM who received either decongestant and/or antihistamine or 
control (no placebo in three trials) found:  
• A lower rate of persisting AOM only in the combined 
decongestant and antihistamine group in two weeks (5 trials; n = 
482; RR 0.63; 95% CI 0.43 to 0.93; P = 0.019; I2 = 0%; NNTB 
10) 
• No significant benefit for early cure rates, resolution of the 
symptoms, or other complications 
• An increased risk of adverse effects in the intervention groups 





A Cochrane review of moderate to high quality evidence from 11 
RCTs (n = 60,733) of children aged up to 12 years found:   
• Most PCVs are effective in reducing the incidence of AOM if 
they are administered during early infancy (age < 1 year).  
• A 7-valent PCV with CRM197 as carrier protein (CRM197-
PCV7) reduced the risk of all-cause AOM in low-risk infants (1 
trial; n = 37,868 children; high quality evidence; relative risk 





• Both CRM197-PCV7 and PCV7 with the outer membrane 
protein complex of Neisseria meningitidis serogroup B as carrier 
protein (OMPC-PCV7) reduced the risk of pneumococcal AOM 
(2 trials; n = 3328 children; high quality evidence; RRR 20% to 
25%, 95% CI 7-11% to 31-37%).  
• A 11-valent PCV conjugated to protein D of H. influenzae 
(PHiD-CV11) reduced the risk of all-cause AOM (1 trial; n = 
4968 children; high quality evidence; RRR 34%, 95% CI 21% to 
44%).  
• Both PHiD-CV10 and PHiD-CV11 reduced the risk of 
pneumococcal AOM (2 trials; n = 12,327 children; high quality 
evidence; RRR 52% to 53%, 95% CI 16-37% to 63-74%).  
• Common adverse events found in the administration of PCV are 
mild local reactions (e.g., redness, swelling) and fever. 
Probiotics [4]. 
 
A Cochrane review of RCTs of children aged up to 18 years found 
that probiotics (e.g., powder, drops, capsule, tablet, spray) containing 
Lactobacillus and Streptococcus reduced: 
• Incidence of AOM episode(s) during treatment (16 trials; n = 
2961 children; moderate-quality evidence; RR 0.77, 95% CI 0.63 
to 0.93; P < 0.01; I2 = 72%; NNTB 10).  
• Incidence of AOM among children who were not prone to AOM 
(11 trials; n = 2227 participants; moderate-quality evidence; RR 
0.64, 95% CI 0.49 to 0.84; P < 0.005; I2 = 59%; NNTB 9) but not 
among children who were otitis prone 
• The risk of having other infection (11 trials; n = 3610 children; 
moderate-quality evidence; RR 0.75, 95% CI 0.65 to 0.87; P < 
0.001; I2 = 64%; NNTB 12).  




A Cochrane review of very low to low quality RCTs of children with 




 therapy or as addition to adenoidectomy when compared to 
observation can reduce AOM recurrence at six months (1 trial; n = 
95; RR 9.49, 95% CI 2.38 to 37.80; P < 0.005; NNTB 3) and 12 
months (1 trial; n = 200; RR 1.41, 95% CI 1.00 to 1.99; P = 0.047; 
NNTB 7), as well as reduce the incidence rate of rAOM at six months 
(1 trial; n = 95; MD -1.50, 95% CI -1.99 to -1.01; P < 0.001) and 12 
months (1 trial; n = 200; MD -0.55, 95% CI -0.17 to 0.93).  
Compared to placebo medication, grommets reduced the risk of 
having a new episode of rAOM (1 trial; n = 42; RR 3.64, 95% CI 1.20 
to 11.04; P = 0.02; NNTB 3) and incidence rate of rAOM (1 trial; n 




A Cochrane review of RCTs and quasi-RCTs of children and adults 
(5 trials, n = 391) who came to primary care centre with intact 
eardrum AOM found that children who received an addition of topical 
analgesics to oral analgesics had a 50% pain reduction compared to 
placebo at 10 minutes (2 trials; n = 117; moderate-quality evidence; 
RR 2.13, 95% CI 1.19 to 3.80; P = 0.01; I2 = 0%; NNTB 5) and 30 
minutes (RR 1.43, 95% CI 1.12 to 1.81; P = 0.003; I2 = 0%; NNTB 4) 
after the initial administration [6]. 
In a multicentre, randomised, parallel RCT (CEDAR trial) [91], 
children aged one to ten years with 24-hour preceding pain in a 1-
week onset of AOM were randomised to receive either anaesthetic-
analgesic ear drops (n = 38) or unblinded usual care (n = 36) in a two-
arm trial (n = 74); or to receive anaesthetic-analgesic ear drops (n = 
12) , placebo ear drops (n = 10) , or unblinded usual care (n = 10) in 
a three-arm trial (n = 32). In the two-arm trial, there were fewer 
children in the active ear drop group who received antibiotics by Day 
8 (1/29 versus 9/30; OR 0.08, 95% CI 0.01 to 0.71, P = 0.023, NNTB 
4. More children in the active ear drop group (n = 32) had a reduction 
of parent-report pain score (0-10 ear pain scale, higher scores 
represent more pain) compared to those in the usual care group (n = 




Day 1. In the 3-arm trial, there was no difference in antibiotic 
consumption between children in the active ear drops and usual care 
groups (0/10 versus 2/8, OR 0.11, 95% CI 0.00 to 3.17, P = 0.201). 
There was no difference in pain score reduction between the active (n 
= 10) and placebo ear drop groups (n = 7) at Day 2 (MD 0.96, 95% 
CI -0.99 to 2.91, P = 0.312) nor in those in the active ear drop group 
compared to the usual care group (n = 9) (MD -1.90, 95% CI -3.85 to 
0.05; P = 0.056). However, children who received placebo ear drops 
had a significant ear score reduction compared to those who received 
usual care (n = 9) (MD -2.86, 95% CI -4.46 to -1.25, P = 0.002).  
However, when 2-arm and 3-arm trials were combined, active ear 
drops were more likely to reduce antibiotic consumption compared to 
usual care (1/39 versus 11/38; OR 0.09, 95% CI 0.02 to 0.55, P = 
0.009, NNTB 4). When two trials were combined, active ear drops (n 
= 42) reduced pain score compared to usual care (n = 39) at Day 2 
(MD -1.70, 95% CI -2.74 to -0.66, P = 0.001). All results were 
consistent after adjusting for pain score at baseline. Although this 





A Cochrane review of low to moderate quality RCTs found Influenza 
vaccines slightly reduced antibiotic use compared to placebo or no 
treatment (2 trials; n = 1223; RR 0.70, 95% CI 0.59 to 0.83; P < 0.001; 
I2 = 0%; NNTB 9). However, the influenza vaccines increased the risk 
of fever (7 trials; n = 10,615; RR 1.15, 95% CI 1.06 to 1.24; P < 0.01; 
I2 = 0%; NNTH 38) and rhinorrhoea (6 trials; n = 10,563; RR 1.17, 
95% CI 1.07 to 1.29; P < 0.01; I2 = 63%; NNTH 19). No serious 
adverse effects were found. 
Xylitol [9]. 
 
A Cochrane review of moderate-quality RCTs and quasi-RCTs (5 
trials; n = 3405) of children aged ≤ 12 years found that xylitol 
supplementation reduced the risk of AOM (3 trials; n = 1826; RR 




reduced antibiotic initiation (1 trial; n = 306; RR 0.64, 95% CI 0.42 
to 0.97; P = 0.03; NNTB 10) compared to control. This review also 
showed xylitol was not beneficial in reducing the incidence of AOM 
among healthy children during respiratory infections or among those 
who are prone to otitis. There was no significant difference in side 
effects (i.e., abdominal symptoms, rash) between the xylitol and 




A systematic review of very low quality RCTs and quasi-RCTs (7 
trials) of children and adults with AOM was conducted to assess the 
effectiveness of herbal medicine alone or combined with non-surgical 
treatment (e.g., antibiotics, decongestants and/or antihistamines) 
compared to other non-surgical treatment: 
• Two trials comparing a combination of herbal medicines of 
Longdan-xiegan (LDXG) decoction or pills or Shenlingbaizhu 
(SLBZ) powder and ampicillin with ampicillin alone showed that 
a combined herbal and antibiotics may improve AOM symptoms 
at Day 5 and Day 10.  
• One study comparing herbal medicine and conventional therapy 
with conventional therapy alone showed a symptom 
improvement at Day 14 (n = 119; RR 1.55, 95% CI 1.23 to 1.93; 
P = 0.0001).  
• A combination of LDXG pills and penicillin reduced symptom 
recovery time by two days compared to penicillin alone (1 trial; 
n = 137; MD -2.40, 95% CI -2.84 to -1.96; p < 0.0001). Symptom 
recovery time was also reduced by Eryanling decoction compared 
to cephalexin by eight days (1 trial; n = 102; MD −7.90, 95% CI 
-11.94 to -3.86; P = 0.0001).  
• One study comparing a combination of Sinupret and amoxicillin 
with amoxicillin alone showed there was significant 
improvement in fever at Day 7 (RR 1.23, 95% CI 1.03 to 1.46; P 




1.23 to 6.81; P = 0.02) and at Day 7 (RR 2.02, 95% CI 1.19 to 




A pilot retrospective study using medical records of 173 children aged 
one to five years with history of rAOM comparing an intervention of 
supervised nasal saline irrigation (NSI) with non NSI showed that 
supervised NSI reduced the incidence of:  
• new episode of AOM (1.03 ± 0.14 versus 2.08 ± 0.16, P < 0.001). 
• spontaneous perforation of tympanic membrane (0.66 ± 0.11 
versus 1.32 ± 0.16, P < 0.001). 
• the requirement for antibiotic treatment (1.48 ± 0.17 versus 2.59 





Two case-control studies found that vitamin D (25(OH) vit D) 
deficiency was mostly found in children with recurrent AOM or 
otitis-prone children compared to healthy children, which indicates a 
low level of serum vitamin D is associated with the incidence and 
recurrence of AOM [12,13]. 
An RCT of children with a history of rAOM who received either 
vitamin D 1000 IU/day or placebo (58 versus 58, respectively) for 
four months showed fewer children in the Vit D group experienced at 
least one episode of AOM compared to the placebo group (26 versus 
38; RR 0.68, 95% CI 0.49 to 0.96; P = 0.03; NNTB 5) in six months. 
This study concluded that vitamin D supplementation with a dose of 
1000 IU/day was likely to improve vitamin D level to at least 30 
ng/mL, which later would significantly reduce the incidence of AOM 








Appendix 1.2. Corticosteroids for acute respiratory and other infections. 
Acute sinusitis [15]. 
 
A Cochrane review of low to moderate quality evidence from five 
RCTs of 1193 adults with acute sinusitis comparing oral 
corticosteroids with control (placebo or NSAIDs) showed short-term 
symptom resolution or improvement only in the oral corticosteroids 
as an addition to antibiotic group compared to the control group: at 
three to seven days (4 trials; n = 869; RR 1.40, 95% CI 1.08 to 1.81; 
P = 0.010; I2 = 75%; NNTB 6) and at four to 14 days (4 trials; n = 
945; RR 1.32, 95% CI 1.04 to 1.68; P = 0.022; I2 = 84%; NNTB 7). 
There was no benefit in the use of corticosteroids as monotherapy.  
Acute sore throat 
[16-18]. 
 
A Cochrane review of moderate to high quality evidence from eight 
RCTs of both children and adults (n = 743) with acute sore throat 
comparing oral corticosteroids as an addition to antibiotics with 
placebo showed those who received corticosteroids: (1) were more 
likely to have complete resolution of pain at 24 hours (4 trials; n = 
286; RR 3.16;  95% CI 1.97 to 5.08; P < 0.001; I2 = 44%; NNTB 4) 
and at 48 hours (3 trials; n = 209; RR 1.65; 95% CI 1.32 to 2.06; P < 
0.001; I2 = 0%; NNTB 3); (2) had a reduced mean time to onset of 
pain relief (6 trials; n = 609; mean difference (MD) -6.32 hours; 95% 
CI -9.29 to -3.35; P < 0.001; I2 = 72%); and, (3) had a reduction in 
the mean time to complete resolution (5 trials; n = 500; MD -14.41 
hours, 95% CI -24.99 to -3.84; P = 0.008; I2 = 78%) [16].  
A recent RCT of adults with acute sore throat without initial antibiotic 
treatment who received either single dose oral dexamethasone or 
placebo found that those who received corticosteroids: (1) were more 
likely to have complete symptom resolution at 48 hours (102/288 
versus 75/277; RR 1.31, 95% CI 1.02 to 1.68; P = 0.030; NNTB 12), 
but not at 24 hours (65 versus 49; RR 1.28, 95% CI 0.92 to 1.78) and 
(2) were less likely to require antibiotic treatment (65/173 versus 




A recent systematic review of moderate to high quality evidence from 
10 RCTs of adults and children (n = 1426) with acute sore throat 
showed that there were more patients in the single low dose 
corticosteroid group who had complete resolution of pain at 24 hours 
(5 trials; n = 1049; RR 2.24; 95% CI 1.17 to 4.29; I2 = 69%; NNTB 
9) and 48 hours (4 trials; n = 1076; RR 1.48; 95% CI 1.26 to 1.75; I2 
= 3%; NNTB 8) [18].  
Croup [19]. 
 
A Cochrane review of low to moderate quality evidence from RCTs 
(43 trials; n = 4565) of children aged up to 18 years with croup 
comparing any corticosteroids, as monotherapy or as an add-on, to 
placebo or other treatment found parenteral dexamethasone: 
• reduced croup symptoms at six hours (6 trials; n = 567; 
standardised mean difference (SMD) -0.62, 95% CI -1.17 to -0.08; 
P = 0.026; I2 = 85%), 12 hours (5 trials; n = 323; SMD -0.85, 95% 
CI -1.55 to -0.15; P = 0.017; I2 = 84%, and 24 hours (6 trials; n = 
245; SMD -0.89, 95% CI -1.55 to -0.22, P = 0.009, I2 = 81%). 
• reduced length of inpatient stay (6 trials; n = 328; MD -18.25, 95% 
CI -27.87 to -8.62; P < 0.001; I2 = 41%) 
• improved croup at 12 hours (3 trials, n = 166; RR 1.52, 95% CI 
1.06 to 2.18, P = 0.024; I2 = 50%; NNTB 4) and at 24 hours (4 




An overview of four systematic review of 20 RCTs assessing the 
effects of any types of corticosteroids in children aged up to 24 
months with bronchiolitis showed systemic corticosteroids only 
slightly reduced clinical scores using a respiratory distress 
assessment instrument compared to placebo or control (3 trials; n = 
178; high-quality evidence; SMD -0.36, 95% CI -0.65 to -0.08) and 
did not reduce the length of stay for patients with/without mechanical 
ventilation, duration of mechanical ventilation, nor mortality based 








In severe community-acquired pneumonia, a systematic review of 
nine RCTs showed that systemic corticosteroids reduced all-cause 
mortality compared to control (9 trials; n = 914; OR 0.63, 95% CI 
0.42 to 0.95; P = 0.03; I2 = 0%; NNTB 18) in adults, in which 
prednisolone or methylprednisolone significantly reduced total 
mortality compared to hydrocortisone (OR 0.37, 95% CI 0.19 to 0.72; 
P = 0.04). In addition, systemic corticosteroids reduced the duration 
of ICU stay (6 trials; n = 287; MD -2.52 days, 95% CI -4.88 to -0.15; 
P = 0.04; I2 = 59%). There were no differences on adverse events (i.e., 
hyperglycaemia, gastrointestinal haemorrhage, cardiac events) 
between the corticosteroids and control groups [21].  
One Cochrane review of moderate to high-quality evidence from 17 
RCTs showed children (four RCTs; n = 301) with bacterial 
community-acquired pneumonia who received systemic 
corticosteroids compared to those received placebo or no treatment, 
had reduction of early clinical failure rates (2 trials; n = 88; high-
quality evidence; RR 0.41, 95% CI 0.24 to 0.70; P < 0.01; I2 = 25%; 
NNTB 3), as well as reduction of time to clinical cure (3 trials; n = 
225; MD -1.57 days, 95% CI -2.55 to -0.60; P < 0.01; I2 = 80%) [22]. 
One common adverse event found in adults was hyperglycaemia (7 
trials; n = 1578; RR 1.72, 95% CI 1.38 to 2.14; I2 = 21%; NNTH 10),  
but no other adverse events were found. 
Wheezing [23,24]. 
 
An RCT of 74 children aged three to 23 months with the first acute 
rhinovirus-induced wheezing (moderate to severe) comparing oral 
prednisolone at dose of 2 mg/kg/day and placebo for three days 
showed prednisolone reduced the duration of cough (6.2 ± 3.6 versus 
8.9 ± 3.7 days; MD -2.8 days, 95% CI -4.5 to -1.0, P = 0.002), noisy 
breathing (5.3 ± 3.3 versus 7.3 ± 3.9 days; MD -2.0, 95% CI -3.6 to -
0.29; P = 0.02), and rhinitis (5.5 (2-9) versus 8.5 (6-11.5) days; MD 
-3, 95% CI -5 to -1; P = 0.008) at two weeks after discharge [23]. 
An recent RCT assessing oral prednisolone (1 mg/kg/day) versus 




virus-induced wheezing showed prednisolone reduced the length of 
stay at the emergency department (ED) compared to control (370 
(121-709) versus 540 (124-971) minutes; unadjusted ratio of 
geometric mean 0.79, 95% CI 0.64 to 0.97, P = 0.023) [24]. There 
were no significant differences in adverse events between the two 
groups in these two studies [23,24]. 
Influenzae [25]. 
 
A Cochrane review of very low-quality evidence from 19 
observational studies (n = 3459) assessing effects of corticosteroids 
as an additional therapy for patients with influenzae or influenzae-
like illness showed corticosteroids may increase mortality (13 




In acute bacterial meningitis, a Cochrane review of moderate to high 
quality evidence from 25 RCTs (n = 4121 children and adults) testing 
any types of corticosteroids as an addition to antibiotic treatment 
showed those who received corticosteroids were less likely to have 
severe hearing loss (17 trials; n = 2437; RR 0.67; 95% CI 0.51 to 0.88; 
P = 0.004; I2 = 0%; NNTB 31) and any hearing loss (20 trials; n = 
2785; RR 0.74; 95% CI 0.63 to 0.87; P < 0.001; I2 = 24%; NNTB 19), 
as well as neurological sequelae (13 trials; n = 1756; RR 0.83, 95% 
CI 0.69 to 1.00; P = 0.046; I2 = 0%; NNTB 27) compared with those 
without. However, corticosteroids did not significantly reduced 
mortality rates.  
Sepsis [27]. 
 
A Cochrane review of low quality evidence from 33 RCTs (n = 4268) 
that included some children but mostly adults with sepsis showed 
long-course of low dose corticosteroids reduced all-cause mortality 
rates at 28 days (22 trials; n = 2266; RR 0.87, 95% CI 0.78 to 0.97; P 
= 0.013; I2 = 16%; NNTB 25). Corticosteroids also ICU stay duration 
(12 trials; n = 1384; MD -1.68 days, 95% CI -3.27 to -0.09; P = 0.038; 
I2 = 31%). Patient who received corticosteroids had significantly 




95% CI 1.16 to 1.37; P < 0.0001; I2 = 26%; NNTH 12) and 
hypernatremia (3 trials; n = 805; RR 1.64, 95% CI 1.28 to 2.09; P < 
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APPENDICES – CHAPTER 3 
 




Research title : The management of acute otitis media in children in DKI Jakarta, Depok, and Bekasi 
Researcher : Prof. Dr. dr. XX 
Dear Mr/Mrs/Ms/Miss, 
We, researchers from Clinical Epidemiology and Evidence Based Medicine (CEEBM) Unit FMUI-CMH and 
Faculty of Health Sciences and Medicine, Bond University Australia, is currently conducting survey study 
on the management of acute otitis media (AOM) in children in Jakarta, Depok, and Bekasi. 
This study aims to determine and identify current clinical practices, attitudes and behaviors of physicians 
(GPs, ENT specialist, and pediatricians) in the management of acute otitis media in children, and to 
identify the incidence of acute otitis media in children at various health care facilities in DKI Jakarta, 
Depok, and Bekasi. In addition, we also want to identify potential interests of the above practitioners to 
participate in further clinical trial regarding the use of corticosteroids as an alternative intervention in 
the treatment of acute otitis media in children. 
The data obtained from this study will be useful to achieve an overview of current clinical practices, 
attitudes, and behaviors of the physicians in the management of acute otitis media in children, 
particularly regarding to the use of antibiotics, as well as the incidence of acute otitis media in children 
in DKI Jakarta, Depok, and Bekasi. It also will be used as a baseline data for the future clinical research 
on the role of corticosteroids in the management of acute otitis media in children, as it can be used as 
an alternative therapy to antibiotics in certain groups of children with acute otitis media, in order to 
reduce antibiotic resistance rates. 
In this study we will distribute questionnaires consist of the initial data (anonymous), current clinical 
practice, attitudes and behaviour, the case scenarios, as well as your potential interest to participate in 
clinical research on the role of corticosteroids in the treatment of acute otitis media in children that will 
be held on February 2017 to February 2018. If you are interested to participate, we also will obtain some 
additional information of biographical data, employment, and education columns.  
This study is voluntary. You are free to decide whether are willing to participate in this study or not, 
without any further affect. 
INFORMATION FORM FOR POTENTIAL PARTICIPANT 
[203]
All data in this study will be kept confidential so it is not possible for others to connect it with you. All 
provided information will only be used for research purposes. It will not affect the assessment of your 
director and other relevant (authorized) committee in your institution. The result of such information 
will be presented in the form of aggregate data covering all participants, instead of personal data of 
each participant. You are free to decide whether you are willing to participate in this study or not. You 
have the opportunity to ask all unclear information related to this study.  
If you require further information regarding this survey study, please do not hesitate to contact Prof. Dr. 
dr. SS at di Unit Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit CMH-FMUI at Building 
H level 2 CMH, Diponegoro 71 Jakarta. Phone number 021-3161760, or email: info@ceebm.org. 
Thank you for your kind attention and contribution. 
Researcher, 
Prof. Dr. dr. SS 
dr. RR 
[204]
I, hereby undersigned: 
Name 
Age 
After receiving information regarding this study from the researcher, herewith I declare the agreement / 
disagreement *) to participate as a respondent in this study entitled: " The management of acute otitis 
media in children in DKI Jakarta, Depok, and Bekasi " 
This statement was made without coercion from any party. 
Who provided statement above, Researcher, 
 Name: 
*Please strikethough your incorrect option
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The World Health Organisation Trial Registration Data set 
Primary Registry and Trial Identifying Number ACTRN12618000049279 
Date of Registration in Primary Registry 16 January 2018 
Secondary Identifying Numbers - 
Source(s) of Monetary or Material Support Self-funded research 
Primary Sponsor Respati W. Ranakusuma, MD, ORL 
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Faculty of Health Sciences and Medicine Bond University, QLD, Australia 
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Public Title Oral prednisolone for acute middle ear infection in children 
Scientific Title Oral prednisolone for acute otitis media in children: a pilot pragmatic 
randomised open-label single-blind study (OPAL study) 
Countries of recruitment Indonesia 
Health Condition(s) or Problem(s) Studied Acute otitis media in children 
Intervention(s) Intervention Name:  
 Active intervention: Prednisolone tablet  
 Active comparator: None  
Intervention Description:  
 Prednisolone tablet with doses based on range of age for five days:  
o 6 months – <2 years: 10 mg/day
o  2 – <6 years: 20 mg/day
o  6 – 12 years: 30 mg/day
 None   
Key Inclusion and Exclusion Criteria Ages eligible for study: 6 months to 12 years 
Sexes eligible for study: both males and females 
Accepts healthy volunteers: no 
Inclusion criteria:  
 children (6 months – 12 years) with acute otitis media, defined as a 
current onset within 48 hours of ear-related symptoms (e.g. ear pain, ear 
tugging/rubbing or irritability) and if possible to assess, otoscopic 
findings of acute inflammation (e.g. erythema) and middle ear effusion 
(e.g. bulging, air-fluid level) 
Exclusion criteria:  
 children with major and severe medical conditions (e.g. heart failure, 
kidney failure) 
 immunocompromised children (e.g. HIV, children receiving cancer 
treatment) 
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 children with congenital malformations and/or syndromes (e.g. cleft 
palate, Down’s syndrome) 
 children with high risk of risk of strongyloidiasis infection 
 children with ear ventilation tube(s) 
 children who had exposed to persons with varicella (chicken pox) or 
active Zoster infection in the past 3 weeks without any prior varicella 
immunisation or infection 
 children who have taken systemic (i.e. oral, injection) or topical steroids 
in the preceding four weeks  
 children who have taken antibiotics in the preceding two weeks; a 
 children who are hypersensitive to prednisolone or prednisone, or other 
corticosteroids. 
Study Type Type of study: interventional 
Method of allocation: stratified, randomised 
Masking: open-label, single-blind (outcome assessor) 
Assignment: parallel 
Purpose: Efficacy  
Phase III 
Date of first enrolment 01 January 2018 
Target sample size 60 children 
Recruitment status Pending (not started): participants are not yet being recruited or enrolled 
at any site 
Outcome(s) (1) Outcome Name: Recruitment rates 
Metric/method of measurement: Informed consent form and case 
report forms (CRFs) 
The timepoint(s) of interest: Baseline visit (visit-0) 
(2) Outcome Name: The success of the study procedures 
Metric/method of measurement: CRFs (i.e. eligibility and 
randomisation form, outcomes form) 
The timepoint(s) of interest: Baseline visit (visit-0) 
(3) Outcome Name: Ability to measure planned outcomes in main study 
Metric/method of measurement: CRFs (i.e. eligibility and 
randomisation form, outcomes form) and symptom diary (e.g. Visual 
Analogue Scale/VAS and Acute Otitis Media – Severity of Symptoms 
Scale/AOM-SOS), and feedback form 
The timepoint(s) of interest: Baseline visit, visit-1 (day-3 to-5), visit-2 
(day-7 to -9), day3, visit-3 (day-3 to -40), and visit-4 (day-90 to -100) 
(4) Outcome Name: Compliance to study and study drug 
Metric/method of measurement: CRF (i.e. outcomes form), the 
symptom diary, and number of left-over drug 
The timepoint(s) of interest: Visit-1 (day-3 to-5), visit-2 (day-7 to -9), 
day3, visit-3 (day-3 to -40), and visit-4 (day-90 to -100) 
(5) Outcome Name: The verification of sample size calculation for main
study 
Metric/method of measurement: CRFs (i.e. eligibility and 
randomisation form) 
The timepoint(s) of interest: Baseline visit (visit-0) 
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Protocol version 
Protocol version No. Date issued 
Protocol OPAL Study Version 1.0.0 (V1.0.0) 27 July 2017 
Protocol OPAL Study Version 1.1.0 (V1.1.0) 17 October 2017 
Protocol Amendment Number:  AM1.0 
Amendment history: 
Amendment No. Protocol version 
no. 
Date issued Author(s) of 
changes 
Detail of changes made 
Amendment No. 1.0 Protocol V1.1.0 17 October 2017 Respati W 
Ranakusuma 
1. The modification of the 
form of trial drug
We planned to use
prednisolone liquid. Due to 
administrative issues 
where the proposed 
pharmaceutical 
manufacturer was unable 
to share confidential 
documents that were 
required for importing the
trial drug to Indonesia, we 
therefore will use 
prednisolone tablet for this 
trial. The pharmacist will 
crush the prednisolone 
tablets and mix it with 
sweetener. The crushed 
tablet will be packed in 
daily paper-package. The 
parents will mix the 
crushed tablet with juice or 
honey. This method is 
commonly practiced in
Indonesia, particularly for 
paediatric patients.
2. The duration of the trial
drug use
We planned to give 
prednisolone for seven 
days. Although 7-day 
duration of corticosteroid 
use is considered as a 
short-term use, we will 
reduce its duration to five 
days to minimise the
potential harms caused by 
corticosteroids.
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Funding 
This research is supported by self-funding of the principal investigator (Dr. Respati W. Ranakusuma, 
ORL).  
We will purchase the trial drug, prednisolone tablets, from PT Pratapa Nirmala, Tangerang, 
Indonesia. This pharmaceutical manufacturer is not linked to this study and does not have authority 
over any procedural implementation, scientific process, or decision in the study.  
Roles and responsibilities 
Protocol contributions 
Name Affiliation Role of protocol contributors 
Dr. Respati W. Ranakusuma, ORL 
ENT surgeon, PhD candidate 
Telp: +61 424 957 129 / +62 8111 012 185 
Fax:  N/A 
Email: rranakus@bond.edu.au /    
    respati.ranakusuma@ceebm.org 
 Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University 
14 University Drive, Robina QLD 4226 
Australia 
 Clinical Epidemiology and Evidence-
Based Medicine Unit, Dr. Cipto 
Mangunkusumo Hospital – Faculty of 
Medicine Universitas Indonesia 
Jl. Diponegoro 71 Jakarta 10430 
Indonesia 
Initiated the study design and 
methodology; developed the protocol 
including case report forms (CRFs), 
informed consent, and symptom diary 
Dr. Amanda McCullough, PhD, PGCHET, 
BSc (Hons) 
Epidemiologist, expert in acute 
respiratory infections and antibiotic 
resistance 
Telp: +61 7 559 55204 
Fax: N/A 
Email: amccullo@bond.edu.au  
Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University, 14 
University Drive, Robina QLD 4226 
Australia 
Initiated the study design from the 
clinical epidemiologic perspective; 
refined the protocol including case 
report forms (CRFs), informed consents, 
and symptom diary 
Associate Professor Elaine Beller, BSc, 
MAppStat 
Clinical trialist, biostatistician 
Telp: +61 7 559 55523 
Fax: N/A 
Email: ebeller@bond.edu.au 
Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University, 14 
University Drive, Robina QLD 4226 
Australia 
Initiated the study design and 
methodology from the clinical trialist 
and biostatistician perspectives; refined 
the protocol including case report forms 
(CRFs), informed consents, and 
symptom diary 
Professor Christopher Del Mar, 
FAFPHM, MBBChir, MA, MD, FRACGP, 
BSc 
Epidemiologist, evidence-based 
practitioner, expert in acute respiratory 
infection and antibiotic resistance 
Telp: +61 7 559 52504 
Fax: N/A 
Email: cdelmar@bond.edu.au  
Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University, 14 
University Drive, Robina QLD 4226 
Australia 
Initiated the study design from the 
clinical perspective; refined the protocol 
including case report forms (CRFs), 
informed consents, and symptom diary 




Telp: +62 21 316 1760 
Fax: N/A 
Email: sudigdo1947@gmail.com 
 Clinical Epidemiology and Evidence-
Based Medicine Unit, Dr. Cipto 
Mangunkusumo Hospital – Faculty of 
Medicine Universitas Indonesia 
Jl. Diponegoro 71 Jakarta 10430 
Indonesia 
 Department of Child Health Faculty of 
Medicine Unit, Universitas Indonesia – 
Dr. Cipto Mangunkusumo Hospital 
DIponegoro 71 Jakarta 10430 
Indonesia 
Provided advice in paediatric 
perspectives, supervising the trial in 
Jakarta 
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Contact information of trial sponsor or funder(s) 
Name Contact information Role of study sponsor and funders  
Dr. Respati W. Ranakusuma, ORL  Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University 
14 University Drive, Robina QLD 4226 
Australia 
 Clinical Epidemiology and Evidence-
Based Medicine Unit, Dr. Cipto 
Mangunkusumo Hospital – Faculty of 
Medicine Universitas Indonesia 
Jl. Diponegoro 71 Jakarta 10430, 
Indonesia 
She is the principal investigator  
Contact information of research team and others overseeing the trial 
Name Affiliation Roles and responsibilities 
Associate Investigators 
Dr. Eka Dian Safitri, ORL 
ENT surgeon 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: ekadian.safitri@ceebm.org  
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
(1) involved in the development of
tympanometry study; (2) providing
training related to using and
interpreting tympanometry to 
physicians, nurses, and 
tympanometry technicians  
Dr. Yupitri Pitoyo, ORL 
ENT surgeon 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: yupitri.pitoyo@ceebm.org 
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
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healthcare centres including the 
physicians and nurses 
Dr. Arie Sulistyowati, MSc, Paed. 
Paediatrician, epidemiologist 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: arie.sulistyowati@ceebm.org 
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
Providing advice and expertise in 
terms of paediatric patients  
Widyaningsih, MPH 
Public Health, qualitative study expert 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: widyaningsih.ade@ceebm.org  
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
(1) submitting a research ethics
application to the Indonesian Medical
Research Ethics Committee; (2)
recruiting primary healthcare centres
including the physicians and nurses 
Research Coordinator 
Dr. Respati W. Ranakusuma, ORL 
ENT surgeon, PhD candidate 
Telp: +62 8111 012 185 
Fax:  N/A 
Email: rranakus@bond.edu.au /    
    respati.ranakusuma@ceebm.org  
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
C0-investigators  
Dr. Tri Juda Airlangga H, ORL 
ENT surgeon 
Telp: +6221 1500 135 
Fax:  N/A 
Email: airlanggamd@gmail.com  
Department of Ear, Nose, and Throat Head 
and Neck Surgery 
Dr. Cipto Mangunkusumo Hospital – Faculty 
of Medicine Universitas Indonesia 
Jl. Diponegoro 71  
Central Jakarta 10430 – Indonesia 
(1) Recruiting patients 
(2) Coordinating patient recruitment
among other clinicians in the
hospital 
Dr. Yulvina, ORL 
ENT surgeon 
Telp: +6221 470 1133 
Fax:  N/A 
Email: yulie_dj@yahoo.com  
Department of Ear, Nose, and Throat Head 
and Neck Surgery 
Persahabatan General Hospital 
Jl. Persahabatan Raya 1  
East Jakarta 13230 – Indonesia 
(1) Recruiting patients 
(2) Coordinating patient recruitment
among other clinicians in the
hospital 
[215]
Oral Prednisolone for Acute otitis media in chiLdren: a pilot pragmatic, randomised, open-label, single-blind 
study (OPAL study) 
Protocol OPAL Study. Version 1.1.0. Date 17 October 2017 
Page 9 of 32 
Dr. Evita Fitria Edyani, ORL 
ENT surgeon 
Telp: +6221 344 1008 
Fax:  N/A 
Email: evitafitria@yahoo.com  
Department of Ear, Nose, and Throat Head 
and Neck Surgery 
Gatot Subroto Army Hospital 
Jl. Dr Abdul Rahman Saleh 24 
Central Jakarta 10410 – Indonesia 
(1) Recruiting patients 
(2) Coordinating patient recruitment
among other clinicians in the 
hospital 
Dr. Yupitri Pitoyo, ORL 
ENT surgeon 
Telp: +6221 884 2121 
Fax:  N/A 
Email: yupitri.pitoyo@ceebm.org 
Department of Ear, Nose, and Throat Head 
and Neck Surgery 
Hermina Bekasi Hospital 
Jl. Kemakmuran 39, South Bekasi 
West Java 17141 – Indonesia 
(1) Recruiting patients 
(2) Coordinating patient recruitment
among other clinicians in the
hospital 
Dr. Respati W. Ranakusuma, ORL 
ENT surgeon 
Telp: +6221 2937 8939 
Fax:  N/A 
Email: rranakus@bond.edu.au  
Department of Ear, Nose, and Throat Head 
and Neck Surgery 
Antam Medika Hospital 
Jl. Pemuda 1A 
East Jakarta 13210 – Indonesia 
(1) Recruiting patients 
(2) Coordinating patient recruitment
among other clinicians in the
hospital 
Dr. Eka Dian Safitri, ORL 
ENT surgeon 
Telp: +6221 425 0451 
Fax:  N/A 
Email: ekadian.safitri@ceebm.org  
Department of Ear, Nose, and Throat Head 
and Neck Surgery 
Jl. Cempaka Putih Tengah I/1 
Central Jakarta 10510 – Indonesia 
(1) Recruiting patients 
(2) Coordinating patient recruitment
among other clinicians in the
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among other clinicians in the
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CHAPTER 1 – INTRODUCTION 
 
1.1 Background and rationale 
1.1.1 Background  
Antibiotic resistance, a major global threat, impacts more than two million people with illness and 
accounts for 23 thousand deaths annually in the United States [1]. One of the key drivers of the 
development of antibiotic resistance is antibiotic prescribing [2].  Antibiotics are mostly prescribed 
for common diseases, such as acute respiratory infections (ARIs) [3]. One of the ARIs commonly 
found in paediatric population with high antibiotic prescribing is acute otitis media [4,5]. In East 
Jakarta, Indonesia, the prevalence of AOM in children (< 18 years) was 5.4% [6]. In contrast, in 
Australia, there were an average of 35 new AOM cases reported by general practitioners per year 
(April 2010 – March 2015) [7].  
Acute otitis media (AOM) is characterised by rapid onset of symptoms (e.g. earache, ear 
tugging/rubbing, irritability), middle ear effusion (e.g. bulging, immobile tympanic membrane, air 
fluid level), and acute inflammation (e.g. erythema) [8]. Almost three quarters of children have an 
episode of AOM in their first five years of life, with the peak incidence at the age of six to 12 months 
[9,10]. Guidelines recommend close monitoring for 48 hours (expectant observation) along with 
adequate pain management for mild AOM (e.g. mild symptoms, fever < 39°C) [8]. Children with 
severe symptoms, young age (< 2 years) with bilateral AOM, and AOM with tympanic membrane 
perforation are more likely to benefit from antibiotic treatment [11]. A high rate of antibiotic 
prescription for AOM is evident. Eighty-nine per cent new AOM cases were managed by antibiotics 
in Australia during 2010 to 2015 [7]. In Indonesia, a survey study using clinical scenarios, 
demonstrated that up to 88% of physicians would prescribe antibiotics for mild case of AOM. 
Unclear clarification of antibiotic use in the Indonesian practice guideline for AOM in the primary 
care may contribute to this [12]. The option of using antibiotics also must be balanced against the 
risks, such as adverse effects (e.g. vomiting, diarrhoea, rash) and antibiotic resistance [13,14]. 
1.1.2 Rationale for the proposed study 
Prednisolone 
Reducing antibiotic use is crucial to lowering the risk of antibiotic resistance. One of the methods 
is to use an alternative treatment that does not involve antibiotics. The current alternative 
treatments (i.e. ear drops, herbal products, probiotics, zinc, decongestants) demonstrate 
insufficient evidence on their benefits for AOM [15,16]. It is important to understand the 
pathophysiology of AOM, which is an inflammatory process involving both cellular and chemical 
inflammatory mediators (i.e. cytokines, chemokines, mast cells, prostaglandins, leukotrienes) in 
the middle ear. These inflammatory mediators contribute in altering the vascular permeability, 
increasing mucous glycoprotein secretion, as well as stimulating the chemotaxis process, the 
activity of epithelial secretion and other mediators [17]. An intervention suppressing this 
inflammatory process, could have an important role in the resolution of AOM. Corticosteroids 
suppress the inflammation process by inhibiting the mediators and cytokines characteristic of AOM, 
the recruitment of leukocytes and monocyte-macrophages into affected areas, and the synthesis 
and/or release of numerous inflammatory mediators and cytokine, and also reducing vascular 
permeability [18].  
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Corticosteroids are produced in the adrenal cortex. Cortisol (glucocorticoids), one of the most 
common corticosteroids, is responsible for anti-inflammatory effects. The production of 
glucocorticoids is controlled by hypothalamus, pituitary, and adrenal (HPA) axis. Corticosteroid 
treatment may affect the production of natural corticosteroid by suppressing the HPA axis [19,20]. 
We have identified prednisolone is commonly used and safe in the treatment of inflammatory and 
autoimmune diseases in children. Prednisolone, a synthetic intermediate-acting glucocorticoid 
with a biological half-life of 12 to 36 hours, is commonly used in the treatment of inflammatory and 
autoimmune diseases in children. Although prednisolone has a lesser anti-inflammatory potency 
compared to other common corticosteroids (i.e. methylprednisolone, dexamethasone), but it has 
lesser growth effect which is one of the concerning issues in the disease management in paediatric 
population [19].  
We will give prednisolone at a dose of 1 mg/kg to 2 mg/kg body weight based on age category, 
once daily for five days. As there is a wide therapeutic dose window for prednisolone, this will 
enable us to operationalise the dose as 10 mg/day for children aged six months less than two years; 
20 mg/day for children aged two to five years; and 30 mg/day for children aged six to 12 years, 
simplifying both randomisation and dosage instructions. The current treatment for AOM does not 
include corticosteroids in the guidelines. Therefore, we determined the dose and duration of 
prednisolone based on the doses regularly used in the paediatric otitis media trials and regular 
dose for other inflammatory and infection diseases in children based on the international and 
national practice guidelines, such as bronchial asthma, juvenile rheumatoid arthritis, and acute 
bacterial meningitis [21-25]. The duration of corticosteroid use in otitis media trials varies between 
three to seven days [18, 26-28]. An animal study [29] using mice infected with Streptococcus 
pneumoniae and non-typeable H. influenzae (NTHi) bacteria demonstrated that most of AOM-
related cytokines peaks at three to six hours after the infections (interleukin-6/IL-6, interleukin-1 
alpha/IL-1α, tumor necrosis factor alpha/TNF-α) an at six hours to three days (interleukin-10/IL-10). 
In general, these cytokines will be progressively reduced between the fourth to sixth day of 
infection and the acute otitis media will be resolved after the sixth day [29]. Therefore, we will give 
the prednisolone for five days in order to boost the natural resolution mechanism in AOM cases 
and to minimize the potential harms of corticosteroid use even though 7-day duration is still 
regarded as short-term use.  
A single daily dose is preferable over divided doses to prevent the hypothalamic-pituitary-adrenal 
(HPA) axis suppression. Prednisolone should be given in a single dose at 6 to 8 am in the morning 
to mimic the normal diurnal rhythm of cortisol production [19,20] and because it is also more 
convenient for children and parents in the study to just take a trial drug once a day.  
Potential harms 
Despite the favourable effect of corticosteroids for inflammation, there are still several potential 
adverse effects related to its short-term use. A systematic review identified side effects of short-
course of corticosteroids (less than two weeks) in children, such as gastrointestinal disturbances 
(i.e. vomiting, gastritis, nausea), behavioural changes (i.e. mood swings, nervousness), HPA axis 
suppression, increased blood pressure, hyperglycaemia, weight gain, and decreased bone 
mineralisation [30]. Even though there were more children experiencing these side effects 
compared to placebo, the included studies used a diverse of corticosteroids’ types and duration, 
as well as the results were uncertain and include both important beneficial and harmful effects of 
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corticosteroid. Vomiting and behavioural disturbances (i.e. anxiety, aggressive behaviour) are the 
common side effects [30].  
Regarding vomiting, there were three studies comparing prednisolone to placebo or control (other 
type of corticosteroids). A good quality RCT [31] included children aged 10 to 60 months with virus-
induced wheezing who received a single dose of inhaled albuterol. These children then were 
randomly allocated to either prednisolone (10 mg oral prednisolone for children aged 2 years and 
younger; 20 mg for aged >2 years) group (n=343) or placebo (n=344). No significant differences on 
clinical outcomes (e.g. time to hospital discharge) or adverse effects between two groups were 
detected. There was one child from prednisolone group who vomited that required the 
discontinuation of the prednisolone [odds ratio (OR) 3.02 (95% confidence interval (CI) 0.12 to 74.33; 
p-value=0.50; number needed to harm (NNTH; number of children who are treated with
prednisolone that will result in one additional event of side effects) = 34 children)] [31]. One study
[32] on children aged one to 17 years with acute asthma presenting to the emergency department
(ED). The children received a dose of inhaled albuterol and either a single dose of oral prednisone
2 mg/kg (n=41) or placebo (n=40). There was no a significant difference in the incidence of vomiting 
after taking the prednisone between the prednisone group (n=3; 7.3%) and the placebo group (n=1; 
2.5%) [OR 3.08 (95% CI 0.31 to 30.92; p-value=0.34; NNH=21)] [32]. The same author with similar
inclusion criteria [33] demonstrated a significant difference on the incidence of vomiting between
children who received single dose prednisone 2 mg/kg/day (n=10/66) and nebulised
dexamethasone 1.5 mg/kg (n=0/62), however the confidence interval was very wide that included
a high number of NNTH (if we treat more than 50 children with prednisone, then we will expect
one additional event of vomiting) [OR 23.23 (95% CI 1.33 to 405.54; p-value=0.03; NNH=7)] [33].
Regarding behavioural changes, one RCT [34] randomly allocated children aged two to 16 years 
with acute exacerbation of mild persistent asthma to receive either oral prednisone/prednisolone 
high dose (2 mg/kg/day) or low dose (1 mg/kg/day) for five days. There were significant differences 
in observed adverse events between high-dose and low-dose groups in regard to anxiety (9/43 vs 
2/43, respectively) [OR 5.43 (95% CI 1.10 to 26.83; p-value=0.04; NNTH=7)] and aggressive behaviour 
(9/43 vs 0/43) [OR 23.96 (95% CI 1.35 to 426.33; p-value=0.03; NNTH=5)]. The wide of intervals 
demonstrated a wide variance in the number of children needed to treat to expect one additional 
adverse event. There were no significant differences in other unfavourable effects (i.e. facial 
fullness and erythema, abdominal pain, diarrhea, euphoria, depression, and hyperactive) [34]. 
Another RCT [35] included children aged two to 15 years with acute exacerbation of asthma who 
were randomly allocated to receive oral prednisolone 1 mg/kg/day for three days (5-day group) vs 
same dose of prednisolone for three days (3-day group). There were no significant differences in 
regard to the incidence of rash and behavioural disturbance (e.g. angriness, aggressiveness, 
crankiness, irritability) between the two groups [35]. 
An RCT of the use of prednisolone for pediatric AOM reported no significant differences between 
children who received oral prednisolone 2 mg/kg/day for five days and placebo group who 
experienced moderate side effects (e.g. drowsiness, nervousness, diaper rash, dry mouth) [18]. 
This study also demonstrated that there was no correlation between the use of corticosteroid and 
the persistence or the emergence of viral infections [18]. Other potential side effects correlated 
with the use of corticosteroids are fluid retention and headache [18,30].  
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Based on these trials, we consider 5-day duration of prednisolone for this study is appropriate 
and safe for children.  
Clinical trial of corticosteroids for acute otitis media in children 
Evidence has demonstrated insufficient benefits and harms of corticosteroids. An RCT 
demonstrated that corticosteroid reduced the duration of ear discharge in AOM children with 
ventilation tubes [26]. Another RCT demonstrated a temporary resolution of middle ear effusion 
after five days of corticosteroid treatment [18]. In a systematic review of randomised placebo-
controlled trials (RCTs) of steroids for AOM, only two small trials [18,27,36] (very low to low quality) 
indicated corticosteroids could be useful in this condition. However, our confidence in the results 
is low, due to small sample size and very wide confidence intervals around the observed results. 
This insufficient evidence creates a research gap in the management of AOM, particularly in non-
severe cases, where antibiotics are not required.  Therefore, we propose an adequately powered 
clinical trial to address this uncertainty. 
We will conduct a large, parallel, pragmatic, multicentre, stratified, double-blind, randomised, 
placebo-controlled trial with the allocation ratio 1:1 to test the effectiveness of corticosteroids for 
760 children with AOM including 60 children for a tympanometric mechanistic sub-study and pilot 
study, described further in this protocol. As a comparator to prednisolone, we will use a placebo 
for the following advantages: (1) it is the most accurate test in assessing the efficacy of a treatment; 
(2) it will show the true additional benefits and/or harms of the prednisolone; and (3) it is crucial
when the outcome is assessed using subjective measurements.  The primary objective and
outcome of this proposed trial is to assess the effectiveness of corticosteroids as a monotherapy
in children with mild AOM, and as an addition to antibiotics in children with severe AOM, on ear
pain at three days after randomisation using visual analogue scale (VAS). The secondary outcomes 
include ear pain at other time points, total duration and severity of pain, adverse effects,
complications of AOM (e.g. perforation of tympanic membrane, mastoiditis), and AOM recurrence. 
1.1.3 Rationale for pilot study 
Prior to our main study, we will conduct a pilot study, described in this protocol. This study will 
mimic the main study in terms of its process and procedures, but on a smaller scale. However, due 
to budget constraints, we will conduct a pilot study as a pragmatic, randomised, open-label, single-
blind study. We will blind outcome assessors (i.e. physicians and tympanometry technicians), so 
they will not aware of the allocation of the intervention. 
The main study will involve many participating physicians and healthcare facilities across Jakarta, 
Bekasi, and Depok, most of whom have not been involved in a clinical trial before, will have a long 
follow-up period up to three months, and will utilise a symptom diary and a specific translated 
instrument to assess the severity of symptoms (acute otitis media – severity of symptom scale or 
AOM-SOS) which is not widely recognised by physicians in Indonesia.  Therefore, this pilot study is 
crucial to test the feasibility of the main study, including the characteristics of our main study 
design, all the study processes and procedures (e.g. the recruitment, stratification, randomisation, 
outcome measurement), and other operational strategies in our proposed main study.  
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1.2 Objectives 
The first objective of our pilot study is to assess the overall process and procedures of the main 
study, as follows: (1) the recruitment criteria; (2) stratification and randomisation processes; (3) 
outcome measures using validated and customised tools (e.g. visual analogue scale/VAS, Acute 
Otitis Media – Severity of Symptoms Scale/AOM-SOS, case report forms/CRFs, symptom diary); (4) 
identification of any potential practical and operational issues that may appear in the main study 
which will require re-structuration of the planned methods and procedures after commencing this 
pilot study; and (5) verification of sample size calculation for main study. 
Our second objective is to conduct a mechanistic explanatory study using tympanometry. It aims 
to assess the efficacy of corticosteroids in improving the resolution of middle ear effusion in AOM. 
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CHAPTER 2 – METHODS 
2.1 Trial design 
This study is a pilot of a parallel, pragmatic, stratified, randomised, open-label, single-blind 
controlled trial of corticosteroids, as monotherapy for mild AOM, and in addition to individually 
prescribed antibiotics for severe AOM. In the main study, we will stratify eligible children based on 
the clinical specialty (primary care or secondary/tertiary care) and severity of AOM (mild or severe). 
However, for this pilot study, we only include ear-nose-throat-specialists (ENTs) who work at 
tertiary centres for the convenience of the implementation of the mechanistic sub-study as 
tympanometry is only available at the hospitals (tertiary centres). Therefore, we will stratify the 
children based on their AOM severity and then will randomly allocate to corticosteroid 
(prednisolone) or control (usual care without prednisolone) (Figure 1) with the allocation ratio of 
1:1. Because it is a n open-label study, the parents/caregivers and an appointed nurse who will 
perform the randomisation will be aware of treatment allocation, whilst the clinicians and 
tympanometry technicians will remain unaware of the treatment. 
2.2 Participants, interventions, and outcomes 
2.2.1 Study setting 
Prior to this study, we conducted a feasibility study to survey the current management of AOM in 
children in three cities in Indonesia and to identify the willingness of physicians to participate in 
our proposed clinical trial of corticosteroids for AOM in children. Based on clinical scenarios, there 
were sufficient number of physicians who would prescribe corticosteroids for AOM. There were 
171 physicians from 87 primary/secondary to tertiary centres (public and private) in DKI Jakarta, 
Depok, and Bekasi who were willing to participate in our proposed main study. However, we will 
only pilot this study at seven public and private hospitals in Jakarta and Bekasi: (1) Dr Cipto 
Mangunkusumo Hospital; (2) Persahabatan Hospital; (3) Gatot Subroto Army Hospital; (4) Antam 
Medika Hospital; (5) Cempaka Putih Islamic Hospital; (6) Proklamasi ENT Hospital; and (7) Hermina 
Bekasi Hospital. 
2.2.2 Eligibility criteria 
2.2.2.1 Inclusion criteria 
We will include 60 children aged six months to 12 years old with AOM, defined as current onset (48 
to 72 hours) of AOM-relevant symptoms (e.g. earache, ear tugging/rubbing or irritability in non-
verbal children). If it is feasible, otoscopic findings of middle ear effusion (e.g. bulged tympanic 
membrane, limited or absent mobility of the tympanic membrane, air fluid level, ear discharge) and 
acute inflammation (e.g. erythema) will confirm the diagnosis.  
2.2.2.2 Exclusion criteria 
We will exclude children: 
1. with major and severe medical conditions (e.g. heart diseases, kidney failure)
2. who are immunocompromised (e.g. HIV, children receiving cancer treatment)
3. with congenital malformations and/or syndromes (e.g. cleft palate, Down’s syndrome)
4. with ear ventilation tube(s)
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5. exposed to persons with varicella (chicken pox) or active Zoster infection in the past three 
weeks without prior varicella immunisation or infection
6. who have high risk of strongyloidiasis infections with symptoms and signs of unexplained
eosinophilia, skin reaction due to larvae penetration into the skin (e.g. inflammation,
oedema, petechiae, severe pruritus), particularly on the feet regions, pulmonary (e.g. dry
cough, throat irritation, dyspnoea, wheezing, haemoptysis, repeated episodes of fever and 
mild pneumonitis), or gastrointestinal symptoms (e.g. upper abdominal pain, diarrhea,
anorexia, nausea, epigastric pain, malabsorption, and vomiting)
7. who have taken systemic (i.e. oral, injection) or topical steroids in the preceeding four
weeks
8. who have taken antibiotics in the preceeding two weeks
9. who are hypersensitive to prednisolone or prednisone, or other corticosteroids
2.2.3 Interventions 
Children in the mild AOM group will be randomly allocated to receive either a single dose of 
prednisolone tablets daily for five days as an addition to expectant observation or expectant 
observation alone (without prednisolone). At the baseline visit, the participating physicians will 
inform the parents/caregivers to closely observe the children for 48 hours without immediate 
antibiotic treatment. 
Children in the severe AOM group will be randomly allocated to receive either a single dose of 
prednisolone tablets daily for five days as an addition to antibiotics according to physicians’ 
preferences or antibiotic alone (without prednisolone). Antibiotic treatment is commonly 
prescribed for AOM with severe symptoms. The information regarding the antibiotics (e.g. 
antibiotic type, dose, duration) will be recorded in the case report forms (CRFs).  
2.2.3.1 Prednisolone and control group 
Prednisolone group 
Prednisolone tablets will be given in the intervention groups in both mild and severe groups. It is 
given at a dose of 1 mg/kg to 2 mg/kg body weight, once daily for five days.  The pharmacist will 
crush the tablets, mix them with sweeteners, and pack them in a daily paper-pack. It should be 
given in a single dose at 6 to 8 am in the morning to mimic the normal diurnal rhythm of cortisol 
production [19,20]. Participating physicians will advise the parents to give the prednisolone at 
about the same time each day as a daily routine for children which will also help parents to 
remember.  
Control group 
Due to budget constraints, we are not able to provide a matched placebo as prespecified for the 
main study. Therefore, we will not give placebo for children in the control group, either in the mild 
or severe group. Children in the control group of the mild AOM group will still receive expectant 
observation and those in the severe AOM group will receive antibiotics, and other concomitant 
treatment based on physicians’ preferences (if necessary). The only difference between the 
intervention and control group is solely whether they receive prednisolone (intervention group) 
or not (control group).  
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2.2.3.2 Criteria for trial drug discontinuation or modification 
When giving the prednisolone to a child, parent can mix the prednisolone powder with jelly or juice. 
If children vomit less than 30 minutes after having a dose of prednisolone, parents should give the 
same dose again. However, if they vomit again after 30 minutes, parents should not give another 
dose of prednisolone until the next dose on the next day. This should be noted in the symptom 
diary. If children keep vomiting after receiving prednisolone, parents should contact the research 
team. If the parents forget to give prednisolone to their children, they can give the missed dose as 
soon as they remember on the same day and they should also note this in the symptom diary. 
If there are any adverse events and adverse drug reactions which have been assessed by research 
team that would require the discontinuation of drug trial and further assessment and treatment, 
then the treatment will be discontinued for this particular case, however follow-up will continue, 
where possible. This will be reported in the CRFs. Serious adverse events will be reported to Bond 
University’s Human Research Ethics Committee (BUHREC) and the Research Committee Ethics 
Faculty of Medicine Universitas Indonesia (FMUI) – Dr. Cipto Mangunkusumo Hospital (CMH). 
2.2.3.3 Adherence monitoring 
Participating physicians will provide information regarding the administration of the prednisolone. 
The researcher will send a daily text-message reminder to all the parents in both prednisolone and 
control groups during the intervention period of five days to take the drug regularly and to 
complete the symptom diary daily. The text-message will also remind all the parents to visit the 
clinic after the 48-hour expectant observation or visit-1 (day-3), visit-2 (day-7), visit-3 (day-30), and 
visit-4 (day-90) for re-assessment. At each visit-1 and visit-2, the parents will return the first and 
second mini-booklets of symptom diary and the left-over drug to the appointed nurse (at visit-2). 
The nurse will then check the symptom diaries and the left-over drug for the adherence in taking 
intervention drugs. We will visit the patients’ homes to collect the third mini booklet of symptom 
diary that will record the symptoms from day-7 to day-14 after the baseline visit. 
2.2.3.4 Concomitant care and interventions 
Physicians may give symptomatic medicine (i.e. ibuprofen, acetaminophen, decongestant, 
mucolytic) according to their usual practice and these will be recorded in the CRFs and symptom 
diary. Parents will record the use of these medicine in the symptom diary. The decision on 
concomitant medication will be made without knowledge of allocation to the prednisolone or 
control group. 
2.2.4 Outcomes 
2.2.4.1. The pilot study outcomes 
Recruitment rate 
Recruitment rate is defined as the proportion of consultations with potentially eligible children 
who provide their consent to be included in the study. As this is recognised as a crucial aspect of 
conducting a clinical trial and may cause study discontinuation due to low recruitment [37], we will 
assess this in our pilot study. We will identify the rates and challenges during the recruitment 
process and determine the best strategy for the main study to overcome these challenges and 
obstacles.  
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The success of the study procedures 
The success of the study procedures includes the following: (1) obtaining informed consent from 
the patients and their parents; (2) the recruitment based prespecified eligibility criteria, including 
the use of otoscope to diagnose AOM if feasible; and (3) the stratification and randomisation 
process, including stratifying eligible children based on the severity and obtaining the allocation 
result whether the children will be allocated to the prednisolone or control group.  
Ability to measure planned outcomes in the main study 
We will assess the ability to measure planned outcomes in main study, which are: (1) the proportion 
of children with pain reduced by at least the minimum clinically important amount, at day-3 after 
randomisation. This will be assessed using a VAS recorded in the patient symptom diary; (2) the 
severity of pain and other AOM-relevant symptoms at various time points using VAS, AOM-SOS, 
and the symptom diary; (3) duration to AOM resolution; (4) adverse effects, defined using standard 
clinical trials criteria, recorded in the diary, and reported to the central office and ethics committee 
as required.; (5) complications of AOM (e.g. perforation of tympanic membrane(s), mastoiditis); 
and (6) AOM recurrence, defined as a new episode of AOM at one to three months after 
randomisation. We will report these narratively due to a limited sample size and insufficient formal 
power calculation for this pilot study to be able to detect actual effects of corticosteroids to 
improve clinical outcomes in AOM. 
The compliance to study and study drug 
The compliance to study and study drug is defined as a proportion of children who regularly take 
the study drug (assessed using the symptom diary and any left-over drug) and come to follow-up 
visits per protocol. Participants will be followed-up closely by clinicians and research staff. Children 
will return for a visit at day-3 after randomisation, ensuring collection of the primary outcome.  
The verification of sample size calculation for main study 
Based on our size calculation, we plan to enrol 760 children in the main study. We estimate that 
there will be 35% of the total sample of children with AOM in the severe group (i.e. children with 
severe symptoms, fever ≥ 39°C, children aged < 2 years with bilateral AOM, AOM with perforation 
of tympanic membrane). Therefore, within this pilot study, we can assess the accuracy of this 
assumption. Also, we will check another assumption of the sample size calculation, which was the 
proportion in the control group with the resolution of pain at three days, which was 42.5%. 
2.2.4.2. The mechanistic or tympanometry sub-study outcomes 
Primary outcomes 
The change in middle ear effusion (MEE) at various time points 
We will assess the change in the MEE at the following time points: baseline visit, visit-1 (day-3), visit-
2 (day-7), visit-3 (day-30), and visit-4 (day-90). We will measure MEE using static acoustic 
admittance, defined as “the amount of energy absorbed by the tympanic membrane and middle 
ear, measured in mmho or mL” [38]. We will also measure the difference of this results between 
the intervention and control group. 
Secondary outcomes 
Duration of MEE  
We will also assess the duration to the resolution of MEE using tympanometry. 
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The correlation between ear pain and other symptoms with the changes in MEE at various time 
points 
We will identify the correlation between ear pain and other symptoms (i.e. ear tugging, irritability, 
crying, lack of sleep, lack of appetite, less of playfulness, fever) with the changes in MEE at various 
time points. 
2.2.5 Participant timeline 
Table 1 illustrates the timeline for visits and follow-ups. We will measure the outcomes at various 
time points: (1) visit-1 after the 48-hour observation (day-3); (2) visit-2 (day-7); (3) visit-3 (day-30); 
and (4) visit-4 (day-90). Patients will visit the hospital at visit-1 and visit-2, whilst the last two visits 
will be a home-visit. However, children in the mechanistic sub-study have to visit the hospitals at 
those follow-up visits. To improve the compliance of the study, the research personnel will send a 
daily text-message reminder to all the parents in the study during treatment period to take the 
drug, complete the symptom diary, and visit the clinic after the 48-hour expectant observation and 
other time points. At visit-2, parents will return the symptom diary and any left-over drug.   
Table 1. Follow-up timeline 
STUDY PERIOD 
Enrolment  
Allocation Post-allocation Close-out 













Eligibility screen X 
Informed consent  X 
Allocation X 
INTERVENTIONS: 
[Intervention A] Prednisolone (5 days) 
[Intervention B] Control (5 days) 
ASSESSMENTS: 
Baseline examination (weight, height, 
BP, body temperature) X X X X* X* 
Severity of pain and duration using VAS X X X 
Overall symptoms and its duration using 
AOM-SOS X X X
Adherence to trial drug X X X 
Adverse effects X X X 
Otoscopic examination X X X X* X* 
Tympanometry examination X+ X+ X+ X+ X+ 
Complication X X X 
Recurrence of AOM X* X* 
BP=blood pressure; VAS=visual analogue scale; AOM-SOS: acute otitis media-severity of symptoms scale 
*The follow-up will be carried out by home-visit and phone, but those in the mechanistic sub-study will have their follow-
up visits to the clinics; +These time-point assessments will be applied only for children in the mechanistic sub-study
Participant enrolment 
In the main study, we will stratify eligible children by the clinical specialty (primary care or 
secondary/tertiary care) and severity of AOM (mild or severe). However, we only include ear-nose-
throat-specialists (ENTs) who work at tertiary care in this pilot study. Therefore, we will stratify the 
children based on their AOM severity and then will randomly allocate these eligible children to 
receive either a single dose prednisolone for five days or without, as an addition to expectant 
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observation in the mild AOM group or as an addition to antibiotics according to physicians’ 






Participating physicians will assess the eligibility of children who come to the hospital based on 
their symptoms and clinical features of AOM. The eligible children will then be stratified based on 
the severity of AOM to either mild or severe AOM group. This process will be assisted using an 
eligibility and randomisation form. The participating clinicians will then obtain a clinical history and 
perform a baseline examination, including general, otoscopic, and tympanometry examination. 
The results of these procedures will be recorded at the baseline history form and outcomes form. 
The tympanometry examination will be conducted by an audiologist or a tympanometry technician. 
The physician will assess and analyse the tympanometry findings and record the results in the 
outcome form. After these procedures, the children will be sent to the appointed nurse who will 
perform the randomisation and dispense the prescription for a study medication (prednisolone) if 
the patient is assigned to the intervention group.   
Is this child eligible for the study? 
Primary vs secondary/tertiary care 
























Figure 1. Flow chart of the stratification and randomization of the study 
suspected AOM 
AND 
aged 6 months to 12 years old 
AND 
symptoms suggestive of AOM (e.g. ear tugging, irritability, pain) 
AND 
Available for follow-up visits 
AND/OR 
otoscopic examination shows bulging, middle ear level, and/or immobile tympanic membrane(s), if feasible 
With moderate to severe symptoms, locally or systemically 
(moderate to severe ear pain, fever ≥39°C, complications) 
OR 
aged <2 years with bilateral AOM 
OR 
both AOM and tympanic membrane perforation 
OR 
additional otoscopic finding: the appearance of moderate to severe bulging and/or 
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2.1.6 Sample size 
We did not determine a sample size for the pilot study. There are several suggestions in calculating 
the sample size for a pilot study (e.g. at least 55 participants or at least 9% of the sample size of the 
main study) [39]. Since we will need 60 children in the mechanistic sub-study, we will include 60 
children with AOM in our pilot study. The sample size of the mechanistic study was determined 
based on the main primary outcome, which is the mean value of static acoustic admittance or 
acoustic compliance in the tympanogram. In a previous study of children with middle ear effusion 
(MEE) who underwent tympanometry assessment and had a history of chronic or recurrent middle 
ear disease [40], the response within each subject group was normally distributed with standard 
deviation 0.3.  If the true difference in the experimental and control means is 0.3 units, we will need 
to study 22 experimental subjects and 22 control subjects to be able to reject the null hypothesis 
that the population means of the experimental and control groups are equal with probability 
(power) 0.9. The Type I error probability associated with this test of this null hypothesis is 0.05. 
With a 20% allowance for dropouts, the total sample size becomes 56 or we will include 60 children 
for this pilot study. 
Using the worst-scenario that of 50 physicians who work at seven appointed hospitals and have 
approximately 97 patients with AOM per week, we estimate that only 30% of the physicians will 
confirm their participation and 25% of the patients will give their consents to participate in our 
study.  We then estimate that it will require nine months to recruit 60 children with AOM in this 
pilot study, including the extra months for potential slow recruitment and last follow-up (three 
months after the baseline visit).   
2.1.7 Recruitment 
Recruitment of physicians 
Our feasibility survey study (April–August 2016) demonstrated there were 352 physicians (general 
practitioners, ear-nose-throat specialists, and paediatricians) who were willing to participate in our 
main study and they had 705 paediatric patients with AOM in the past seven days. For our pilot 
study, we identified 50 physicians from the most feasible seven hospitals located in DKI Jakarta 
who were willing to participate in our study and had approximately 97 paediatric patients with 
AOM in a week.  
Recruitment of participants 
After physicians deliver the patient information and obtain the consent from the eligible children, 
they will use the eligibility and randomisation form to assist them in stratifying the children based 
on their AOM severity. Physicians then will complete other CRFs, as the following: baseline history 
form and outcome form. Physician will assist the parents to complete the symptom diary.  The 
similarity on the forms and sequences of both outcome CRF and symptom diary will help parents 
to be able to fill those correctly.  
2.3 Assignment of interventions 
2.3.1 Allocation  
Sequence generation and implementation 
All children and their parents who are eligible and consented will be enrolled, and stratified based 
on their AOM severities or clinical features. The randomisation process will be performed by the 
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appointed nurse who will randomly allocate children to either prednisolone and expectant 
observation or control (expectant observation alone) in the mild group and either antibiotic with 
prednisolone or control (antibiotic alone) in the severe group. A permuted block randomisation 
sequence will be computer-generated by the Centre for Research in Evidence-Based Practice Bond 
University, Gold Coast, Australia. Random numbers will not be disclosed to the outcome assessors 
(i.e. participating clinicians and audiologists/tympanometry technicians), to ensure allocation 
concealment. Batches of intervention packages will be dispatched to participating centres from a 
central pharmacy facility at the Clinical Research Supporting Unit, Faculty of Medicine Universitas 
Indonesia (CRSU FMUI). 
Allocation concealment mechanism and implementation 
The information of the eligibility and stratification which is provided by the participating physicians 
will help the appointed nurses to obtain the information from the randomisation website, whether 
the children will be allocated to the prednisolone or control group, identified by the 2-digit patient 
ID numbers. During the consultation, the physician will prescribe study medication for every 
subject with the dose based on the patient age and insert the prescription in the CRF folder. The 
nurse who performs the randomisation will give the prescription to the subjects who are allocated 
to the intervention group (prednisolone group). The subject then will give the prescription to the 
pharmacy, where the pharmacist will prepare the prednisolone by crushing the tablets, mixing 
them with sweeteners, packing the prednisolone mixed powder in a daily individual paper-pack for 
five days, and dispense these to the subjects along with instructions for preparation.  The 
pharmacist will record the dispensing on the form provided by the study for this purpose.   
2.3.2 Blinding (masking) 
In this study, the appointed nurses and the children and their parents will know the allocation of 
the intervention. We will ensure that the participating physicians and the audiologists/ 
tympanometry technicians will be blinded to the intervention allocation during the study. 
Emergency unblinding 
The unblinding process should be done if there are serious adverse events and limited only to that 
particular participating physician.  
2.4 Data collection, management, and analysis 
2.4.1 Data collection methods 
We will assess the outcomes using CRFs, patient symptom diary, and feedback forms. The CRFs 
consist of eligibility-and-randomisation, baseline history, outcomes, serious adverse events (if 
applicable), and drug dispensing and returned forms. The outcome form will record the severity of 
pain and overall symptoms with their durations using VAS and AOM-SOS, as well as the resolution 
of AOM signs using otoscopic and tympanometry examinations (for the mechanistic study).   
We will identify the recruitment rate by assessing the proportion of children who provide their 
consents divided by the proportion of consultations with potentially eligible children during the 
trial. We will use the informed consent and a study recruitment log book to record the reason(s) 
why children were not randomised. 
We will assess the success of the study procedures using feedback forms. On the feedback form, 
patients and their parents and participating physicians will rate their understanding and challenges 
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they have during the implementation of study procedures (e.g. obtaining the randomised 2-digit 
patient ID numbers and their allocation of the treatment, completing the informed consent forms 
and CRFs) using grading scale ranged from one to five (1=very easy; 2= easy; 3=moderate/neutral; 
4=difficult; 5=very difficult). 
To assess the ability to measure planned outcomes in main study, we will also use a feedback form 
to identify the understanding, the challenges, the complexity of the outcome assessment tools 
utilised for this study (e.g. CRFs and patient symptom diary which includes VAS and AOM-SOS) 
from the perspective of the patients and their parents and the participating physicians. The CRFs 
and symptom diary will record the clinical history and symptoms (e.g. VAS, AOM-SOS), as well as 
physical examination (e.g. temperature, blood pressure, otoscopic examination if feasible). This 
information will be obtained from the perspectives of the patients and their parents and the 
clinicians.  
The VAS is acknowledged as a well-established and validated scale for assessing pain [41].  It has a 
100-mm horizontal scale with ‘no pain’ anchor at the left endpoint and ‘the most severe pain’ at
the right endpoint of the scale. The patient will mark a vertical line along the horizontal line as the
representation of their pain level. The scale will be determined by measuring the distance from the 
left endpoint (‘no pain’) to the marked line [42]. A 10-mm difference has been reported to indicate 
a clinically significant change [43,44]. The AOM-SOS is used to assess the severity of other AOM-
relevant symptoms daily. particularly in non-verbal children. Table 2 illustrates several AOM-related 
symptoms described as “no”, “a little”, and “a lot”. This scale was developed as an outcome
reporting tool scoping symptom and activity limitation due to AOM in the proceeding 12 to 24 hours 
[45]. Shaikh et al. [45] used the mean of 4.2 points as a minimal important difference. We have
translated the original English) version of AOM-SOS to Indonesian version of AOM through forward 
and backward translation process.
Table 2. Acute otitis media severity of symptoms scale (AOM-SOS) [45] 
We are interest finding out how your child has been doing. For each question, please place a 
check mark in the box corresponding to your child’s symptoms. Please answer all questions 
No A Little A Lot 
Over the past 12 h, has your child been tugging, rubbing, or    
     holding the ear(s) more than usual? 
Over the past 12 h, has your child been crying more than usual? 
Over the past 12 h, has your child been more irritable or fussy  
     than usual? 
Over the past 12 h, has your child been having more difficulty  
     sleeping than usual? 
Over the past 12 h, has your child been less playful or active  
     than usual? 
Over the past 12 h, has your child been eating less than usual? 
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Over the past 12 h, has your child been having fever or feeling  
     warm to touch? 
The compliance to the study and study drug will be identified by assessing the completion of CRFs 
and symptom diary, particularly on the attendance of patients and the parents on their scheduled 
follow-up visits, the completion of the trial drug based on the symptom diary and the left-over drug. 
We will identify the parents who have low literacy during the informed consent process.  For 
parents who have low literacy, we will visit their home one day after the initial visit to identify a 
person who lives nearby (e.g. family members, neighbours) that are able to assist the parents in 
completing the symptom diary, daily for two weeks. If there is noone can assist them, then the 
research personnel will assist them in completing the symptom diary by phone. If it is not feasible, 
we will visit their home daily to be able to assist them.  
To assess the verification of sample size calculation for main study, we will use the CRFs. 
To ensure that all the outcome data can be sufficiently collected and recorded properly according 
to prespecified plans, we will conduct an individual/institutional training for participating 
physicians prior the implementation of this pilot study. The training will include following sections: 
(1) introduction and summary of the study; (2) introduction of international clinical practice
guidelines of AOM; (3) The diagnosis of AOM using otoscope and reporting the otoscopic results;
(4) the introduction and dissemination of the principles of quality methodology clinical trial (e.g.
eligibility, randomisation, blinding, outcome assessment) and good clinical practice (e.g. patient
consents, confidentiality, data management); (5) practical steps of eligibility assessment,
stratification, and randomisation; and (6) practical steps in completing study documentation (i.e.
patient informed consents, CRFs, feedback forms, patient symptom diary).
2.4.2 Data management 
The integrity and completion of data will be maintained through mechanisms such as consistency 
checks during data entry, and cross-checks between items after data entry. All the actions and 
modifications to data stored in the database will be documented and retrievable for viewing. 
Missing data or errors will be detected before final submission to the electronic database and will 
be recorded in a summary along with the descriptions for each missing and/or error data. The 
summary will then be notified to the co-investigators in that hospital for further investigation by 
checking and confirming the original forms or other resources for correction or completion for 
those with missing and/or erroneous data. The modification to original forms will be done by 
research personnel at that hospital and will be documented on paper and electronic versions. It 
will be annotated with the date, name, and signature of the person who is responsible for making 
modifications.  
The central data coordinator will check the validity and completeness of study data on a regular 
basis. All data in the central database will be protected with a regular complete back up system.  
2.4.3 Statistical methods 
For the recruitment rate, we report the outcome as the proportion of children in percentages (%). 
For the success of the study procedures and the ability to measure planned outcomes in main study, 
we will report the outcomes as the proportion of clinicians in percentages based on the grading 
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scale of their feedback reporting on prespecified outcome measure tools. For the compliance to 
study and study drug, we will report the outcomes as the proportion of children in percentages 
who attend the follow-up visits and complete the cycle of study drug.  
To assess the verification of sample size calculation for main study, we will report this outcome as 
the proportion of children in each stratum (mild and severe AOM group) and those with pain at 
Day-3 after randomisation in the control group.  
For the mechanistic sub-study, we will report continuous variables (i.e. the change in MEE at 
various time points (mean in days standard deviation), the duration of MEE) as a mean difference 
(MD) with 95% confidence intervals (CI) also the difference between two groups. We also will
report the correlation between ear pain and other symptoms with the changes in MEE at various
time points.
2.5 Monitoring 
2.5.1 Data monitoring 
Data monitoring committee 
Since this is a short study, we do not need data monitoring committee for this pilot study. However, 
independent personnel from Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit, Dr 
Cipto Mangunkusumo Hospital (CMH) – Faculty of Medicine Universitas Indonesia (FMUI), who is 
not involved in this study, will assess the process and the quality of patient recruitment, data entry, 
and a compilation of research data in central database. Her feedback will be important to improve 
the implementation of our main study. 
Interim analysis 
Due to the small number of recruited patients to the trial and the duration of the trial will be lesser 
than one year, we will not perform an interim analysis.  
2.5.2 Harms 
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily have 
to have a causal relationship with trial drug; whereas adverse effects or adverse drug reaction, is 
defined as all noxious and unintended responses to a trial drug related to any dose.  
At the Visit-2 (Day-3), the appointed nurse is the first person who will identify any adverse effects 
(AEs). These will be identified by history taking (e.g. interview) and the symptom diary. The parents 
will provide information in the symptom diary regarding the adverse effects and whether they seek 
any treatment or medical assistance to manage AEs. The nurse then will report the adverse effects 
to the physicians along with the information of the intervention group which the child was 
allocated to. This information will be provided after the physician assess and record the primary 
outcome (i.e. ear pain three days after the randomization) on the 'Outcome form'. This is important 
to keep the concealment. 
Adverse events and adverse drug reaction will be collected after they sign the written consents 
and being enrolled in the trial. All adverse events occurring after the enrolment into the study, 
during the additional treatment or hospitalization due to adverse events and/or ADR will be 
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recorded. A subject who experiences a serious adverse event (SAE), defined as any untoward 
medical occurrence at any dose that may result in-patient and/or prolonged hospitalization, 
persistent or significant disability, medically important events, life threatening events, and death, 
will receive sufficient treatment and will be recorded and reported to the Research Committee 
Ethics FMUI – CMH and the Bond University’s Human Research Ethics Committee (BUHREC). We 
will responsible for any additional examinations and/or treatment that are required to manage AEs. 
We will not report SAE occurring after the trial discontinuation, unless there is a temporal 
relationship between trial drugs or other protocol procedure to the events, as well as whether the 
event is unexpected or unexplained given the subject’s clinical course, previous medical conditions, 
and concomitant medications. All the SAE will be recorded in SAE form. 
2.5.3 Auditing 
For the main study, we will establish an audit committee from the CRSU FMUI and CEEBM Unit 
CMH-FMUI which is independent from the trial investigators and the funding body. However, this 
will not occur separately from monitoring for the pilot study. This independent committee will 
conduct monitoring of source paper and electronic documents in the website system, monitor the 
conduct of trial in multicentre sites, interviewing the investigators and coordinators, and check the 
storing, distribution, and the use of trial drugs. At the start of the trial, the committee will ensure 
that the research staff are capable in data entry and in using the website system. Observation and 
quality assessment of the whole trial will be ensured to be always in accordance with the protocol 
and International Conference Harmonization – Good Clinical Practice (ICH-GCP) standards.  
2.6  Ethics and dissemination 
2.6.1 Research ethics approval 
This study will be conducted according to the Declaration of Helsinki and ICH-GCP guidelines. We 
will seek ethics approval from: (1) the Bond University’s Human Research Ethics Committee 
(BUHREC) Bond University, Queensland, Australia; (2) the Medical Ethics Committee of the Faculty 
of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 
(3) the Directorate-General for Politics and General Government – The Ministry of Internal Affairs
Republic Indonesia; (4) the Health Agency for the Province of DKI Jakarta; and (5) local research
committee at each participating hospital.
2.6.2 Protocol amendments 
Any modifications to the protocol which may impact on the trial process (e.g. the modification of 
study objectives, study design, study population, sample sizes, the procedures, and significant 
administrative sectors), potential benefits and harms/safety of the patients will require a formal 
amendment to the protocol. This amendment will be notified and approved by the funding body 
and the Ethics committee prior to its implementation. Notification is also applied to the health 
authorities in accordance with local regulations. Minor modifications that may not impact on the 
trial process will also be notified and approved by the funding body and will be notified to The 
Ethics Committee. 
2.6.3 Consent 
The participating physician will provide patient information sheet and obtain informed consent 
from the parent(s) or legal guardian of patients, before conducting the recruitment and 
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randomisation process. In obtaining the consent, the investigators will inform the trial process 
including known and potential risks from the trial. As children are considered a vulnerable 
population, those aged younger than 12 years old are considered not competent to give research 
consent and the parent or their legal guardian will make the decision. The parent can also make 
decision for children aged 12 years, however there should be assent from children to participate in 
the research. For parents who are illiterate, we will identify the literacy level before we start the 
informed consent session and will ensure that the language used in the oral and written 
information about the trial, including the written informed consent form, should be 
understandable to the parents and justified to their literacy level. During the process, the 
participating physician will confirm the participant’s understanding of the process of the trial, 
including the risks and benefits. For particularly crucial topics, the participating physician will ask 
several questions related to that topic to ensure they are well-informed and understand. Gaining 
informed consent will be a major topic discussed during training sessions for staff. 
The person who delivers the consent (i.e. participating physician, research assistant) also will 
provide their signatures on the consent form, stating that they have provided information and 
opportunity for potential participants to understand and raise relevant questions according the 
trial. We will ensure that the consent process is free of coercion.  As the participation into the trial 
is voluntary, we will emphasise their rights to withdraw from the trial at any time without any 
consequences, particularly on the quality of their healthcare services. 
2.6.4 Confidentiality 
All information related to the trial will be stored securely at the study site and the research office. 
All participant information will be stored in locked file cabinets in areas with limited access. All data 
collection, including CRFs, test results, and administrative forms will be kept confidential by only 
using coded IDs as identifiers and will be stored separately from all forms and records that contain 
names or other identifiers (e.g. informed consents forms). All databases will be secured with 
limited access using password-protected access systems. All counselling sessions and general to 
specific examinations (e.g. ear, nose, throat examination, otoscopic and tympanometry 
examination) will be conducted in private rooms in the participating physicians’ clinics or hospital. 
All the involved research staffs such as physicians, nurses, and audiologists will be required to sign 
agreements to preserve the confidentiality of all participants.  
The confidentiality of every participant will be maintained and will not be distributed externally 
without the written permission of the participant, except as necessary for trial monitoring by 
national regulatory authorities related to the medical and research safety. 
2.6.5 Declaration of interests 
Respati W. Ranakusuma (RWR) has nothing to disclose.  
Amanda McCullough (AMC) has nothing to disclose. 
Elaine M. Beller (EMB) has nothing to disclose. 
Christopher Del Mar (CDM) has nothing to disclose. 
Eka Dian Safitri (EDS) has nothing to disclose. 
Yupitri Pitoyo (YPO)has nothing to disclose.  
Widyaningsih (WID) has nothing to disclose. 
Arie Sulistyowati (ARS) has nothing to disclose. 
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Sudigdo Sastroasmoro (SSO) has nothing to disclose. 
 
2.6.6   Access to data 
The Principal Investigator will be given access to the cleaned data sets. She will also have direct 
access to each sites’ data sets and by request. Project data sets will be secured using password. 
To ensure confidentiality, data dispersed to project team members will be blinded of any 
identifying participant information. 
2.6.7 Ancillary and post-trial care 
Short-term corticosteroids are very unlikely to have harm outside those we will be measuring. 
However, we will responsible for the adverse effects that occurring from the trial drug during the 
trial (immediate) and post-trial (ancillary care) related to trial drug. The compensation will include 
the treatment cost relevant with the trial drug, such as the consultation visit, additional 
examinations, and treatment (e.g. medicine, hospitalization cost). Due to other potential 
concurrent treatments within the drug trial, there will be robust review and analysis process to 
conclude the cause of adverse events. Participating physicians will explain the procedure for the 
management of adverse effects of trial drug during the process of consent approval before 
entering the trial. We will also include this information on the patient symptom diary, including the 
24-hour emergency call and list of recommended healthcare providers.  
2.6.8 Dissemination policy 
2.6.8.1 Trial results 
Trial results, either statistically significant or non-significant, and other components of the trial 
(literature review, survey study, pilot study, etc.) will be reported in a journal manuscript after 
being distributed to all the principal investigators to be reviewed. 
2.6.8.2 Authorship 
The authorships and contributions of this trial will be acknowledged on the protocol, manuscript, 
and the report. Before the publication in medical journal or paper presentation, the principal 
investigators (PIs) will provide written consent of their acknowledgment and contribution in the 
reported trial. 
 Respati W Ranakusuma contributes in: (1) designing and developing the protocol; (2) 
conducting the trial; and (3) interpreting and reporting the trial in the final trial report and 
manuscript for publication. 
 Amanda McCullough contributes in: (1) the protocol development (study design and 
methods); (2) interpreting the results; and (3) the writing process of the final trial report 
and manuscript for publication. 
 Elaine M Beller contributes in: (1) the protocol development (study design, methods, and 
statistics); (2) interpreting the results; and (3) the writing process of the final trial report 
and manuscript for publication. 
 Chris Del Mar contributes in: (1) the protocol development (study design, methods, and 
statistics), and (2) the writing process of the final trial report and manuscript for 
publication  
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 Sudigdo Sastroasmoro contributes in: (1) supervising the conduct of the trial in Indonesia; 
(2) interpreting the result; and (3) the writing process of the final trial report and
manuscript for publication.
 Eka Dian Safitri contributes in: (1) developing the mechanistic study using tympanometry; 
(2) providing training related to using and interpreting tympanometry to physicians, nurses, 
and tympanometry technicians; (3) interpreting the tympanometry findings; and (4)
reviewing the final study report and manuscript for publication
 Yupitri Pitoyo contributes in: (1) recruiting secondary and tertiary healthcare centres 
including the physicians and nurses; (2) interpreting the tympanometry findings; and (3) 
reviewing the final study report and manuscript for publication 
 Widyaningsih contributes in: (1) submitting a research ethics application to the Medical 
Research Ethics Committee in Indonesia; (2) submitting clinical trial permits to Indonesian 
institutions; (3) supporting the data collection and management; and (4) reviewing the 
final study report and manuscript for publication 
 Arie Sulistyowati contributes in: (1) providing advice and expertise in terms of paediatric 
patients; (2) supporting the data analysis; and (3) reviewing the final study report and 
manuscript for publication 
2.6.8.3 Reproducible research 
We will make the full protocol of this study to be publicly available to maintain its transparency and 
reproducibility. This full protocol will include detailed information regarding the study, particularly 
on study design and conduct that not are commonly include in the published protocol or 
information description in clinical trial registry. We will register the protocol into trial registry such 
as the Indonesia registry web portal (https://www.ina-registry.org/) and Australian New Zealand 
Clinical Trials Registry (http://www.anzctr.org.au/). We also will publish the results of this study in 
relevant medical journal as two separate papers as the following: (1) results of the pilot study and 
(2) results of the mechanistic sub-study. If necessary, we will include the anonymised participant-
level dataset in its appendix or online.  Unpublished outcomes will be reported in the full trial
report that will be linked to the published study.
APPENDICES 
Appendix 1. Flow chart of patient during the baseline and other visits 
Appendix 2. Patient information and consent form 
Appendix 3. Case report forms 
Appendix 4. Study recruitment log book 
Appendix 5. Patient symptom diary 
Appendix 6. Product (Lupred®) information summary 
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Appendix 4.2. Case report form 
Case report forms (CRFs) for the pilot study were made available to readers as an additional 
file in the published paper. A few changes were made based on the results of the pilot. The 
revised CRFs are in the appendices of the next chapter (Chapter 5).  
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Acute otitis media (AOM) is an inflammation of the middle ear commonly found in children 
with symptoms of rapid onset (less than 48 hours) of ear pain, acute inflammation, and middle ear 
effusion (e.g. air fluid level, bulging) [1]. AOM is often self-limiting. In general, 60% of AOM cases will 
have clinical symptom improvement in the first 24 hours and 80% of cases in 72 hours without 
antibiotic treatment [2,3]. However, antibiotics are frequently prescribed regardless of the fact they 
do not relieve pain symptoms in most cases [3-5]. We conducted a survey study using clinical 
scenarios that demonstrated up to 88% of 352 physicians in Jakarta, Depok, and Bekasi (Indonesia) 
would prescribe antibiotics for mild AOM. However evidence shows that only one-third of cases 
benefit from antibiotics, generally the more severe cases, such as AOM with moderate-to-severe 
local or systemic symptoms, young children (< 2 years) with bilateral AOM, and AOM with tympanic 
membrane perforation [6]. In addition, frequent use of antibiotics leads to increased risk 
of unfavourable side effects (e.g. diarrhea, vomiting, rash) and antibiotic resistance, a serious threat 
to health globally [3,7].   
Proposed alternatives or additions to antibiotics include various herbal preparations, decongestants, 
and corticosteroids [8,9]. However, the evidence for these is too weak to recommend for clinical 
practice. The anti-inflammatory effect of corticosteroids suggests it could be a viable treatment 
alternative for AOM. Our survey study demonstrated that 44% of ENT specialists would prescribe 
corticosteroids for children with AOM. We also conducted a systematic review of randomised 
placebo-controlled trials (RCTs) of steroids for AOM. Although only two small trials [10-12], indicated 
corticosteroids could be useful in this condition, our confidence in the results is low, due to small 
sample size and very low to low quality evidence. Therefore, we propose an adequately powered 
parallel, double-blind, stratified, randomised, placebo-controlled pragmatic trial of corticosteroids 
for acute otitis media in children (OPAL study), to address this uncertainty.    
Prior to this, we will conduct a pilot study. This study will mimic the main study in terms of its 
process and procedures, but on a smaller scale. However, due to budget constraints, we will conduct 
a pilot study as a pragmatic, randomised, open-label, single-blind study, without using a placebo. 
The objectives of our pilot study are to: (1) assess the overall process and procedures of the main 
study; (2) verify a sample size calculation for main study; and (3) conduct a mechanistic explanatory 
study using tympanometry. We will include 60 children with AOM, who then, based on their AOM 
severity, will be stratified as mild or severe AOM, and randomly allocated to an intervention group 
(prednisolone) or control group (without prednisolone). An appointed nurse who performs the 
randomisation, patient, as well as the parents will be aware of treatment allocation, however both 
physicians and audiologists will remain unaware of the allocation at least until the data collection at 
Day-3. We will assess the following outcomes: (1) recruitment rate: (2) the success of the study 
procedures; (3) ability to measure planned outcomes in the main study; (4) the compliance to study 
and study drug; and (5) the verification of sample size calculation for main study. In the mechanistic 
study using tympanometry, we will assess: (1) the change in middle ear effusion at various time 
points; (2) the duration of middle ear effusion; and (3) the correlation between ear pain and other 
symptoms with the changes in middle ear effusion at various time points.  
If corticosteroids prove effective in relieving pain or other relevant symptoms in children, and are 
safe, they could become a useful alternative to antibiotics in mild cases of AOM, and an addition to 
antibiotics in severe cases. The treatment is relatively cheap, easy to dispense and administer. It can 
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also reduce antibiotic use, particularly in mild cases of AOM. This could lead to a reduction in 
antibiotic resistance, thus saving precious antibiotics for severe diseases where rapid response to 
antibiotics is critical.  
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The Protocol  
See Appendix 1. Protocol of Oral Prednisolone for Acute otitis media in chiLdren: a pilot 
pragmatic, randomised, open-label, single-blind controlled study (OPAL study).  
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Case Report Forms (CRFs)  
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Setting Up The Study Site   
 
Prior to the trial, the research team will set up the site for the trial. We will provide a starting kit 
along with an inventory checklist. The appointed nurse who works at the site will receive the starting 
kit. The starting kit contains:   
1. Office stationery set (e.g. pen, highlighters, scissor, glue stick, stapler)  
2. File binders:  
a. Confidential study document binder:  
i. FORM01: Study registration log book 
ii. CRF01: Completed consent form 
iii. CRF02: Completed study registration form 
iv. CRF08: Completed randomisation form 
b. Case report form binder:  
i. CRF01: Participant information sheet and consent form (will be separated to 
confidential study binder at the end of the initial visit) 
ii. CRF02: Study registration form  (will be separated to confidential study 
binder at the end of the initial visit) 
iii. CRF03: Eligibility form 
iv. CRF04: Baseline information form 
v. CRF05: Outcome form 
vi. CRF06: Symptom diary 
vii. CRF07: Prescription of study medication 
viii. CRF08: Randomisation form (will be separated to confidential study binder 
at the end of the initial visit) 
ix. CRF09: Follow-up visit card 
x. CRF10: Serious adverse event reporting form 
xi. CRF11: Feedback form  
xii. FORM07: Guideline of antibiotics for acute otitis media in children 
xiii. FORM08: Prednisolone dose for OPAL study 
xiv. FORM09: Instruction of prednisolone use for parents 
xv. FORM10: Lupred pharmaceutical brochure 
c. Study medication storage binder for the pharmacists:  
i. FORM02: Study medication stock form 
ii. FORM03: Study medication dispensing form 
d. Completed case report form and non-participating subject binder: 
i. FORM05: Recapitulation of completed case report form 
ii. FORM06: Recapitulation of non-participating subject form (e.g. not-eligible, 
not-consented individual forms) 
e. Study medication return binder:  
i. FORM04: Study medication return form 
3. Medicine in a transparent storage container:  
a. Prednisolone tablets (Lupred® 5)  
b. Sirplus, a sweetener syrup 
c. FORM10: Pharmaceutical Lupred brochure 
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4. Study souvenirs: 
a. Initial visit (Day-0): Lunch box 
b. Visit-1 (Day-3): Water bottle  
c. Visit-2 (Day-7): Toys 
d. Visit-3 (Day-30): Mini towel 
e. Visit-4 (Day-90): Bag 
5. Transportation cost reimbursement @$15   
6. Inventory checklist form  
The research team will visit and monitor the study sites at the end of the first week to check the 
completeness of study documentation (e.g. study document binders, case report forms), study 
medication stock and other supporting tools. The next monitoring visit will be conducted once every 
one or two weeks, depending on the recruitment flow of each site.   
 
Study medication delivery and storage  
A research member will visit the site once every one or two weeks to deliver the study 
medication. When receiving the study medication, the pharmacist will record the quantity, the batch 
number of study medication, and the date of medicines received on FORM02: Study medication 
stock form (see Appendix 2).  
The study medication will be stored at the pharmacy, in a cool dry place, protected from direct 
sunlight, where the temperature stays below 30°C, separately from other medication.   We will 
provide FORM10: Lupred pharmaceutical brochure. The pharmacist will provide the brochure to the 
parents, along with the study medication and the instruction of its use. 
Rooms and other equipment for the study 
In order to conduct the trial, we need several rooms and equipment which will be used for various 
activities, as follows:  
1. Rooms:  
a. Nurse station:  
i. Identify the symptoms of acute otitis media using FORM01: Study 
recruitment log book. 
ii. Performing a general examination to measure body weight, height, 
temperature, and blood pressure. 
b. Consultation room:  
i. Delivering the information regarding the trial and obtain consent from 
the parents using CRF01: Participant information sheet and consent 
form. 
ii. Identifying the eligibility for the study and stratify the eligible children 
based on the severity of acute otitis media  using CRF03: Eligibility 
form. 
iii. Obtaining baseline history information usimg CRF04: Baseline 
information form. 
iv. Identifying symptoms and signs of acute otitis media, including the 
severity of symptoms (using VAS and AOM-SOS), complication of acute 
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otitis media, medicine which have been taken prior the visit using 
CRF05: Outcome form. 
v. Assessing the condition of nose, throat, as well as the ears using 
otoscope (if feasible)   
vi. Explaining and tutor the parents in completing CRF06: Symptom 
diary. 
vii. Assessing, interpreting, and recording the tympanometry results into 
CRF05: Outcome form. 
viii. Preparing the CRF07: Prescription of study medication (see Appendix 
10) for every study participant with doses according to their ages. The 
guideline for prednisolone dose is available in FORM08: Prednisolone 
dose for OPAL study and at the top of CRF07. Prescription of study 
medication 
ix. Prescribing other medications, such as antibiotics for children with 
severe AOM based on physician’s clinical preference or based on 
FORM07: Guideline of antibiotics for AOM in children and 
symptomatic medications, if necessary  
c. Audiology room/corner:  
i. Conducting a tympanometry examination.  
d. Private room for randomisation process:  
i. Performing and recording the randomisation of intervention allocation 
using CRF08: Randomisation form  
ii. Dispensing the prescription of study medication for study 
participants who are allocated to intervention (prednisolone) group.   
iii. Reconfirming the parent’s understanding and ability in completing 
CRF06: Symptom diary  
iv. Educating the parents on the use of prednisolone, identification of 
potential side effects, and provide the information regarding 24-
hour emergency call centre. The nurse will provide FORM09: 
Instructions of prednisolone use for parents  
v. Requesting the parent to complete CRF02: Study registration  
vi. Completing CRF09: Follow-up visit card with scheduled visits in the 
next three months  
vii. Providing the study souvenir and transport cost reimbursement to 
each study participant 
viii. Collecting and checking all the study documents, storing them 
according their binder, and secure the binders in a locked filing 
cabinet:   
1. The confidential study document binder (compilation with other 
study participant documents):   
a. FORM01: Study registration log book.  
b. CRF01: Completed consent form  
c. CRF02: Completed study registration form.  
c. CRF08: Completed randomisation form. 
2. The case report form binder (no name on each form and only 
identified by an ID registration):  
a. CRF03: Eligibility form 
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b. CRF04: Baseline history form  
c. CRF05: Outcome form  
e. CRF10: Serious adverse events reporting form   
f. CRF11: Feedback form  
2. Equipment:   
a. Weight scale 
b. Measuring tape  
c. Thermometer  
d. Paediatric tensimeter  
e. Head lamp  
f. Tongue depressor  
g. Rhinoscope 
h. Otoscope   
i. Tympanometry 
j. Copy machine/scanner 
k. Office stationery  
l. Smart phone with internet connection 
m. Telephone 
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Step-by-step Procedure  
The nurse station  
Objective(s)  
1. Initially identify of children with acute otitis media  
2. Perform general examination (weight, height, body temperature, blood pressure)  
3. Provide CRF01: Participant information sheet and consent form and CRF02. Study 
registration form for the parents 
4. Prepare the study binders and case report forms  
Tool(s)  
1. Weight scale  
2. Height measurement  
3. Thermometer 
4. Paediatric tensimeter  
5. FORM01. Study recruitment log book  
6. Case report form binder  
7. Registration ID labels 
8. OPAL study stickers  
Personnel  
1. Attending nurse.  
  
Procedures  
1. When the medical record arrives, the attending nurse will identify whether the patient has 
AOM symptoms using three screening questions in FORM01: Study recruitment log book 
(see Figure 1), as follows:  
a. Has your child experienced ear pain in the past 48 hours?  
b. Has your child been tugging or rubbing her/his ear(s) and been more irritable or 
fussy or crying more than usual over the past 48 hours?  















 Figure 1. FORM01: Study recruitment log book. 
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2. If the parent responds ‘YES’ to one of these three questions, the attending nurse will then 
perform general examination (i.e. body weight and height, temperature, blood pressure) 
and record the results on FORM01. Study recruitment log book. The nurse will also prepare 
the case report forms which are compiled in one binder (case report form binder), as 
follows:   
a. CRF01: Participant information sheet and consent form.  
b. CRF02: Study registration form 
c. CRF03: Eligibility form.  
c. CRF04: Baseline information form.  
d. CRF05: Outcomes form.  
e. CRF06: Symptom diary.  
f. CRF07: Study medication prescription.  
g. CRF08: Randomisation form  
h. CRF09: Follow-up visit card 
l. CRF10: Serious adverse events reporting form 
m. CRF11:  Feedback form  
m. FORM07: Guideline of antibiotics for acute otitis media in children 
i. FORM08: Prednisolone dose for OPAL study 
i. FORM09: Instruction of prednisolone use for parents  
j. FORM10: Lupred pharmaceutical brochure 
3. If possible, the nurse will provide CRF01: Participant information sheet and consent form 
and CRF02: Study registration form for the parents so they can read the information sheet 
and complete the registration form while they are waiting for consultation. 
4. The nurse will then report this patient to a physician as a potential study participant along 
with FORM01: Study recruitment log book and the case report form binder with a specific 
registration ID label attached on every form in the binder.  The form and binder will be 
inserted in the medical record of that particular patient. Therefore, the physician will notify 
this patient as a potential study participant for OPAL study 
 
The consultation room  
Study consent, recruitment, and stratification 
Objective(s)  
1. Identify the eligibility of potential children to be included in the trial  
2. Provide sufficient information regarding the research, including the overall process 
and potential effects caused by the study   
3. Obtain the consent from eligible patients and their parents to participate or not 
to participate in the study  
4. Stratify the eligible patients based on their AOM severities 
Tool(s)  
1. FORM01: Study recruitment log book  
2. Case report form binder: 
a. CRF01: Participant information sheet and consent form  
b. CRF02: Study registration form 
c. CRF03: Eligibility form  
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3. Non-participating subject form binder:
a. FORM06: Recapitulation form of non-participating subject form. 
 
Personnel  
1. Participating clinicians  
Procedures  
1. The attending nurse will notify the physician that the patient has AOM symptoms and 
provide the physician with FORM01: Study recruitment log book and Case report form 
binder. 
2. The physician will re-confirm the eligibility of the patient using inclusion and 
exclusion criteria on the CRF03: Eligibility form (see Appendix 1. Protocol, section ‘Eligibility 
criteria’, page 15-16). If the parent has responded ‘YES’ to all inclusion criteria and ‘NO’ 
to all exclusion criteria, then the patient is eligible for the study. However, if the parent has 
responded at least one ‘NO’ to the inclusion criteria or one ‘YES’ to the exclusion criteria, 




























3. After it has been confirmed that the child is eligible for the trial, then the 
physician will deliver the information regarding the trial and obtain the consent for the trial 
using CRF01: Participant information sheet and consent form (see Appendix.1 Protocol, 
section ‘Consent’, page 26-27). The physician will give the opportunity for the parents to 
Figure 2. CRF03: The eligibility form – The inclusion and exclusion criteria. 
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read the information sheet and raise questions, and will provide further information if 
necessary.  
4. After the physician identifies the eligibility and obtains the consent for the study, the 
physician will then stratify the study participant based on the severity of the AOM symptoms 
according to the following criteria on CRF03: Eligibility form (see Appendix.1 Protocol, 
section ‘Participant enrolment’, page 19-20). :  
a. Moderate to severe symptoms, locally or systemically (e.g. moderate to severe ear pain, 
fever ≥ 39°C, complications)  
b. Aged <2 years with bilateral acute otitis media  
c. AOM with perforation of tympanic membrane(s)  
d. If visible, otoscopic finding shows moderate to severe bulging and/or yellowish purulent 






















5. If the study participant has at least one ‘YES’ on the criteria of a to c, then the patient will 
be allocated to ‘SEVERE AOM’ group. If the patient has all ‘NO’ for a to c criteria, then the 
patient will be allocated to ‘MILD AOM’ group. The fourth criterion (otoscopic finding) is an 
optional criterion because of the difficulty in identifying the tympanic membranes in small 
children. However, if it is visible, the physician will tick the circle corresponding to the 
otoscopic finding  
6. For children who are stratified to ‘SEVERE AOM’ group, the physician will prescribe 
antibiotics according to their clinical preferences. However, we will provide FORM07: 
Guideline of antibiotics for acute otitis media in children. 
7. The physician will then complete FORM01: Study recruitment log book by providing 
information regarding:   
a. Whether the patient participated in the study 
b. Reasons (i.e. not eligible, did not give consent, was not approached) for those who 
did not participate in the study  
8. The nurse will  complete the column ‘The randomisation ID for those who went to the study’ 
after the child has been randomised to either intervention or control group.  
9. The physician will separate the case report form of children who are not eligible or do not 
give consent. Their eligibility forms will be removed from their case report binders and will 
be stored in the Non-participating subject form binder, after they ensure that all forms 
Figure 3. CRF03: The eligibility form – The consent and stratification based on severity. 
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have the registration ID label on the top right of each form. This will be recorded on 
FORM06: Recapitulation of non-participating subject form. 
Collecting baseline data and examination   
Objective(s)  
1. Obtain relevant information to acute otitis media   
2. Identify of AOM complications, severity of AOM symptoms, and history of medication 
3. Perform ear, nose, and throat examination, as well as interpret the tympanometry 
examination result 
4. Teach the parents of study participant to complete the symptom diary  
Tool(s)  
1. Head lamp  
2. Tongue depressor   
3. Rhinoscope   
4. Otoscope 
5. Tympanometry   
6. Case report form binder: 
a. CRF04: Baseline information form 
b. CRF05: Outcomes form   
c. CRF06: Symptom diary  
d. CRF07: Study medication prescription  
e. FORM07: Guideline of antibiotics for acute otitis media in children  
f. FORM08: Prednisolone dose for OPAL study 
Personnel  
1. Participating physicians  
2. Audiologist 
Procedures  
1. The physician will obtain further baseline information using the CRF04: Baseline information 
form, such as the breastfeeding history, day-care attendance, vaccination history. 
2. The physician will then obtain more detailed information relevant to acute otitis media using 
CRF05: Outcome form, such as symptoms and complications of acute otitis media: ear 
discharge, intense pain in and behind the ear, swelling behind the ear, or facial asymmetry  
3. The physician will copy the result of general examination from FORM01: Study recruitment 
log book  (i.e. body weight, height, temperature, blood pressure) measured by 
the attending nurse.  
4. The physician will identify the condition of nose and throat and record the results by ticking 
the circles corresponding to the findings (see Figure 4). 
5. The physician will perform an otoscopic examination and record the result by ticking the 
circles corresponding to the findings: normal, erythema, air-fluid level, complete 
effusion, opacification and mild bulging, moderate to severe bulging, bulla, and/or 







Manual of Operations of the OPAL Study. Version 1.1. Date 21 November 2017 







































6. The physician will then identify and record any medications that have been taken before the 
baseline visit prescribed by other physicians or purchased over-the-counter (e.g. antibiotics, 
analgesics, decongestants). The physician will also record the name and dose of medications 
prescribed for the study participants.   
7. The physician will identify the severity of the ear pain using visual analogue scale (VAS) (see 
Appendix 1. Protocol, section ‘Data collection methods’, page 22-23). The VAS is a 100-mm 
horizontal line. The left end of the line represents ‘no pain’ and the right end of the line 
represents ‘pain as bad as it could possibly be’. The physician will ask the parent to place a 
vertical line across the horizontal line that corresponding to the severity of ear pain during 






















Figure 4. CRF05: The outcome form – General, ear, nose, throat, and otoscopic 
Figure 5. The otoscopic characteristics of acute otitis media. 
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the past 24 hours. This will also be included in CRF06. Symptom diary; therefore at the same 
time, the physician will teach the parent to complete this scale in the diary, so the 













8. The physician will then identify the severity of other relevant-symptoms of acute otitis 
media using acute otitis media severity (AOM-SOS) (see Appendix 1. Protocol, section ‘Data 
collection methods’, page 23-24). This consists of seven questions identifying several 
symptoms over the past 12 hours, as follows: has the child (1) been tugging/rubbing the 
ear(s)?; (2) been crying?; (3) been more irritable or fussy?; (4) been having more difficulty 
sleeping; (5) been less playful or active?; (6) been eating less than usual?; and (7) been 
having fever or feeling warm to touch?. These questions are very important for young 
children, particularly those who cannot express their symptoms (non-verbal children). The 
parent will tick the circle corresponding to the child’s symptoms. This will also be included in 
the CRF06: Symptom diary; therefore, the physician will teach the parent to complete this 
















9. The physician then will provide CRF06: Symptom diary to the parent. The symptom diary 
consists of three mini booklets:  
a. The first mini booklet: The parent must complete the booklet after the baseline visit 
to Day-3. The appointed nurse will collect this mini booklet at Visit-1 (Day-3)  
b. The second mini booklet: The parent must complete the booklet at Day-4 to Day-7. 
The appointed nurse will collect this mini booklet at Visit-2 (Day-7)  
Figure 6. CRF05: Outcome form – Visual analogue scale (VAS). 
Figure 7. CRF05: Outcome form – Acute otitis media using acute otitis media severity (AOM-SOS). 
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c. The third mini booklet: The parent must complete the booklet at Day-8 to Day-14. 
The research team will collect this mini booklet at Day-14 during the home visit   
10. The physician will then send the study participant to the audiology room for tympanometry 
examination after ensuring the ear canals are free from obstructing ear wax. Prior to this, 
the physician will explain the purpose and the procedure of tympanometry examination to 
the parents 
11. After the tympanometry examination, the study participant and the parent will return to the 
consultation room with the tympanometry result. The physician will analyse and interpret 
the tympanometry findings by completing the curve type of the tympanogram.  
12. Before the study participant leaves the consultation room to meet the nurse who will 
conduct a randomisation, the physician will prepare CRF07: Prescription of 
study medication (see Figure 8) and put it back in the case report form binder. The 
prednisolone dose can be accessed in FORM08: Predisolone dose for OPAL study and at the 
top of CRF07: Precription of study medication. This prescription will be dispensed by the 






















13. The physician will also prescribe antibiotics for study participants with severe AOM based on 
the physician’s clinical preference. We will provide FORM07: Guideline of antibiotics for 
AOM in children for their reference. The physician may prescribe symptomatic medication. 
We will ask them not to prescribe oral steroids 
14. The physician will advise the parent to closely observe the study participant for 48 hours for 
persistence or the worsening of the symptoms (i.e. ear pain, fever) and potential 
complications (i.e. ear discharge, swollen on the back of the ear). If the parents identify any 
condition above, they should bring the study participant back to the hospital at any time for 
re-assessment and the initiation of antibiotic treatment 
15. At the following visits (Day-3), the physician will identify any side effects such as abdominal 
pain, vomiting, diarrhea, anxiety. The physician will also identify whether the parent should 
Figure 8. CRF07: Prescription of study medication. 
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seek any medical help due to the side effects (e.g. go to other physicians, go the emergency 
department) and whether the parent should continue or stop the medication   
16. The physician will record the additional medication or treatment or examination that is given 
due to the side effects or whether the study participant requires a hospitalisation.  
 
Tympanometry test   
Objective(s)  
1. Measure the condition in the middle ear  
Tool(s)  
1. Tympanometer  
2. Otoscope   
3. Case report form binder: 
a. CRF05. Outcome form   
4. Glue stick  
5. Copy machine or scanner  
Personnel  
1. Audiologist or trained nurse  
Procedures  
1. The audiologist will explain the procedure of tympanometry examination  
2. The audiologist will ask the parent to hold the child’s head firmly. Then the audiologist will 
identify the condition of ear canal using an otoscope to identify any ear wax and estimate 
the size of the ear cuffs. After connecting the ear cuffs to a probe tip, the audiologist 
will slowly insert the probe tip into the ear canal until the graphs appear on the screen. This 
procedure will be repeated on the other side of the ear. After the graphs indicate sufficient 
results (e.g. no air leak, no block), the result is then ready to be printed.  
3. The audiologist will document the tympanometry results on CRF05: Outcome form – 
Tympanometry examination (see Figure 9), as follows: (1) ear canal volume; (2) compliance; 
(3) static acoustic admittance; (4) middle ear pressure for both ears. Several  
tympanogram machines use terminology ‘compliance’ for ‘statistic acoustic 
admittance’, therefore we provide both components in this section to avoid confusion. 
















 Figure 9. CRF05: Outcome form – Tympanometry examination. 
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4. The audiologist will attach the study registration ID label and write the date of examination 
on the printed tympanometry result paper, copy (using the copy machine or scanner), 
and attach the copied tympanometry result on the ‘Tympanometry examination’ section.  
5. After the examination, the audiologist will send the study participant and the parent back to 
the consultation room. The physician then will analyse and interpret the tympanometry 
findings and conclude the consultation in his/her usual way.  
 
Randomisation   
Objective(s)  
1. Randomly allocate the children to receive either prednisolone (intervention group) or none 
(control group)  
Tool(s)  
1. Smart phone or computer with internet connection for accessing the randomisation 
website  
2. Telephone to call a randomisation call-centre 
3. Case report form binder: 
a. CRF01: Participant information sheet and consent form 
b. CRF02: Study registration form 
c. CRF03: Eligibibility form 
d. CRF06: Symptom diary 
e. CRF07: Prescription of study medication 
f. CRF08: Randomisation form 
g. CRF09: Follow-up visit card 
h. FORM08: Prednisolone dose for OPAL study 
i. FORM09: Instruction of prednisolone use for parents 
j. FORM10: Lupred pharmaceutical brochure 
4. Confidential study document binder: 
a. Completed FORM01. Study recruitment log book 
b. Completed CRF01. Completed consent form 
c. Completed CRF02. Completed study registration form 
d. Completed CRF08. Completed randomisation form 
5. Completed case report form and non-participating subject binder: 
a. Non-participating subject form (e.g. not-eligible, not-consented individual forms) 
6. Study souvenirs 
7. Transport cost reimbursement envelope 
Personnel  
1. Appointed nurse  
Procedures  
1. The appointed nurse will complete CRF0: Randomisation form to randomise the 
intervention allocation for each patient (see Figure 10). The appointed nurse requires 
FORM01: Study recruitment log book; CRF01: Consent form; and CRF02: Eligibility form to 
be able to answer several questions and confirm the answers, as follows: 
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a. Part 1 – Eligibility criteria: all ‘YES’ for all inclusion criteria and all ‘NO’ for all 
exclusion criteria. The nurse will check the eligibility of the study participant using 
FORM01: Study recruitment log book and CRF03: Eligibility form  
b. Part 2 – Consent to the study: consent to the study has been given. The nurse will 
check the consent to the study using CRF01: Consent form and CRF03: Eligibilty 
form 
c. Part 3 – Randomisation information: Parents’ mobile numbers, the severity of AOM 
(The nurse will check the severity using CRF03: Eligibilty form), and patient’s date of 
birth and age. 
d. Part 4 – Randomisation result: randomisation ID, intervention allocation 
(prednisolone or no prednisolone / control group), and prednisolone dosage for 
patient who is allocated to prednisolone group. The nurse will use FORM08: 
Prednisolone dose for OPAL study as a guidance for the prednisolone dose. The 
dosages of prednisolone will be determined based on age, as follows: 
i. Children aged 6 months to < 2 years will receive 10 mg per day (or 2 tablets 
per day) for 5 days  
ii. Children aged 2 years to < 6 years will receive 20 mg per day (or 4 tablets 
per day) for 5 days 
iii. Children aged 6 years to 12 years will receive 30 mg per day (or 6 tablets per 




















2. The nurse will use Part 1 to Part 3 to obtain the randomisation result in Part 4 section. This 
can be accessed within two ways, as follows: 
a. Randomisation website: 
i. The appointed nurse will receive an invitation email from MASCOT.org.au. This 
email will notify the nurse regarding the name of the study, which is OPAL STUDY, 
and the name of institution (e.g. Cipto Mangunkusumo Hospital, etc.). Prior to the 
study, we obtained a list of email addresses of potential appointed nurses during the 
training session. For practice, we sent the invitation email from MASCOT.org.au with 
Figure 10. CRF08: Randomisation form. 
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the title of study of PRACTISE STUDY. The nurses were able to use this link to 
practice as much as they like until they are competent to use this tool. 
ii. At the end of the email, there is a link to the MASCOT study randomization system 
















iii. After clicking the link, the attending nurse will automatically open the login page of 
the MASCOT study randomization system website. The first page will confirm the 
name and institution. If the information  is correct, the nurse will click ‘Begin’ button 













 After that, the page will ask the nurse to insert the Registration ID of the study 
participant (see Figure 13). The nurse will use the ID based on the Registration ID 










Figure 11. The MASCOT study randomization system – Invitation email for MASCOT study 
Figure 12. The MASCOT study randomization system – The enroler confirmation page. 
Figure 13. The MASCOT study randomization system – The study 
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iv. The next page presents several questions regarding the eligibility criteria (inclusion 
and exclusion criteria) and whether the consent the study has been given, as follows: 
1. All ‘YES’ for all inclusion criteria 
2. All ‘NO’ for all inclusion criteria 
3. Has consent been given 
The nurse will then click ‘Select’  ‘Yes’ to all questions to be able to proceed to 
the next step. To proceed, the nurse will click ‘Check Eligibility’ button at the left 























v. The next page will show whether the study participant is allocated to prednisolone 
or control (no prednisolone) group. The attending nurse will insert the date of birth 
using an available calendar or put the month (mm) / date (dd) / year (yyyy) 
manually. The nurse will check the date of birth on the available calendar. The page 
will automatically convert this information to age of that particular patient (please 
recheck the age). The nurse will select the severity of AOM based on the information 
in CRF03. Randomisation form, as a ‘Mild AOM’ or ‘Severe AOM’ accordingly. To 
proceed, the nurse will then select ‘Submit Answers’ button. The nurse must ensure 
that the submitted answers are correct as there will be no opportunity to correct 








Figure 14. The MASCOT study randomization system – The eligibility page. 
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vi. If the patient is allocated to the prednisolone group, then the page will require 
information of the dose of prednisolone:  
1. Children aged 6 months to < 2 years will receive 10 mg per day (or 2 tablets per 
day) for 5 days  
2. Children aged 2 years to < 6 years will receive 20 mg per day (or 4 tablets per 
day) for 5 days 
3. Children aged 6 years to 12 years will receive 30 mg per day (or 6 tablets per 
day) for 5 days 
The nurse must ensure that the prednisolone has been prescribed according to the 
dose on CRF07. Prescription of OPAL study. This must be prepared by the physician 
before the randomisation process. The nurse can also check the dose using FORM08. 
Prednisolone dose of OPAL study. The nurse will then select the dose accordingly. 

















Figure 15. The MASCOT study randomization system – The date of birth and 
AOM severity page. 
Figure 16. The MASCOT study randomization system – The prednisolone dose. 
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vii. The next page will provide the randomisation results (see Figure 17), as follows: 
1. Treatment group: the prednisolone or control (no prednisolone) group 
2. Dosage of prednisolone for patient who is allocated to the prednisolone group. 
This information will not be available for patient who was allocated to the 
control group. 
3. Registration ID. This will confirm the Registration ID that the nurse has 
submitted at the start of the randomisation process 
4. Randomisation ID. This is a new specific ID for patient that has been 
randomised. 






















viii. The nurse will copy the randomisation result to CRF08: Randomisation form. This 
form will then be separated from the case report form binder to the confidential 
study document binder. This information will be concealed from the physicians and 
audiologists 
ix. If the nurse is using a computer that is connected to the printer, then the nurse can 
directly print the randomisation result page. However, if using smart phone, then the 
nurse can download the page to be recalled and printed later. The nurse can click 
‘Add Another’ button if there is another patient to be randomised. 
b. By phone: 
i. The attending nurse can contact the principal investigator (+62 8111 012 185) or the 
research assistant (+82 812 8799 0123) who will access the MASCOT study 
randomization system website.  
ii. The attending nurse has to complete CRF08: Randomisation form and report all 
information from this form to the research assistant by phone, as follows: 
1. Name of the appointed nurse and the institution 
2. Registration ID 
Figure 17. The MASCOT study randomization system – The randomisation result page for 
the prednisolone and control groups. 
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3. All ‘YES’ for all inclusion criteria 
4. All ‘NO’ for all inclusion criteria 
5. Has consent been given? 
6. Date of birth and age of the patient 
7. Dose of the prednisolone (please confirm with FORM08: Prednisolone dose 
for OPAL study and CRF07: Prescription of study medication) 
8. Severity of AOM 
iii. The research assistant will require five minutes to access the randomisation system 
website and provide the randomisation allocation results back to the nurse. 
iv. The research assistant will call the attending nurse and provide the information, as 
follows: 
1. Randomisation ID 
2. Treatment group: prednisolone or control (no prednisolone) group 
3. Dosage of prednisolone for patient who is allocated to the prednisolone 
group. This information will not be available for patient who was allocated to 
the control group. 
v. This information will be recorded at the bottom column of CRF08: Randomisation 
form. This form will then be separated from the case report form binder to the 
confidential study document binder. This information will be concealed from the 
physicians and audiologists.  
3. For patients who are allocated to the prednisolone group, the nurse will dispense CRF07: 
Prescription of study medication to the parent(s). The nurse will provide information 
regarding the use of prednisolone, as follows: 
a. Taking the medication all at once, in the morning before 9 am after breakfast, 
everyday, for five days as  
b. Mixing the medication with sweetener syrup that has been provided by the study 
c. Mixing the medication with milk, juice, jam, or jelly, if necessary 
d. Giving back one dose of medication if the child vomits less than 30 minutes after 
taking the medication. However, if the child vomits after 30 minutes, then the 
parent should not give another dose.  
The nurse will also provide FORM09: Instruction of prednisolone use for parents 
4. For every patient, the nurse will confirm whether the parent(s) have already had CRF06: 
Symptom diary and understood how to complete it. 
5. The nurse will provide CRF09: Follow-up visit card for each patient. The nurse will write 
scheduled dates for follow-up visits, based on the initial visit. 
6. The nurse will ask the parent(s) to complete CRF02: Study registration form, if it has not 
been completed. 
7. The nurse will remind the parent(s) to observe the patient and come to the hospital for 
follow-up visit after 48 hours (day-3) or if the study participant’s condition worsens at any 
time or does not show clinical improvement within 48 hours. The nurse will inform the 
parent(s) that the parent(s) can contact the 24-hour call centre for any questions or 
assisstances at anytime. 
8. The nurse will also ensure the study participant and the parent(s) will not inform their 
physician and audiologist regarding the intervention they received in the trial (prednisolone 
or without prednisolone) until at least the outcome measurement or data collection at Day-
3.  
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9. The nurse will give Rp. 150.000,- (approx. $15) cash for transportation
cost reimbursement in an envelope to the parent(s).
10. The nurse will provide study souvenirs to the patient in each visit, as follows:
a. Initial visit (Day-0): Lunch box
b. First visit (Day-3): Water bottle
c. Second visit (Day-7): Toys
d. Third visit (Day-30): Mini towel
e. Fourth visit (Day-90): Study bag
11. Before sending the patient home, the nurse will check the completeness of all study
documents from the binders:
a. Case report form:
i. CRF01: Consent form
ii. CF02: Study registration form
iii. CRF03: Eligibility form
iv. CRF04: Baseline information form
v. CRF05: Outcome form
vi. CRF08: Randomisation form
vii. CRF10: Serious adverse events reporting form
viii. CRF11: Feedback form
b. Confidential study document binder:
i. FORM01: Study recruitment log book, including copy the randomisation ID
to the form, and reasons if patient has not been recruited to the study. 
12. The nurse will apply a sticker on the patient medical record as an identification that the
patient is in the OPAL study (see Figure 18), as well as on the page of consultation page in
the medical record (see Figure 19).
 
13. When the process is over, the patient has left the room, and all documents are well
completed, the nurse will then separate the forms into the binders:
a. Case report form:
i. CRF03. Eligibility form
ii. CRF04. Baseline information form
iii. CRF05. Outcome form
iv. CRF10. Serious adverse events reporting form
v. CRF11. Feedback form
b. Confidential study document binder:
Figure 19. The OPAL study identification sticker 
for the medical record page. 
Figure 18. The OPAL study identification sticker 
for the cover of medical record. 
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i. FORM01. Study recruitment log book 
ii. CRF01. Consent form 
iii. CRF02. Study registration form 
iv. CRF08. Randomisation form 
c. Completed case report form and non-participating subject binder: 
i. FORM06. Non-participating subject form (e.g. not-eligible, not-consented 
individual forms).  
14. The nurse will then secure all documents and binders in the locked cabinets. 
 
 
Preparing and dispensing the study medication   
Objective(s)  
1. Prepare the prednisolone tablets in form of powder and the sweetener syrup  
2. Dispense the study medication along with the instruction for its use  
3. Record the dispensing using the FORM03: Study medication dispensing form   
Tool(s)  
1. CRF07: Prescription of study medication  
2. Prednisolone tablets  
3. Sweetener syrup 
4. FORM03: Study medication dispensing form 
5. FORM10: Lupred pharmaceutical brochure 
Personnel  
1. Pharmacist  
Procedures  
1. The pharmacist will receive CRF07: Prescription of study medication from the parents 
and prepare the study medication according to the prescribed dose. Prior to this, the 
pharmacist will recheck the dose using the prednisolone dose guideline attached on the 
top of the prescription.  
2. The pharmacist will then prepare the prednisolone by crushing the prednisolone tablets, 
mixing them with sweeteners, and packing them in five daily paper-packs.  
3. The pharmacist will dispense the study medication with the instruction, as follows:  
a. give the medicine in the morning, after breakfast and in the morning (before 9 
am), everyday for five days 
b.  mix the medicine with sweetener syrup of a ratio of 1:3 
c. give the medicine with a glass of water, milk, or juice, or mix it with a small 
amount of soft food such as jam, or yoghurt 
d. give the medication all at once 
e. if the child vomits in less than 30 minutes after taking the study medication, 
then the parent should give another dose.  
The pharmacist will also provide FORM10. Lupred pharmaceutical brochure for the  
parents 
4. The pharmacist will complete FORM03: Study medication dispensing form by recording 
the registration ID, the study medication dose, and date dispensed for the study 
medication  
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Returning the study medication   
Objective(s)  
1. Identify the adherence to the study medication by collecting the left-over medication  
1. Record the study medication return using FORM04. Study medication return form  
Tool(s)  
2. FORM04. Study medication return form  
Personnel  
1. The appointed nurse  
Procedures  
1. At Day-7, the appointed nurse will collect the left-over study medication, including the 





























Figure 20. FORM04: Study medication return form (for nurse).  
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Follow-up Visits   
 
Each study participant will have additional four follow-up visits after the baseline visit (Visit-0), as 
follows (see Appendix 1. Protocol, section ‘Participant timeline’, page 19):  
1. First visit (Visit-1) on day-3 (48 hours after the baseline visit)  
2. Second visit (Visit-2) on day-7 after the completion of 5-day cycle of study medication   
3. Third visit (Visit-3) on day-30 or month-1  
4. Fourth visit (Visit-4) on day-90 or month-3  
Using the information of parents’ mobile phone numbers provided on CRF02: Study registration 
form, a research assistant will send a daily text message as a reminder: (1) to remind the parents to 
give the prednisolone (for study participant in the prednisolone group) every morning for five days, 
(2) to observe any adverse events; (3) to visit the hospital at Day-3 and Day-7, and (4) to complete 
the symptom diary for two weeks. For the third and fourth visits, the research coordinator will send 
reminder text messages one week and one day before the follow-up dates (see Appendix 1. 
Protocol, section ‘Adherence monitoring’, page 17).  
First follow-up visit (Day–3)  
The study participant and the parent(s) will have the first visit after 48 hours observation or on the 
third day after the baseline visit. If they miss the follow-up visit at Day-3, they can still come until the 
next two days (Day-4 to Day-5) after the scheduled date.    
The study participant will come to the nurse station. The attending nurse will:  
1. Identify the patient as a study participant by the OPAL study sticker on the front page of 
medical record. 
2. Measure and record the weight, height, body temperature, and blood pressure  
3. Report and send the study participant to the appointed nurse. 
  
The appointed nurse will:  
1. Use the registration ID label on the OPAL study sticker to find that particular case report 
form binder from the filing cabinet.  
2. Check the completeness of the case report forms in the binder 
3. Obtain information from the parents regarding the symptom of AOM, any complications (i.e. 
mastoiditis, perforation of tympanic membrane, and the adherence on the study medication 
use, as well as identify side effects, and complications of acute otitis media) from the first 
mini-booklet of the symptom diary.   
4. Check the completeness and collect the first mini booklet of CRF06: Symptom diary. The 
nurse will  confirm the symptoms, complication, or any side effects reported in the symptom 
diary. The nurse will place the first mini booklet of symptom diary back to the case report 
form binder. The nurse will remind the parent to continue completing the second mini 
booklet of symptom diary. the parent should complete the symptom diary in the next 
morning before administering any medicine to their children.  
5. Check whether the study participant still has a sufficient number of study medication for the 
next two days.   
6. Report the study participant to any participating physician on duty that day, along with the 
case report from binder.  
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7. After the study participant finish the consultation and data collection with the participating 
physician, the study participant again will meet the appointed nurse. The appointed nurse 
will check the completeness of all study documents in the case report form binder. 
8. Record the visit date on CRF09: Follow-up visit card 
9. Remind the parent to take the study medication regularly, complete the second mini booklet 
of the symptom diary, and to come  for the next follow-up visit (Visit-2) at the Day 7. 
10. Hand over a study souvenir (lunch box) and transport cost reimbursement envelope for each 
study participant. 
  
The participating physician will: 
1. Identify any complications of AOM and perform ENT, otoscopic, and tympanometry 
examination. 
2. Identify the severity of AOM symptoms using VAS and AOM-SOS on CRF05: Outcome form. 
3. Assess whether there is a sufficient improvement of symptoms over the past 48 hours. If 
there is no improvement or worsening of the symptoms of acute otitis media, based on the 
clinical judgement, the physician may prescribe antibiotics for the study participant in the 
mild AOM group or change the antibiotics for the study participant in the severe group. This 
will be recorded in CRF05: Outcome form.  
4. Identify any side effects. If it is necessary to determine the treatment for the side effects, 
the physician can retrieve the information from the nurse whether the study participant was 
allocated to prednisolone or control group. However, this must be done after the physician 
complete assessing and recording all outcome data in CRF05: Outcome form. 
5. Prescribe the study medication accordingly, if the study participant require more 
medication. 
6. Send the participant back to the appointed nurse. 
 
Second follow-up visit (Day–7)  
The process is similar to Visit–1. If the study participants and the parents miss the follow-up visit at 
Day-7, they can still come until the next two days (Day-8 to Day-9) after the scheduled date.  The 
study participant will come to the nurse station, where the attending nurse will identify a patient as 
a study participant by the OPAL study sticker on the front page of the medical record. The nurse will 
measure the weight, height, body temperature, and blood pressure of the study participant. The 
nurse will then report this to the appointed nurse. Using the registration ID number attached on the 
OPAL study sticker on the front page of the medical record, the attending nurse will collect that 
particular subject’s case report form binder. 
The appointed nurse will:  
1. Identify any adverse effects or complications since the last visit  
2. Check the completeness and collect the second mini booklet of CRF06: Symptom diary  
3. Remind the parents to complete the third mini booklet of CRF06: Symptom diary on the 
next morning until Day-14. The nurse will inform the parents that at Day-14, a research 
staff will visit their home to collect the diary. The research staff will also obtain feedback 
from the parents regarding their experience and obstacles during the past 14 days of the 
study, using CRF11: Feedback form. 
4. Collect the left-over study medication from those in the prednisolone group. This will be 
recorded in FORM04: Study medication return form. The appointed nurse will complete 
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the study registration ID, returning date, and numbers of left-over study medication. She 
can add some comment regarding the use of prednisolone if necessary.   
5. Report the study participant to any participating physician on duty that day, along with 
the case report from binder.  
6. After the study participant finish the consultation and data collection with the 
participating physician, the study participant again will meet the appointed nurse. The 
appointed nurse will check the completeness of all study documents in the Case report 
form binder. 
7. Record the visit date on CRF09: Follow-up visit card 
8. Remind the parent to come  for the next follow-up visit (Visit-3) at the Day 30. 
9. Hand over a study souvenir (toys) and transport cost reimbursement envelope for each 
study participant. 
 
 The participating physician will: 
1. Identify any complications of AOM and perform ENT, otoscopic, and tympanometry 
examination. 
2. Identify the severity of AOM symptoms using VAS and AOM-SOS on CRF05: Outcome form. 
3. Identify any side effects. If it is necessary to determine the treatment for the side effects, 
the physician can retrieve the information from the nurse whether the study participant was 
allocated to prednisolone or control group.  
4. Send the study participant back to the appointed nurse. 
 
Third follow-up visit (Day–30)  
At the third visit, the patient will come on Day–30. If the study participant misses the scheduled 
follow-up visit, then the study participant can come on any other day up to one week after the 
scheduled date. Similar to previous visits, the nurse will identify the study participant using the OPAL 
study sticker attached on the front page of the medical record and perform a general examination. 
The attending nurse will report this subject to the appointed nurse. The appointed nurse will collect 
and prepare the case report form binder, and bring the study participant with the binder to the 
participating physician on duty.  
The physician will identify whether in the past one month, the study participant experiences a new 
episode of ear pain or any other symptoms related to acute otitis media. The physician will also 
conduct a nose and throat examination, as well as an ear examination using otoscope. This 
information will be recorded in CRF05: Outcome form. The study participant will then undergo a 
tympanometry examination and will go back to the consultation room for the assessment of the 
tympanometry result. At the end of the visit, the physician will hand over the completed study 
documents in the case report form binder back to the appointed nurse where she will check the 
completeness of the forms and store it back in the locked filing cabinet.   
 
Fourth follow-up visit (Day–90)  
The process is similar to Visit–3. At the end of the visit, the physician will hand over the completed 
study documents in the case report form binder to the appointed nurse where the nurse will then 
check the completeness of the forms. The appointed nurse will collect al the study documents form 
the case report form binder and clip them together, and separate the document to a plastic sleeve in 
the completed case report form and non-participating subject binder. The nurse will then record 
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the randomisation ID, date enrolled to the study, whether the study participant come to all follow-
up visits, and date of completion of the study.  
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Assessing Adverse Events   
The appointed nurse will be the first person who identifies adverse events on the first visit at Day-
3 (48 hours after the baseline visit). The adverse events will be identified by obtaining information of 
any unfavourable effects after taking the study medication in forms of: (1) interview and (2) the 
assessment of the completed first mini-booklet of the symptom diary (see Appendix 1. Protocol, 
section ‘Harms’, page 25-26).   
The nurse will report any adverse events to the physician without acknowledging the study 
intervention that the patient has received. However, if it necessary to determine the treatment for 
the adverse events, the physician may have the information of intervention allocation. The physician 
will check other medications that have been prescribed (e.g. antibiotics, decongestants, mucolytic) 
at the baseline visit and obtain more detailed information regarding the adverse events to identify 
its correlation with trial drug or other concomitant drugs. The physician will then record this on 
CRF05: Outcome form.  
The physician will record severe adverse event(S) on CRF10: Serious adverse events reporting form 
and inform this to the chief investigator (CI). The physician will report any adverse events that cause 
the modification or discontinuation on study medication to the CI. The decision to discontinue study 
medication will be determined by the physician based on the clinical judgment and the CI based on 
perspective of good clinical practice (GCP). If the patient requires other tests and/ treatments, the 
physician will provide these services. All the costs will be reimbursed by the study. However, this 
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Feedback Form  
As this study is a pilot study, we will obtain information from all individuals involved in the study (i.e. 
participating physicians, appointed nurses, audiologists, pharmacists, study participants, and the 
parents) to identify their experience and obstacles that they encountered during the study.   
For the participating physicians, audiologists, the appointed nurses, and pharmacists, we will obtain 
their feedback using CRF11: Feedback form in an interview session. We will interview them after 
they have enrolled at least five children into the study.  
We will obtain the feedback from the parents at Day-14 during the home visit. The home visit will be 
conducted to collect the third mini-booklet of the symptom diary, where we will also interview the 
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Closing Out The Study  
When closing out the study, the research team will check several documents to validate the 
compatibility and the completeness of the data:   
1. FORM01: Study recruitment log book, will be checked for its compatibility with CRF01: 
Consent form; CRF03: Eligibility form; and CRF08: Randomisation form in the case 
report form binder of each study participant. 
2. The completeness and the date of follow-up visit in CRF05: Outcome form, will 
be checked for its compatibility with the visit dates on CRF06: Symptom diary and 
CRF09: Follow-up visit card. 
3. The number of CRF11: Feedback form will be checked for its compatibility with the 
number of participating physicians, audiologists, appointed nurses, pharmacies, and the 
parents who are involved in the study  
 
In regards to study medication, the research team will check the numbers of unused medication at 
the pharmacy and the left-over medicine on the parents, and compare the numbers with FORM03: 
Study medication dispensing form; FORM04: Study medication return form; and the number of 
used paper-packs accordingly.  
In regards to administrative work, the research team will:  
1. Collect the left-over envelopes for the reimbursement of patients’ transportation cost and 
check the compatibility with the numbers of follow-up visits recorded in CRF09: Follow-up 
visit card. 
2. Confirm the hospital cashier regarding the study-related payment (e.g. registration fee, 
tympanometry examination, any additional test or treatment due to adverse events) 
according approved Memorandum of Agreement (MoU) with the numbers of follow-up visits 
recorded in CRF09: Follow-up visit card and CRF05: Outcome form for any additional tests 
or treatments for side effects.  
3. Confirm the inventory list with the starting kit container. 
At the end of study, as part of the dissemination of the study results, the research team will:  
1. Provide a study summary that will include the examination results of individual study 
participants and the overall result of the study to each participant.  
2.  Provide a report document of the study to the Bond University’s Human Research Ethics 
Committee, the Research Committee Ethics Faculty of Medicine Universitas Indonesia 
(FMUI) – Dr. Cipto Mangunkusumo Hospital (CMH), and all participating hospitals.  
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Baseline history taking 
Outcomes assessment using CRF 
and otoscope 
Providing a symptom diary and 
training 
Providing study medication 
prescriptions 




Study medication prescription 
dispensing 
Study document collection and 
storage  
List the follow-up visits on the 
follow-up reminder card 
Hand over the study bag 
Reimbursing the transport costs  
Appointed nurse 
















Baseline Visit (Visit-0) 
Attending Nurse  
Identifying potential AOM 
patients using the checklist on 
the study registration log book 
Preparing the case report form 
(CRFs) 
Collecting data of body weight, 
height, body temperature, and 
blood pressure 
Preparing and handing over the 
study document (I.e. study 
recruitment log book, CRFs) to 
the physician 
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Identification adverse effects 
and complications 
Outcomes assessment using CRF 
and otoscope 
Checking the symptom diary 
Checking and interpreting the 
tympanometry findings 
Checking the additional 
medication  
Physician 
Checking the completion of study 
document 
Identification adverse effects and 
complications 
Checking the symptom diary 
Checking the number of study 
medication, whether they will be 
available for the next two days 
Completing the follow-up 
reminder card 
Collecting the first mini-booklet of 
symptom diary and provide the 
second mini booklet at Visit-1 
Handing over the study document 
and reporting any adverse effects 
or complications to the physician 
Collecting the second mini-booklet 
of symptom diary and provide the 
third mini booklet at Visit-2 
Collecting the left-over drug 
(prednisolone group) at Visit–2 
and completing the drug 
dispensing and returning form 
Appointed Nurse 
















Other visits (Visit-1 to Visit-4) 
Attending Nurse 
Collecting data of body weight, 
height, body temperature, and 
blood pressure  
Preparing and handing over the 
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60% of AOM cases will be 
resolved in 24 hours
80% of AOM cases will be 
resolved in 72 hours
3Background (2)
Australia: 89% of new AOM cases were treated with antibiotics (2010 – 2015). 
Our survey study (2016) demonstrated that 88% of physicians would prescribe antibiotics for mild AOM.
Oral prednisolone for acute otitis media in children (OPAL) study
[281]
Alternative treatment for AOM
4
Clinical practice guidelines 
versus 
Daily clinical practice
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Oral prednisolone for acute otitis media in children (OPAL) study
5Clinical trials of corticosteroids for AOM
[282]
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6Research question
Research Gap
A quality clinical trial
The effectiveness of corticosteroids as a monotherapy or 
as an addition to antibiotics for AOM
A pragmatic, parallel, randomized, placebo-controlled, double blind study of 
corticosteroids for AOM in children
Oral prednisolone for acute otitis media in children (OPAL) study
7Prednisolone
Doses
10 mg/day: aged 6 months to < 2 years
20 mg/day: aged 2 years to < 6 years
30 mg/day: aged 6 years to 12 years
Frequency




Otitis media clinical trial and 
national/international guidelines of 
paediatric infectious and inflammation 
disorders. 
Range of prednisolone dose: 
0.25 – 2 mg/kg body weight/day
Ranged 3 to 7 days
AOM cytokines peaked: 3 hours to 3 days.
Progressively decreased: 4 to 6 days
Normalization: > 6 days
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8Objectives of the study
Primary 
objectives
To assess the overall process and procedures of a large main study, including 
(1) the recruitment criteria; (2) the process of stratification and randomisation; (3) 
clinical outcomes measures using validated and customized tools.
To identify any practical and operational issues that potentially occur in the large 
main study. 
To verify a sample size calculation for the large main study.
Secondary 
objectives
To identify and explain the mechanism of corticosteroids in improving middle ear 
effusion and other clinical symptoms of AOM in a mechanistic sub-study using 
tympanometry.
Oral prednisolone for acute otitis media in children (OPAL) study
9A Pilot study and a mechanistic sub-study
P Children aged 6 month to 12 years with acute otitis media (AOM) [N=60].
Oral prednisolone plus expectant observation (mild AOM)
OR
Oral prednisolone plus antibiotics (severe AOM)I
Without prednisolone plus expectant observation (mild AOM)
OR
Without prednisolone plus antibiotics (severe AOM)
C
Recruitment rates
The success of study procedures
Ability to measure planned outcomes in main study
Compliance to study and study drug
The verification of sample size calculation for main studyO
The change in middle ear effusion at various time points
Duration of middle ear effusion
The correlation between ear pain and other symptoms with the changes in MEE at various time points
T
9 months 
[Dr Cipto Mangunkusumo Hospital, Persahabatan Hospital, Gatot Soebroto Army Hospital,
Antam Medika Hospital, Islamic Hospital, Proklamasi ENT Hospital]
[284]
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10Study timeline
 STUDY PERIOD 
 
Enrolment  
Allocation Post-allocation Close-out 
TIMEPOINT 0 t1 (day-3 to -5) t2*(day-7 to -9) t3*(day-30 to -40) t4*(day-90 to -100)
ENROLMENT:      
Eligibility screen X     
Informed consent  X     
Allocation X     
INTERVENTIONS:      
[Intervention A] Prednisolone      
[Intervention B] Control      
ASSESSMENTS:      
Baseline examination (weight, height, 
BP, temperature) X X X X* X* 
Severity of pain and duration using VAS X X X   
Overall symptoms and its duration using 
AOM-SOS X X X   
Adherence to trial drug X X X   
Adverse effects X X X   
Otoscopic examination X X X X** X** 
Tympanometry examination X+ X+ X+ X+ X+ 
Complication X X X   
Recurrence of AOM    X* X* 
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11Recruitment process
Initial screening
[Attending nurse & Phycisian]
Consent to study
[Physician]





Ear pain in the past 48 hours
OR
Holding/pulling out the ear, irritable in the 
past 48 hours
OR 
Experiencing ear discharge in the past 48 
hours
FORM01. Study recruitment log book
The research summary





CRF01. Information sheet and consent form 
children (6 months – 12 years) with AOM, defined as a 
current onset within 48 hours of ear-related symptoms 
(e.g. ear pain, ear tugging/rubbing or irritability) and if 
possible to assess, otoscopic findings of acute 
inflammation (e.g. erythema) and middle ear effusion (e.g. 
bulging, air-fluid level)
Inclusion criteria
Children with or who:
1. major and severe medical conditions (e.g. heart/kidney failure)
2. immunocompromised children (e.g. HIV, in cancer treatment)
3. congenital malformations and/or syndromes (e.g. cleft palate)
4. high risk of strongyloidiasis infection
5. ear ventilation tube(s)
6. had exposed to persons with varicella or active Zoster infection in the 
past 3 weeks without any prior varicella immunization/ infection
7. have taken oral or topical steroids in the preceding four weeks 
8. have taken antibiotics in the preceding two weeks
9. are hypersensitive to prednisolone other corticosteroids.
Exclusion criteria
CRF03. Eligibility form
• Mild ear pain
• fever < 39 C
• Otoscopy: mild bulging
• Complication (-) 
Mild AOM
• Moderate to severe ear pain
• Fever  39 C
• Otoscopy: moderate-to-severe bulging, 
suppurative appearance 
• Children aged < 2 years with bilateral AOM








Dispense the prescription of study medication (prednisolone group), 
including provide the Information of prednisolone use 
Confirm the completion of symptom diary
Complete the study registration form
Observation and identification of complication and side effects
Follow-up visits and the card
Keep the intervention allocation confidential 
Provide study souvenirs and transport reimbursement
CRF07. Prescription of study medication
CRF06. Symptom diary
CRF09. Follow-up visit card
FORM09. Instruction of prednisolone use for parents
FORM10. Lupred pharmaceutical brochure




[An appointed nurse for randomosation]
Tympanometry examination















Baseline information and history
General examination 
ENT examination, including otoscopy
Tympanometry examination
Severity of AOM symptoms using VAS and AOM-SOS
Complications of AOM
Previous and current treatment
Prescribe the study medication (and antibiotics for 
severe AOM) and other symptomatic medications 
Teach how to complete a symptom diary
CRF04. Baseline information form
CRF05. Outcome form
CRF06. Symptom diary
CRF07. Prescription of study medication
FORM07. Guideline of antibiotics for AOM
FORM08. Prednisolone dose for OPAL study
Check the completeness all study documents and 
separate the confidential ones to the confidential 
study document binder, as follows:
Confidential study document binder: (1) FORM01. 
Study recruitment log book; (2) CRF01. Consent 
form; (3) CRF02. Study registration form; and 
(4) CRF08. Randomisation form.
Case report form: (1) CRF03. Eligibility form; (2) 
CRF04. Baseline information form; (3) CRF05. 
Outcome form; (4) CRF10. Serious adverse event 
reporting form; (5) CRF11. Feedback form
Case report form binder
Confidential study document binder





















































16Obtaining the consent to the study
In obtaining and documenting IC, the investigator should comply with the applicable regulatory requirement(s), GCP and 
to the ethical principles that have their origin in the Declaration of Helsinki. 
The subject or the subject’s legally acceptable representative should be informed in a timely manner if new relevant 
information becomes available. The communication of this information should be documented.
Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to participate or to continue to 
participate in a trial.
None of the oral and written information concerning the trial, including the written IC form, should contain any language 
that causes the subject or the subject's legally acceptable representative to waive or to appear to waive any legal rights, 
or that releases or appears to release the investigator / institution for negligence.
The investigator, or a person designated by the investigator, should fully inform the subject or, if the subject is unable to
provide IC, the subject's legally acceptable representative, of all pertinent aspects of the trial including the written 
information and the approval/ favourable opinion by the IRB/IEC.
Oral prednisolone for acute otitis media in children (OPAL) study
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17Information in the consent form
The trial involves 
research Purpose of the trial
The trial treatment(s) 
& the probability for 
random assignment to 
each treatment.




Those aspects of the 
trial that are 
experimental
The reasonably 
foreseeable risks or 
inconveniences to the 
subject 
The reasonably 
expected or no 
intended benefits, 
including the risks 
The alternative procedure(s) 
or course(s) of treatment 
that may be available to the 
subject, including important 
potential benefits and risks.
The compensation and/or 
treatment available to the 
subject in the event of 
trial related injury.
The anticipated 




and the subject may 
refuse to participate or 
withdraw from the trial, at 
any time
The auditor(s) or IRB/IEC will 
be granted direct access to 
the subject's medical 
records for verification of 
clinical trial procedures
The records identifying 
the subject will be kept 
confidential 
the subject or the 
subject's legally 
representative will be 
informed if relevant 
information becomes 
available 
The person(s) to contact 
for further information 





reasons under which the 
subject's participation in 
the trial may be 
terminated.
The expected duration 
of the trial, including 
the approximate 
number of subjects 
involved in the trial.
[288]
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Prednisolone dose for those 
allocated in the prednisolone group
RECORD THE RANDOMISATION 
RESULT TO CRF08. RANDOMISATION FORM
[295]




























Confirming the ability of 
parents to complete CRF05. 
Symptom diary
Dispensing CRF07.Prescription 
of study medication for children 
allocated to Prednisolone group
Completion of CRF02. Study 




Provide FORM09. Instruction of 
prednisolone use for parents 
whose children were allocated 
to the Prednisolone group





































FORM01. Study Recruitment 
Log Book 
CRF01. Consent Form
CRF02. Study Registration Form
CRF08. Randomisation Form
CASE REPORT FORM 
BINDER
CRF03. Eligibility Form
CRF04. Baseline Information  
Form
CRF05. Outcome Form
CRF10. Serious Adverse Event 
Reporting Form
CRF11. Feedback Form
FORM7. Guideline of 
Antibiotics for AOM





FORM05. Recapitulation of 
Completed Case Report Form
FORM06. Recapitulation of 
Non-Participating Subject Form
[296]






   
34
PREPARATION OF STUDY 
MEDICATION DISPENSING THE STUDY MEDICATION
Oral prednisolone for acute otitis media in children (OPAL) study
FOLLOW-UP VISITS 35
[297]
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36Follow-up timeline
Research team will send reminder text messages to remind the parents:
1. Give the study medication regularly to their children
2. Complete the Symptom Diary regularly
3. Come to the hospital for follow-up visits
Audiologist / Trained staff
[Tympanometry room/corner]
Tympanometry examination and record the results on CRF05. Outcome 
form. The Physician then will interpret the result
Physician
[Consultation room]
Identify the eligibility to the study using CRF03. Eligibility form
Provide information of the study and obtain the consent from the 
parents to the study using CRF01. Information sheet and consent 
form
Stratify based AOM severity using CRF03. Eligibility form
Data collection (interview for clinical history and ENT, otoscopic 
and tympanometry examination) using CRF04. Baseline 
information form and CRF05. Outcome form 
Prescribe study medication using CRF07. Prescription of study 
medication and other medications
Inform and teach the parents in completing CRF06. Symptom 
diary
Appointed Nurse
Conduct randomisation using CRF08. Randomisation form by accessing 
the randomisation system website or calling the randomisation call-centre
Hand over CRF07. Prescription of study medication for those who were 
allocated to the prednisolone group
Complete CRF09. Follow-up visit card by writing scheduled follow-up visit 
for the next three months
Confirm that the ability of the parents in completing CRF06. Symptom 
diary
Provide information of prednisolone use for those who were allocated to 
the prednisolone group and provide FORM09. Instruction of prednisolone 
use for parents
Remind the parents to keep the information of intervention allocation 
confidential from the physician and audiologist
Provide the transportation reimbursement and study souvenirs
Compile and check the completion of all study documents, including 
CRF02. Study registration form and store them in the binders
Secure the binders in a locked filing cabinet
Pharmacy
Prepare and dispense the study 
medication, including the 
sweetener syrup
Record the dispensing process 

















Identification of paediatric patients with AOM symptoms who 
come to the clinic using FORM01. Study recruitment log book
General examination (weight, height, temperature, blood 
pressure)
Inform the appointed nurse or prepare the study binders
Provide CRF01. Information sheet and consent form and CRF02. 
Study registration form to be read and completed while waiting 
for consultation
37
















Identify the patients as a study subject in OPAL study
Perform general examination 
Report this to the Appointed Nurse with the results of general examination
Physician
[Consultation room]
Identify any complications, symptoms, side effects, conduct ENT and otoscopic examination
Record the examination results on CRF05. Outcome form or CRF10. Serious adverse events 
reporting form for any serious side effects
Interpret the tympanometry results
Oral prednisolone for acute otitis media in children (OPAL) study
Appointed Nurse
Identify side effects by interview and check CRF06. Symptom diary. These will be reported to 
the physician without acknowledging him about the intervention allocation, if possible
Collect the First mini-booklet of symptom diary and check its completion and the adherence in 
taking the study medication, as well as check the left-over study medication
Report this subject to physician
Prepare the study documents in Case report form binder and copy the general examination 
results to CRF05. Outcome form
38
Appointed nurse
Ask the Physician for prescription of study medication, if needed
Complete CRF09. Follow-up visit card and remind the parents 
for the scheduled next visit
Provide the transportation reimbursement and study souvenirs
Compile and check the completion of all study documents and 
store them in the binders
Secure the binders in a locked filing cabinet
Oral prednisolone for acute otitis media in children (OPAL) study
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40Good Clinical Practice (GCP)
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording and reporting trials that involve the participation of 
human subjects. 
Compliance with this standard provides public assurance that the rights, safety and well-
being of trial subjects are protected, consistent with the principles that have their origin in 
the Declaration of Helsinki, and that the clinical trial data are credible.
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41The principles of GCP (1) 
1. Clinical trials should be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s).
2. Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit 
for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits 
justify the risks.
3. The rights, safety, and well-being of the trial subjects are the most important considerations and should prevail 
over interests of science and society.
4. The available nonclinical and clinical information on an investigational product should be adequate to support 
the proposed clinical trial.
5. Clinical trials should be scientifically sound, and described in a clear, detailed protocol.
6. A trial should be conducted in compliance with the protocol that has received prior institutional review board 
(IRB)/independent ethics committee (IEC) approval/favourable opinion
[300]
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42The principle of GCP (2) 
7. The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility 
of a qualified physician or, when appropriate, of a qualified dentist.
8. Each individual involved in conducting a trial should be qualified by education, training, and experience to 
perform his or her respective task(s).
9. Freely given informed consent should be obtained from every subject prior to clinical trial participation.
10. All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation and verification.
11. The confidentiality of records that could identify subjects should be protected, respecting the privacy and 
confidentiality rules in accordance with the applicable regulatory requirement(s).
12. Investigational products should be manufactured, handled, and stored in accordance with applicable good 
manufacturing practice (GMP). They should be used in accordance with the approved protocol.
13. Systems with procedures that assure the quality of every aspect of the trial should be implemented.
Oral prednisolone for acute otitis media in children (OPAL) study
43Essential terms in GCP (1)
Blinding 
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4) Private room for randomisation
5) Pharmacy
Oral prednisolone for acute otitis media in children (OPAL) study
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9) Smart phone or PC with internet  
connection
10) Filing cabinet with lock
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Physicians Nurses Audiologists
51Feedback
Oral prednisolone for acute otitis media in children (OPAL) study
Pharmacists Parents
[305]
Thank you for your participation in the OPAL study.
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Appendix 5.1. Diagnostic criteria for acute otitis media (AOM) 
Mild AOM  Severe AOM 
Symptoms 
[1,2] 
Mild ear pain  Symptoms  
[1-3] 
Moderate to severe ear pain 
Fever < 39°C   Fever ≥ 39°C 
Mildly ill (e.g. alert, 
responsive, well-response 
to antipyretics) 
  Moderate or severely ill 
(e.g. vomiting, irritable, 




Mild hyperaemic TM  Otoscopic 
signs [4] 
Moderate to severe 
hyperaemic TM 
 Mild bulging   Moderate to severe 
bulging, bulla formation, 
yellowish purulent 
appearance of TM  
    TM perforation [5] 
Other [1] Children aged ≥ 2 years 
with bilateral AOM 
 Other [1] Children aged < 2 years 
with bilateral AOM 
TM: tympanic membrane 
Reference: 
1. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et 
al. Clinical practice guideline: the diagnosis and management of acute otitis media. 
Pediatrics. 2013;131:e964–e99.  
2. Le Saux N, Robinson JL, Canadian Paediatric Society Infectious Diseases and 
Immunization Committee. Management of acute otitis media in children six months of 
age and older. Paediatr Child Health. 2016;21(1):39-44. 
3. Queensland Emergency Care Children Working Group. Acute otitis media – Emergency 





4. Kitamura K, Iino Y, Kamide Y, Kudo F, Nakayama T, Suzuki K, et al. Clinical Practice 
Guidelines for the diagnosis and management of acute otitis media (AOM) in children 
in Japan – 2013 update. Auris Nasus Larynx. 2015;42:99-106 
5. Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et 
al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. 
Lancet. 2006;368:1429-1435. 
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Page 1 of 6 
PARTICIPANT INFORMATION SHEET AND CONSENT FORM
Oral prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind,  
placebo-controlled study (OPAL study) 
[Steroids or anti-inflammatory drug for middle ear infection in children] 
Invitation 
You are invited to participate in a research study into the use of steroids (prednisolone) or an anti-inflammatory drug for 
middle ear infection in children. The study is being conducted by Dr. Respati W. Ranakusuma, an otorhinolaryngologists 
and a researcher at the Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit Dr. Cipto Mangunkusumo 
Hospital–Faculty of Medicine Universitas Indonesia. It is part of an international collaborative study between CEEBM 
CMH-FMUI and the Institute for Evidence-Based Healthcare (IEBH), Bond University, Queensland, Australia.  
Before you decide whether or not you wish to participate in this study, it is important for you to understand why the 
research is being done and what it will involve. Please take the time to read the following information carefully and 
discuss it with others if you wish. 
1. What is the purpose of this study?
The purpose is to investigate the effect of steroids (prednisolone), as an alternative treatment, in children with acute
or recent (less than 48 hours) middle ear infection in reducing: (1) ear pain and other symptoms related to middle
ear infection; (2) the need of antibiotic treatment in children with mild symptom or shortening the duration of
antibiotic use in children with severe symptom; (2) the risk of having complication (e.g. ruptured eardrum); and (3)
the risk of having a new episode of middle ear infection in one and three months. To be able to assess the actual
effect of the steroids, your child will receive either the steroid or the steroid dummy for five days. The dummy
steroid will have similar taste, colour, and smell making it is not possible to differentiate with the real steroid.
2. Why have my child and I been invited to participate in this study?
Your child and you have been invited because your child age between six months and 12 years and having
symptoms/signs of acute middle ear infection (in 48 hours or less), such as ear pain, holding ear more frequently,
more irritable. If visible, the ear examination using an otoscope will show red, yellowish, or bulging ear drum(s), or
ear discharge. Otoscope is a tool consisted of a lamp, magnifying glass, and a silicone/plastic probe that will be
inserted into the ear canal to identify the condition of the ear canal and ear drum. This examination is painless and
generally takes 2 to 5 minutes. It may take longer if you child is uncooperative or have ear wax.
3. What does participation in this study involve?
If you agree to participate in this study, your physician will ask you more questions regarding the history of your 
child’s previous infection, allergy, vaccination, concurrent diseases, and the symptom severity in more detail,
including your personal data and phone numbers to allow us contacting you if necessary. As only your child and you 
as the parent know the best of how severe the symptoms are, we will ask you to describe the pain severity and other
symptoms using two pain measuring tools. The first tool is called Visual Analogue Scale (VAS). It is a 100-mm
horizontal line, whereas the left end of the line represents ‘no pain’ and the right end represents ‘the most painful’. 
We will ask you to draw a vertical line across this line at the point representing how bad the symptom that your child
has been experiencing. The second tool is called Acute Otitis Media – the Severity of Symptoms scale (AOM-SOS)
Appendix 5.2. Case report form CRF01. Information and consent form
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 STUDY ID 
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
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which has seven questions. You will be asked to choose one of the severity scales (‘no’, ‘a little’, or ‘a lot’) that 
corresponds to your child’s conditions. We will provide you a symptom diary that you have to complete every day for 
two weeks. This symptom diary is consisted of three booklet which listed two measuring tools, signs of complications, 
and medication taken each day. The will help us and your physician to assess your child improvement in daily basis. 
Your physician, nurse, or our research assistant will teach you how to complete the symptom diary.  
We will ask you to come to the primary care centre or hospital at Day 3 and Day 7 following your first visit. During 
these visits, we will investigate whether the steroid will help reducing the ear pain and other relevant symptoms and 
whether it give unfavorable effects. We will also ask you to bring the symptom diary booklets, as well as the left-over 
and used paper wrap of study medication so we can ensure your child have taken the medication as ordered and 
have enough medication for five days. The nurse/research assistant will measure your child’s weight, height, and 
temperature. The physician will examine your child ear, nose, and throat, and may order other tests (e.g 
tympanometry) if necessary.  You then will meet the nurse/research assistant who will allocate your child to either 
receive the steroid (treatment group) or steroid dummy (placebo group). Your child has 50% chance for being 
allocated to receive the steroid and 50% chance to receive steroid dummy. We will do this process randomly, which 
will be conducted by the nurse/research assistant, where no one can predict or acknowledge in which group your 
child will be allocated to, as the results will be identified with codes. This process will require approximately 15 to 30 
minutes.  The nurse will copy the code in the prescription, which you will give away to the pharmacy at that primary 
care centre/hospital. The pharmacist will prepare the study medication by crushing the tablets, mixing it with 
sweeteners, and packing the study medication in a daily paper-package (you will receive five daily packages), and 
also provide a additional sweetener syrup which you can mix it with crushed tablet with a ratio of 3:1 to make the 
medication more palatable for your child. The nurse will give an instruction for taking the study medication. We 
strongly suggest you to give the study medication as a whole, every morning, once daily for five days. You can give 
this medicine with a glass of milk or juice, or with a small amount of soft food such as jam or yoghurt. The whole 
process will require 60 to 120 minutes depends on the cooperativity of your child.  
At Day 14, we will visit your home to collect the symptom diary. We will contact you by phone at Day 30 (one month) 
and Day 90 (three months) to identify whether during these time, your child experiences a new episode of acute 
middle ear infection. To make this easy for you, our research personnel will send you a daily reminder text-message.  
If you agree to participate in this study, you will be asked to sign the Consent Form. 
4. What if I do not want to take part in this study, or if I want to withdraw later?
Participation in this study is voluntary. It is completely up to you or both of you and your older child (aged 12 years), 
whether or not you participate. If you decide not to participate, it will not affect the treatment your child receive
now or in the future. Whatever your decision, it will not affect your relationship with the staff caring for your child.
You may ask for consultation with another doctor, if you feel uncomfortable after deciding not to participate in the 
study. However, it may not be possible to withdraw your data from the study results if these have already had your
identifying details removed.
5. How is this study being paid for?
The study is being for by Dr. Respati W. Ranakusuma, ORL which is supported by self-funded.
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6. Are there risks to my child in taking part in this study?
The foreseeable risks in taking part in this study are the bitter taste of study medication and potential side effects of
prednisolone such as nausea, vomiting, abdominal pain, nervousness, mood swings, headache, increased blood sugar 
and weight gain, etc. Growth disorder could be one of the side effects however it usually occurs on the longer use of
the steroids. We cannot predict whether your child will have one of these effects or not at all. The evidence from
published studies, ensures us that the corticosteroids within the range of our dose and duration are safe and 
commonly used for children. You may feel that the whole process of this study will take longer time compared to
usual doctor visit due to collection of information that will be conducted in this study. It may add some work for you 
to complete a symptom diary daily for the next 14 days. However, this is very important to be able to assess the day-
by-day progress of your child condition.
7. What happens if my child suffers injury or complications as a result of the study?
We will responsible of costs of consultation, test or examination, and treatment related to the side effects or
complication from the use of study medication. We will monitor your child closely. You are also advised to contact
our 24-hour call centre if you have any enquiries or questions regarding the study.
8. Will I benefit from the study?
This study aims to further medical knowledge of future less-antibiotic-use treatment for acute middle ear infection, 
particularly in mild cases where usually antibiotics are being prescribed. This is very important since antibiotic use
can increase the risk of side effects and antibiotic resistance. Antibiotic resistance is a condition where bacteria that
making people sick, does not respond to antibiotic that aimed to kill them. This has been a health problem across the
world due to its ability to increase the risk of having a worse or longer disease and causing death. However, this
study may not directly benefit you.
9. Will taking part in this study cost me anything, and will I be paid?
Participation in this study will not cost you anything, nor you will be paid. You will be reimbursed for reasonable
travel expenses ($15) and we will provide souvenirs for your child. We will cover the registration and consultation 
fees for the additional two follow-up visits. We will provide the study medication and a sweetener syrup, but not for
the other medications (e.g. antibiotics, flu/cough syrup) or additional tests or laboratory examination (e.g.
tympanometry, x-ray, endoscopy examination) ordered by your physician.
10. How will my confidentiality be protected?
Any identifiable information that is collected about your child in connection with this study will remain confidential,
will be held securely, and will be disclosed only with your permission, or except as required by law. We will use your
personal contact data (e.g. phone number, home address) to send a reminder text message, a home visit at Day-14,
and to interview you by phone at one and three months.
11. What happens with the results?
If you give us your permission by signing the consent document, we may report the study progress and result for
monitoring and safety purposes, if necessary. We will also publish the study result in peer-reviewed journals or
presentation at conferences or other professional forums. In any publication, information will be provided in such a
way that you child cannot be identified.
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12. What should I do if I want to discuss this study further before I decide?
When you have read this information, your physician or our research personal will discuss any queries you may have
with you. If you would like to know more at any stage, please do not hesitate to contact Dr. Respati W. Ranakusuma,
ORL by phone on +62 8111 012 185.
13. Who should I contact if I have concerns about the conduct of this study?
This study has been approved by the Medical Ethics Committee FMUI and the Bond University’s Human Research
Ethics Committee (BUHREC) Bond University, Queensland, Australia. Any person with concerns or complaints about
the conduct of this study should contact Dr. Respati W. Ranakusuma on +62 8111 012 185, or email
OPAL.study@bond.edu.au. 
The conduct of this study at Proklamasi ENT Hospital, Antam Medika Hospital, and several primare care centres in 
East and Central Jakarta, has been authorised by the the Health Agency for the Province of DKI Jakarta and the
Directorate-General for Politics and General Government – The Ministry of Internal Affairs Republic Indonesia.
Thank you for taking the time to consider this study. If you wish to take part in, please sign the attached consent form. 
This information sheet is for you to keep 
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CRF01. CONSENT FORM
Oral prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind,  
placebo-controlled study (OPAL study) 
[Steroids or anti-inflammatory drug for middle ear infection in children] 
1. I, _________________________________________________________________________________
of ________________________________________________________________________________
agree to participate in the study described in the participant information statement set attached to this form.
2. I acknowledge that I have read the participant information statement, which explains why my child has been
selected, the aims of the study, and the nature and the possible risks of the investigation, and the statement has
been explained to me to my satisfaction.
3. Before signing this consent form, I have been given the opportunity of asking any questions relating to any
possible physical and mental harm my child might suffer as a result of my child participation and I have received
satisfactory answers.
4. I understand that my child can withdraw from the study at any time without prejudice to either my child and my
relationship to my physician and the _______________________________________ Hospital.
5. I agree that research data gathered from the results of the study may be published, provided that I cannot be
identified.
6. I understand that I have any questions relating to my participation in this research, I may contact Dr. Respati W.
Ranakusuma, ORL on telephone +62 8111 012 185, who will be happy to answer them.
7. I acknowledge receipt of a copy of this Consent Form and the Participation Information Statement.
Complaints may be directed to the OPAL Study Support Office at the Clinical Epidemiology and Evidence-Based Medicine 
Unit, Dr Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia, Building H Dr Cipto Mangunkusumo 
Hospital, Diponegoro 71, Jakarta 10430, Indonesia (phone +62 21 316 1760, email OPAL.study@bond.edu.au). 
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REVOCATION OF CONSENT
Oral prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind,  
placebo-controlled study (OPAL study) 
[Steroids or anti-inflammatory drug for middle ear infection in children] 
I hereby wish to WITHDRAW my consent to participate in the study described above and understand that such 
withdrawal WILL NOT jeopardise any treatment or my relationship with the ___________________________ hospital or 
my medical attendants. 


















The section for Revocation of Consent should be forwarded to Dr. Respati W. Ranakusuma, ORL at: 
Clinical Epidemiology and Evidence-Based Medicine Unit  
Dr Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia (CEEBM CMH-FMUI) 
Dr Cipto Mangunkusumo Hospital Building H, 2nd floor 
Jl Diponegoro 71, Jakarta 10430, Indonesia 
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PATIENT’S INFORMATION
Patient’s name Sex   O Male O Female
Place and date of birth __________________  ,  _______________________________________ 
Education O None O Pre-school    O Elementary school
O Middle junior school O High school
School attending hours O once a week    from: _____  am/pm to _____ pm/pm 
O Twice a week      from: _____  am/pm to _____ pm/pm 
O three time a week      from: _____  am/pm to _____ pm/pm 
O Four times a week      from: _____  am/pm to _____ pm/pm  
O Daily (five times a week)    from: _____  am/pm to _____ pm/pm  
O More than five times a week from: _____  am/pm to _____ pm/pm
Day care O Yes O No
Day care hours O once a week    from: _____  am/pm to _____ pm/pm 
O Twice a week      from: _____  am/pm to _____ pm/pm 
O three time a week      from: _____  am/pm to _____ pm/pm 
O Four times a week      from: _____  am/pm to _____ pm/pm  
O Daily (five times a week)    from: _____  am/pm to _____ pm/pm  
O More than five times a week from: _____  am/pm to _____ pm/pm
Home address 
Home telephone number 
CRF02. STUDY REGISTRATION FORM 
Go to the next page for 
‘Parents’ information’ 
Appendix 5.3. Case report form CRF02. Study registration form
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Place and date of birth 
Education O None O Elementary school          O Middle junior school
O High school          O Diploma/College             O Bachelor
O Masters   O Doctoral
Occupation O None O Government employee  O Private employee
O Entrepreneur   O Others : ______________________________
Home address O Same with patient’s address
O Different address: ___________________________________________
_____________________________________________________________  
Home telephone number O Same with patient’s telephone number





Place and date of birth 
Education O None O Elementary school          O Middle junior school
O High school          O Diploma/College             O Bachelor
O Masters   O Doctoral
Occupation O Housewife O Government employee  O Private employee
O Entrepreneur   O Others : ______________________________
Home address O Same with patient’s address
O Different address: ___________________________________________
_____________________________________________________________  
Home telephone number O Same with patient’s telephone number
O Different number: __________________________________________
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 Doctor ID   
|___|___| – |___|___| – 201 |___| 
|___|___|___|    Site ID   |___|___|___|  
   
INCLUSION CRITERIA
Definite or suspected acute 
otitis media with maximum 
onset of 48 hours  




Aged 6 months to 12 years OYes     ONo
Available for follow-up visits OYes     ONo
Is this child eligible for the trial? 
At least one ‘NO’ at the inclusion criteria, OR 
At least one ‘YES’ at the exclusion criteria 
Not eligible, then EXCLUDE  
All ‘YES’ at the inclusion criteria, AND 
All ‘NO’ at the exclusion criteria 
Eligible, then INCLUDE
Obtaining the CONSENT NOT giving CONSENT    EXCLUDE  
Do they have the following symptom(s)? 
Giving CONSENT INCLUDE
Moderate to severe symptoms, locally or systemically 
(moderate to severe ear pain, fever ≥39°C, complications) 
OYes  ONo
Aged younger than 2 years with bilateral acute otitis media OYes    ONo
With perforation of tympanic membrane(s) OYes    ONo
If visible, otoscopic finding shows moderate to severe bulging 
and/or yellowish purulent tympanic membrane(s) 
OYes    ONo
At least one ‘YES’ 
All ‘NO’ MILD AOM  SEVERE AOM  
EXCLUSION CRITERIA
Major medical conditions (e.g. heart/renal failure, DM) OYes     ONo
Immunocompromised (e.g. cancer treatment, HIV) OYes     ONo
Congenital malformation/syndromes (cleft palate) OYes     ONo
Ventilation tube(s) OYes     ONo
Exposed to persons with varicella/active Zoster infection 
in the past 3 weeks with no prior history of varicella 
infection or immunisation 
OYes     ONo
Has taken oral/injection/topical steroids in the past 4 
weeks OYes     ONo
Has taken oral antibiotics in the past 2 weeks OYes ONo
Hypersensitive to prednisolone or other steroids  OYes     ONo
With high risk of strongyloidiasis infection OYes     ONo 
CRF03 – ELIGIBILITY FORM 
Appendix 5.4. Case report form CRF03. Eligibility form
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 Study ID 
CRF04 – BASELINE HISTORY FORM 
1      Did (do) you breastfeed your child?    O Yes O No 
  If you do, until the age of          O ≤ 2 months O > 2 – 6 months O > 6 months
2     Have your child had an influenzae vaccine?                   O Yes O No                  O Do not know 
   If yes, how many times :   _________ 
3     Have your child had a pneumococcus vaccine (PCV)?       O Yes O No                  O Do not know 
 If YES, how many times :   _________ 
4     How many episodes of acute respiratory infection (e.g. runny nose, cough, sore throat, fever) in the past 12 months? 
        O ≤ 3 episodes                   O > 3 episodes to 6 episodes                        O > 6 episodes
5    Did your child have a history of 3 or more episodes of ear infection (e.g. ear pain, ear discharge) in the past 12 months?     
O Yes O No
 If YES, the last episode was in: month  _________   year ___________ 
6     Is this the first time your child has ear infection?   O Yes O No 
       If NOT, at what age did the first episode of ear infection start? 
                O ≤ 6 months       O > 6 to 12 months  O >12 to 24 months  O > 2 to  5 years      O > 5 years 
7     Have your child had discharge from the ear?  O Yes O No 
If YES, on:       O Right ear                          O Left ear      The last time in: month  ________  year  _______    
  Has any doctor have confirmed that the ear drum is closed/healed?      O Yes O No 
The confirmation using otoscope                               O Yes O No                 O Not sure
8     Does your child have an allergy?  
O Asthma 
     O Allergic rhinitis 
     O History of atopy in family
     O None of the above. Others  ________________________________
9      Number of children (including the patient) who live in the house         ____________  children 
10    Number of persons who smoke at home        ____________  person(s) 
Appendix 5.5. Case report form CRF04. Baseline history form
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CRF05 – OUTCOMES FORM 
Baseline Visit (Day – 0) : |___|___| – |___|___| – 20 |___|___| 
Complications (completed by physician)   
1 Does your child experience discharge from the ear(s)?    O Yes    O No
2 Does your child experience intense ear pain and pain behind the ear?   O Yes    O No
3 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s)?     O Yes    O No
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes    O No
Physical examination (completed by physician)  
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp     ________ °C 
6 Nose O Normal O Oedema         O Hyperaemic O Livid O Discharge* serous / mucoid  /  mucopurulent
7 Tonsils        O Normal O Hyperaemic    O Detritus O Tonsil T1     O Tonsil T2       O Tonsil T3-4
8 Pharynx   O Normal O Hyperaemic    O Oedema O Granules     O Post nasal drip (PND)
Otoscopic examination (completed by physician)   
  9.1  Right Ear (AD) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
9.2  Left Ear (AS) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
 O Serous O Mucoid  O Mucopurulent
Other diagnostic tests (completed by physician) 
10   Does this child require specific or  
       additional tests or examination? 
O No
O Yes. Please specify with the results:
   O Naso/oto-endoscopy    O Tympanometry     O X-ray  O Other  : _________
     Results:___________________________________________________________  
     _________________________________________________________________ 
     _________________________________________________________________ 
11  Diagnosis (completed by physician) 
O Unilateral AOM – Right Ear (AOM AD) O Unilateral AOM – Left Ear (AOM AS) O Bilateral AOM (AOM ADS)
12  Other diagnosis: 
O Acute rhinitis         O Acute rhinosinusitis              O Acute tonsillitis/pharyngitis O Adenoiditis
O Allergic rhinitis       O Chronic rhinosinusitis           O Chronic tonsillitis/pharyngitis O Adenoid hypertrophy
Appendix 5.6. Case report form CRF05. Outcome form
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O Others: _______________________
13  Medicines that have been taken before the baseline visit  (please circle your dose measurement)  
1. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
2. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
3. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
4. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
14  Medicines prescribed by you  
Antibiotic 
Dose    :  _______mg / Drops/ Teaspoon / Tablespoon        Frequency   :   ____ times / day for _______ days 
Other medicine 
1. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
2. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
3. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
4. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
5. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
Symptoms (for patient/parents) 
15 Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past 
24 hours?  
16 We are interest finding out how your child has been doing. For each question, please place a check mark in the circle 
      corresponding to your child’s symptoms. Please answer all questions 
16.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more 
  than usual? 
O No     O A little     O A lot 
16.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
16.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
16.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
16.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
16.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
16.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Additional test / examination results (if available): 
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Follow-up Visit-01 (Day-3) : |___|___| – |___|___| – 20 |___|___| 
Complications (completed by physician) 
1 Does your child experience discharge from the ear(s)?    O Yes   O No
2 Does your child experience intense ear pain and pain behind the ear? O Yes    O No
3 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s )?     O Yes    O No
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?   O Yes    O No
Physical examination (completed by physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 
6 Nose O Normal O Oedema         O Hyperaemic O Livid O Discharge* serous / mucoid  /  mucopurulent
7 Tonsils        O Normal O Hyperaemic    O Detritus O Tonsil T1     O Tonsil T2       O Tonsil T3-4
8 Pharynx   O Normal O Hyperaemic    O Oedema O Granules     O Post nasal drip (PND)
Otoscopic examination (completed by physician)   
  9.1  Right Ear (AD) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
9.2  Left Ear (AS) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
10  Medicines prescribed by you (please circle your dose measurement)      
Antibiotic 
Dose    :  _______mg / Drops/ Teaspoon / Tablespoon        Frequency   :   ____ times / day for _______ days 
Other medicine 
1. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
2. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
3. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
4. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
5. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
Symptoms (for patient/parents) 
11 Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past 
24 hours? 
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12 We are interest finding out how your child has been doing. For each question, please place a check mark in the circle    
corresponding to your child’s symptoms. Please answer all questions 
12.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more 
   than usual? 
O No     O A little     O A lot 
12.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
12.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
12.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
12.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
12.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
12.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
13 Side effects 
Does your child have these complaints after taking the medicine 
13.1  Increased appetite O Yes     O No 13.8   Drowsiness  O Yes     O No
13.2  Increased urine amount O Yes     O No 13.9   Anxiety/distractibility/mood swing O Yes     O No
13.3  Weight gain O Yes     O No 13.10  Headache O Yes     O No
13.4   Gastritis/abdominal pain O Yes     O No 13.11  Skin rash or diaper rash O Yes     O No
13.5   Nausea O Yes     O No 13.12  Candidiasis O Yes     O No
13.6   Vomiting O Yes     O No 13.13  Dry mouth / throat irritation O Yes     O No
13.7   Diarrhea O Yes     O No 13.14  Sleep disturbance O Yes     O No
Others: ______________________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No Reason: _______________________________ 
_______________________________ Medicine prescribed: 
Has your child has been admitted to 
clinic or hospital? 
O Yes     O No
Reason: 
_______________________________ 
Medicine prescribed: _______________________________ 
Regarding the side effects, your action 
is/are (you may answer more than 
one): 
O Discontinuation of the study medication
O Continuation of the study medication 
O Discontinuation of other concomitant drugs as follows:
1. _____________________ 3. _____________________
2. _____________________ 4. _____________________
The treatment you prescribed for the 
management of side effects 
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day
4. _____________________; Dose  ___________;  Frequency  ______  / day
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Does this child require specific or 
additional tests or examination? 
O No
O Yes. Please specify with the results:
   O Naso/oto-endoscopy    O Tympanometry     O X-ray  O Other  : _________
     Results:___________________________________________________________   
     _________________________________________________________________ 
     _________________________________________________________________ 
Does this child require specific or 
additional treatment/medicine 
O No
O Yes. Please specify the treatment:
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day
4. _____________________; Dose  ___________;  Frequency  ______  / day
Does this child require a 
hospitalisation? 
O No
O Yes. Please explain your reasons to hospitalise this child and the treatment
      will be given 
      Reason: _________________________________________________________ 
       _________________________________________________________ 
The treatment:  
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day
Additional test  /examination results (if available): 
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Follow-up Visit 02 (Day-7) : |___|___| – |___|___| – 20 |___|___| 
Complications (completed by physician) 
1 Does your child experience discharge from the ear(s)?    O Yes    O No
2 Does your child experience intense ear pain and pain behind the ear?    O Yes    O No
3 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s)?      O Yes    O No
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?   O Yes    O No
Physical examination (completed by physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp     ________ °C 
6 Nose O Normal O Oedema         O Hyperaemic O Livid O Discharge* serous / mucoid  /  mucopurulent
7 Tonsils        O Normal O Hyperaemic    O Detritus O Tonsil T1     O Tonsil T2       O Tonsil T3-4
8 Pharynx     O Normal O Hyperaemic    O Oedema O Granules     O Post nasal drip (PND)
Otoscopic examination (completed by physician)   
  9.1  Right Ear (AD) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
9.2  Left Ear (AS) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete 
effusion        O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
10  Medicines prescribed by you (please circle your dose measurement)      
Antibiotic 
Dose    :  _______mg / Drops/ Teaspoon / Tablespoon        Frequency   :   ____ times / day for _______ days 
Other medicine 
1. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
2. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
3. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
4. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
5. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
Symptoms (for patient/parents) 
11 Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past 
24 hours? 
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12 We are interest finding out how your child has been doing. For each question, please place a check mark in the circle  
       corresponding to your child’s symptoms. Please answer all questions 
12.1  Over the past 12 h, has your child been tugging, rubbing, or holding the  ear(s) more  
   than usual? 
O No     O A little     O A lot 
12.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
12.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
12.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
12.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
12.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
12.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
13 Side effects 
Does your child have these complaints after taking the medicine 
13.1  Increased appetite O Yes     O No 13.8   Drowsiness  O Yes     O No
13.2  Increased urine amount O Yes     O No 13.9   Anxiety/distractibility/mood swing O Yes     O No
13.3  Weight gain O Yes     O No 13.10  Headache O Yes     O No
13.4   Gastritis/abdominal pain O Yes     O No 13.11  Skin rash or diaper rash O Yes     O No
13.5   Nausea O Yes     O No 13.12  Candidiasis O Yes     O No
13.6   Vomiting O Yes     O No 13.13  Dry mouth / throat irritation O Yes     O No
13.7   Diarrhea O Yes     O No 13.14  Sleep disturbance O Yes     O No
Others: ______________________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No Reason: _______________________________ 
_______________________________ Medicine prescribed: 
Has your child has been admitted to 
clinic/hospital? 
O Yes     O No Reason: _______________________________ 
Medicine prescribed: _______________________________ 
Regarding the side effects, your 
action is/are (you may answer more 
than one): 
O Discontinuation of the study medication
O Continuation of the study medication 
O Discontinuation of other concomitant drugs as follows:
1. _____________________ 3. _____________________
2. _____________________ 4. _____________________
The treatment you prescribed for the 
management of side effects 
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day
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Does this child require specific or 
additional tests or examination? 
O No
O Yes. Please specify with the results:
   O Naso/oto-endoscopy    O Tympanometry     O X-ray  O Other  : _________
     Results:___________________________________________________________  
     _________________________________________________________________ 
     _________________________________________________________________ 
Does this child require specific or 
additional treatment/medicine 
O No
O Yes. Please specify the treatment:
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day
Does this child require a 
hospitalisation? 
O No
O Yes. Please explain your reasons to hospitalise this child and the treatment
      will be given 
      Reason: _________________________________________________________ 
       _________________________________________________________ 
The treatment:  
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day
Additional test  /examination results (if available): 
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Follow-up 03 by Interview (Day-30) : |___|___| – |___|___| – 20 |___|___| 
Recurrence 
1 Within the past one month, does your child 
experience a new episode of ear pain  
O Yes             O No 
When?       __________ days / weeks ago 
How long?    __________ days / weeks  
Did you bring your child to doctor  O Yes             O No 
The treatment:  
1. ____________________; Dose  ______;  Frequency  ______  / day
2. ____________________; Dose  ______;  Frequency  ______  / day
3. ____________________; Dose  ______;  Frequency  ______  / day
4. ____________________; Dose  ______;  Frequency  ______  / day 
2 Within the past one month, does your child 
experience common cold? 
O Runny nose           O Cough      O Sore throat            O Fever 
O Others:  _____________________________
When?           __________ days / weeks ago 
How long?    __________ days / weeks  
Did you bring your child to doctor  O Yes             O No 
The treatment:  
1. ____________________; Dose  ______;  Frequency  ______  / day
2. ____________________; Dose  ______;  Frequency  ______  / day
3. ____________________; Dose  ______;  Frequency  ______  / day
4. ____________________; Dose  ______;  Frequency  ______  / day 
Symptoms 
3 Does your child experience pain in the ear (s)?     O Yes   O No
    If YES, which ear  O Right ear   O Left ear
4 Does your child experience discharge from the ear(s)?    O Yes   O No
5 Does your child experience intense ear pain and pain behind the ear?    O Yes    O No
6 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s )?     O Yes    O No
7 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?   O Yes    O No
8 We are interest finding out how your child has been doing. For each question, please place a check mark in the circle    
corresponding to your child’s symptoms. Please answer all questions Otoscopic findings 
8.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more 
   than usual? 
O No     O A little     O A lot 
8.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
8.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
8.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
8.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
8.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
8.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
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Follow-up 04 by Interview (Day-90) : |___|___| – |___|___| – 20 |___|___| 
Recurrence 
1 Within the past two months, does your child 
experience a new episode of ear pain  
O Yes             O No 
When?      __________ days / weeks ago 
How long?    __________ days / weeks  
Did you bring your child to doctor  O Yes             O No 
The treatment:  
1. ____________________; Dose  ______;  Frequency  ______  / day
2. ____________________; Dose  ______;  Frequency  ______  / day
3. ____________________; Dose  ______;  Frequency  ______  / day
4. ____________________; Dose  ______;  Frequency  ______  / day 
2 Within the past two months, does your child 
experience common cold? 
O Runny nose           O Cough      O Sore throat            O Fever 
O Others:  _____________________________
When?           __________ days / weeks ago 
How long?    __________ days / weeks  
Did you bring your child to doctor  O Yes             O No 
The treatment:  
1. ____________________; Dose  ______;  Frequency  ______  / day
2. ____________________; Dose  ______;  Frequency  ______  / day
3. ____________________; Dose  ______;  Frequency  ______  / day
4. ____________________; Dose  ______;  Frequency  ______  / day 
Symptoms 
3 Does your child experience pain in the ear (s)?     O Yes   O No
    If YES, which ear      O Right ear   O Left ear
4 Does your child experience discharge from the ear(s)?  O Yes   O No
5 Does your child experience intense ear pain and pain behind the ear?    O Yes    O No
6 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s )?     O Yes    O No
7 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?   O Yes    O No
8 We are interest finding out how your child has been doing. For each question, please place a check mark in the circle    
corresponding to your child’s symptoms. Please answer all questions Otoscopic findings 
8.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more 
   than usual? 
O No     O A little     O A lot 
8.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
8.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
8.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
8.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
8.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
8.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
*** End *** 
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Additional visit : |___|___| – |___|___| – 20 |___|___| 
Complications (completed by physician) 
1 Does your child experience discharge from the ear(s)?    O Yes    O No
2 Does your child experience intense ear pain and pain behind the ear? O Yes    O No
3 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s)?      O Yes    O No
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?   O Yes    O No
Physical examination (completed by physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp     ________ °C 
6 Nose O Normal O Oedema         O Hyperaemic O Livid O Discharge* serous / mucoid  /  mucopurulent
7 Tonsils        O Normal O Hyperaemic    O Detritus O Tonsil T1     O Tonsil T2       O Tonsil T3-4
8 Pharynx   O Normal O Hyperaemic    O Oedema O Granules     O Post nasal drip (PND)
Otoscopic examination (completed by physician)    9 
  9.1  Right Ear (AD) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
9.2  Left Ear (AS) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
10  Medicines prescribed by you (please circle your dose measurement)      
Antibiotic 
Dose    :  _______mg / Drops/ Teaspoon / Tablespoon        Frequency   :   ____ times / day for _______ days 
Other medicine 
1. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
2. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
3. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
4. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
5. _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon    Frequency   :    ______ / day 
Symptoms (for patient/parents) 
11 Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past 
24 hours? 
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12  We are interest finding out how your child has been doing. For each question, please place a check mark in the circle 
       corresponding to your child’s symptoms. Please answer all questions 
12.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more 
   than usual? 
O No     O A little     O A lot 
12.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
12.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
12.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
12.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
12.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
12.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
13 Side effects 
Does your child have these complaints after taking the medicine 
13.1  Increased appetite O Yes     O No 13.8   Drowsiness  O Yes     O No
13.2  Increased urine amount O Yes     O No 13.9   Anxiety/distractibility/mood swing O Yes     O No
13.3  Weight gain O Yes     O No 13.10  Headache O Yes     O No
13.4   Gastritis/abdominal pain O Yes     O No 13.11  Skin rash or diaper rash O Yes     O No
13.5   Nausea O Yes     O No 13.12  Candidiasis O Yes     O No
13.6   Vomiting O Yes     O No 13.13  Dry mouth / throat irritation O Yes     O No
13.7   Diarrhea O Yes     O No   13.14  Sleep disturbance O Yes     O No
Others: ______________________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No Reason: _______________________________ 
_______________________________ Medicine prescribed: 
Has your child has been admitted to 
hospital? 
O Yes     O No Reason: _______________________________ 
Medicine prescribed: _______________________________ 
Regarding the side effects, your action 
is/are (you may answer more than 
one): 
O Discontinuation of the trial drug (prednisolone)
O Continuation of the trial drug 
O Discontinuation of other concomitant drugs as follows:
1. _____________________ 3. _____________________
2. _____________________ 4. _____________________
The treatment you prescribed for the 
management of side effects 
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day
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Does this child require specific or 
additional tests or examination? 
O No
O Yes. Please specify with the results:
   O Naso/oto-endoscopy    O Tympanometry     O X-ray  O Other  : _________
     Results:___________________________________________________________  
     _________________________________________________________________ 
     _________________________________________________________________ 
Does this child require specific or 
additional treatment/medicine 
O No
O Yes. Please specify the treatment:
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day
Does this child require a 
hospitalisation? 
O No
O Yes. Please explain your reasons to hospitalise this child and the treatment
      will be given 
      Reason: _________________________________________________________ 
       _________________________________________________________ 
The treatment:  
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day
4. _____________________; Dose  ___________;  Frequency  ______  / day
Additional test  /examination results (if available): 
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Additional visit : |___|___| – |___|___| – 20 |___|___| 
Complications (completed by physician) 
1 Does your child experience discharge from the ear(s)?    O Yes    O No
2 Does your child experience intense ear pain and pain behind the ear?    O Yes    O No
3 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s)?      O Yes    O No
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?   O Yes    O No
Physical examination (completed by physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp     ________ °C 
6 Nose O Normal O Oedema         O Hyperaemic O Livid O Discharge* serous / mucoid  /  mucopurulent
7 Tonsils        O Normal O Hyperaemic    O Detritus O Tonsil T1     O Tonsil T2       O Tonsil T3-4
8 Pharynx   O Normal O Hyperaemic    O Oedema O Granules     O Post nasal drip (PND)
Otoscopic examination (completed by physician)   
  9.1  Right Ear (AD) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
9.2  Left Ear (AS) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
10  Medicines prescribed by you (please circle your dose measurement)      
Antibiotic 
Dose    :  _______mg / Drops/ Teaspoon / Tablespoon        Frequency   :   ____ times / day for _______ days 
Other medicine 
1 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
2 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
3 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
4 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
5 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
Symptoms (for patient/parents) 
11 Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past 
24 hours? 
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12 We are interest finding out how your child has been doing. For each question, please place a check mark in the circle 
       corresponding to your child’s symptoms. Please answer all questions 
12.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more  
   than usual? 
O No     O A little     O A lot 
12.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
12.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
12.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
12.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
12.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
12.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
13 Side effects 
Does your child have these complaints after taking the medicine 
13.1  Increased appetite O Yes     O No 13.8   Drowsiness  O Yes     O No
13.2  Increased urine amount O Yes     O No 13.9   Anxiety/distractibility/mood swing O Yes     O No
13.3  Weight gain O Yes     O No 13.10  Headache O Yes     O No
13.4   Gastritis/abdominal pain O Yes     O No 13.11  Skin rash or diaper rash O Yes     O No
13.5   Nausea O Yes     O No 13.12  Candidiasis O Yes     O No
13.6   Vomiting O Yes     O No 13.13  Dry mouth / throat irritation O Yes     O No
13.7   Diarrhea O Yes     O No 13.14  Sleep disturbance O Yes     O No
Others: ______________________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No Reason: _______________________________ 
_______________________________ Medicine prescribed: 
Has your child has been admitted to 
hospital? 
O Yes     O No Reason: _______________________________ 
Medicine prescribed: _______________________________ 
Regarding the side effects, your action 
is/are (you may answer more than 
one): 
O Discontinuation of the trial drug (prednisolone)
O Continuation of the trial drug 
O Discontinuation of other concomitant drugs as follows:
1. _____________________ 3. _____________________
2. _____________________ 4. _____________________
The treatment you prescribed for the 
management of side effects 
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day
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Does this child require specific or 
additional tests or examination? 
O No
O Yes. Please specify with the results:
   O Naso/oto-endoscopy    O Tympanometry     O X-ray  O Other  : _________
     Results:___________________________________________________________  
     _________________________________________________________________ 
     _________________________________________________________________ 
Does this child require specific or 
additional treatment/medicine 
O No
O Yes. Please specify the treatment:
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day
Does this child require a 
hospitalisation? 
O No
O Yes. Please explain your reasons to hospitalise this child and the treatment
      will be given 
      Reason: _________________________________________________________ 
       _________________________________________________________ 
The treatment:  
1. _____________________; Dose  ___________;  Frequency  ______  / day
2. _____________________; Dose  ___________;  Frequency  ______  / day
3. _____________________; Dose  ___________;  Frequency  ______  / day
4. _____________________; Dose  ___________;  Frequency  ______  / day
Additional test  /examination results (if available): 
[335]
 Study ID 
For each question, please tick ( ) your answer on the circles or write you answer on ______ 
Outcome Form. Version 1.2 Date 8 July 2019 
Page 17 of 19 
Additional visit : |___|___| – |___|___| – 20 |___|___| 
Complications (completed by physician) 
1 Does your child experience discharge from the ear(s)?    O Yes    O No
2 Does your child experience intense ear pain and pain behind the ear?    O Yes    O No
3 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the ear(s)?      O Yes    O No
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?   O Yes    O No
Physical examination (completed by physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp     ________ °C 
6 Nose O Normal O Oedema         O Hyperaemic O Livid O Discharge* serous / mucoid  /  mucopurulent
7 Tonsils        O Normal O Hyperaemic    O Detritus O Tonsil T1     O Tonsil T2       O Tonsil T3-4
8 Pharynx   O Normal O Hyperaemic    O Oedema O Granules     O Post nasal drip (PND)
Otoscopic examination (completed by physician)   
  9.1  Right Ear (AD) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
9.2  Left Ear (AS) 
O Normal O Cerumen       O Hyperaemic
O Retraction O Air fluid level   O Mild bulging 
O Moderate/severe bulging O Complete effusion
O Opacification O Bulla
O Perforation O Dry    O  Discharge 
   O Serous O Mucoid  O Mucopurulent
10  Medicines prescribed by you (please circle your dose measurement)      
Antibiotic 
Dose    :  _______mg / Drops/ Teaspoon / Tablespoon        Frequency   :   ____ times / day for _______ days 
Other medicine 
1 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
2 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
3 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
4 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
5 _________________________   Dose    :  _______mg/ Drops / Teaspoon / Tablespoon         Frequency   :    ______ / day 
Symptoms (for patient/parents) 
11 Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past 
24 hours? 
[336]
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For each question, please tick ( ) your answer on the circles or write you answer on ______ 
Outcome Form. Version 1.2 Date 8 July 2019 
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12 We are interest finding out how your child has been doing. For each question, please place a check mark in the circle 
       corresponding to your child’s symptoms. Please answer all questions 
12.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more 
   than usual? 
O No     O A little     O A lot 
12.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
12.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
12.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
12.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
12.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
12.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
13 Side effects 
Does your child have these complaints after taking the medicine 
13.1  Increased appetite O Yes     O No 13.8   Drowsiness  O Yes     O No
13.2  Increased urine amount O Yes     O No 13.9   Anxiety/distractibility/mood swing O Yes     O No
13.3  Weight gain O Yes     O No 13.10  Headache O Yes     O No
13.4   Gastritis/abdominal pain O Yes     O No 13.11  Skin rash or diaper rash O Yes     O No
13.5   Nausea O Yes     O No 13.12  Candidiasis O Yes     O No
13.6   Vomiting O Yes     O No 13.13  Dry mouth / throat irritation O Yes     O No
13.7   Diarrhea O Yes     O No 13.14  Sleep disturbance O Yes     O No
Others: ______________________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No Reason: _______________________________ 
_______________________________ Medicine prescribed: 
Has your child has been admitted to 
hospital? 
O Yes     O No Reason: _______________________________ 
Medicine prescribed: _______________________________ 
Regarding the side effects, your action 
is/are (you may answer more than 
one): 
O Discontinuation of the trial drug (prednisolone)
O Continuation of the trial drug 
O Discontinuation of other concomitant drugs as follows:
1 _____________________                        3.   _____________________
2 _____________________                        4.   _____________________
The treatment you prescribed for the 
management of side effects 
1 _____________________; Dose  ___________;  Frequency  ______  / day   
2 _____________________; Dose  ___________;  Frequency  ______  / day 
3 _____________________; Dose  ___________;  Frequency  ______  / day 
4 _____________________; Dose  ___________;  Frequency  ______  / day   
Does this child require specific or 
additional tests or examination? 
O No
O Yes. Please specify with the results:
   O Naso/oto-endoscopy    O Tympanometry     O X-ray  O Other  : _________
     Results:___________________________________________________________   
[337]
 Study ID 
For each question, please tick ( ) your answer on the circles or write you answer on ______ 
Outcome Form. Version 1.2 Date 8 July 2019 
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     _________________________________________________________________ 
     _________________________________________________________________ 
Does this child require specific or 
additional treatment/medicine 
O No
O Yes. Please specify with the results:
   O Naso/oto-endoscopy    O Tympanometry     O X-ray  O Other  : _________
     Results:___________________________________________________________  
     _________________________________________________________________ 
   _________________________________________________________________
Does this child require a 
hospitalisation? 
O No
O Yes. Please explain your reasons to hospitalise this child and the treatment
      will be given 
      Reason: _________________________________________________________ 
       _________________________________________________________ 
The treatment:  
1 _____________________; Dose  ___________;  Frequency  ______  / day   
2 _____________________; Dose  ___________;  Frequency  ______  / day 
3 _____________________; Dose  ___________;  Frequency  ______  / day 
4 _____________________; Dose  ___________;  Frequency  ______  / day    
Additional test  /examination results (if available): 
[338]
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Patient Symptom Diary. Version 1.1. Date 22 August 2017 
Page 1 of 39 
This book belongs to: 
____________________________ 
Appendix 5.7. Case report form CRF06. Symptom diary
[339]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
Page 2 of 39 
http://tinyurl.com/thankswithflower
Hello Uncle / Aunty!! 
My name is_____________________ 
I was born in________________  
On date _____ month ________ year ___________ 
If you find this Diary, I would be very grateful if you can 
return it to my Dad (mobile no. _______________) or  
my Mom (mobile no. _______________).   
[340]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 3 of 39 
Day-0 (your first visit) : |___|___| – |___|___| – 20 |___|___|
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
Medicines given (please write the name, dose, and frequency) 
Medicines have 
been given to your 
child before going 
to the hospital 
(from other 
doctor or chemist 
store) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 4 of 39 
Thank you for filling the diary this morning.  
Now please give your child the study medicine. 
Notes:  
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
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Day – 1* : |___|___| – |___|___| – 20 |___|___|          
*On the morning after your first visit to the hospital or doctor
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 6 of 39 
Has your child has been 
admitted to hospital?  




Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Thank you for filling the diary this morning.  
Now please give your child the study medicine. 
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
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Day-2 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
Medicines given (please write the name, dose, and frequency) 
Medicines have 
been given to your 
child before going 
to the hospital 
(from other 
doctor or chemist 
store) 
_________________________    Dose    :  _____ mg / body weight kg         Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg         Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg         Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg         Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg         Frequency   :    ______ / day 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 8 of 39 
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  




Medicines given (please write the name, dose, and frequency) 
Medicines have 
been given to your 
child before going 
to the hospital 
(from other 
doctor or chemist 
store) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Thank you for filling the diary this morning.  
Now please give your child the study medicine 
Notes:  
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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 For each question, please tick ( ) your answer on O or write you answer on ______ 
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Day – 3  :  |___|___| – |___|___| – 20 |___|___| 
First visit to the primary care centre / hospital 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 
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Has your child has been 
admitted to hospital?  
O Yes       O No Medicine prescribed: ________________________________
________________________________ 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Thank you for filling the diary this morning.  
Now please give your child the study medicine. 
Notes: 
Thank you for completing the First Diary. 
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 For each question, please tick ( ) your answer on O or write you answer on ______ 
Patient Symptom Diary. Version 1.1. Date 22 August 2017 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Patient Symptom Diary. Version 1.1. Date 22 August 2017 
Page 12 of 39 
Notes:  
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 13 of 39 
http://tinyurl.com/thankswithflower
Hello Uncle / Aunty!! 
My name is_____________________ 
I was born in________________  
On date _____ month ________ year ___________ 
If you find this Diary, I would be very grateful if you can 
return it to my Dad (mobile no. _______________) or  
my Mom (mobile no. _______________).   
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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 For each question, please tick ( ) your answer on O or write you answer on ______ 
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Day-4 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 





Patient Symptom Diary. Version 1.2. Date 8 July 2019 
[352]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 15 of 39 
Has your child has been 
admitted to hospital?  
O Yes       O No Medicine prescribed: ________________________________
________________________________ 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Thank you for filling the diary this morning.  
Now please give your child the study medicine. 
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 16 of 39 
Day – 5 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
[354]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 17 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Thank you for filling the diary this morning.  
Now please give your child the study medicine. 
Notes: 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 18 of 39 
Day-6 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
[356]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 19 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 20 of 39 
Day – 7 : |___|___| – |___|___| – 20 |___|___| 
Second visit to the primary care centre / hospital 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 





Patient Symptom Diary. Version 1.2. Date 8 July 2019 
[358]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 21 of 39 
Has your child has been 
admitted to hospital?  
O Yes       O No Medicine prescribed: ________________________________
________________________________ 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Thank you for completing the Second Diary. 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Patient Symptom Diary. Version 1.1. Date 22 August 2017 
Page 22 of 39 
Thank you for completing the second Diary. 
[360]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Patient Symptom Diary. Version 1.1. Date 22 August 2017 
Page 23 of 39 
[361]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 24 of 39 
http://tinyurl.com/thankswithflower
Hello Uncle / Aunty!! 
My name is_____________________ 
I was born in________________  
On date _____ month ________ year ___________ 
If you find this Diary, I would be very grateful if you can 
return it to my Dad (mobile no. _______________) or  
my Mom (mobile no. _______________).   
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 25 of 39 
Day – 8  : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
[363]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 26 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
[364]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 27 of 39 
Day – 9 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 28 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 29 of 39 
Day – 10 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 30 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 31 of 39 
Day – 11 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 32 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
[370]
   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 33 of 39 
Day – 12 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 34 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 35 of 39 
Day – 13 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 36 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 37 of 39 
Day – 14 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past
      12 hours? Please write the time accordingly ……. (am/ pm) 
2. We are interest finding out how your child has been doing. For each question, please place a check mark in O
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than 
       usual? 
O No     O A little     O A lot
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects 
Does your child have these complaints after taking the medicine 
7.1  Increased appetite O Yes       O No 7.8   Drowsiness O Yes       O No
7.2  Increased urine amount O Yes       O No 7.9   Anxiety/distractibility/mood swing O Yes       O No
7.3  Weight gain O Yes       O No 7.10  Headache O Yes       O No
7.4   Gastritis/abdominal pain O Yes       O No 7.11  Skin rash or diaper rash O Yes       O No
7.5   Nausea O Yes       O No 7.12  Candidiasis O Yes       O No
7.6   Vomiting O Yes       O No 7.13  Dry mouth / throat irritation O Yes       O No
7.7   Diarrhea O Yes       O No 7.14  Sleep disturbance O Yes       O No
Others _______________________________________________________________________ 
Did you bring your child to 
doctor (clinic or outpatient)? 




Has your child has been 
admitted to hospital?  
O Yes       O No Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Page 38 of 39 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
_________________________    Dose    :  _____ mg / drop / teaspoon / tablespoon    Freq. :    ____ /day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm
Notes: 
Thank you for completing the Last Diary. 
Patient Symptom Diary. Version 1.2. Date 8 July 2019 
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   Study ID 
 For each question, please tick ( ) your answer on O or write you answer on ______ 
Patient Symptom Diary. Version 1.1. Date 22 August 2017 
Page 39 of 39 
[377]
Prescription of OPAL study medication. Version 1.1. Date 8 July 2019 
Date ________________________ 
CRF07. Prescription for OPAL study medication 
Randomisation ID : 
Name  : ___________________________ 
Age  : _________________ months / year(s) [write and circle your answer]  
Study medication dose : _________  mg per day =  _________  tablets per day 
R/ OPAL study medication tablet 5 mg       ____    tab 
     Sach lact    add 
m.f. pulveres dtd No. V 
∫ 1 dd 1 pc (before 9 am)
R/ Sirplus sweetener syrup                                   fl     ____ 
     ∫ 1 dd 1 pc (mix with study medication powder with ratio of 3:1) 
Pharmacist’s name:  
Prednisolone doses: 
 Aged 6 months to < 2 years old    = 10 mg per day 
 Aged 2 years to < 6 years old         = 20 mg per day 
 Aged 6 years to 12 years old           = 30 mg per day 
Appendix 5.8. Case report form CRF07. Prescription for OPAL study 
medication
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pilot pragmatic, randomised, double-blind, placebo-controlled study (OPAL Study)
[378]
    Study ID 
For each question, please tick ( ) the circle corresponding to your answers or write you answer on ___  or  |___| 
Randomisation Form. Version 1.2. Date 8 July 2019 
Page 1 of 1 
Nurse ID : |___|___|___| Site ID : |___|___|___|       Date : |___|___| – |___|___| – 201 |___| 
 
Eligibility criteria (cross-check with ‘CRF01. Eligibility form’ in the ‘Case Report Form Binder’ of this 
subject). 
All ‘YES’ for inclusion criteria?  O  Yes O  No 
All ‘NO’ for exclusion criteria? O  Yes O  No 
Consent to participate in the study (cross-check with ‘Form01. Informed consent’ in the ‘Case Report 
Form Binder’ of this subject). 
Has the consent been obtained? O  Yes O  No 
RANDOMISATION 
Father’s mobile phone no. 
Mother’s mobile phone no. 
AOM Severity O  Mild AOM O  Severe AOM 
Date of Birth Date Month Year Age month/year* 
RANDOMISATION RESULT 
Randomisation ID 
Name of personal who 
conducted randomisation 
Signature Date of 
randomisation 
Access to the MASCoT by clicking the link attached in the invitation email  
https://mascot.org.au/collaborate/5d35f9b4-8ca8-41ce-b340-ae8ec9791abb  
or 
Contact 24-hour Call Centre +62 8111 012 185 
CRF08 – RANDOMISATION FORM 




 Clinical Epidemiology and Evidence-Based Medicine Unit (CEEBM) 
Dr Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Institute for Evidence-Based Healthcare 
Faculty of Health Sciences and Medicine, Bond University, Australia 
Follow-Up Reminder 
Card
Name :  ___________________________ 
Address  :  ___________________________ 
   ___________________________ 
Mobile No          :  ___________________________ 














Baseline / Initial Visit 
(Day 0) 
First Follow-Up Visit  
(Day 3) 
Second Follow-Up Visit 
(Day 7) 
Third Follow-Up Call 
(Day 30) 
Fourth  Follow-Up Call 
(Day 90) 
Please bring this card to every follow-up visit 
Hospitals and Call Centre contact numbers 
Proklamasi ENT Hospital 
Jl. Proklamasi No.43 
Operator : 021 390 0002, 021 392 4891 Ext. 0, 101, 227, 229 
ENT Outpatient Clinic : Ext. 100, 236 244 
Emergency Department  : Ext. 235 
Antam Medika Pulogadung Hospital 
Jl. Raya Pemuda No. 1A 
Operator : 021 806 14 888 
ENT Outpatient Clinic : Ext. 1027 
Paediatric Outpatient Clinic : Ext. 1019 
Emergency Department  : Ext. 1045 
Kemayoran Primary Care Centre 
Jl. Harapan Mulia Barat No. 1A 
Operator : 021 425 1018, 021 428 01847 
Pulo Gadung Primary Care Centre 
Jl. Kayu Putih Selatan III No. 2B 
Operator : 021 489 0519, 021 478 69633 
24-Call Centre OPAL Study
Dr. Respati W. Ranakusuma, Sp.THT-KL : 08111 012 185 
[381]
For each question, please tick ( ) your answer in the box and fill ____ 
Adverse Event Assessment Form. Version 1.0. Date 8 July 2019 
Page 1 of 1         
Study ID 
 
Assessor name __________________________________    Date         _____________________________ 
The adverse event(s) is likely related to the 
study medication (prednisolone) 
  Unrelated – clearly not related to prednisolone 
  Unlikely – doubtfully related to prednisolone 
  Possible – may be related to prednisolone 
  Probable – likely related to prednisolone 
  Definite – clearly related to prednisolone 
Note: _____________________________________________________ 
__________________________________________________________ 
The adverse event(s) is likely related to other  
co-medication administered during the study 
  Yes                                                                No 




This adverse event(s) is considered as 
a serious adverse event 
        Yes                                                                 No 
Note: _____________________________________________________ 
__________________________________________________________ 
Should this event be reported to 
the Ethics Committee? 






Any recommendations for the ongoing study  





CRF10. ADVERSE EVENT ASSESSMENT FORM 
Appendix 5.11. Case report form CRF10. Adverse event assessment form
[382]
Serious adverse events reporting form. Version 1.1. Date 9 July 2019 
Page 1 of 1 
Weight (kg) |____|____| , |____|____| kg 
Describe clinical history, 
pre-existing medical 
conditions, and any 




Report type    Initial report   Follow-up   Final 
Reason for reporting    Requires or prolongs hospitalization  
   Permanently disabling or incapacitating 
  Overdose 
  Other (please specify) 
 Congenital anomaly  
      Life threatening 
      Death 
      Date of death 
      Cause of death 
SUSPECTED DRUG 
Name of suspected drug Generic name 
Dose details Name of manufacturer 
Date of occurrence |____|____| - |____|____| - |____|____|____|____| (date – month – year) 
Duration of event |____|____| month(s)  |____|____| day(s) 
Starting date of medication |____|____| - |____|____| - |____|____|____|____| (date – month – year) 
Route of administration  Indication 
Discontinuation of drug 
because of event 
   No    Yes Dated (date / month / year) : 
If stopped/lowered dose, did the event resolve after this?    Yes    No    N/A 
If reintroduced did the event reappear?    Yes    No    N/A 
Outcomes   Recovered 
  Change in SAE 
  Recovered with sequelae 
  Patient died 
 Continuing 
  Unknown 
Severity   Mild   Moderate   Severe 
Action taken with study 
drug 
  None 
  Dose temporarily reduced   
  Dose reduced 
  Discontinued temporarily 
  Discontinued 
Other action*   None   Treated with medication   Other 
Withdrawn from the trial 
due to SAE 
  No   Yes 
REPORTER INFORMATION 
Signature of reporter Full name 
Date of signing |____|____| - |____|____| - |____|____|____|____| (date – month – year) 
CRF11. SERIOUS ADVERSE EVENTS REPORTING FORM 
Appendix 5.12. Case report form CRF11. Serious adverse events reporting 
form STUDY ID
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dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind, placebo-controlled study (OPAL Study)
Please write ‘Y’ for ‘YES’ and ‘N’ for ‘NO’.  
Study recruitment log book. Version 2.1. Date 9 July 2019 
Page 1 of 1 















go on the 
study? 
(YES or NO) 
If YES,  
what is the 
Randomisation 
ID 

































or NO). Write 
the reason 
FORM01 – STUDY RECRUITMENT LOG BOOK
Study title :  
Oral prednisolone for acute otitis media in children:  a pragmatic, randomised, double-blind, placebo-controlled study  
Hospital ID : 
Appendix 5.13. Case report form FORM01. Study recruitment logbook
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dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind, placebo-controlled study (OPAL Study)
Study drug stock form. Version 1.2. Date 9 July 2019 
Page 1 of 1 
Site ID : |___|___|___| 













FORM02. STUDY DRUG STOCK FORM 
Appendix 5.14. Case report form FORM02. Study drug stock form
[385]
Drug dispensing form. Version 1.3. Date 9 July 2019 
Page 1 of 1 










First dose or 
Additional 
(‘F’ or ‘A’) 
Pharmacist’s 
name 
FORM03. DRUG DISPENSING FORM 
Appendix 5.15. Case report form FORM03. Drug dispensing form
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind, placebo-controlled study (OPAL study)
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dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind, placebo-controlled study (OPAL Study)
Drug return form. Version 1.3. Date 9 July 2019 
Page 1 of 1 
 Site ID    : |___|___|___| 
Randomisation ID Date Returned Number of  
left-over drug 
Reasons for return Nurse’s name 
FORM04. DRUG RETURN FORM (FOR THE NURSE) 
Appendix 5.16. Case report form FORM04. Drug return form
[387]
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind, placebo-controlled study (OPAL Study) 
Completed Case Report Form. Version 1.1. Date 9 July 2019 
Page 1 of 1 
FORM05. COMPLETED CASE REPORT FORM 
Study title: Oral prednisolone for acute otitis media in children:  a pragmatic, randomised, double-blind, placebo-
controlled study (OPAL study) 
Site ID : 
No Randomisation ID Enrolment date  Date of Visit-1 
(Day-3) 








Date of the 
completion of the 
study 
Please tick if patient completed these accordingly 
Appendix 5.17. Case report form FORM05. Completed case report form
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dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind, placebo-controlled study (OPAL Study)
Antibiotics for acute otitis media. Version 1.0. Date 31 August 2017 
FORM06. ANTIBIOTICS FOR ACUTE OTITIS MEDIA 
Initial immediate or delayed antibiotic therapy Antibiotics after 48-72 hours of failure of initial antibiotic therapy 
Recommended first-line 
treatment 





Amoxicillin (80-90 mg/kg per day in 
2 divided doses) 
OR 
Amoxicillin-clavulanatea (90 mg/kg 
per day of amoxicillin, with 6.4 
mg/kg per day clavulanate 
(amoxicillin to clavulanate ration, 
14:1) in 2 divided doses) 
Cefdinir (14 mg/kg per day in 1 or 2 
doses) 
Cefuroxime (30 mg/kg per day in 2 
divided doses) 
Cefpodoxime (10 mg/kg per day in 
2 divided doses) 
Ceftriaxone (50 mg IM or IV per 
day for 1 or 3 days) 
Amoxicillin-clavulanatea (90 
mg/kg per day of amoxicillin, with 
6.4 mg/kg per day in 2 divided 
doses) 
OR 
Ceftriaxone (50 mg IM or IV per 
day for 3 days) 
Ceftriaxone, 3 days Clindamycin 
(30-40 mg/kg per day in 3 divided 
doses), with or without third-
generation cephalosporin (50 mg 
IM or IV per day for 3 days) 
Failure of second antibiotic 
Clindamycin (30-40 mg/kg per day 




a may be considered in patients who have received amoxicillin in the previous 3 o days or who have the otitis conjunctivitis syndrome; 
b Perform tympanocentesis/drainage if skilled in the procedure, or seek a consultation from an otolaryngologist for tympanocentesis/drainage if the 
tympanocentesis reveals multidrug/resistant bacteria, seek an infection disease specialist consultation. 
Reference: Lieberthal AS, Carroll AE, Chonmaitree T, et al. Clinical Practice Guideline: The diagnosis and management of acute otitis media. The American Academy of 
Pediatrics. Pediatrics. 2013;131:e964-e99 
Appendix 5.18. Case report form FORM06. Antibiotics for acute otitis media
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dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pragmatic, randomised, double-blind, placebo-controlled study (OPAL Study)
Prednisolone Dose Card. Version 1.1. Date 28 August 2019 
FORM07. STUDY MEDICATION DOSE CARD 
Aged two years to up to 
six years old 
20 tablets of Study
Medication for 5 days 
Dose: 20 mg/day of Study Medication 
(prednisolone or placebo)  
(4 tablets/day) 
Aged six months to up to 
two years old 
10 tablets of Study
Medication for 5 days 
Dose: 10 mg/day of Study Medication 
(prednisolone or placebo) 
(2 tablets/day) 
Aged six years to 12 years 
old 
30 tablets of Study
Medication for 5 days 
Dose: 30 mg/day of Study Medication 
(prednisolone or placebo)  
(6 tablets/day) 
Appendix 5.19. Case report form FORM07. Study medication dose card
[390]






This leaflet has been written for parents and carers about how 
to use this medication in children. This information may differ 
from that provided by the pharmaceutical company, because 
their information is usually aimed at adult patients. Please 
read this leaflet carefully. 
We copied cited and copied the information on the leaflet from: 
Medicine for children – information for parents and carers: prednisolone for asthma. http://www.medicinesforchildren.org.uk/prednisolone-asthma 
FORM08.Instruction for using Prednisolone 
Name of drug 
Lupred tablet contains of prednisolone. 
When should I give prednisolone? 
Prednisolone is usually given once each day, usually in the 
morning. Give the medicine at about the same time each day 
so that this becomes part of your child’s daily routine, which 
will help you to remember.  
How much should I give? 
Your doctor will work out the amount (the dose) that is right 
for your child. It is important that you follow your doctor’s 
instructions about how much to give. 
How should I give it? 
The pharmacist will prepare the prednisolone tablets by 
crushing the tablets, mixing it with the sweetener, and 
packing them in a daily paper-pack for your child.  
You can mix it with a small amount of soft food such as 
yogurt, honey, or jam, or give a glass of milk or juice. Make 
sure your child swallows it straight away, without chewing. 
When should the medicine start working? 
Prednisolone usually takes 4–6 hours to have its full effect. 
What if I forget to give it? 
You can give your child the missed dose as soon as you 
remember on the same day. If you remember after they have 
gone to bed, do not give them the missed dose. Give the next 
dose in the morning as usual. Never give a double dose of 
prednisolone 
Are there any possible side-effects? 
We use medicines to make our children better, but sometimes 
they have other effects that we don’t want (side-effects). It is 
unlikely that your child will have side-effects if they only take 
prednisolone for a few days. They are more likely to get side-
effects if they are on a high dose, have extra doses or take 
prednisolone for a long time.  
Side effects that you must do something about 
 If your child has bad stomach pain or repeated vomiting 
(being sick), contact us straight away. This may be due to 
an ulcer or inflammation of the pancreas 
 If your child develops a rash or severe/unexplained 
bruising, contact us straight away, as there may be a 
problem with your child’s blood 
 If your child has eye pain or changes in their vision, contact 
us straight away 
  Other side effects you need to know about 
 child may have stomachache, feel sick or be sick (vomit) or 
may have indigestion (heartburn). Giving the medicine 
with some food may help 
 Your child may have an increased appetite and may gain 
weight while taking prednisolone. You can help by making 
sure your child has plenty of physical activity, and by 
offering fruit and vegetables and low-calorie food, rather 
than food that is high in calories (e.g. cakes, biscuits, 
sweets) 
 Your child may have trouble sleeping and nightmares and 
may feel depressed, or their behaviour may change in 
other ways. Contact us for advice if you are concerned  
What if I give too much? 
It can be dangerous to give too much prednisolone. If you 
think you may have given your child too much prednisolone, 
contact us immediately.  
What if my child is sick (vomits)? 
If your child is sick less than 30 minutes after having a dose of 
prednisolone, give them the same dose again. 
If your child is sick more than 30 minutes after having a dose 
of prednisolone, you do not need to give them another dose. 
Wait until the next normal dose. 
If your child is sick again, please contact us.  
Appendix 5.20. Case report form FORM08. Instruction for using Prednisolone
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ORAL PREDNISOLONE FOR ACUTE OTITIS MEDIA IN CHILDREN (OPAL STUDY) 
WHO TO CONTACT FOR MORE INFORMATION 
OPAL STUDY 24-HOUR CALL CENTRE 
08111 012 185 
Can other medicines be given at the same time? 
You can give your child medicines that contain paracetamol or 
ibuprofen, unless your doctor has told you not to. Check with 
us or your doctor before giving any other medicines to your 
child. This includes herbal or complimentary medicines. 
Where should I keep this medicine?  
 Keep the medicine in a cupboard, away from heat 
and direct sunlight. It does not need to be kept in the 
fridge 
 Make sure that children cannot see or reach it. 
 Keep the medicine in the container it came in 
Side effects with high doses or long courses 
 Prednisolone can slow growth and affect puberty. It can 
also cause growth of body hair and irregular periods in girls 
 Your child may be more at risk of severe infections. They 
should stay away from anyone with an infection (such as 
chicken pox, shingles, measles) if they have not had these 
illnesses or have not been vaccinated for measles 
 If your child is unwell and you are worried about an 
infection, contact us straight away 
 Your child’s skin may become thinner and heal more 
slowly than usual. Acne (spots) may become worse or your 
child may develop mouth ulcers or thrush (candidiasis). If 
you are concerned, contact us 
 Your child may develop problems with their hip bones, or 
their bones may become weaker (osteoporosis). The 
muscles around the hips and shoulders may also become 
weaker. If your child has any difficulty walking or moving 
around, contact us 
 Occasionally, prednisolone causes diabetes. If your child 
seems more thirsty than normal, needs to pass urine (wee) 
often, or starts wetting the bed at night, contact us 
There may, sometimes, be other side-effects that are not 
listed. above. If you notice anything unusual and are 
concerned, please contact us. 
Is there anything else I need to know about 
prednisolone?  
For children who have been taking prednisolone in high doses 
or for longer than 2-3 weeks 
 They must not stop taking the medicine suddenly because 
they may get withdrawal symptoms: they will feel unwell, 
dizzy and thirsty and may be sick (vomit). If this occurs, 
you should contact us straight away 
 If your doctor decides to stop prednisolone, they will 
reduce the dose gradually before stopping it completely. 
Make sure you follow your doctor’s instructions 
 Make sure that you always have enough medicine.  
[392]
Introduction Intervention
Acute otitis media (AOM) is an acute middle ear 
infection commonly found in children. High rate of 
antibiotic prescribing is evidence, although most 
AOM is non severe and will be improved under 
close observation and adequate pain 
management. Only one third of children with 
AOM having severe symptoms and signs, will 
benefit from antibiotics. Antibiotic use increases 
the risk of both unfavourable effects (e.g. 
vomiting, diarrhoea) and antibiotic resistance. 
Due to potential harms of antibiotic use, 
alternative treatments for AOM that do not 
involve antibiotics is required. Current alternative 
treatments (i.e. decongestants, herbal products) 
demonstrate insufficient evidence of their 
benefits for AOM. Since AOM is mostly caused by 
the inflammation in the middle ear, thus 
corticosteroids as anti-inflammatory agents, could 
be potential treatment candidate for AOM. 
Although corticosteroids are effective for 
particular infection diseases, its effects for AOM 
remain uncertain. A large and high-quality clinical 
trial is required. Therefore, we are conducting a 
parallel, pragmatic, multicentre, randomised, 
double-blind, placebo-controlled trial.  
We randomly allocated children to receive either 
prednisolone or placebo. This is a double-blind 
study, thus physician, research team, or the 
parents will not acknowledge the intervention 
received by children.  
Prednisolone and placebo given dose were based 
on age: 10 mg (6 month – 2 year), 20 mg (2–6 
year), and 30 mg (6–12 year). 
Physician may prescribe other medications if 
necessary. However, we strongly advise NOT to 
prescribe oral corticosteroid during this study, if 
possible. We also kindly ask you to provide a 
prescription copy to allow us to record other 
medication prescribe during the study.  
Aim
To assess the effectiveness of oral corticosteroid 
as a monotherapy for children with mild AOM and 
as an addition to antibiotics for severe AOM. 
INFORMATION CARD 
Oral prednisolone for acute otitis media in children:  
a pragmatic, randomised, double-blind, placebo-controlled study 
(OPAL study) 
Please do not hesitate to contact our 
principal investigator of this study for any 
enquires or questions: 
Dr Respati W Ranakusuma, SpTHT-KL 
08111 012 185 
OPAL.study@bond.edu.AU 
Appendix 5.21. Case report form FORM09. Information card
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I001404-PG-1043 
Lupred ® 5 
Prednisolone 5 mg 
TABLET 
COMPOSITION 
Each tablet contains: 
Prednisolone 5 mg 
PHARMACOLOGY 
Prednisolone is a systemic corticosteroid with glucocorticoid and anti-inflammatory potencies. The mechanism 
of action of corticosteroids is thought to be by control of protein synthesis. Corticosteroids react with 
receptor proteins in the cytoplasm of sensitive cells in many tissues to form a steroid-receptor complex. 
INDICATION 
Allergic reaction, inflammation and other diseases that require glucocorticoid treatment, such as 
rheumatoid arthritis, collagen diseases, and dermatology disorders. 
DOSAGE AND INSTRUCTION 
Adults: 1 – 4 tablets per day or according to the doctor’s instruction. 
The dosage reduces gradually until reach the lowest effective dose. 
PRECAUTION  Avoid the abrupt discontinuation in a long-term use  
 Use with caution in paediatric patients who are still in the growing process 
 Not recommended for pregnant and breast-feeding women 
 Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible 
damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi 
or viruses 
 Risk of secondary adrenocortical insufficiency could be reduced by gradual reduction of dosage 
 Use with caution in patients with diabetes mellitus because it can increase the gluconeogenesis and reduce 
the sensitivity to insulin 
 Use with caution in patients with hypothyroidism because it can enhance the effect of corticosteroids 
 Use with caution in patients with heart failure, infection diseases, chronic renal failure, and elderly 
ADVERSE EFFECTS 
 Water balance and electrolytes disturbance: Natrium retention, excretion of potassium, hypokalaemic 
alkalosis, hypertension, and congestive heart failure 
 Musculoskeletal: Muscle weakness, steroid-induced myopathy, osteoporosis, vertebral compression 
fractures and pathologic fractures of long bones 
 Gastrointestinal: Peptic ulceration with haemorrhage and perforation, pancreatitis, abdominal distension 
and ulcerative esophagitis 
 Dermatological: Impaired wound healing, thinning of the skin, facial plethora, increased sweating 
 Neurological:  seizures, intracranial hypertension with papilloedema (cerebral pseudotumour), vertigo, 
headache 
Appendix 5.22. Case report form FORM10. Lupred information
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I001404-PG-1043 
 Endocrine: Disorders of menstruation, suppression of growth in children, secondary adrenocorticoid and 
non-responsive pituitary (particularly in stress, trauma, surgery or illness), metabolic effects, primarily 
involving the carbohydrates 
 Ophthalmological: Posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and 
exophthalmos 
 Metabolic: Nitrogen depletion due to protein catabolism 
 Hypersensitivity: anaphylactic reaction 
CONTRAINDICATION 
 Patients who are known hypersensitivity to prednisone or prednisolone  
 Peptic ulceration, active tuberculosis, osteoporosis, neurological disorders, renal and heart disorders 
 Systemic fungal infections and ocular herpes simplex 
INTERACTION WITH OTHER MEDICINES 
 The use of aspirin and corticosteroid is not recommended in patients with non-specific ulcerative colitis 
 Rifampicin, phenytoin, phenobarbital can increase the metabolism of corticosteroids 
 Vaccination with live vaccine must be avoided 
OVERDOSAGE 
There is no specific antidot. Treatment is symptomatic with the dosage being reduced or the drug withdrawn. 
STORAGE CONDITION 
Store below 30°C.  
DOCTOR’s PRESCRIPTION IS A MUST 
Manufactured by: 
PT. PRATAPA NIRMALA 
Tangerang – Indonesia  
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